








 Characterization of Bioactive Com
ponents in Edible Algae   •   Leonel Pereira
Characterization of Bioactive 
Components in Edible Algae

Characterization of Bioactive 
Components in Edible Algae
Special Issue Editor
Leonel Pereira
MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin
Special Issue Editor
Leonel Pereira







This is a reprint of articles from the Special Issue published online in the open access journal
Marine Drugs (ISSN 1660-3397) (available at: https://www.mdpi.com/si/marinedrugs/edible
algae).
For citation purposes, cite each article independently as indicated on the article page online and as
indicated below:




Cover image courtesy of Leonel Pereira.
c© 2020 by the authors. Articles in this book are Open Access and distributed under the Creative
Commons Attribution (CC BY) license, which allows users to download, copy and build upon
published articles, as long as the author and publisher are properly credited, which ensures maximum
dissemination and a wider impact of our publications.
The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons
license CC BY-NC-ND.
Contents
About the Special Issue Editor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Preface to ”Characterization of Bioactive Components in Edible Algae” . . . . . . . . . . . . . ix
Leonel Pereira
Characterization of Bioactive Components in Edible Algae
Reprinted from: Mar. Drugs 2020, 18, 65, doi:10.3390/md18010065 . . . . . . . . . . . . . . . . . 1
Adriana Leandro, Leonel Pereira and Ana M. M. Gonçalves
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Preface to ”Characterization of Bioactive Components
in Edible Algae”
Numerous factors affect the quality of modern life, so the population must be aware of
the importance of foods that contain substances that help to promote health by improving
their nutritional status. The incidence of death from cancer, cardiovascular accidents, stroke,
atherosclerosis, and liver disease, among others, can be minimized through good eating habits.
Functional and nutraceutical foods have been commonly considered synonymous; however,
functional foods should be in the form of common foods, consumed as part of the diet and
produce specific health benefits, such as reducing the risk of various diseases and maintaining good
physical and mental health. Biologically active substances found in functional foods can be classified
as probiotics and prebiotics, nitrogenous foods, pigments and vitamins, phenolic compounds,
polyunsaturated fatty acids, and fibers. The marine environment provides a huge source of many
healthy foods, including algae (green, red, and brown macroalgae), which are an example of a marine
product that is part of the diet in several countries around the world. In addition, marine samples are
sources of an abundance of chemicals, many of them with biological properties so are therefore called
bioactive compounds. These chemicals can be extracted and incorporated into various food matrices,
showing potential as new functional foods. With little fat, seaweed has polysaccharides that behave,
most of the time, as non-caloric fibers. Therefore, algae appear to be the best way to correct current
global nutritional deficiencies (in developed, emerging, and/or underdeveloped countries) due to
their varied range of essential constituents including minerals (iron and calcium), proteins (with all
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Introduction
From the origin of our planet, about 4.6 billion years ago, 1.400 million years had to pass in
order for an event of maximum transcendence to develop in the evolutionary history of life on Earth:
the appearance of the first photosynthetic organisms, with which the biochemical machinery that
maintains ecological dynamics was launched, as we know it today, both in the aquatic environment,
where it was born, as well as terrestrially [1].
Photosynthesis allowed them to synthesize organic matter, the basis of the feeding of every living
being, from inorganic compounds, at the same time that it was an oxygen contribution, which at that
time generated a radical change in the composition of that primitive atmosphere and conditioned
the next steps of evolution. Among these pioneers are the most primitive algae, with a precarious
unicellular constitution that lacks a nucleus (prokaryotic cell organization). They are known as
Cyanobacteria or blue-green algae, although today there is a discrepancy between systematics when
considering them as bacteria or algae [2].
The next step in the evolutionary process was the formation of a complete cellular system with a
true nucleus (eukaryotic cellular organization), shared by unicellular and multicellular algae, which
happened just 1.4 billion years ago, with an atmosphere that was already rich in oxygen. However, 700
million years had to pass before the great algae and the first invertebrate animals were developed,
and 300 million more so that, from the green algae, the first vascular plants colonized the terrestrial
environment, free of living beings until that moment. The last stage in plant evolution was reached
with the appearance of flowering plants (phanerogams) only 100 million years ago, which, if we
compare the age of the Earth with the average life expectancy of human beings, is equivalent to two
years in the life of a person [1].
Algae as Food
Larger seaweeds, macroalgae, are a source of food ignored in the western world, while constituting
an essential part of, for example, the Japanese diet. Macroalgae are, in many respects, optimal for
human nutrition since they contain a prodigality of minerals, trace elements, vitamins, proteins, iodine,
and essential polyunsaturated fatty acids, as well as an abundance of both soluble and insoluble dietary
fibers, with few calories [3].
In the same way, macroalgae have an enormous and unexplored potential for gastronomic
innovation. They can be used practically in any dish of the daily kitchen as well as haute cuisine.
Considering that there are about 10,000 species worldwide of edible algae and that the genetic
differences between any of these species are as large as those between plants and animals, it is clear
that this splendid abundance provided by the oceans of the planet deserves greater attention from
scientists and the inhabitants of the western world [4,5].
Today, the societies of western countries, so-called developed, live immersed in an illusory
abundance and diversity of food. We are driven to consumption without rules or dietary care and to
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fast food, high in calories and unsaturated fats. This appears to be the miraculously adequate response
to the hectic pace of urban life—so much so that we have even adopted the designation of ready food,
or fast food, as a style and misperception of a reality, where food is seen merely as organic fuel doses to
meet our most immediate energy needs. The consequences of such a diet (antagonistic to traditional
slow food, more carefully prepared), where the lack of essential nutrients is evident, are obesity (and
collateral diseases) as well as other diseases related to excessive intake of sugars (diabetes) and fats
(arteriosclerosis), among others [3,6].
On the other hand, this illusion does not express itself with the same impact in underdeveloped
or transitional countries, as seen from an economic perspective, or on those emerging economies;
although in the latter, the tendency is towards their imposed consolidation rather than towards its
eradication. Countries such as Brazil, with a considerable coast, face the same dilemma and have before
them the path that other countries can take: where food practices can and should be adapted to local
resources. Less-developed countries with an appreciable coastline, such as Angola and Mozambique,
may adopt new food strategies to overcome the strong shortages still felt [7].
The question that arises at this point of consciousness is simple—what contribution or benefits
can seaweed bring to the human diet in terms of food, gastronomy, or diet? The answer seems simple
in the light of current knowledge—it is the exact opposite of the concept of fast food: a natural, yet
wild and abundant food (with a growth rate capable of sustaining an intensive culture), capable of
providing high nutritional value but at reduced caloric value. Poor in fat, seaweed has polysaccharides
that behave, for the most part, as non-calorie fibers. Therefore, algae seem to be the best way to correct
not only the lack of food for ingestion but also the nutritional deficiencies of the current diet worldwide
(in developed, emerging, and/or underdeveloped countries) due to their wide range of essential
constituents—minerals (iron and calcium), proteins (with all essential amino acids), vitamins and
fiber [3]; nutrients that are absolutely necessary for human primary metabolism. They are, therefore, a
guarantee of survival, which the human being, sooner or later, will resort to, now more out of whim
and curiosity (thanks to some pioneering work and investments that are starting to pay off) and later,
of course, to meet the demands of an explosively-growing human population that already numbers
more than 7 billion people, increasingly concentrated in Asia and Africa [8].
The marine environment provides a huge source of many healthy foods including algae
(seaweed–green, red, and brown macroalgae), an example of a marine product that has been part of
the diet in several countries around the world. Furthermore, marine specimens are also sources of
an abundance of chemicals, many of them with biological properties and therefore called bioactive
compounds. These chemicals can be extracted and incorporated in several food matrices leading to
new potential functional foods [6,9].
Some of the edible species referred to in this special issue have been the subject of studies related to
some of their bioactive compounds, from lipids to algal phlorotannin, various phycocolloids (alginates
and carrageenans), to the sulfated polysaccharides such as Ulvan and Fucoidan.
Among the species of macroalgae studied in the articles of this special issue, we find, for example,
the species harvested in Indonesia and Japan, where lipid content variations were evaluated. Susanto
et al. (2019) [10] concluded that the total lipid (TL) content and fatty acid composition were strongly
affected by sampling location. The TL and n-3 PUFA levels tended to be higher in temperate seaweeds
compared to those in tropical seaweeds. In this study were analyzed four species of edible green
algae (Chlorophyta; edible seaweeds of the world): Caulerpa lentillifera and Ulva reticulata, harvested in
Indonesia; Ulva intestinalis, U. australis, and U. reticulata, harvested in Japan; five species of red
algae (Rhodophyta): Gracilariopsis longissima, harvested in Indonesia, Gloiopeltis furcata, Chondrus
yendoi, Mazzaella japonica and Chondria crassicaulis, harvested in Japan; and six species of brown algae
(Ochrophyta, Phaeophyceae): Sargassum aquifolium, harvested in Indonesia, Costaria costata, Undaria
pinnatifida, Saccharina japonica, Sargassum fusiforme and S. horneri, harvested in Japan [5,10].
Brown (Phaeophyceae) and red (Rhodophyta) algal sulfated polysaccharides have been widely
described as anticoagulant agents. However, data on green (Chlorophyta) seaweed, especially on
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the Ulva genus, are limited. In the work conducted by Adrien et al. (2019) [11], the anticoagulant
activity of the ulvan extracted from U. rigida is evaluated. The authors of the paper conclude that the
chemically-sulfated ulvan fraction could be a very interesting alternative to heparins, with different
targets and high anticoagulant activity [11].
Ecklonia cava, an edible brown alga growing abundantly on the shores of Japan and Korea
where it is consumed as part of the daily diet, is studied by the team of Oh et al. (2019) [12], which
evaluated phlorotannin, phlorofuroeckol A (PFF-A), produced by this alga, and the osteoblastogenesis
enhancing effects, which can be utilized against bone-remodeling imbalances and osteoporosis-related
complications [12].
Natural compounds can be effective candidates for various skin diseases, especially phlorotannins
extracted from seaweeds, which have interesting properties that make them useful for cosmeceutical
applications. This is the theme explored by Zhen et al. (2019) [13] in an article on the effect of Eckol,
extracted from edible brown seaweed Ecklonia cava harvested in Jeju, Korea, on the protection of
dermal cells from apoptosis by inhibiting the MAPK signaling pathway. This was further reinforced
by detailed investigations using MAPK inhibitors [13].
Another edible brown seaweed, Cystoseira barbata [5], harvested from the Romanian Black Sea
coastal zone, is used in an experimental work by Trica et al. (2019) [14] for alginate extraction and a
subsequent test to determine the adsorption capacity of Cu2+ and Pb2+ heavy metals [14].
The chemical, structural, and cytotoxic characterization of the invasive brown alga Sargassum
muticum and the red alga Osmundea pinnatifida, collected on the Portuguese coast (Atlantic), was
determined from enzymatic extractions. The team of Rodrigues et al. (2019) [15] determined from
FTIR-ATR and 1H-NMR spectra the presence of important polysaccharide structures in the extracts,
namely, fucoidans from S. muticum or agarans as sulfated polysaccharides from O. pinnatifida. No
cytotoxicity against normal mammalian cells was observed, making these seaweed extracts very
interesting functional ingredients, which could be explored as a food ingredient (salt replacer, nutrient
vector) or nutraceutical supplement [15].
In the experimental work of Hwang et al. (2019) [16], the immune-modulatory effects of
orally administrated crude fucoidan extracted from the edible brown algae Saccharina japonica
(formerly Laminaria japonica) [5], collected in Taiwan, on the innate immune response, adaptive
immune response, and MP antigen-stimulated immune response, was investigated. The hope of the
researchers is that fucoidan, a natural food supplement, can enhance the immune responses needed for
immunopotentiation and attenuate the Mycoplasma pneumoniae (MP) infectious disease [16].
In the work of Hofer et al. [17], seven bromophenols are isolated from a methanolic extract of
the epiphytic red alga Vertebrata lanosa, an edible seaweed [5] collected in Brittany, France. Bioactivity
of seven isolated bromophenols was tested in agar diffusion tests against Staphylococcus aureus and
Escherichia coli bacteria. Three compounds showed a small zone of inhibition against both tested
organisms [17].
As described by Valado and collaborators [18], changes in lipid profile constitute the main risk
factor for cardiovascular diseases. The daily intake of a vegetable jelly (with carrageenan E-407) for
60 days showed a reduction in serum total cholesterol (TC) and low-density lipoprotein cholesterol
(LDL-C) levels in women, allowing them to conclude that carrageenan has bioactive potential in
reducing TC concentrations [18].
In the study by Cotas et al. (2019) [19], Gigartina pistillata (Rhodophyta) carrageenans, from
specimens harvested from the western coast of Portugal, are evaluated against colorectal cancer stem
cell (CSC)-enriched tumor-spheres. Carrageenans extracted from two G. pistillata life cycle phases have
antitumor potential against colorectal cancer stem-like cells, especially the Lambda-family carrageenans
extracted from the tetrasporophyte (T) phase [19].
Cho and Rhee’s review [20] focuses on research on the health benefits of consuming substances
present in high concentrations in the laver, such as porphyran, vitamin B12, and taurine, with an
evaluation of the expected effects of the consumption of these red algae. Mitigation of chemical and
3
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microbiological hazards and the adoption of new technologies to preserve and exploit the biochemical
characteristics present in the Porphyra/Pyropia are reviewed as key strategies to further improve the
quality of products based on these species (Laver/Nori).
Funding: This work was supported by Foundation for Science and Technology (FCT) through the strategic projects
granted to MARE—Marine and Environmental Sciences Centre UID/MAR/04292/2019.
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Abstract: The aim of this paper is to review the multiplicity of the current uses of marine macroalgae.
Seaweeds are already used in many products and for different purposes, from food products to medicine.
They are a natural resource that can provide a number of compounds with beneficial bioactivities
like antioxidant, anti-inflammatory, anti-aging effects, among others. Despite studies directed in
prospecting for their properties and the commodities already marketed, they could, surely, be even
more researched and sustainably explored.
Keywords: macroalgae/seaweed; natural resources; health; food; feed; agriculture
1. Marine Macroalgae Diversity and Ecology
The marine environment is home for many diverse organisms such as algae, molluscs, sponges,
corals, tunicates. Currently, oceans are already considered the “lungs of the Earth” due to Cyanobacteria
and other algae that live in seawater. In fact, these beings provide up to 80% of the atmospheric oxygen,
which we rely on to breathe. Cyanobacteria are blue colored, aquatic, photosynthetic, and because
they are bacteria, they usually are unicellular, but they often grow in colonies large enough to be seen.
Cyanobacteria are prokaryotic organisms while algae are eukaryotic organisms. Algae are almost
ubiquitous, between microscopic and macroscopic species, they can be found in every wet environment
in land, in fresh water or in oceans [1].
In this review, the focus is the marine macroalgae or seaweeds, which are multicellular, macroscopic,
eukaryotic, and autotrophic organisms. They are taxonomically organized in three large and distinct groups,
based on the color of the thallus: Chlorophyta (green algae), Rhodophyta (red algae), and Ochrophyta—
Phaeophyceae (brown algae). All of them accumulate starch in the interior of their cells as energy
store, and other different polysaccharides of large molecular chain. The green algae produce ulvan and
contain carotene and xanthophylls and chlorophylls a and b (what sustains the idea that they are the
ancestors of the plants) as pigments. The red algae (most common in hot seas) have chlorophylls a and
d and carotenoids and their staining is due to the presence of phycoerythrin (pigment) in their cells.
In the brown algae are found the pigments fucoxanthin, chlorophylls a and c and carotenoids and,
as reserve substances, oils, and polysaccharides (such as laminarin) [2,3].
Like plants in terrestrial land, seaweeds have similar ecological roles but in aquatic territory. Some
macroalgae species may serve as bioindicators of the quality of water and some can do bioremediation
by bioabsorption and bioaccumulation [4–6].
As other vegetables, seaweeds are primary producers, the base of the marine food chain, sustaining
several benthic animal communities [7]. They also compete for light, nutrients, and space, in addition
to the need of carbon dioxide and water to develop. Inclusively algae and plants produce the same
storage compounds and use similar defence strategies against predators and parasites [2]. They have also
developed effective mechanisms to survive many biotic threats, like bacteria, virus, or fungal infections.
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Because they are sessile organisms, seaweeds have evolved to live in variable, extreme, and hostile abiotic
environmental and stress conditions, like temperature changes, salinity, environmental pollutants, or UV
radiation exposure. That caused these beings to be able to produce a wide range of compounds called
‘secondary metabolites’, like pigments, vitamins, phenolic compounds, sterols, and other bioactive agents.
Besides these, they also produce amino acids and proteins, saturated/unsaturated fatty acids and all kinds
of polysaccharides which are directly implicated in the development, growth, or reproduction conditions
to perform physiological functions. So, based on the production of these molecules, in addition to its
ecological importance, marine macroalgae also have great importance at commercial level. That’s why,
a few years ago, the interest in the cultivation and exploitation of macroalgae in the most varied forms
increased. Seaweeds are already used in many countries for very different purposes, like industrial
phycocolloids extraction or extraction of compounds with antiviral, antibacterial, or antitumor activity [8].
They can also be, directly or indirectly, used for human and animal nutrition (livestock) or farming
(biofertilizers) [9].
Although there is still much to investigate and find out about these living beings, it is known that
several of the substances they synthesize have great potential to be used in areas such as pharmaceutical,
cosmetics and the food industry. As their interest, cultivation and applications increase, their value in
the market rises too. It is estimated that in 2024 this value will exceed twice the achieved in 2017 (see
Figure 1) [10].
 
Figure 1. Value of the seaweed market worldwide in 2017 and 2024 (in billion U.S. dollars) [10].
2. Marine Macroalgae Applications
2.1. Human Food
Asian countries, especially China and Japan, are known for being large seaweed consumers
for many centuries. The first records show that the harvesting of macroalgae, such as Laminaria
spp., Undaria pinnatifida, Sargassum fusiforme (formerly Hizikia fusiforme) (commonly known as kombu,
wakame, and hiziki, respectively), for human consumption was already carried out by people in China,
at least from 500 B.C. [7]. While in Europe it occurred a thousand years later [9].
More than 600 species of edible seaweeds are categorized. Now it is recognized that edibles
seaweeds have great nutritional content as they are a low caloric food, but rich in vitamins, minerals,
and dietary fibers [7,9]. Their nutritive value may vary depending on the geographic location, season
of the year, growth stage, part of the seaweed harvested, etc [11]. Thus, to assure the nutritional value
of seaweeds, they need to be evaluated before being used as supplements.
Seaweeds draw from the sea an incomparable wealth of mineral elements, macro elements,
and trace elements. They are known as an excellent source of vitamins and minerals, especially
potassium and iodine (i.e., Palmaria palmata, Fucus vesiculosus, Laminaria sp.), and potentially good
sources of proteins (i.e., red algae such as Pyropia tenera (formerly Porphyra tenera), Grateloupia filicina),
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long-chain polysaccharides (i.e., P. tenera) and soluble and insoluble dietary fibers (i.e., G. filicina,
Chondrus crispus, Ulva lactuca) [12]. It was found that the ashes of edible seaweeds contained higher
amounts of macrominerals (8.083–17.875 mg/100 g; Na, K, Ca, Mg) and trace elements (5.1–15.2 mg/
100 g; Fe, Zn, Mn, Cu), than those reported for edible land plants. So edible brown and red seaweeds
could be used as a food supplement to reach the recommended daily intake of some essential minerals
and trace elements [13]. For example, the consumption of 10 g of the green alga Ulva lactuca provides
70% of the body’s daily magnesium requirements and over half of its iron requirements [12,13].
Macroalgae can be used like other vegetables, being equally or even more versatile than them.
Sea vegetables, as they are known, could be commercialized and/or eaten in many forms, such as fresh,
dried, in flakes, flour or powder, or incorporated in other food products (added-value products) (see
Table 1).
Table 1. Examples of seaweed-derived food products.
Seaweed species Extract Product(s) Reference(s)
Chlorophyta (green seaweed)




Fresh or dry Sea vegetable [14]
Ulva pertusa Fresh or dry Sea vegetable (known as green nori) [15]
Ulva rigida Fresh or dry
Sea vegetable
Seasoning in ready to eat canned fish
Added to marine salt
[16]





Seasoning in ready to eat canned fish
Added to marine salt
[16,17]
Himanthalia elongata Dry Sea vegetablePasta [18,19]
Himanthalia elongata,
Undaria pinnatifida






Sargassum fusiforme Fresh or dry Sea vegetable [15]
Undaria pinnatifida Fresh or dry Sea vegetablePasta [14,19]
Rhodophyta (Red seaweed)
Chondrus crispus Fresh or dry Sea vegetable [14,16]
Meristotheca papulosa Fresh or dry Sea vegetable [14]













Added to marine salt
[15,16,19,21]
1 The extract/compound used in the product(s) is not specified in the reference.
The entire organism can be eaten freshly harvested or after dried and then re-hydrated and
cooked [7,16]. They are already commercialized under multiple brands, and labeled with “fat-free”,
“gluten-free”, “mineral rich”, “low carbohydrates”, and “low calories” [14,15,18,21]. There are natural
and healthier substitutes of pasta or bacon (i.e., Himanthalia elongata, as spaghetti, and Palmaria palmata,
as sea bacon, both from Seamore food company), the well-known nori sheets (genus Porphyra/Pyropia) to
prepare sushi rolls or crispy thin snacks, and many other recipes such as wraps with Undaria pinnatifida
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(wakame) and H. elongata, or the laverbread, a paste prepared with boiled nori (also recognized as
laver) [15,18] and in desserts like in innovative Spanish nougats with crushed nori algae [21]). Above all
this nutritional value, macroalgae are donors of a number of great ‘side-effects’ acting as nutraceuticals.
A study with Japanese children revealed that seaweeds intake in the diet was significantly negatively
related to systolic blood pressure in girls and with diastolic blood pressure in boys. This study suggests
that seaweeds have beneficial effects on blood pressure [22].
As we can see, macroalgae can be incorporated in food products after processed into flakes,
flour, powder or even in more specific extracts. Their pigments, like carotenoids, are, in fact, one of
the products of interest for the food industry [23]. Traditionally, carotenoids have been used in that
industry due to their properties as natural color enhancers. However, those that are synthetically
obtained are now suspected of being promoters of carcinogenesis and liver and renal toxicity. So, there
is a strong market demand to replace them with natural pigments. Seaweeds are a great source of
many pigments, especially β-carotene which besides its anticancer activity, has been reported that it is
absorbed 10 times more easily by the body than the synthetic one [24].
Pigments are important in this industrial range, but there are some constitutes of algae that are
even more, their hydrocolloids, such as carrageenan, alginic acids, and agar. These are the main
constituents of red and brown algal cell walls and are widely used in several food industries (see
Table 2).
Table 2. Phycocolloids utilized in food industries and its properties.





















Macrocystis sp. Alginate yoghurts, ice creams
Emulsifying, Gelling,
Stabilizer [27]
Carrageenan is a natural phycocolloid and is one of the main additives used by the food industry,
in many dairy products (e.g. yoghurts, flavoured milkshakes, flans, jellies, ice creams, and beers) and
meat products (e.g. hams), as thickening, emulsifier or stabilizing agent [3,25,26]. Extracted from
several families of the order Gigartinales. These polygalactans are sulfated and have a linear structure
formed by galactose residues with alternating α (1–3) and β (1–4) bonds. Regulatory authorities
(FDA) have established a minimum value for the molecular weight of the carrageenan to be used
in food preparations. The commercial carrageenans usually range from 400 to 600 kDa, having the
minimum of 100 kDa. This minimum value was established by the response to reports of highly
degraded carrageenan-induced ulceration of the colon. There are three main varieties of carrageenan,
differing in their sulfation degree. Kappa (κ)-carrageenan has one sulfate group per disaccharide,
Iota (ι)-carrageenan has two sulfates and Lambda (λ)-carrageenan has three sulfates per disaccharide.
The type of carrageenan selected is dependent on the desired finished product characteristics. Iota and
kappa carrageenans are gelling carrageenans, while lambda is a thickening/viscosifier carrageenan [28].
Agar is other phycocolloid, composed of a variable combination of agarose and agaropectin,
depending of the species and seasonal factors. Agarose, which is the primary component of agar,
is a linear polymer of agarobiose, a disaccharide composed of D-galactose and 3,6-anhydro-L-
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galactopyranose. Agaropectin, which occurs usually in minor amounts, is a heterogeneous mixture of
β-1,3-linked D-galactose which contains substituted sulfate and pyruvate moieties. Like carrageenan,
agar has a similar application, so it also has gelling properties, but while carrageenan gels by both
ionic and hydrogen bonds, agar gels only by hydrogen bonds. Extracted from several species of red
algae, mainly the Gelidium sp., Gracilaria sp. and Pterocladiella sp., it is frequently used as thickener
in food products and a vegetarian substitute for gelatine [7,9]. Currently, agar is also being used to
develop a new biomaterial for packaging. Made from agar and other natural raw materials, these new
wrappers are sustainable, biodegradable, and constitute an alternative to plastics [29].
Alginate is also a gelling agent found and extracted from brown seaweed (eg. Ascophyllum sp.,
Laminaria sp., Lessonia sp., Macrocystis sp.). In fact, it is the most abundant marine biopolymer and, next
to cellulose, the most abundant biopolymer in the world. Alginate is a linear acidic polysaccharide
that can be a homopolymer or a heteropolymer of β-d-mannuronate and/or α-l-guluronate [27]. It is
used as a stabilizer in many food products like ice cream, yogurt, cream, and cheese. It is also used
in the food industry as a thickener, emulsifier for sauces, dressings, and jam, and it needs no heat to
gel. It is most commonly used with calcium lactate or calcium chloride in the spherification process,
a technique performed in molecular cooking.
2.2. Livestock and Agriculture
The consumption of macroalgae is not only for humankind, but also for other animal species.
European usage of seaweeds in animal husbandry has come since the time of the Romans. Countries
such as Iceland, France, and Norway usually use them in domestic animal nutrition [30]. In fact,
the first seaweed meal for animal feed was produced in Norway. It was made from brown seaweeds
that were collected, dried, and milled [7].
Besides its direct uses as feed, macroalgae are already introduced in other type of feed as a nutritive
additive, and as a nutraceutical compound. Currently the feeding of the animals is supplemented by
algae to fill the deficiency in mineral pastures in the U.S.A., Australia and New Zealand. Seaweed meal,
used principally as a vitamin and mineral supplement, is produced mainly from the kelps Ascophyllum
nodosum, Fucus spp., Laminaria spp., Macrocystis spp. [30].
Extracts like macroalgae-derived sulfated polysaccharides are added to animal feed. It was proven
that these meals can improve animal intestinal integrity and efficient immune response [31].
On the other hand, feeding seaweeds and macroalgal products has been shown to reduce enteric
methane emission from rumen fermentation, [32] which makes this type of feeding a promising
candidate as a biotic methane mitigation strategy in the largest milk or beef producing [33].
Moreover, seaweed and seaweed-derived products have been widely used in agriculture to
improve crop production systems due to the existence of a number of plant growth-stimulating
compounds [34–36]. Inclusively, since ancient times, they were traditionally used to fertilize the fields,
they have long been used to augment plant productivity and food production in various regions of the
world [30].
Seaweeds and their compounds can promote early seed germination, root and plant growth,
confer tolerance to freezing, resistance to biotic stresses, and increase the plant nutrient absorption
capacity [37,38]. For example, auxins, a plant hormone responsible for the vegetative growth, and auxin-
like compounds were detected in some seaweeds [39].
However, the biostimulator potential of many of these compounds has not been fully exploited
due to the lack of scientific data on growth factors present in seaweeds and their mode of action in
affecting plant growth [36]. The effects are complex and dependent on the crop, the local environmental
conditions and on the interactions of the algae species with the soil community [30]. Seaweeds’ extracts,
like laminarin, have been shown to stimulate natural defence responses in plants and are involved in
the induction of genes encoding various pathogenesis-related proteins with antimicrobial properties.
Also, it has been demonstrated that alginate oligomers show growth-promoting effects on certain
higher plant species [35].
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Studies suggest that adding strongly polar degraded fucoidan, alginate, etc., to soils improves
crumb structure and aeration, thus stimulating microorganisms and root systems which improves
plant growth [40].
The current commercial extracts are manufactured mainly from the brown seaweeds Ascophyllum
nodosum, Laminaria spp., Saccorhiza spp., Ecklonia maxima, Fucus spp., Sargassum spp., and Durvillaea
spp., although other species such as Ulva intestinalis, Ulva lactuca, Codium sp. (Chlorophyta), Gelidium
sp., and Chondrus crispus (Rhodophyta) are also used [30].
2.3. Cosmetics
The definition of cosmetic product, according to the European Commission, is: “Any substance
or mixture intended to be placed in contact with the external parts of the human body (epidermis,
hair system, nails, lips, and external genital organs) or with the teeth and the mucous membranes of
the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their
appearance, protecting them, keeping them in good condition, or correcting body odours” [41].
More recently, there is another category—the ‘cosmeceuticals’—which is attracting the industry’s
attention and is of interest to the most attentive consumers. Despite still being without legal meaning
nowadays, the industry continues to use this designation referring to a product that lies between the
benefits of cosmetics and pharmaceuticals [42,43].
There is a growing demand for more natural cosmetics, those made with natural/organic
ingredients, due to the benefits they offer, and the absence of many harmful chemicals which are
present in conventional cosmetics products. Consequently, the cosmetic industry is rapidly expanding
to meet these increased demands. Some of the key active-based natural ingredients used in cosmetics
are extracted from marine organisms, like seaweeds (see Table 3).
Marine macroalgae are one of the most abundant sources of vitamins, minerals, amino acids,
antioxidants, and essential fatty acids. Seaweeds are unique in containing bioavailable ingredients,
meaning that its active, nutrient-rich compounds are more readily absorbed by the skin and the body.
Because of its bioavailable nature, seaweeds provide a multitude of benefits including reducing the
appearance of redness and blemishes, brightening, hydrating, re-mineralizing, reducing the appearance
of sun damage, and firming skin [44–46].
Algae can be incorporated into these products as algal extracts of selected elements or, alternatively,
pieces of dried seaweeds can be crushed and ground and incorporated into skin care products such as
exfoliating lotions, face masks, face washes and soaps. Cosmetic products, such as creams and lotions,
sometimes show on their labels that the contents include “marine extract”, “extract of alga”, “seaweed
extract”, or similar [7,44]. Usually this means that one of the hydrocolloids extracted from seaweeds
was added to the product. Alginate or carrageenan are water-binding agents, which means they help
hold water onto the skin and hair, increasing the moisture balance [47]. Both can be found in multiple
products like lotions, creams, shampoos, conditioners, and toothpastes [48].
Seaweeds can be used in two ways in cosmetics: they can either be a vehicle, serving as a stabilizing,
emulsifying, or other type of agent necessary for product preparation; or as the active therapeutic ingredient
in the product, for example in anti-aging skin treatments or after-sun skin care products [13,48,49].
Algae are rich in saturated and unsaturated fatty acids that are bioactive compounds. For example,
palmitic acid and other fatty acids, that are present in large quantities in marine seaweeds, are used
in cosmetics as emulsifiers, and its derivated ascorbyl palmitate is an antioxidant that is effective for
anti-aging and anti-wrinkle effects [48,50].
Purified phlorotannins extracted from brown seaweeds are included in cosmetics, since these
molecules have the role of preventing and slowing down the skin aging process, which is mainly
associated with free radical damage and with the reduction of hyaluronic acid concentration [51].
Wang et al. [52] compared the moisture-absorption and retention properties of polysaccharides
extracts from five different seaweed species [52]. Marine algae are reported to produce different
polysaccharides, including alginates, ulvans, laminarans, and fucoidans [53]. These molecules usually
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contain large proportions of L-fucose and sulfate, together with minor amounts of other sugars such
as xylose, galactose, mannose, and glucuronic acid [45]. In their study, Wang et al. [52] reported that
the polysaccharides extracted from brown seaweed (more precisely the fucoidan obtained from the
Saccharina japonica) exhibited the best moisture-absorption and retention capacity, while the green ones
were the worst. This ability of polysaccharides is influenced by its sulfated content, molecular weight
(length of chain), and by the type of algae that they are extracted from [52]. An example of it is a
cosmetic, CODIAVELANE®, composed of propylene glycol, water, and Codium tomentosum extract.
It is proven that it normalizes and balances skin’s moisture content by adding oligo-elements and
increasing surface hydration [49].
A group of small water-soluble compounds, mycosporine-like amino acids (MAA), found in marine
algae, is biologically relevant because of its photo-protective potential. In addition, its antioxidant and
skin protective strategies raise the interest for possible pharmaceutical and cosmetic applications [54,55].
An extract of Asparagopsis armata (ASPAR’AGE™) containing this MAA molecules is already incorporated
in some lotions with anti-aging properties [56].
Besides the numerous existing and marketed cosmetics and cosmeceuticals, there are many other
seaweed extracts that are under investigation. Kamei et al. [57] discovered a compound from Sargassum
macrocarpum, Sargafuran, that was bactericidal and completely killed Propionibacterium acnes by
lysing bacterial cells [57]. The results suggest that this substance could be applied in new skin care
cosmetics to prevent or improve acne.
Table 3. Cosmetical products containing seaweed parts or extracts.
Seaweed species. Extract Product(s) Properties Reference(s)
Chlorophyta (green seaweed)
Caulerpa lentillifera
Extract (Rich in unsaturated
fatty acids and vitamin A
and C)





Cladophora glomerata Extract (Rich in unsaturatedfatty acids and polyphenols)
Skin care products
(emulsion, cream, lotion) Moisturizing; anti-aging [48,50]
Codium tomentosum Extract Codiavelane®
Skin care products
(creams, lotions) Anti-aging; moisturizing [49,52,59]
Monostroma sp. Extract (rich in water-solublepolysaccharides) Extract 1
Skin care products (e.g.
slimming and anti-cellulitis
formulations)
Hair and nails care products















aosaine consists of amino





















Ochrophyta, Phaeophyceae (brown seaweed)
Alaria esculenta Extract (rich in fatty acidsand trace elements)
Skin care products
(creams, lotions) Moisturizing; anti-aging [59,64]
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Table 3. Cont.
Seaweed species. Extract Product(s) Properties Reference(s)
Ascophyllum nodosum Extract 1 Skin care product (cream)
Anti-ageing; skin softness
and elasticity restoring [59]
Bifurcaria bifurcata Extract 1




Fucus serratus Extract 1 Oral-care product
Protecting agent (reduces
gingivorrhagia) [58]

























(as Hizikia fusiforme) Extract
1 Skin care products (creams) Whitening/lightening; [58]









Laminaria hyperborea Extracts 1




Laminaria ochroleuca Extract ANTILEUKINE 6™Extracts 1








Extract (w/ hyaluronic acid
and polysaccharides;
sodium and potassium ions;
phlorotannins
(polyphenols))
Skin care product (cream) Antioxidant; anti-aging;anti-blemishes [59]





Pelvetia canaliculata Extracts 1





























(aromatherapy oil; face and

























Extract (rich in minerals,
trace elements and
amino acids)
Skin care product (lotion) Skin softness andelasticity restoring [59]
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Table 3. Cont.












Gracilaria conferta Extract 1 Skin care products (creams) Moisturizing; nourishing [58]
Palmaria palmata Extract 1
Skin care products (Facial









1 Skin care products (creams) Sun protector [58]
Porphyra umbilicalis Extract 1





(as Polysiphonia lanosa) Extract
1 Skin care products (creams) Moisturizing; nourishing [52,65]
1 The extract/compound used in the product(s) is not specified in the reference.
2.4. Pharmaceutics
The overuse of antibiotics can lead to the development of resistant pathogenic bacteria. New antibiotics
that are effective against new and resistant bacterial strains are needed. As previously mentioned,
seaweeds have evolved to survive many environmental stresses and threats. Besides the predators/
herbivores, they have to continuously face high concentrations of infectious and surface-fouling bacteria
that are indigenous to ocean waters [8]. So, the macroalgae have evolved and developed certain
mechanisms of defence like the production of bioactive compounds. Substances such as phlorotannins,
polysaccharides, and peptides allow seaweeds to avoid bacterial invasion [8], and some have been
investigated about other potential pharmacological effects (antiviral, antitumoral, immunogenic
effects). One example is the peptide kahalalide F and its isomer, iso-kahalalide F, extracted from a green
macroalga, Bryopsis pennata, which present cytotoxic effects and were used in anticancer clinical trials.
Despite its great potential, this molecule is under modification tests to improve its water solubility,
stability, and effectiveness [70].
Sometimes the extract used can be obtained from a mix of various algae species, and even of
different seaweed groups. For example, there is a patent of green and/or brown seaweed extract
for the treatment of type 2 diabetes and its complications. This has brown seaweeds such as Fucus
vesiculosus or Ascophylum nodosum and green algae, selected from the group consisting of Cladophora
sp., Monostroma sp., Ulva compressa (as Entoromorpha compressa), Codium sp., among others [71].
According to another study, methanolic extracts of some brown, red and green algae are effective at
inhibiting the growth of pathogenic Gram-positive (Staphylococcus aureus, Micrococcus luteus, Enterococcus
faecalis) and Gram-negative bacteria (Enterobacter aerogenes, Escherichia coli) [72]. The species were
Corallina officinalis (Rhodophyta), Cystoseira barbata, Dictyota dichotoma, Halopteris filicina, Cladostephus
spongiosus (Ochrophyta, Phaeophyceae), and Ulva rigida (Chlorophyta).
The seaweed-derived substances that received most attention from pharmaceutical companies
are the sulfated polysaccharides (negatively charged sugar polymers due to the presence of sulfate
groups). Sulfated polysaccharides are extracted from red algae (carrageenans and agarans), brown
algae (e.g. fucoidans) and green algae (e.g. ulvans). Their value lies on their bioactivities, namely their
antibacterial, antiviral activity, antitumoral, and immunomodulatory potential [8,70,72,73].
On the other hand, other polysaccharides, like alginate, are also used in pharmaceutical
formulations as excipients. Alginate polymers have a wide potential in drug formulation due
to their lack of toxicity and they can be tailor-made to suit the demands of applicants in both the
pharmaceutical and biomedical areas. This brown seaweed—derived group of polymers owns a
few characteristics that makes it useful as a formulation aid, both as a conventional excipient and
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more specifically as a tool in polymeric-controlled drug delivery [8,74], and it is commonly used as
bio-adhesive in pharmaceutical applications [75]. Other application of alginate is in wound healing
dressing due to the excellent swelling properties and biocompatibility [76]. In fact, not only the alginate,
but seaweed extracts—like the Laminaria spp.—are being studied and used for the development of
biodegradable wound care products, since they contain healing accelerator substances: alpha keto
isovalerate, alpha keto glutarate, and alpha keto oxaloacate [77].
It has been demonstrated that alginate has therapeutic effects in mammalian systems such as
anticoagulants and antitumor activities. Also containing alginate, there is some gastrointestinal
formulations and protectors (i.e., Gaviscon), that neutralize the acids, prevents the contact of stomach
contents with the oesophagus (reflux), and relieve symptoms of heartburn and indigestion [78].
Agar, which was initially used as a laxative agent in the preparation of medicines, in western
countries [26], is now used as an ingredient in tablets and capsules, as well as in different types of
emulsions. Like alginate, the main role of agar in the pharmaceutical industry is as an excipient.
The three main types (ι, κ, λ) of carrageenan form thermo-reversible gels in aqueous solutions and
in the presence of cations. Therefore, they are used in pharmaceutical formulations for stabilization
of disperse systems and viscosity modification [75]. In addition to its hydrating properties, it has
also been found in some studies to block the growth of viruses like human papillomavirus, making it
potentially even more protective in sexual lubricants (in which it is already included). Studies in vitro
demonstrated that carrageenan, even when diluted a million-fold, presents activity against a range of
common sexually transmitted HPV types that can cause cervical cancer and genital warts [47]. So, due
to these properties, carrageenans might have a great interest in the composition of sexual lubricant.
Also the polymer galactofuran (extracted from Undaria pinnatifida) was proven as an effective Herpes
virus inhibitor [79].
Among polysaccharides, fucoidans were particularly studied as they showed interesting biological
activities (anti-thrombotic, anti-coagulant, anticancer, anti-proliferative, and anti-inflammatory) [66,80–82].
Other group of small molecules (previously indicated in this article), the MAAs, have skin
protective and wound healing effects. Like the porphyra-334 was able to suppress ROS (reactive
oxygen species) production in human skin fibroblast cells [83]. Pigments isolated from seaweeds
also have bioactivities. Like the fucoxanthin, obtained from Saccharina japonica (as Laminaria japonica),
that has been reported to suppress tyrosinase activity in UVB-irradiated guinea pig and melanogenesis
in UVB-irradiated mice. Oral treatment of fucoxanthin significantly suppressed skin mRNA expression
related to melanogenesis, suggesting that fucoxanthin negatively regulated melanogenesis factor at
transcriptional level [45].
Seaweed phlorotannin extracts from Ascophylum nodosum are reported to have potential in the
treatment of diabetes [84] while those from Ecklonia cava are now marketed for potential health
benefits due to their antioxidant activities [85]. These phlorotannins are phenols structurally different
from those obtained from plants, since these are oligomers and polymers of phloroglucinol (1,3,5-tri-
hhydroxybenzene) and the terrestrial ones are based on gallic acids or flavones [86]. The brown
algal polyphenols were investigated in an SKH-1 hairless mouse skin model with UVB-induced skin
carcinogenesis. This in vivo report demonstrated that both dietary feeding and topical treatment of
brown algal polyphenols has suppressed cyclooxygenase-2 (COX-2) expression and cell proliferation [87].
These results suggest the role of brown algae polyphenols, phlorotannins, as potential cancer
chemo-preventive agents against photo-carcinogenesis and other adverse effects of UVB exposure.
That reveals these compounds may be used as active ingredients in drugs or cosmetic/cosmeceutical
formulations, like in sunscreen or anti-aging creams [87].
Marine brown algae-derived phlorotannins have also been investigated for their human beneficial
aspects that include hypoallergenic, anti-inflammatory, and hyaluronidase inhibitory activities. In vitro
studies with the methanol extracts from marine brown algae Eisenia arborea have shown inhibition of
histamine release from rat basophile leukaemia cells (RBL-2H3) sensitized with anti-dinitrophenyl (DNP)
IgE and stimulated with DNP-BSA [88]. Shibata et al. [89] also studied some length-varied phlorotannins
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obtained from Ecklonia bicyclis (as Eisenia bicyclis) and Ecklonia kurome in their ability to inhibit
hyaluronidase activity in vitro. In fact, they proved that those molecules have a stronger inhibitory
effect on hyaluronidase than the well-known inhibitors catechins and sodium cromoglycate [89].
3. Conclusions
This review intended to demonstrate the versatility and the multiple applications of marine macroalgae.
Many products we consume or use daily contain seaweed extracts in their composition, such as
ham, ice cream, bottled chocolate drinks, and toothpaste or deodorizers, although most people
probably do not even imagine such thing. Nowadays, there is a growing interest in seaweeds due to the
recognition of numerous new bioactive compounds. Antioxidants, antimicrobials, anti-inflammatory,
anti-aging, anticancer, are just some of its amazing properties to use as pharmaceuticals, cosmeceuticals,
nutraceuticals, or even in agriculture or feeding.
There is more and more awareness of sustainable use of natural resources, rather than synthetic
and processed products with eventual harmful side effects to the consumer. All the growing interest in
these potentialities led to the fostering of macroalgae production, as well as to do research on them.
Seaweeds are a resource to maintain and preserve with unique properties.
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Abstract: The growing interest in laver as a food product and as a source of substances beneficial to
health has led to global consumer demand for laver produced in a limited area of northeastern Asia.
Here we review research into the benefits of laver consumption and discuss future perspectives on
the improvement of laver product quality. Variation in nutritional/functional values among product
types (raw and processed (dried, roasted, or seasoned) laver) makes product-specific nutritional
analysis a prerequisite for accurate prediction of health benefits. The effects of drying, roasting, and
seasoning on the contents of both beneficial and harmful substances highlight the importance of
managing laver processing conditions. Most research into health benefits has focused on substances
present at high concentrations in laver (porphyran, Vitamin B12, taurine), with assessment of the
expected effects of laver consumption. Mitigation of chemical/microbiological risks and the adoption
of novel technologies to exploit under-reported biochemical characteristics of lavers are suggested as
key strategies for the further improvement of laver product quality. Comprehensive analysis of the
literature regarding laver as a food product and as a source of biomedical compounds highlights the
possibilities and challenges for application of laver products.
Keywords: raw laver; processed laver product; edible seaweed; nutritional value; functional substance;
health functionality; processing technology; microbial risk; chemical risk; omics-based technology
1. Introduction
Lavers are red seaweed species mainly consumed as processed food products or used as a source
of health-promoting substances. They belong to the genera Porphyra and Pyropia (which contains
many species formerly included in Porphyra) (Phylum: Rhodophyta; Class: Bangiophyceae; Order:
Bangiales; Family: Bangiaceae) [1]. Traditionally, lavers were staple foods in limited regions of Asia,
but increased awareness of their health benefits and the globalization of processed food products
has led to dramatic increases in consumption across the world [2]. The growth of global seaweed
aquaculture as a source of pharmaceuticals and biomaterials (e.g., Alga Technologies, Cyanotech, etc.)
is expected to contribute to the expansion of the laver industry [3,4]. Global laver production has
increased from 517,739 t/US $945.1 billion in 1987 to 841,131 t/US $1285.0 billion in 1997; 1,510,911 t/US
$1403.9 billion in 2007; and 2,563,048 t/US $2319.7 billion in 2017 (Figure 1) [5]. Commercial production
of laver products (e.g., gim snack (seasoned laver), mareun-gim (dried laver), okazu nori (laver for
side dish), yakinori (roasted laver), zicai tang (laver soup), etc.) are concentrated in northeastern Asia,
with South Korea, China, and Japan producing 99.87% of total world production in 2017 (Figure 1) [5].
This reflects the traditional consumption of laver in these countries and also regional environmental
conditions favorable for aquaculture [6].
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Figure 1. Global aquaculture production of the dominant production regions of the laver: (a) production
quantity, (b) production value. Data (production quantity and value of ‘Laver (Nori)’ for Republic
of Korea, ‘Nori nei’ for China, ‘Laver (Nori)’ for Japan) was obtained from FAO’s Fisheries and
Aquaculture statistics (FishStatJ) [5].
Currently, Algaebase [7] lists 188 and 77 species for Porphyra and Pyropia, respectively. As shown
in Table 1, species found mainly in northeastern Asia and suitable for aquaculture have been used as
the target organisms for research studies on the food production (raw and/or processed laver) and/or
substances potentially beneficial to health (e.g., porphyran, taurine, vitamins, etc.). Previous studies on
laver exploitation focused on the main species produced commercially in the Republic of Korea (Pyropia
tenera (Kjellman) Kikuchi et al., 2011, P. yezoensis (Ueda) Hwang and Choi, 2011, P. seriata (Kjellman)
Kikuchi and Miyata, 2011, P. dentata (Kjellman) Kikuchi and Miyata, 2011), China (Pyropia haitanensis
(Chang and Zheng) Kikuchi and Miyata, 2011, P. yezoensis) and Japan (Pyropia tenera, P. yezoensis,
P. pseudolinearis (Ueda) Kikuchi et al., 2011) [8].
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Table 1. Major species of lavers.
Genus Species 1
Porphyra
P. acanthophora, P. columbina, P. dentata, P. dioica, P. fucicola, P. haitanensis,
P. kanakaensis, P. perforata, P. pseudolinearis, P. purpurea, P. sanjuanensis
P. seriata, P. tenera, P. umbilicalis, P. vietnamensis, P. yezoensis
Pyropia 2
P. acanthophora, P. columbina, P. dentata, P. fucicola, P. haitanensis,
P. kanakaensis, P. nitida, P. orbicularis, P. perforata, P. pseudolinearis
P. seriata, P. tenera, P. vietnamensis, P. yezoensis
1 Species used as the target organisms from research studies cited in this review were summarized. 2 This taxonomy
was based on the generic revision of laver (Porphyra and Pyropia) [1].
Laver can be consumed as food, either raw or processed (e.g., dried, roasted, seasoned) or as
a source of substances beneficial to health. In northeastern Asia, laver is consumed mainly as a
side-dish and thus is generally perceived as a foodstuff rather than as a source of health functionality
substances. By contrast, studies of other edible seaweeds (e.g., green or brown algae) focused mainly
on their non-food roles as sources of nutraceuticals, food additives, and biomaterials. Nutritional
values and bioactive components of algal species linked to major health benefits were reported,
highlighting the potential for growth of the laver industry as both an edible seaweed and a source of
useful compounds [4,9–18]. However, although practical studies of the utility of laver as an edible
seaweed reported the distinct characteristics of various product types (i.e., material composition,
effects of manufacturing processes), there is no comprehensive analysis of the literature regarding the
nutritional/functional characteristics of laver and the technological basis for its quality control.
This review evaluates the results of research into the nutritional/functional characteristics of laver
products (consumed as food or for health benefits) and the application of technology to those products,
through the categorization of current issues (Sections 2 and 3) and discussion of future perspectives
(Section 4). To analyze advances over the decade 2009 to 2019, we review literature retrieved from the
following databases: PubMed, EBSCO, Research Information Sharing Service (RISS), National Digital
Science Library (NDSL), SCOPUS, Web of Science, and WIPO IP Portal. The aims of this work are (1)
to comprehensively review recent findings on the utility of edible lavers in both raw and processed
products and (2) to identify priority areas for future research on the exploitation of lavers.
2. Food Products Containing Lavers
Food products may contain either raw or processed lavers. Studies reporting the distinct
nutritional/functional values for each product type are reviewed here, the major factors determining
the expected effects of consumption are identified, and their implications are discussed. Whereas it
should be noted that since overall dietary habit defines total intake of nutritional substances with
potential health functionality, consuming those substances is likely to have no effect on health (if total
intake is already adequate) or even results in negative health consequences (in case of excessive intake).
2.1. Raw Lavers
Published analyses of the nutritional and health benefits of raw laver can be divided into studies
of raw wet laver directly consumed as edible seaweed and studies of raw laver pre-treated for
measurement of dry weight composition. Nutritional values vary widely among product types due to
the high-water content of raw wet laver (Table 2). The water content of raw wet laver was generally
reported as ca. 90% [19] (Table 2). Thus, data on compounds of nutritional and health value available
in raw wet laver can only be estimated by analysis of raw wet laver itself rather than the dehydrated
product used for dry weight-based analysis. However, most previous studies of nutritional values
presented analytical data based on dry weight [20–27], and wet-weight values are rarely reported [19].
Since seasoned raw wet laver is often consumed without dehydration or further processing, data on
nutritional value relative to wet weight are needed to accurately estimate the potential health benefits.
25
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With respect to the nutritional composition of raw laver by dry weight (Table 3), most parameter
values are similar to those obtained from other edible seaweeds (carbohydrate, dietary fiber, protein,
lipid, and ash). Other nutritional components analyzed for raw laver are those generally used for
assessing the health benefits of edible seaweeds, namely minerals, fatty acids, amino acids, sterol,
antioxidants, phenolic compounds, pigments, and vitamins.
2.2. Processed Laver Products
The CODEX regional standard for laver products (CXS 323R-2017) categorizes these according
to the processing methods (i.e., dried, roasted, seasoned) and raw materials (i.e., single or multiple
edible seaweed species) [28]. Dried laver is the most common type and can be divided into primary
dried products (i.e., washed, chopped/cut, molded, dehydrated, and dried after harvesting) and
secondary dried products (made by re-drying primary dried products for long-term storage). Roasted
laver is dried laver roasted without seasoning, while seasoned laver is dried material treated with a
variety of ingredients using several processing methods (e.g., roasting, frying, treating with edible
oil) before or after seasoning. The seasoned category also includes laver seasoned for brewing and
broken and roasted/stir-fried dried laver seasoned for consumption after addition of boiling water.
Maximum water contents of primary dried, secondary dried, roasted, and seasoned laver are set as 14%,
7%, 5%, and 5%, respectively. Nutritional values of processed laver products show the expected range
of composition as described for raw laver in Section 2.1 (Table 3). Moreover, as noted for each product
type, this variation in the nutritional/functional content implies a need for further analysis of nutritional
values of specific product types to accurately estimate the potential for health benefits arising from the
consumption of those products. Composition of processed laver products is standardized according to
the CODEX regional standard (CXS 323R-2017) for products based on Pyropia spp. (and containing
other optional ingredients) [28]. Edible seaweed other than Pyropia spp. is one of the major optional
ingredients and can be intentionally or unintentionally included in processed laver products. Multiple
species of edible seaweeds such as Ulva spp. (green laver), Ecklonia cava Kjellman, 1885, or Capsosiphon
fulvescens (C. Agardh) Setchell and Gardner, 1920, can be combined in a single processed laver product
to improve palatability or to create specific organoleptic characteristics. These optional ingredients
have distinct nutritional and potential for health-promoting features [29]. The nutritional value of the
combined product depends on raw material composition and enhancement of product quality with
respect to potential health functionalities and organoleptic properties [30].
27
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Nutritional values obtained from processed laver products (i.e., dried, roasted, or seasoned) are
broadly similar (Table 3). However, major differences in nutritional values and product quality can
arise as a result of processing method, either by drying of raw laver or subsequent roasting or by
seasoning. The drying process can affect various nutraceutical components including dietary fiber,
phenolic compounds, pigments, and antioxidants [36]. The higher content and bioavailability of
Vitamin B12 (VitB12) in raw, as opposed to dried, laver may imply the conversion of VitB12 in raw laver
to its analogues (which are not bioavailable to mammals) by the air-drying process [37]. Drying of
laver by lyophilization was suggested to prevent loss of bioactive VitB12 [38]. With respect to further
processing, roasting or deep-frying of dried laver results in decreased mineral content (calcium, iron,
magnesium, phosphate, potassium). Deep-frying (160–180 ◦C for 10 sec) decreased mineral content by
a factor of 2–6 compared with roasting (300 W for 2 min) [39]. Simulated domestic cooking of dried,
roasted, and seasoned laver showed consistent trends in (1) decreased water content (9.69%, 3.66%,
and 1.49% for dried, roasted, and seasoned laver, respectively), (2) denaturation of amino acids
(mainly glycine, citrulline, valine, isoleucine, leucine, and gamma-aminobutyric acid), and (3) higher
mineral contents in dried than in roasted or seasoned laver (calcium: dried 4976 mg/g, roasted 2202
mg/g, seasoned 2037 mg/g; potassium: dried 31210 mg/g, roasted 29540 mg/g, seasoned 28800 mg/g;
zinc: dried 45.12 mg/g, roasted 24.33 mg/g, seasoned 18.37 mg/g; copper: dried 6.49 mg/g, roasted
6.11 mg/g, seasoned 4.71 mg/g) [40]. However, lower contents of functional substances in processed
laver products than in dried laver does not always implicate the processing steps as causal factors:
Although VitB12 content was lower in seasoned (51.7 μg/100 g) than in dried laver (133.8 μg/100 g),
the destruction of VitB12 by the roasting process was not detected, and thus, the addition of optional
ingredients (e.g., seasoning) is thought to be the cause of the difference [41]. With respect to other
measures of product quality, roasting may cause color deterioration by its effects on pigments such
as chlorophyll [42]. Since the processing of laver has acted as essential role for the quality control of
products (e.g., drying greatly improves shelf-life of laver to facilitate wider accessibility for individuals
as a food source), the application of optimal processing conditions ensuring both nutritional/functional
values and the product quality is important.
Lavers can be a component of other food products such as seaweed chips, salads,
laverbread, laver cake, onigiri (rice ball), kimbab (seasoned rice roll), and laver soup [10,13,15,16].
However, previous studies of these processed products focused on organoleptic characteristics with
sensory evaluation, rather than on potential for health and/or nutritional benefits.
3. Lavers as Functional Foods: Unique Health Benefits of Laver
Seaweeds have long been regarded as a rich source of health-promoting substances.
However, relevant studies mainly focused on internationally produced and consumed seaweeds,
including brown [43] and green algae [44], and on red algae other than laver [45]. This section reviews
the available information on the health benefits of lavers, with particular reference to active substances
unique to this group of edible seaweeds. Table 4 summarizes the major components of laver linked to
well-known health benefits based on the currently reported research studies investigating the putative
health effects of each component, highlighting the necessity for future research regarding long-term
outcomes of laver consumption on human health.
Since most of the reported health benefits of laver could also be gained by consumption of
other edible seaweeds [11], this section focuses on studies that report unique health functionalities of
laver derived from components not found in other edible seaweeds, namely, porphyran, VitB12 and
taurine [9,10].
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Porphyran is the distinctive dietary fiber found in laver, and its health effects were intensively
studied to determine the nutritional/functional quality of lavers [83]. Important bioactivities that
can be attributed to porphyran include anti-cancer, antioxidant, and anti-inflammatory effects and/or
immunomodulation and prevention of diseases such as cardiovascular, nervous, bone, and diabetic
disorders [9,10]. Those bioactivities have been demonstrated by the examination of porphyran
extracted from laver species as reported in following research studies. The anti-cancer effect of
porphyran was demonstrated by using human cell lines including the hepatic carcinoma (Hep3B),
cervical cancer (HeLa), and human breast carcinoma (MDA-MB-231) cell lines [53]. The anti-cancer
effect of porphyran was also evaluated using human gastric cancer cells through the induction of
apoptosis [46] and the inhibition of cell proliferation [47]. In dietary experiments using rats, prevention
of cardiovascular disease may be achieved by the anti-hyperlipidemic effect revealed by the decrease
in serum cholesterol level [57,84]. The basis of these effects was shown to be reduced secretion of the
essential component of very low-density lipoprotein (VLDL) in blood (i.e., apolipoprotein B100) [58].
Properties of porphyran derivatives were also reported, especially for antioxidant effects assessed by
radical scavenging and reducing power [62,63]. Immunomodulatory effects were shown as immune
responses to myelosuppression by the oral administration of porphyran to rats [68]. Anti-inflammatory
activity was evaluated by inhibition of secretion of inflammatory markers (nitric oxide and tumor
necrosis factor alpha) by macrophages (RAW264.7 cell) [72], and the suppression of activation of
immune cells [73]. Neuroprotective effects may be attributable to oligo-porphyran, with the mechanism
for the protection of neurons shown to be regulatory effects linked to the inhibition of apoptosis in
neuronal cells [77]. Therapeutic effects against bone diseases by suppression of osteoclast formation
induced by the receptor activator of nuclear factor κB ligand were demonstrated using RAW 264.7
cells [78].
The beneficial health effects of the vitamin B complex (e.g., choline, inositol) in laver include
the synthesis of major nutritional factors (i.e., carbohydrate, protein, and lipid), anti-cancer effects,
and enhanced immunomodulation [18,56,85,86]. Lavers produce exceptional quantities of VitB12 and
thus can be used to counter the deficiency of VitB12 (e.g., methylmalonic acidemias) in vegan diets by
the consumption of laver [86–88]. The bioavailability of VitB12 was also confirmed by increases in the
hepatic VitB12 level of rats by the intake of laver [38,89] and by the release of VitB12 from laver after
human consumption simulated through in vitro gastrointestinal digestion experiments [41].
Taurine is a major amino acid in laver and other red algae but rarely present in brown or
green algae [90]. Decreased plasma cholesterol levels in rats after the consumption of taurine
were reported [56,61]. Promotion of neuronal development by taurine in laver extracts was also
experimentally demonstrated by the primary culture of hippocampal neurons [76].
4. Future Perspectives on Technical Advances in Laver Utilization
The main current issue in laver utilization is the elimination of potential risk factors in the process
from farming to the manufacture of laver products. For the future, we need to consider the application
of new technologies for the identification of useful constituents. This section covers the development of
technologies for the control of chemical/microbiological risks and novel techniques that may promote
the consumption of lavers as edible seaweeds, in particular, omics-based research linked to the health
benefits of lavers.
4.1. Management of Current Issues: Control of Potential Risks from Farming to Processing of Lavers
The sequence from cultivation of laver in aquaculture farms to the final drying steps [91] is
common to most processed laver products because roasted and seasoned laver are manufactured using
dried laver as a basic material.
For processed laver food products, effective control of chemical and microbiological risk factors
is the prerequisite for human consumption. Since major risk factors and their extent vary across the
production process, it is important to establish intervention strategies based on a detailed understanding
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of the overall production process. Management strategies effective in the identification and control of
chemical/microbiological risks should also be established for individual product types.
4.1.1. Control of Chemical Risks
The chemical risks can be defined as the consumption of excessive levels of substances that lead
to side-effects and/or the exposure to toxic agents (such as heavy metals) in laver products [92,93].
Major food constituents with side-effects are iodine, fibers, and sodium (in seasoned laver). Iodine has
beneficial effects on thyroid gland functioning, but excessive intake should be avoided to prevent
potential adverse effects such as autoimmune thyroiditis or hypothyroidism [94–98]. Overconsumption
of fibers can lead to vomiting or abdominal pain with diarrhea in people with sensitive stomachs and
may cause dyspepsia even in healthy people due to generation of gases in the digestive system [99].
The much greater sodium content of seasoned (relative to dried) laver shows that salts added during
processing can result in consumption of excessive levels of sodium [32]. Heavy metals (As, Cd,
Cr, Cu, Hg, Ni, Pb, Zn, etc.) were detected in both raw and processed laver products (Table 5). It
should be noted that the contents of heavy metals in laver have been reported as variable according
to a range of factors including the cultivar, species, season, and processing conditions [100,101].
Most previous studies recorded acceptable levels of contaminants according to the hazard quotient
(HQ) of heavy metals in laver products or provisional tolerable weekly intake (PTWI) set by the Food
and Agriculture Organization/World Health Organization (FAO/WHO) [42,102]. Guidance values for
tolerable intake [PTWI, provisional tolerable monthly intake (PTMI), provisional maximum tolerable
daily intake (PMTDI)] for major heavy metals detected from laver were set as follows: Al (PTWI 2.0
mg/kg bw/week), Cd (PTMI 25 μg/kg bw/month), Cu (PMTDI 0.5 mg/kg bw/day), and Hg (PTWI 4.0
μg/kg bw/week) [103]. However, high levels of aluminum in laver (388.6–623.4 mg/kg dry weight)
were reported as indicators of food pollution [104]. In addition, arsenic is the major heavy metal
contaminant in laver [42,102,105,106], and the potential risk of production of toxic metabolites by the
human digestive process was also stressed [107,108].
Table 5. Research studies regarding the chemical risk of laver products.
Category Product Type 1 Target
Results








cadmium (Cd) 0.40–1.21 [100]
2.83–3.54 [101]
chromium (Cr) 0.32–0.86 [100]
copper (Cu) 7.92–16.9 [100]
1.94–6.94 [101]





mercury (Hg) 0.005–0.006 [100]
0.03 [109]
nickel (Ni) 0.69–1.04 [100]
0.74–1.51 [101]
zinc (Zn) 18.0–57.7 [100]
21.1–70.1 [101]
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Table 5. Cont.
Category Product Type 1 Target
Results

















chromium (Cr) 0.46–0.66 [100]
copper (Cu) 5.02–8.64 [100]










nickel (Ni) 0.17–1.49 [100]
zinc (Zn) 27.1–57.7 [100]
DL, RL arsenic (As) 2.1–21.6 [107]
- 5
aluminum (Al) 15.50 6 [110]
arsenic (As) 2.07 6 [110]
cadmium (Cd) 0.109 6 [110]
lead (Pb) 0.063 6 [110]
mercury (Hg) <LOD [110]
1 DL: dried laver; RL: roasted laver. 2 dw: dry weight. 3 LOD: limit of detection. 4 ND: not detected. 5 Specific
product type was not indicated in the cited literature. 6 Average value.
Setting recommended-intake limits to prevent overconsumption of nutritional components
(i.e., iodine, dietary fiber, sodium) that pose potential chemical risks is the primary strategy for risk
management, and specific control methods for these factors are generally not required. By contrast,
since reducing the heavy metal content of laver can lower the risks, intervention technologies for the
elimination of heavy metal contaminants were developed. Cadmium, chromium, and lead can be
removed by immersion of laver in acid solution (citric, hydrochloric, or nitric) of pH 2.5–4.0 for 20
min, and this method could be applied because laver undergoes color changes only in more acidic
conditions (pH 2.0) [111]. Heavy metal contents of processed (roasted or seasoned) laver products
indicate a reduction in the levels of lead, mercury, and cadmium during the cooking process [40].
However, the increase in bioaccessible arsenic after human digestion may be a result of the roasting
process [10,112]. A correlation between the arsenic content of laver and that of seawater in the
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cultivation area was also reported, suggesting environmental management as one of the risk control
strategies [105].
4.1.2. Control of Microbiological Risks
Potential microbiological risks can be identified in the national standards and regulations for
laver products. China, in particular, has strict regulations (GB 2733-2005) specifying maximum
permitted values for aerobic plate counts (APC; 30,000 CFU/g), coliforms (30 MPN/100 g), mold (300
CFU/g), Salmonella spp. (not detected), Vibrio parahaemolyticus (Fujino et al.) Sakazaki et al., 1963 (not
detected), Staphylococcus aureus Rosenbach, 1884 (not detected), and Shigella spp. (not detected) [113].
However, laver is generally contaminated with marine bacteria [114,115], and inappropriate processing
conditions may allow the growth of contaminants not only from the natural habitat but also from
surrounding environments [42,116]. The importance of microbiological quality was stressed by
contamination reports relating to raw and processed laver [117,118] and also to food products based
on laver (e.g., sushi, kimbab) [119,120].
Table 6 summarizes microbiological contamination data for laver categorized as (1) processed
laver products, (2) food products containing laver, and (3) intermediate and end-products from
manufacturing plants. Aerobic plate count is the main indicator of microbiological quality. An APC
value of 6.5 log CFU/g recorded from commercial dried laver products [121,122] indicates a high level
of contamination. Microbiological quality factors represented by viable cell counts and coliforms were
also reported for dried (7.6 log CFU/g and 3.2 MPN/100 g, respectively) and roasted laver (7.5 log
CFU/g and 3.7 MPN/100 g, respectively) as the end-products from manufacturing plants. The close
similarity of these values suggests that the processing of dried into roasted laver has a very limited
antimicrobial effect [123,124]. Microbial populations of commercial products also differ according
to product type (APC: 6.9, 3.4, and 4.9 log CFU/g; coliforms: 2.1, 1.6, and 1.0 log CFU/g, for dried,
roasted, and seasoned laver, respectively) [125]. Aerobic plate count, coliforms, yeast/mold, and
Bacillus cereus Frankland and Frankland, 1887 from processed laver products were also reported
as 4.3–7.2 log CFU/g, 1.9–2.2 log CFU/g, 2.1–4.9 log CFU/g, and 2.3 log CFU/g, respectively [126].
Microbiological quality factors (APC, coliforms) were used to identify laver as the main source of
microbial contaminants in ready-to-eat foods (e.g., kimbab) containing this edible seaweed: dried
laver APC: 8.8 log CFU/g [127–129]; dried and roasted laver APC: 6.0–7.0 log CFU/g; and coliforms:
2.0–3.0 log CFU/g [130]. Bacillus cereus (detection rate: 12%) and Clostridium perfringens (Veillon and
Zuber) Hauduroy et al. 1937 (detection rate: 3%) were also reported in dried laver [131]. In the case
of intermediate and end-products from the manufacture of processed laver products, changes in the
microbial level for each step indicate critical control points for the management of microbiological risks.
Intermediate products from the manufacture of dried laver (i.e., after primary scrubbing in salt water,
primary debris elimination, secondary scrubbing in salt water, secondary debris elimination, chopping
and scrubbing in fresh water, molding, drying, and packaging) from seven companies showed an
increase in total viable cell count (TVC) during the drying step (final products TVC: 5.6–8.0 log CFU/g;
coliforms: 54–27,600 MPN/100 g) compared with the first manufacturing step (primary scrubbing in
salt water TVC: 1.5–2.8 log CFU/g; coliforms: 18–75 MPN/100 g). This indicates the drying step as
a critical control point for the microbiological quality of dried laver [42]. Samples collected from six
companies producing seasoned laver showed high levels of microorganisms in the dried laver raw
material (APC: 4.4–7.8 log CFU/g; coliforms: 54–27,600 MPN/100 g). Changes in microbial counts
during the manufacturing process (i.e., primary roasting, seasoning, secondary roasting, counting,
and packaging) highlighted second roasting as the key intervention step for microbial control [116].
Sequential changes in APC at each stage in the manufacture of seasoned laver (i.e., primary roasting,
secondary roasting, counting, and packaging) also indicate secondary roasting as the most effective
decontamination process [132,133].
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Standard 4.48 log CFU/g [113]
DL 6.5 log CFU/g [121]
DL 7.6 log CFU/g [123]
RL 7.5 log CFU/g
DL 6.9 log CFU/g
[125]RL 3.4 log CFU/g
SL 4.9 log CFU/g
DL 5.6–7.2 log CFU/g
[126]RL 3.6 log CFU/g
SL 4.3–6.0 log CFU/g
Coliforms
Standard 30 MPN 3/100 g [113]
DL 3.2 MPN/ 100 g [123]
RL 3.7 MPN/ 100 g
DL 2.1 log CFU/g
[125]RL 1.6 log CFU/g
SL 1.0 log CFU/g
DL 1.9–2.2 log CFU/g [126]
Yeast/mold
Standard 2.48 log CFU/g [113]
DL 4.3–4.9 log CFU/g
[126]RL 2.1 log CFU/g
SL 2.1–4.7 log CFU/g





Standard 4.48 log CFU/g [113]
DL 8.8 log CFU/g [127]
DL ca. 7.0 log CFU/g [130]
RL ca. 6.0 log CFU/g
DL 5.3 log CFU/g [131]
Coliforms
Standard 30 MPN/100 g [113]
DL ca. 3.0 log CFU/g [130]
RL ca. 2.0 log CFU/g
DL detection rate 6% [131]
B. cereus DL detection rate 12% [131]
Clostridium
perfringens DL detection rate 3% [131]
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Standard 4.48 log CFU/g [113]
DL 5.6–8.0 log CFU/g [42]
DL 4.4–7.8 log CFU/g [116]
SL 1.3–5.9 log CFU/g
DL 4.7–4.8 log CFU/g [132]
SL ND 4–1.0 log CFU/g
DL 3.4–3.6 log CFU/g [133]
SL 1.4–2.8 log CFU/g
Coliforms
Standard 30 MPN/100 g [113]
DL 54–27,600 MPN/100 g [42]
1 DL: dried laver; RL: roasted laver; Standard: permitted values standardized by China which has strict regulations
(GB 2733-2005) were indicated as reference data [113]. 2 This table is adapted and modified from [91].3 MPN: Most
probable number.4 ND: Not detectable.
Antimicrobial treatments to mitigate potential risks were applied to a range of product types
from raw materials to processed foods (Table 7). Little research was conducted into decontamination
of harvested raw laver because subsequent manufacturing steps (washing, drying, roasting) have
generally been considered effective for the control of microbial contaminants. Park et al. [134] reported
that exposing Bacillus cereus and Escherichia coli (Migula) Castellani and Chalmers, 1919 in raw laver
to 200 ppm NaOCl with 60 min of ultrasound could achieve reductions of 2.6 and 3.2 log CFU/g,
respectively. Decontamination methods can be applied to both processed laver products and to other
processed foods containing lavers. Gamma irradiation (3 kGy for 24 h) used as an antibacterial treatment
for kimbab [120,127,130] and dried laver [127] produced a reduction of up to 2 log in mesophilic bacteria
(initial population: 6.0–8.8 log CFU/g), and an inactivation of foodborne pathogens to levels undetectable
by plate-count methods (e.g., Salmonella typhimurium, Staphylococcus aureus, and Listeria monocytogenes
(E. Murray et al.) Pirie, 1940; initial population: 6–7 log CFU/g). Corona discharge plasma jet and
low-pressure air plasma achieved a 1.5 log reduction in mesophilic bacteria on dried laver without
post-treatment color changes [135]. An electron beam (e-beam) can be used as a more energy-efficient
alternative to gamma irradiation. A 4 kGy treatment achieved a 1.4 log CFU/g reduction of APC from
dried laver [136]. Using heat-assisted low dose e-beam irradiation, coliforms could be eliminated from
dried laver (> 1.5 log reduction) by 1–4 kGy without any changes in color or pigment contents [137,138].
Optimal treatment conditions ensuring product quality (i.e., thermophilic acidophilic bacterial count:
~103 CFU/g; water content: 5%; acceptable palatability score from sensory evaluation) were suggested
by response surface analysis as an irradiation dose of 1.8–3.0 kGy and heating at 154–170 ◦C for
10–18 s [139]. Not only for research studies regarding the development and application of intervention
methods for microorganisms, patents specified for laver processing have been reported including raw
wet laver [140], dried laver [141,142], and roasted laver [143]. However, although decontamination
technologies reported from both academic research cases and patents were shown to reduce microbial
populations to acceptable levels, there is major limitation in burden on the adoption of additional
treatment devices for manufacturers. Since most those techniques are physical treatments generally
applied to final products, further research into chemical/physicochemical treatment technologies
applicable from intermediate products to end-products is required to support the wider application of
microbial risk management strategies by manufacturers.
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4.2. Future Issues: Identifying the Health-Promoting Properties of Laver
Omics-technology is the most advanced research method for detailed understanding of the
biological characteristics of edible seaweeds. This section covers the recent findings from the
omics-technologies applied to laver as a future issue for obtaining useful information linked to the
health functionalities and quality control of laver including the growth characteristics and biochemical
composition. Especially since these research studies have also identified the key determinant factors on
the quality of laver with the perspectives to its potential health-promoting properties, the improvement
on long-term outcomes of laver consumption on human health can be expected, and thus, practical
evaluation should be followed as further studies. The genome, microbiome, transcriptome, proteome,
and metabolome of laver species were all analyzed (Table 8).
The plastid and mitochondrial genomes of red algae were first analyzed in Porphyra purpurea
(Roth) C. Agardh, 1824 [144–146], with subsequent genomic research conducted using next-generation
sequencing technologies [146–154]. Laver is regarded as the model genome for red algae, and detailed
analysis has provided data for phylogenetic, taxonomic, and evolutionary studies [146,147,155].
Genomic data from Porphyra and Pyropia species were generated by whole genome sequencing (WGS)
and comparative genomics (Table 8). WGS of laver has allowed identification of genomic features
associated with nutritional/functional characteristics [147] and/or product quality (e.g., color) [154].
In Porphyra umbilicalis Kützing, 1843, structural characteristics are linked to major nutritional/functional
constituents and are believed to confer resistance to stressful habitat conditions, such as repeated
desiccation and rehydration in the intertidal zone [147]. WGS of Pyropia yezoensis followed by annotation
of major functional genes governing photosynthesis has identified new genes involved in the control of
laver color. Designation of biomarkers based on these gene sequences is expected to provide practical
information to the laver industry, allowing prediction of color and also details of diseases responsible
for color fading [154]. Genomic data reveal the sequences for gene sets associated with the specific
metabolism of laver, and this genome-wide identification can be used to target key functional genes
for further transcriptomic analysis [156]. Comparative genomic analysis is an effective method of
species determination in morphologically simple organisms such as lavers. It was suggested that
destructive sampling and DNA extraction from fragmentary material may be useful in the identification
of type specimens [146]. Phylogenetic analysis can clarify the distinct characteristics of laver compared
with other red algae [153]. Complete mitochondrial genome analysis can also allow recognition of
unidentified algal species by comparison of gene sequences with those of morphologically similar
organisms [148]. Phylogenetic analyses of Pyropia and Porphyra also broaden our understanding of
biodiversity within these genera, with Pyropia haitanensis [150] and P. yezoensis [151] providing examples
of this. Biomarkers for the differentiation of laver cultivated in different regions can be identified from
gene sequences based on the divergence in genomic features [152].
From the perspective of the laver industry, transcriptomic analysis can provide a detailed
understanding of the unique life cycle (linked to laver yields) and stress response (linked to laver
quality) (Table 8). Advances in applied transcriptome analysis include identification of housekeeping
genes involved in internal control processes [157]. With respect to the life cycle, previous studies
focused on characterization of the evolutionary aspects of the distinct stages [158,159], development of
applied technologies including the designation of biomarkers [160], and treatments affecting the
regulation of gene expression linked to reproductive processes [161]. A major focus for genomic
research has been the interpretation and/or comparative analysis of transcriptomic data relating to the
responses of laver species to abiotic stress [162,163], principally environmental conditions such as high
temperature [164–166], repeated desiccation-rehydration [167,168], and hypersalinity [169].
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The microbiota of laver is generally host-specific and changes according to the physiological
state of the alga or according to factors in the surrounding environment [170]. Because the spatial
heterogeneity of microbiota on laver can make accurate characterization of microbial communities
difficult, a database of the determining factors affecting microbiome analysis was established [171].
Changes in the microbiome can be regarded as indicators of environmental conditions in the farming
area [172,173]. Analysis of the microbial community of laver has revealed not only seasonal variation
in the microbiota but also evidence of host-microbiota interactions from the identification of bacteria
affecting the morphogenesis and growth of laver [155]. In the sea water of seedling pools, the emergence
of filament diseases resulted in clear changes in microbial community composition. Healthy seedling
pools showed a dominance of Sediminicola spp. and Roseivirga spp. Seedling pools with diseased laver
showed increased abundance of Vibrio spp. and Polaribacter spp., suggesting they may be suitable
biomarker organisms for monitoring laver disease [174].
Proteomic studies of the impact of stress factors on laver have focused on stress-response
mechanisms and the effects of mutation. Abiotic and biotic stresses associated with the sequential
steps from farming to processing of laver include high temperature [175,176], desiccation [177,178],
and pathogen infection [179]. High temperature is one of the main determining factors of
nutritional/functional quality and yield for laver strains able to tolerate elevated temperature [175,176].
A major topic in proteome research is the coordinated activation of various pathways governing
desiccation tolerance, which is triggered under natural conditions by exposure to low tide [177,178].
Metabolic responses to seaweed pathogens and other aspects of host-pathogen interaction can be
explored by comparative proteomic analysis before and after infection [179,180]. In the case of
mutation, identification of key proteins is the primary step for the production and/or isolation of
stress-tolerant strains of laver. Experimental mutagenesis aims to produce cultivated laver strains
capable of efficient growth with resistance to environmental stress factors and has been induced by
chemical (ethyl methane sulfonate exposure) [181] or physical (gamma irradiation) treatments [182].
Lipidomic studies have mainly focused on lipid biomarkers, which play an important role in
stress-response metabolism, and on the assessment of the nutritional/functional quality of lavers.
Elevated habitat temperature as a result of global warming is regarded as a key stress factor for laver,
and thus, lipidomic changes under high temperature were examined to determine the acclimation
strategies of laver [183,184]. Clear differences in the lipidomic profiles of blade (gametophyte) and
conchocelis (sporophyte) stages have identified the main health-promoting lipids characterizing the life
cycle stages. This provides reference data for the selection of appropriate life cycle stages for practical
uses as food and for functional ingredients and/or biotechnological applications [185].
Since metabolites can determine the nutritional quality of laver and organoleptic characteristics
(such as flavor), metabolomic analysis can contribute to the identification of the major metabolites and
suggest optimal strategies to produce high-quality products. Metabolomic variations reported in raw,
recently harvested laver (changes in glutamine, alanine, aspartate, taurine, and isofloridoside) [186]
and in processed laver products during manufacturing (changes in dominant metabolites including
amino acids, carboxylic acids, choline metabolites, and sugars) [187] highlight the importance
of metabolomic data with respect to the effects of these determinant factors on product quality.
Moreover, since metabolite profiles of major edible seaweeds show distinct, species-specific
characteristics, metabolomic data specific to laver are also required [188].
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5. Conclusions
The comprehensive information regarding advances in research reporting health functionality
and quality control of laver analyzed in this study demonstrates the need for consistent research
studies specializing on laver. Major findings from the analysis of literatures are as follows:
(1) nutritional/functional values can be variable according to the type of laver product (raw laver
and processed laver products), (2) potential health functionalities linked to the unique substances
in laver have been demonstrated by in vitro and in vivo research whereas long-term outcomes
of laver consumption on human health should be further examined, (3) intervention methods
for chemical/microbial risks should be improved for wider application to manufacturers’ use,
(4) omics-technologies have revealed the clues for understanding biological nature linked to product
quality of laver. Although previous research studies reported the nutritional/functional values
of laver products (raw laver, processed laver products) as useful edible seaweeds, most of those
studies highlighted that the accumulation of laver-specific data should be accelerated for the in-depth
understanding of the biological nature of laver. The current and future issues described in this study
regarding the usefulness of laver are expected to contribute to the balanced progress on both the
utilization of lavers as edible seaweeds and the source of the health functionality components.
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Abstract: Bromophenols are a class of compounds occurring in red algae that are thought to play a role
in chemical protection; however, their exact function is still not fully known. In order to investigate
their occurrence, pure standards of seven bromophenols were isolated from a methanolic extract of
the epiphytic red alga Vertebrata lanosa collected in Brittany, France. The structures of all compounds
were determined by nmR and MS. Among the isolated substances, one new natural product, namely,
2-amino-5-(3-(2,3-dibromo-4,5-dihydroxybenzyl)ureido)pentanoic acid was identified. An HPLC
method for the separation of all isolated substances was developed using a Phenomenex C8(2)
Luna column and a mobile phase comprising 0.05% trifluoroacetic acid in water and acetonitrile.
Method validation showed that the applied procedure is selective, linear (R2 ≥ 0.999), precise
(intra-day ≤ 6.28%, inter-day ≤ 5.21%), and accurate (with maximum displacement values of 4.93%
for the high spikes, 4.80% for the medium spikes, and 4.30% for the low spikes). For all standards
limits of detection (LOD) were lower than 0.04 μg/mL and limits of quantification (LOQ) lower
than 0.12 μg/mL. Subsequently, the method was applied to determine the bromophenol content in
Vertebrata lanosa samples from varying sampling sites and collection years showing values between
0.678 and 0.005 mg/g dry weight for different bromophenols with significant variations between
the sampling years. Bioactivity of seven isolated bromophenols was tested in agar diffusion tests
against Staphylococcus aureus and Escherichia coli bacteria. Three compounds showed a small zone of
inhibition against both test organisms at a concentration of 100 μg/mL.
Keywords: marine algae; macro algae; bromophenols; HPLC; quantification; isolation
1. Introduction
Naturally occurring organobromine compounds are very unique in the plant kingdom,
as bromination does not take place in terrestrial plants. Marine organisms are able to biosynthesize
such substances because they have direct access to bromides naturally occurring in seawater but
also by virtue of a rare enzyme called vanadium bromoperoxidase [1]. These brominated molecules
are thought to be responsible for the typical sea-like taste and flavor of seafood [2]. Bromophenols
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as a subtype of this group can mainly be found in red algae; for example, in the genera Odonthalia,
Polysiphonia, Rytiphlaea, Vadalia, and Symphocladia [3]. A broad range of pharmacologically relevant
activities has been reported for this class of substances in vitro and in vivo, ranging from antioxidant,
antimicrobial, antithrombotic, and antidiabetic to anticancer effects in humans [4]. Although some
of these phytochemicals are thought to play a role in the chemical protection of marine organisms,
their functional role is still not fully understood, as most studies on brominated molecules focus on
their bioactivity rather than their ecological relevance [5,6].
Various bromophenols have been isolated and structurally identified from different red algae in
the past, but little information is available on their actual content, their seasonal variation [7], and the
possible influences of their sampling location and other environmental factors. Phillips and Towers
(1980) developed an HPLC diode array detection (HPLC-DAD) method for the determination of different
bromophenols in red algae. However, baseline separation could not be achieved for all of their standards,
and therefore only one bromophenol (lanosol) was determined quantitatively [8,9]. More recently,
HPLC-MS/MS and HPLC with fluorescence detection have been used for the quantification of
bromophenols in other matrices such as seafood or water samples [10,11].
In our study, a fully validated HPLC method with simple and cost-efficient UV detection was
used for the determination and quantification of seven bromophenolic compounds in the red alga
Vertebrata lanosa (L.) T.A.Christensen (formerly Polysiphonia lanosa (L.) Tandy). This species grows as
an obligate epiphyte on the brown alga Ascophyllum nodosum (L.) Le Jolis, which inhabits intertidal
rocky shores of Northern Atlantic coasts [12]. Pure standards were isolated from the methanolic extract
of a sample collected in Brittany (France) by using various chromatographic techniques followed by
structural elucidation of all isolated compounds by nmR spectroscopy and MS. The isolated standards
include one new bromophenolic substance and six that have previously been reported from other
red algae [13–16]. Their content was determined in Vertebrata lanosa from different collection years
and sampling sites. To investigate the hypothesis that bromophenols might protect against microbial
infestations, antimicrobial activity of the seven standards was tested using agar diffusion tests.
2. Results
2.1. Structural Elucidation of Compound 1
Seven bromophenolic compounds (see Figure 1 for structures) could be isolated from V. lanosa;
among them was one new natural product, compound 1.
Compound 1 (Figure 2a) was obtained as a light purple amorphous powder and its purity was
confirmed by HPLC-MS and nmR. The positive ESI-MS spectrum of the substance showed the typical
isotopic pattern for dibrominated molecules at m/z 454/456/458 in the ratio of 1:2:1 [M + H]+ as shown
in Figure 2b. High-resolution ESI-MS data ([M + H]+ = 455.9618) corresponded to the molecular
formula C13H1779Br80BrN3O. The substance showed optical rotation ([α]
20
D = –53.03 (c 0.7, MeOH))
and a UV λmax at 216 and 292 nm.
The 1H nmR spectrum of 1 displayed one aromatic proton at δ 6.84 (s, H-6′), protons of
methylene groups as two doublets at δH 4.28 (1H, J = 16.0 Hz) and 4.23 (16.0 Hz), and multiplets
at δH 3.23, 3.11, 1.89, and 1.60. One proton resonance was also observed at δH 3.57 (t, 6.0 Hz).
The nmR shifts of the protons and the corresponding carbons of the substructure were unambiguously
assigned by 1H-1H COSY, HSQC, and HMBC experiments. The main HMBC and 1H-1H COSY
correlations are shown in Figure 2a. In the HMBC spectrum, correlations from H-6′ to C-2′ and
C-4′ and C-7′, in addition to signals typical for two brominated quaternary carbons (δC < 110 ppm)
and two oxygenated carbons on the aromatic ring (δC < 140 ppm) revealed the substructure of a
(2,3-dibromo-4,5-hydroxybenzyl)amino group. The 1H-1H COSY signals between H-2 and H-3, H-3
and H-4, and H-4 and H-5, in combination with signals of a primary amino group at C-2 (δC 55.88)
and a carboxyl group at C-1 (δC 174.38), which were assigned by their HMBC correlations between
H-3/H-2 and C-1, confirmed the presence of an ornithyl moiety. These two units were connected via a
56
Mar. Drugs 2019, 17, 675
ureido part structure which could be determined by HMBC correlations from H-5 to C-6 and H-7′
to C-6, as well as the characteristic shift value of C-6 (δC 160.95). Collectively, the structure of 1 can
be described as 2-amino-5-(3-(2,3-dibromo-4,5-dihydroxybenzyl)ureido)pentanoic acid; nmR shift
values can be found in Table 1 and original nmR spectra of this compound in the Supplementary
Material (Figures S4–S5). It is a new natural product and we named this new bromophenol Vertebratol.
The nmR data of the known bromophenolic compounds 2 to 7 (see Table S1, Supplementary Materials)
were in good agreement with values from the literature [13–16].
Figure 1. Structures of the isolated standard compounds.
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Figure 2. (a) Key HMBC correlations (H→C) and 1H-1H COSY (bold line) correlations and (b) high
resolution ESI-MS data of compound 1 (Vertebratol).
Table 1. NMR shift values for compound 1 (Vertebratol) in MeOD; the spectra were recorded on a
600 MHz nmR instrument.
Bromophenol m/z = 455.9618 [M +H]+
13C 1H HMBC a
1 174.38, C
2 55.87, CH 3.57, t (6.0) 1, 3, 4
3 29.40, CH2 1.89, m 1, 2, 4, 5
4 27.07, CH2 1.60, m 3, 5







6′ 114.78, CH 6.84, s 2′, 4′, 7′
7′ 46.010, CH2 4.28, d (16.0); 4.23, d (16.0) 1′, 2′, 6
a HMBC correlations are stated from proton(s) to the indicated carbon.
2.2. HPLC Method Development
The HPLC separation of seven bromophenols contained in Vertebrata lanosa in less than 25 min
was possible with the setup shown in Figure 3. The previously described compounds (Figure 1)
were used as standards for method development. During its initial phase, four stationary phases,
namely, Phenomenex Synergi MAX-RP (150 mM × 2.0 mM), Phenomenex Synergi POLAR-RP (150 mM
× 4.6 mM), YMC Triart (150 mM × 3.0 mM)m and Phenomenex Luna C8(2) (150 mM × 2.0 mM,),
all with comparable particle sizes (3–4 μm), were tested with two different mobile phase systems, i.e.,
methanol/water and acetonitrile/water. It was observed that the latter column yielded the overall
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best results together with acetonitrile/water, not only concerning separation of the standards but also
for the analysis of the crude V. lanosa extract to avoid interference with other naturally occurring
substances. The addition of 0.05% trifluoroacetic acid to the mobile phase was advantageous, whereas
using 0.1% phosphoric acid or a 10 mM ammonium acetate buffer decreased the quality of separation.
The optimum temperature was found to be 30 ◦C, and the elution gradient was carefully optimized.
Ideal elution was performed at a flow rate of 0.25 mL/min by starting at a concentration of 2% B and
rapidly increasing it to 20% within only 0.1 min, followed by an increase to 50% B in 15 min and
to 70% B in another 20 min. The acetonitrile content was then raised to 98% B in a further 5 min;
this composition was maintained for an additional 10 min, leading to a total runtime of 55 min.
Of note, changes in the starting conditions in particular (e.g., leaving the concentration at 2% B for
longer than 0.1 min (see Supplementary Figure S1b) or immediately starting the gradient at 20% B
(see Supplementary Figure S1c) had a negative impact on the separation of peaks 2 and 3. During
analysis the DAD was set to 210 nm and the injection volume was adjusted to 5 μL.
Figure 3. (a) HPLC separation of seven bromophenols under optimized conditions and (b) HPLC
separation of a methanolic extract of Vertebrata lanosa (sample 1). The applied analytical conditions
were column: Phenomenex Luna C8(2) (150 mM × 2.0 mM, 3 μm particle size); mobile phase: water
(A) and acetonitrile (B), both containing 0.05% trifluoroacetic acid; gradient: 2% B at 0 min, 20% B
at 0.1 min, 50% B at 15 min, and 70% B at 35 min; injection volume: 5 μL; flow rate: 0.25 mL/min;
column temperature: 30 ◦C; and detection: 210 nm.
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2.3. Method Validation
Following assay development, the method was validated. Selectivity was deduced from consistent
UV spectra within the peaks of interest (by using the peak purity function available in the software) and
no signs of co-eluting compounds, visible by e.g., peak shoulders, were observed. The slightly wider
peak of compound 2 (Methylrhodomelol) in the extract was compared to that of the corresponding
standard, which was found to be highly pure based on HPLC, HPLC-MS, and nmR experiments.
Additionally, the standard of Methylrhodomelol was eluted as a broader peak, indicating that this was
a substance specific effect not caused by impurity. Calibration curves were established for all of the
seven standards. Coefficients of determination were always 0.999 or higher in a concentration range
of 102 to 0.05 μg/mL for compound 1, of 181 to 0.06 μg/mL for compound 2, of 95 to 0.02 μg/mL for
compound 7, and of approximately 50 to 0.02 μg/mL for compounds 3, 4, 5, and 6. LOD values varied
from 0.008 and 0.038 μg/mL and LOQ ranged from 0.024 to 0.116 μg/mL. All summarized calibration
data can be found in Table 2. Assay precision was assured by repeatedly extracting and analyzing
sample 1 (sample Vertebrata lanosa, Brittany, France 2018) under optimized conditions (see Table 2).
Intra-day (relative standard deviation ≤ 6.28 %) and inter-day (relative standard deviation ≤ 5.21%)
variance was shown to be in the acceptable range, especially as algal material always shows a certain
degree of inhomogeneity, which is reflected in the slight variations observed in the samples collected
at the same time and location. Accuracy was determined by spiking a defined amount of grounded,
dried material with three different concentrations of each of the standards (low, medium, and high)
prior to sample preparation. The observed recovery rates showed maximum displacement rates of
4.93% (2, high spike), confirming the validity of this parameter, too.
Table 2. Validation parameters of the HPLC method.








1 y = 83407x + 5.5502 R2 = 1.0000 102–0.05 0.017 0.053
2 y = 98794x + 18.324 R2 = 0.9999 181–0.06 0.038 0.116
3 y = 156713x + 34.799 R2 = 0.9991 47–0.02 0.008 0.024
4 y = 126302x + 44.688 R2 = 0.9990 49–0.02 0.011 0.034
5 y = 164091x + 25.645 R2 = 0.9998 56–0.03 0.014 0.043
6 y = 126669x - 28.684 R2 = 0.9995 49–0.05 0.032 0.097
7 y = 114941x + 42.574 R2 = 0.9996 95–0.02 0.015 0.047
Accuracy and Precision of the Assay












1 89.5 97.3 2.67 1 69.0 71.3 3.29
2 135.1 142.1 4.93 2 49.5 51.3 3.51
3 41.1 41.6 1.23 3 28.1 26.8 4.68
4 48.3 49.5 2.45 4 27.9 27.3 1.96
5 49.8 51.7 3.60 5 29.8 28.5 4.80
6 43.9 45.2 2.85 6 25.3 25.1 1.12
7 87.9 87.7 0.24 7 46.0 45.0 2.15






Displace-ment 4 Day 1 Day 2 Day 3 Inter-day
1 50.7 51.4 1.33 1.83 0.71 1.21 2.33
2 29.1 30.4 4.07 1.26 0.76 1.16 2.35
3 12.5 13.0 3.57 2.15 0.62 1.06 2.93
4 9.7 10.1 4.30 2.59 1.71 3.86 2.93
5 6.9 7.0 0.54 3.83 6.28 2.56 5.21
6 5.8 5.6 3.56 1.23 0.84 2.87 1.74
7 23.6 23.5 0.51 1.23 0.43 2.28 2.11
1 LOD: limit of detection determined with the purified standards. 2 LOQ: limit of quantification determined with
the purified standards. 3 Values in μg/mL. 4 Displacement in percent (sample Vertebrata lanosa, Brittany, 2018).
5 Maximum relative standard deviation based on the peak area given in percent.
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2.4. Quantitative Analysis of Samples
Three V. lanosa samples collected in Brittany, together with one commercial sample and specimens
from Ireland and Norway (Table 3) were used for quantitative analysis. Two of the samples from
Brittany were collected at the same sampling site and season but across two different years. The third
sample originated from a different place but was also collected in June 2019. The compounds were
assigned at 210 nm by matching retention times and UV spectra compared to the standards; additionally,
LC-MS experiments were performed. For quantification, each of the samples was measured at least in
triplicates with maximum relative standard deviations of 5.21% (see Table 4).
Table 3. Origin of analyzed Vertebrata lanosa samples.
Sample Collection Site and Date
1 2018, Roscoff, Brittany, 48.727559
◦ N; 3.987924◦ W, host alga Ascophyllum nodosum, collected and identified by
U. Karsten and S. Heesch, University of Rostock
2 2019, Roscoff, Brittany, 48.727559◦ N; 3.987924◦ W, host alga Ascophyllum nodosum, collected and identified by S. Hofer, University of Innsbruck
3 2019, Saint Pol de Léon, 48.676896
◦ N; 3.966533◦ W, host alga Ascophyllum nodosum, Brittany, collected and identified by S. Hofer,
University of Innsbruck
4 Commercially available; Arctic Algae AS, Bodø, Norway
5 2019, Lettermore, Ireland, 53.298468
◦ N; 9.712704◦ W, host alga Ascophyllum nodosum, collected and identified by R. Bermejo, National University
of Ireland, Galway
6 2019, Bukken, Raunefjorde, Norway, 60.241183
◦ N, 05.20225◦ W, host alga Ascophyllum nodosum, collected and identified byK. Sjøtun,
University of Bergen
Table 4. Determination of bromophenol content in six different Vertebrata lanosa samples.
Content of Bromophenols




















1 0.678 (*) 2.33 0.035 0.55 0.029 4.52
2 0.175 (*) 2.35 0.027 0.64 0.013 4.08
3 0.158 2.93 0.032 0.66 0.008 4.18
4 0.094 2.93 0.015 0.68 T 1 -
5 0.028 (*) 5.21 - - - -
6 0.029 1.74 0.007 2.75 - -
7 0.030 2.11 T 1 - - -




















1 0.045 0.41 0.025 0.67 0.006 2.85
2 0.048 2.66 0.140 0.36 0.105 0.30
3 0.035 0.40 0.313 (*) 0.76 0.259 0.64
4 0.014 1.99 0.339 (*) 0.51 0.059 0.46
5 0.014 1.37 0.006 2.05 0.005 1.24
6 0.011 1.91 0.445 (*) 0.43 0.052 0.29
7 T1 1.76 0.062 (*) 1.08 0.055 0.27
1 T = found in traces 2 Main compounds are shown in bold writing (*) = Highest measured value of the given
compound, when compared to the other samples.
All samples contained compounds 1 to 4. However, compounds 5 to 7 could not be found in
all specimens. For example, the sample collected in Roscoff 2019 (sample 2) did not exhibit a peak
corresponding to 5, and compound 7 could only be detected in traces. The second sample from Brittany
from 2019 (sample 3, collected in Saint Pol de Léon) did not show any signals for compounds 5–7,
and compound 4 was present only in minor amounts. On the other hand, sample 1, collected in the
previous year in Brittany (Roscoff, same sampling site and season as sample 2) as well as samples 4–6
contained all of the seven isolated bromophenols. In addition, in quantitative terms the bromophenol
content varied significantly. This becomes clear when comparing the quantitative results of the three
samples from Brittany. Here, the main bromophenol was always compound 1. However, its content
was approximately 20 times higher in sample 1 (0.678 mg/g) compared to samples 2 (0.035 mg/g) and 3
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(0.029 mg/g). When comparing the results for sample 1 with those of other origins, fluctuations were
found to be even larger, e.g., reaching up to 113 times lower values for compound 1 in sample 6.
The main bromophenol in sample 4 was compound 2, which had a concentration of 0.048 mg/g
dried algal material, while in sample 5 the predominant bromophenol was compound 6 (0.445 mg/g),
and in sample 6 it was compound 3 (0.259 mg/g). The overall highest concentrations of compounds
1 (0.678 mg/g), 2 (0.175 mg/g), and 5 (0.028 mg/g) were found in sample 1 (2018, Roscoff, Brittany).
However, the highest contents of compounds 3 (0.313 mg/g), 4 (0.339 mg/g), 6 (0.445 mg/g), and 7
(0.062 mg/g) were observed in sample 5 (2019, Lettermore, Ireland).
In the course of our investigations 20 additional samples were analyzed with the given method (19
species of macroalgae and one lichen, see Table S2). The results showed that the seven bromophenols
could not be found in any of the other samples.
2.5. Antimicrobial Activity
Compounds 5–7 (all tested at a concentration of 100 μg/mL) showed a small zone of inhibition
in agar diffusion tests, while compounds 1–4 (100 μg/mL) and the controls did not inhibit bacterial
growth. The diameter of the zone of inhibition was 11 mM for compound 5 and 9 mM for compounds
6 and 7 against Staphylococcus aureus ATCC 6538. Escherichia coli ATCC 11229, inhibition was minimal,
with a 7 mM diameter observed for compounds 5–7, and again, there was no inhibition for the other
bromophenols and the controls.
3. Discussion
While halogenated compounds commonly occur in marine organisms, especially in macroalgae,
the role of bromide-containing compounds in red algae is not well understood and data regarding their
occurrence are inconsistent. To better understand their functional role in the plant kingdom but also
the triggers for bromophenol formation, a fully validated HPLC method for the determination and
quantification of seven bromophenolic compounds in the red alga Vertebrata lanosa (L.) T.A.Christensen
was developed which offers the potential to monitor bromophenol concentrations of larger sample sets.
To obtain the standards seven bromophenols occurring in V. lanosa were isolated. Among them
was one new natural product, 2-amino-5-(3-(2,3-dibromo-4,5-dihydroxybenzyl)ureido)pentanoic acid
(Vertebratol). In the past, two related compounds with a 3-(2,3-dibromo-4,5-dihydroxybenzyl)ureido
core structure have already been isolated from two other marine red algae of the family Rhodomelaceae,
namely Rhodomela confervoides (Hudson) P.C.Silva and Symphocladia latiuscula (Harvey) Yamada [17,18];
however, in contrast to those molecules, the new molecule is linked to an ornithyl moiety. Interestingly,
this compound was observed to occur in very high concentrations of up to 0.678 mg/g dried algal
material in some of the V. lanosa samples. The concentrations of all seven bromophenols were
determined in the methanolic extracts of several samples of this alga with our newly developed and
fully validated HPLC method, which enabled their identification and precise quantification in less than
24 min. To further verify that peaks of interest in unknown samples correspond to the known standards,
the method can easily be coupled to MS; however, 0.05% trifluoroacetic acid in the mobile phase
has to be replaced with 0.1% formic acid in order to avoid ion suppression. Excellent determination
coefficients (R2 ≥ 0.999) were achieved with low LOD values of between 0.008 and 0.038 μg/mL
and limits of quantification (LOQ) ranging from 0.024 to 0.116 μg/mL. Thus, the method offers the
potential to provide not only qualitative but also quantitative information about the occurrence of
those bromophenols in algae even if only small amounts of material are available.
It is known that bromophenols are not randomly distributed. They usually only occur in particular
genera and species as their biosynthesis requires certain enzymes and thus the corresponding genetic
information. Consequently, the presence of a specific set of bromophenolic compounds can be used
as a taxonomic marker for the discrimination of different species [19]. In our study, six Vertebrata
lanosa samples were measured, and, interestingly, the determined concentrations of the different
bromophenols showed great differences within the samples. For example, the values for the new
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natural product, substance 1 (Vertebratol), varied by up to 23 times within samples from Brittany
from different years and sampling sites and even by up to 115 times when compared to samples from
other countries. Additionally, the concentrations of the other six bromophenols were not uniform
within the different samples. In qualitative terms, samples from Norway and Ireland showed different
main bromophenols compared to the samples from Brittany. These results are in accordance with the
literature because it has been reported that the content of brominated compounds like Isorhodolaureol
in certain red algae such as Laurencia dendroidea J. Agardh vary extensively from year to year, even if the
collection site is the same, showing that there have to be specific triggers that enhance the formation of
bromophenols in some Rhodomelacean species [19,20]. As the number of samples was limited in the
current work, we cannot deduce any environmental parameters which may determine the occurrence
of bromophenolic compounds in Vertebrata lanosa. Further research will be necessary to identify them
and their functional role in the algae. However, the method presented herein might serve as a useful
tool for the analysis of samples in a larger number, as it is a cost-efficient and fast approach that was
moreover fully validated according to the ICH guidelines.
In the past, bromophenols have been reported to possess radical scavenging activities [13],
even though their antioxidant properties have so far been only determined in vitro [21,22].
These compounds have, moreover, been attributed with deterring herbivores and epiphytes:
Shoeib et al. (2006) have noted that V. lanosa does not seem to be grazed upon much and appears
remarkably free of epiphytes, both of which the authors suggested could be due to the presence
of bromophenolic compounds [7]. However, a recent study on V. lanosa from Norway shows that
microscopic epiphytes are present all year round, while (limited) macroscopic fouling does occur,
especially during late autumn [23]. While some bromophenols have been shown to inhibit competitors
or deter predators, for example in marine invertebrates such as worms [24,25], conclusive studies
demonstrating the deterrence of herbivores and epiphytes in vivo are still lacking for V. lanosa as well
as for other red algae. From published bioactivity data [4], it can be hypothesized that bromophenols
might potentially play a role in defense against microbial infestations. Additionally, in our study
compounds 5 (3-bromo-4-(2,3-dibromo-4,5-dihydroxybenzyl)-5-methoxymethylpyrocatechol),
6 (5-((2,3-dibromo-4,5-dihydroxybenzyloxy)methyl)-3,4-dibromobenzene-1,2-diol), and 7
(2,2’,3,3’-tetrabromo-4,4’,5,5’-tetrahydroxydiphenylmethane) showed weak antimicrobial activity
against E.coli and S. aureus in the micro molar concentration range, which is similar to natural but also
synthetic bromophenols that have been tested in the literature [26,27]. Interestingly, only substances
that possess two 2,3-dibromo-4,5-dihydroxybenzyloxyl moieties were active. Whether this aspect is
really essential for activity will be studied in further investigations.
4. Materials and Methods
4.1. Samples and Reagents
The origin of all V. lanosa samples is given in Table 3. The algal material used to isolate the
standards was morphologically and genetically identified by two of the authors (Ulf Karsten and
Svenja Heesch GenBank accession number LR738856), and voucher specimens were deposited at the
Institute of Pharmacy, Pharmacognosy, at the University of Innsbruck, Austria. The solvents used for
analytical work were of analytical grade, and they were obtained from Merck (Darmstadt, Germany).
HPLC grade water was prepared by a Satorius arium 611 UV water purification system (Göttingen,
Germany).
4.2. Isolation of Bromophenols from Vertebrata Lanosa
The methanol soluble fraction of the methanol extract of sample 1 was used for the isolation of the
seven bromophenols shown in Figure 1. To achieve a targeted isolation, fractions were analyzed by
HPLC-DAD-MS on an Agilent Technologies 1260 Infinity II instrument with an InfinityLab LC/MSD
detector (Waldbronn, Germany) prior to further isolation steps using the optimum HPLC conditions
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(gradient as described in Section 2.2) on the Phenomenex C8(2) Luna column. However, for that purpose
0.05% trifluoroacetic acid had to be replaced with 0.1% formic acid in the mobile phase. A respective
chromatogram of the crude extract is shown in the Supplementary Information in Figure S2. This step
was useful, firstly because the brominated molecules show very characteristic isotopic patterns due to
the relative abundance of the brome isotopes (see Figure 2b), and secondly because all of the isolated
bromophenols exhibit two absorption maxima, one at 210 nm and a weaker one around 280–290 nm.
The structures of all compounds were elucidated based on nmR and MS experiments and a comparison
to literature values (if possible). MS data as well as characteristic nmR shift values can be found in
the Supplementary Information. For the new compound 1 (Vertebratol), the original nmR spectra are
shown there as well, while those of the other compounds can be provided upon request.
Air-dried and powdered Vertebrata lanosa material (600 g) was extracted with methanol at room
temperature to obtain 70 g of crude extract. The methanol soluble part of this extract (40 g) was
fractionated on a silica gel column using gradient elution (EtOAc to methanol to methanol:water 80:20),
resulting in 14 fractions. Fractions 2 and 3 were combined and further fractionated on a Sephadex
LH-20 column in methanol to afford 19 individual fractions. Fractions 10 and 12 were individually
processed using a 4 g silica cartridge and a Reveleris® X2 iES flash chromatography system (both
from Büchi, Flawil, Switzerland). Elution was performed using a gradient of toluol (A) and EtOAc (B):
0–5 min: 2% B, 10 min: 30% B, 29 min: 70% B, 35 min: 100 % B, and 35–45 min: 100% B. The flow rate
was set to 5 mL/min and detection was carried out at 254, 280, and 320 nm.
Flash chromatography of fraction 10 (123 mg) directly resulted in the isolation of compound 4
(9 mg) and the same procedure with fraction 12 led to the isolation of compound 3 (50 mg). Another flash
chromatography fraction (fraction 7) required an additional purification step using a semi-preparative
HPLC with a Synergi 4 u Polar-RP (250 mM × 10 mM, 4 μm; Phenomenex, Torrance, CA, USA) column
and a Dionex UltiMate 3000 HPLC (Thermo, Waltham, MA, USA). Water (A) and methanol (B) were
used as mobile phases with the following gradient: 0 min: 20% B to 96.5% B in 38 min at 45 ◦C. After a
final purification step on a small Sephadex LH-20 column in methanol the isolation of compound 2
(16 mg) could be achieved.
The fractions 16, 17, and 18 of the first Sephadex column were subjected to semi-preparative
HPLC on the same Synergi Polar-RP column using water (A) and acetonitrile (B), both containing 0.1%
formic acid, as the mobile phase. The temperature was set at 30 ◦C and the flow rate to 2 mL/min.
The applied gradient was: 0 min: 30% B, 13 min: 51.5% B, 40 min: 51.5% B, and 45 min: 98% B. This
step resulted in the isolation of compounds 5 (6.6 mg), 6 (9 mg), and 7 (6 mg).
Furthermore, the initial fraction 12 (6.5 g) also showed a main peak with an isotopic pattern typical
for brominated molecules. The fraction was dissolved in water and used for liquid–liquid extraction in
a separatory funnel with EtOAc followed by butanol (BuOH). The BuOH fraction was then used for a
further separation step with flash chromatography, applying a C-18 40 g cartridge from Büchi on the
same flash chromatography system as previously mentioned. The flow rate was set to 12 mL/min and
the following elution gradient (solvent A: water; solvent B: methanol) was applied: 0–5 min: 2% B,
10 min: 30% B, 35 min: 100% B, and 35–45 min: 100% B. The flash sub-fraction 13 (79 mg) was finally
purified by semi-preparative HPLC using the Synergi Polar-RP (250 mM × 10 mM, 4 μm) column with
water (A) and methanol (B). Isocratic elution at 30% B led to the isolation of compound 1 (30 mg).
4.3. Structure Elucidation
NMR experiments were performed on a Bruker Avance II 600 spectrometer (Karlsruhe, Germany)
at 600.19 (1H) and 150.91 MHz (13C). The pure isolated compounds were dissolved in deuterated
methanol from Euriso-Top (Saint Aubin, France). An Agilent InfinityLab LC/MSD System (Santa
Clara, CA, USA) was used to measure the low-resolution mass spectra in positive mode at a capillary
energy of 4000 V and nebulizer gas of 40.0 psi (dry gas), at 10.0 L/min and at a temperature of 300 ◦C;
the recorded scan range was 100–1500 m/z. The high-resolution mass spectra were recorded on a
micrOTOF-Q II mass spectrometer (Bruker-Daltonics, Bremen, Germany). The experiments were
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conducted in the positive as well as negative ESI mode by applying the following parameters: capillary
energy, 4500 V for positive mode and 3500 V for negative mode; nebulizer gas, 6.4 psi; dry gas, 4.0 L/min
at a temperature of 180 ◦C; and recorded scan range of 100–600 m/z.
4.4. Sample Preparation
The dried and finely milled algal material (0.1 g) was extracted five times with 1.5 mL of MeOH
for 20 min each on an ultrasonic bath to achieve an exhaustive extraction of all compounds of
interest. The supernatants were combined after centrifugation (1000× g for 5 min) and the solvent
was evaporated.
The bromophenols were quantified at 210 nm, a wavelength where all the respective compounds
show strong UV absorbance. However, when analyzing the samples, a broad and partially interfering
peak was observed at min 7.6 (see Supplementary Figure S3a). The peak could successfully and
selectively be removed by re-dissolving the crude extract in water and applying it onto a solid phase
extraction cartridge (Phenomenex Strata C18-E, 55 μm, Torrance, CA, USA). The cartridge was then
washed with water to elute the impurities (Supplementary Figure S3b), followed by an elution step with
methanol to recover the enriched analytes as shown in Supplementary Figure S3c. After evaporation,
samples were re-dissolved in 2 mL of methanol.
4.5. Analytical Conditions
All analytical experiments were performed on an Agilent 1100 HPLC (Waldbronn, Germany)
using a Luna C8(2) column (150 mM × 2.0 mM, 3 μm particle size; Phenomenex, Torrance, CA, USA)
as the stationary phase and a mobile phase comprising 0.05% trifluoroacetic acid in water (A) and
acetonitrile (B).
Elution started at 2% B. This proportion was rapidly increased to 20% B in only 0.1 min, followed
by an increase of up to 50% B in the first 15 min and to 70% in another 20 min. In the next 5 min elution
was increased to 98% B and this composition was maintained for additional 10 min. The column was
then re-equilibrated for 10 min prior to the next run. The DAD-wavelengths were adjusted to 210,
280, and 310 nm, whereas flow rate, sample injection volume, and column temperature were set at
0.25 mL/min, 5 μL, and 30 ◦C, respectively.
4.6. Method Validation
The newly developed HPLC method was validated according to ICH guidelines in order to ensure
that it fulfilled regulatory standards. All validation results are summarized in Table 2. To establish
calibration curves and to determine the linear range, a stock solution of all standards (approximately
2 mg, accurately weighed, per compound dissolved in 5.00 mL MeOH) was prepared. This solution
was used for serial dilution in the ratio of 1:1. LOD and LOQ values were calculated according to the
guidelines based on the given standard deviations of the response and the slope of calibration curves
for each compound. The selectivity of the method was estimated by evaluating the photodiode array
data and assessing the peak purity with the respective option in the operating software. Precision
was confirmed by individual preparation of five sample solutions of sample 1 on each of three
consecutive days and analyzing them. Variations in peak areas were calculated for all the relevant
analytes and given for one day (intra-day precision) and for the three-day period (inter-day precision).
Accuracy was assured by spiking sample 1 with three different concentrations of all the standards (high,
medium, and low concentrations). Samples were then prepared as previously described and recovery
rates determined as percentages of the actually present concentrations compared to the theoretically
calculated ones.
4.7. Determination of Antimicrobial Activity
The test bacteria Staphylococcus aureus ATCC 6538 and Escherichia coli ATCC 11229 were grown on
Mueller-Hinton (MH) agar plates. Overnight cultures from a single colony from these plates were
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grown at 37 ◦C in tryptic soy broth. Bacteria were spread separately on fresh MH plates with a swab.
A punch with a diameter of 5 mM was made in each plate and filled with the respective test solution.
Compounds 1–4 were dissolved in 50% methanol and compounds 5–7 dissolved in 50% dimethyl
sulfoxide to a concentration of 1 mg/mL. These solutions were tenfold diluted in distilled water so
that the final concentration of the compounds in the test solution was 100 μg/mL. Inoculated agar
plates were grown at 37 ◦C overnight, and the zone of inhibition was observed. Controls containing
5% methanol and 5% DMSO were done in parallel.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/12/675/s1,
Table S1: nmR shift values for Compounds 2–7, Figure S1: HPLC separation of 7 standards with different gradients,
Figure S2: HPLC-MS analysis of the methanolic Vertebrata lanosa extract. Figure S3: HPLC analysis after sample
enrichment on an SPE cartridge, Figure S4: 1H-NMR and 13C-NMR spectra of the new compound, Figure S5:
HMBC, COSY and HSQC spectra of the new compound.
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Abstract: The present study describes the variation in lipid components from 15 species of
seaweeds belonging to the Chlorophyta, Ochrophyta, and Rhodophyta phyla collected in tropical
(Indonesia) and temperate (Japan) areas. Analyses were performed of multiple components, including
chlorophylls, carotenoids, n-3 and n-6 polyunsaturated fatty acids (PUFAs), and alpha tocopherol
(α-Toc). Chlorophyll (Chl) and carotenoid contents varied among phyla, but not with the sampling
location. Chl a and b were the major chlorophylls in Chlorophyta. Chl a and Chl c were the main
chlorophylls in Ochrophyta, while Chl a was the dominant chlorophylls in Rhodophyta. β-Carotene
and fucoxanthin were detected as major seaweed carotenoids. The former was present in all species
in a variety of ranges, while the latter was mainly found in Ochrophyta and in small quantities in
Rhodophyta, but not in Chlorophyta. The total lipids (TL) content and fatty acids composition were
strongly affected by sampling location. The TL and n-3 PUFAs levels tended to be higher in temperate
seaweeds compared with those in tropical seaweeds. The major n-3 PUFAs in different phyla, namely,
eicosapentaenoic acid (EPA) and stearidonic acid (SDA) in Ochrophyta, α-linolenic acid (ALA) and
SDA in Chlorophyta, and EPA in Rhodophyta, accumulated in temperate seaweeds. Chlorophylls,
their derivatives, and carotenoids are known to have health benefits, such as antioxidant activities,
while n-3 PUFAs are known to be essential nutrients that positively influence human nutrition and
health. Therefore, seaweed lipids could be used as a source of ingredients with health benefits for
functional foods and nutraceuticals.
Keywords: seaweeds; chlorophylls; carotenoids; n-3 PUFAs; EPA
1. Introduction
The consumption of seaweeds has existed for millennia, not only in Japan, Korea, and China,
but also in some Southeastern Asian countries, such as Malaysia, the Philippines, and Indonesia [1].
Recently, global seaweed production has risen considerably with more than 291 exploited species for
food, feed, paper, fertilizer, medicinal, and industrial product uses [2]. This might be because of the
increasing interest in seaweeds as nutraceuticals, functional foods, cosmetics, and pharmaceuticals
because of the presence of characteristic nutrients and bioactives in seaweeds [3].
Seaweeds, promising marine products owing to their sustainability, contain valuable bioactive
compounds that possess potential benefits for human health, such as anti-obesity, anti-diabetes,
anticancer, and cardioprotective activities [4–13]. The most abundant nutrients in seaweeds are
non-starch polysaccharides and minerals. The lipid content of seaweeds is low (1%–5% of the weight
of a dry weight (DW) sample); however, the lipids comprise many kinds of bioactives, such as n-3 and
n-6 polyunsaturated fatty acids (PUFAs), chlorophylls, carotenoids, terpenoids, and sterols [14–18].
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Seaweeds are marine algae that are rich sources of lipid soluble pigments, such as chlorophylls
and carotenoids. These natural pigments from seaweeds show several biological activities. Specifically,
there have been many studies on the nutritional properties of seaweeds’ carotenoids, such as
fucoxanthin (Fx) [19]. Fx is a specific carotenoid found in brown seaweeds and known to help
manage obesity and type 2 diabetes mellitus [20]. Chlorophylls and their various derivatives have
a long-established history of use in traditional medicine and for therapeutic purposes [21]. Antioxidant
and antitumor activities have been reported as general physiological activities of chlorophylls and
their derivatives [21,22]. In addition, chlorophylls from seaweeds exhibit therapeutic effects, such as
anti-degranulation properties in RBL-2H3 cells [23,24], anti-inflammatory activity in RAW 264.7
cells [25,26], and neuroprotective activity in PC12 cells [27]. Because of their valuable health benefits,
these natural pigments have attracted interest in their potential application in functional foods,
cosmetics, and pharmaceuticals [28], while more efforts are needed to clarify the detailed biological
activities of chlorophylls from seaweeds.
In addition to the pigments, seaweed lipids generally contain high levels of PUFAs, such as
α-linolenic acid (18:3n-3, ALA), stearidonic acid (18:4n-3, SDA), and eicosapentaenoic acid (20:5n-3,
EPA) as n-3 PUFAs, and arachidonic acid (20:4n-6, ARA) as an n-6 PUFAs [14,16,18,29]. Many studies,
including substantial epidemiological, case-control, clinical, genetic, and nutrigenetic approaches,
demonstrate a reduction in cardiovascular disease risk from intake of n-3 PUFAs, such as EPA and
docosahexaenoic acid (22:6n-3, DHA), which are the active forms of n-3 PUFAs [16,30]. ARA also
plays an important role in biological systems, such as in the immune response, thrombosis, and brain
function [16]. ARA and DHA are used as supplements in commercial infant formulas because both
PUFAs are essential for infant neurodevelopment. Furthermore, the combination of ARA and DHA
has also been found to improve age-related disorders of the brain and cognitive function [31].
Tropical seaweed species have significantly lower lipid content than cold-water species [16].
Comparative studies have revealed that the total lipids (TL) content of a major brown seaweed family,
Sargassaceae, was higher in subarctic zones (approximately 5% of the DW) than in tropical zones
(0.9%–1.8% of the DW) [14,32–34]. In addition, different seaweed species have different TL contents,
and some species have shown exceptionally high TL contents. For example, Gosch et al. [35] found
higher TL contents in three tropical brown seaweed species (10.80%–11.91% of the DW) and two
tropical green seaweed species (12.14%–13.04% of the DW) collected in tropical North Queensland,
Australia. Higher TL contents have also been reported in brown seaweeds collected in the Indian
Ocean (7%–8% of the DW) [36], as well as the Hawaiian coast (16%–20% of the DW) [37]. Therefore,
seaweed lipids content varies greatly by species, geographical location, season, temperature, salinity,
and light intensity, as well as interactions among these factors [14,34,38–42]. The content of lipid-soluble
bioactive compounds in seaweeds also depends on several factors, such as species, sampling sites,
environment, and seasonal variation [14,34,37–47].
Although many papers have reported variations in the lipid components from different species of
seaweeds collected in various areas, most of them have focused on the fatty acids composition [48–51]
and on specific bioactives, such as Fx [14,34,38]. In finding a potential target in seaweed as an ingredient
for foods, animal feed, cosmetics, and nutraceuticals, information on the wide range of lipid and
related compound profiles, especially on lipid soluble pigments, will be required. Among seaweed
pigments, chlorophylls play a key role in photosynthesis, while carotenoids serve as antenna pigments
by absorbing and passing light energy to chlorophyll. Both pigments are not only essential for
photosynthesis, but also show various health benefits, as described above. However, little information
is available on both lipid soluble pigment levels in seaweeds. The investigation of lipid-soluble
compounds in seaweed grown near the coast of Indonesia and northern coast of Japan is limited [34].
Therefore, the primary aim of this study was to determine chlorophylls and carotenoids in
15 different species of seaweeds belonging to Ochrophyta (brown seaweeds), Chlorophyta (green
seaweeds), and Rhodophyta (red seaweeds). In addition, the present study also revealed the fatty acids
and α-tocopherol (α-Toc) profiles of these different seaweeds. Each sample was collected from tropical
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(Indonesia) or temperate (Japan) waters. The present study will be useful for the comparison between
the characteristics of lipid soluble compounds from seaweeds collected from the two different areas.
2. Results
2.1. Total Lipids
The TL of seaweeds from Indonesia (tropical area) and Japan (temperate area) are described
in Table 1. The TL level varied among species, ranging from 6.91 to 62.48 mg·g−1 DW. On average,
the highest TL content was recorded in Ochrophyta (42.44 mg·g−1 DW), followed by Chlorophyta
(34.60 mg·g−1 DW), and Rhodophyta (17.75 mg·g−1 DW). In the present study, the lowest TL content
was reported in Chondrus yendoi (6.91 mg·g−1 DW), while Ulva australis had the highest total lipids
content among all seaweeds tested.
2.2. Pigments
The primary photosynthetic pigments in seaweed are comprised of chlorophylls and carotenoids.
In this study, we investigated the variation of these pigment contents in different phyla of seaweeds,
which were collected from two regions (Tables 2 and 3). Chlorophylls easily decompose to produce their
derivatives, pheophytins, by elimination of magnesium. This change from chlorophylls to pheophytins
is accelerated by heat treatment. In the dried samples from tropical seaweeds, chlorophyll a (Chl a)
and chlorophyll b (Chl b) levels were very low or undetected, while their corresponding derivatives,
pheophytin a (Phy a) and pheophytin b (Phy b), were major chlorophyll components in these seaweeds.
The lower level of Chl a and Chl b in the tropical seaweeds was derived from the decomposition of
these chlorophylls to corresponding pheophytin derivatives during the drying process.
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Although Chl a was detected in all seaweeds from the temperate area, its level widely ranged from
1.74 (Chondria crassicaulis) to 268.82 (Sargassum horneri) mg·100 g−1 DW. Chlorophyll b, the characteristic
pigment in Chlorophyta, was present in small amounts and ranged from 16.83 (Caulerpa lentillifera) to
101.50 (U. intestinalis) mg·100 g−1 DW. A unique finding was the occurrence of chlorophyll c (Chl c),
the characteristic accessory pigment in Ochrophyta. It was not only found in Ochrophyta, but also in
Rhodophyta (C. crassicaulis and Mazaella japonica). Phy a was abundantly found in seaweeds of the
Laminariaceae family and Rhodomelaceae family, while Phy b was only found in Chlorophyta.
Table 2. Composition of chlorophylls and pheophytins in 15 species of seaweeds (mg·100 g−1 DW) *.
Seaweeds Chl a Phy a Chl b Phy b
Chl c
(c1 + c2) b
Total
Chlorophylls
Caulerpa lentillifera n.d. 118.68 ± 44.41 16.83 ± 4.60 90.28 ± 8.97 n.d. 225.79
Ulva australis 81.90 ± 4.94 26.17 ± 3.27 64.45 ± 9.36 n.d. n.d. 172.52
Ulva intestinalis 115.57 ± 51.28 165.98 ± 14.70 101.50 ± 29.21 64.38 ± 11.30 n.d. 447.43
Ulva reticulata n.d. 115.85 ± 21.17 18.04 ± 0.61 267.69 ± 158.86 n.d. 401.58
Costaria costata 16.28 ± 3.80 291.92 ± 67.84 n.d. n.d. 21.78 ± 0.84 329.97
Undaria pinnatifida 54.67 ± 14.60 423.42 ± 57.72 n.d. n.d. 38.58 ± 5.03 518.67
Saccharina japonica 26.13 ± 16.79 425.42 ± 19.17 n.d. n.d. 17.11 ± 2.91 469.24
Sargassum aquifolium a 12.17 ± 4.02 149.64 ± 56.00 n.d. n.d. 2.12 ± 0.21 163.93
Sargassum fusiforme 210.72 ± 43.63 107.59 ± 30.30 n.d. n.d. 18.20 ± 0.34 336.51
Sargassum horneri 268.82 ± 59.93 220.86 ± 22.84 n.d. n.d. 23.29 ± 4.9 512.97
Gloiopeltis furcata 2.98 ± 1.96 28.21 ± 4.92 n.d. n.d. n.d. 31.19
Chondrus yendoi 4.77 ± 2.10 29.29 ± 2.21 n.d. n.d. n.d. 34.06
Mazzaella japonica 6.70 ± 1.28 16.25 ± 1.85 n.d. n.d. 7.63 ± 1.25 30.58
Gracilariopsis longissima n.d. 14.66 ± 2.24 n.d. n.d. n.d. 14.66
Chondria crassicaulis 1.74 ± 1.19 322.72 ± 56.48 n.d. n.d. 10.18 ± 1.29 334.64
* The data value is expressed as the mean ± SD of three replicate measurements; a non-edible seaweed; b Chl c
composes of Chl c1 and Chl c2. However, both chlorophylls could not be separated on HPLC to be detected as one
peak; therefore, Chl c1 and Chl c2 were expressed as Chl c altogether in the present study. Quantification of Chl c
was done using the calibration curve of c1 standard, because Chl c1 has been reported to be the major chlorophyll
c in brown seaweeds [37]. n.d. = not detected. Abbreviations: Chl a: chlorophyll a; Chl b: chlorophyll b; Chl c:
chlorophyll c; Phy a: pheophytin a; Phy b: pheophytin b.
Carotenoids, accessory pigments in photosynthesis, also varied among seaweed species (Table 3).
Provitamin A carotenoids, α-carotene (α-Car) and β-carotene (β-Car), exhibited different patterns.
β-Car was present in all species with a range from 1.12 to 58.24 mg·100 g−1 DW, while α-Car was
detected only in Chlorophyta and Rhodophyta. Fx was mainly found in Ochrophyta and found in
a small amount in Rhodophyta, but not in Chlorophyta. In addition, Zeaxanthin (Zx) content was
relatively higher in two Sargassum species (S. horneri and S. fusiforme) and Undaria pinnatifida collected
from the temperate area. Lutein (Lut) was found in Rhodophyta and Chlorophyta with a range
from 0.62 mg·100 g−1 DW (M. japonica) to 124.82 mg·100 g−1 DW (U. australis), but was not found
in Ochrophyta. Violaxanthin (Vx) was only found in Ochrophyta and Chlorophyta collected from
Japan with a range from 1.45 mg·100 g−1 DW (Costaria costata) to 23.30 mg·100 g−1 DW (U. australis).
Neoxanthin, only present in Chlorophyta, also showed a wide range in its content from 30.63 mg·100
g−1 DW (U. reticulata) to 185.56 mg·100 g−1 DW (U. australis). Higher total carotenoid levels were found
in Ochrophyta (S. aquifolium, C. costata, S. japonica, U. pinnatifida, S. fusiforme, S. horneri) from the two
different areas. Chlorophyta species collected from the temperate area (U. australis and U. intestinalis)
also showed higher total carotenoid levels, whereas Chlorophyta from the tropical area (C. lentillifera
and U. reticulata) showed relatively low levels. The same trend was also found among Rhodophyta
species collected from the temperate area (C. crassicaulis, C. yendoi, Gloiopeltis furcata, M. japonica) and
those collected from the tropical area (Gracilariopsis longissima).
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2.3. Fatty Acids
The details of fatty acids composition in seaweed lipids are listed in Table 4 and Tables S1a,
S1b and S1c. All values are expressed as percentages of total fatty acids (FAs) content. The absolute
content of total n-3 PUFAs (mg·g−1 DW) is also shown in Table 4. The fatty acids composition varied
widely among seaweed species and sampling locations.
In the three phyla, Ochrophyta, Chlorophyta, and Rhodophyta, palmitic acid (C16:0) was the
predominant fatty acids (Tables S1a, S1b and S1c). The temperate seaweeds contained much more total
PUFAs (28.15% (C. crassicaulis) to 51.28% (S. japonica)) than the tropical seaweeds (13.06% (C. lentillifera)
to 25.75% (U. reticulata)) (Table 4). Specifically, the absolute amounts of total n-3 PUFAs in the temperate
seaweeds were much higher than those in the tropical seaweeds. Total saturated fatty acids (SFAs)
contents in the tropical seaweeds were relatively higher than those in the temperate seaweeds, except
for M. japonica. Furthermore, monounsaturated fatty acids (MUFAs), dominantly comprising C16:1n-7
and C18:1n-9, were higher in temperate Rhodophyta, namely, C. crassicaulis. Overall, in the tropical
seaweeds, SFAs accounted for 29.80% to 47.78%, followed by PUFAs (13.06% to 25.75%) and MUFAs
(6.88% to 18.88%), while PUFAs (36.23% to 51.28%) were the most dominant FA class in the temperate
seaweeds, except for C. crassicaulis (28.15%) and M. japonica (31.21%). Furthermore, Chlorophyta
contained relatively less C20 FAs; however, C20 FAs were the major FAs in Ochrophyta (S. horneri,
S. fusiforme) and in Rhodophyta, especially those collected in the temperate area (Table 4).
Total PUFAs levels varied among species, ranging from 13.06% (C. lentillifera) to 51.28% (S. japonica)
of total fatty acids. These seaweeds contained EPA (C20:5n-3), ARA (C20:4n-6), ALA (C18:3n-3),
and SDA (C18:4n-3) as the major PUFAs; however, there was significant variation in the level of
these PUFAs in the TL content from each species. The main PUFAs in Ochrophyta collected from the
temperate area were ARA (10.55% (U. pinnatifida) to 14.87% (S. horneri)) and EPA (8.36% (C. costata)
to 13.04% (S. japonica)), whereas the main PUFAs in Ochrophyta collected from the tropical area
(S. aquifolium) was ALA (10.40%), and the EPA level of this seaweed was very low (0.96%) (Table S1a).
The same trend was found in Rhodophyta (Table S1c). Rhodophyta collected from the temperate area
contained relatively high levels of EPA (13.08% (C. crassicaulis) to 35.81% (G. furcata)) and of ARA
(3.33% (C. crassicaulis) to 17.26% (C. yendoi)); however, the main PUFAs of Rhodophyta collected in the
tropical area (G. longissima) was ARA (11.41%), and the EPA level was 0.21%. Chlorophyta collected
from the two geographical locations contained ALA as its major PUFAs (Table S1b). Among the 15
seaweeds analyzed, G. furcata exhibited the highest value of total n-3 PUFAs (38.11%) with 35.81% EPA,
whereas U. intestinalis exhibited the highest value of n-3 PUFAs expressed in mg·g−1 DW (9.84 mg·g−1
DW) (Table 4).
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2.4. Nutritional Quality Index
The nutritional quality index based on the fatty acids composition was calculated in this
study (Table 5). The n-6/n-3 ratio was less than 3, except for G. longissima (7.69), and most
of the ratios were less than 1.0. In general, the atherogenicity index (AI) and thrombogenicity
index (TI) values increase with the decreasing degree of unsaturation of FAs, while the fatty acids
hypocholesterolemic/hypercholesterolemic ratio (h/H) increases with the increasing unsaturated fatty
acids composition. Therefore, AI and TI tended to be higher in the tropical seaweeds compared with
those in temperate seaweeds. The h/H ratios of all temperate seaweeds were higher than those of the
tropical seaweeds. In addition, the unsaturation index (UI) in all seaweeds was more than 3, and in
Rhodophyta collected in the temperate area, it was more than 4.
Table 5. Nutritional quality index of different seaweeds judged from fatty acids composition.
Seaweeds n-6/n-3 PUFAs AI TI h/H UI
Caulerpa lentillifera 0.79 ± 0.05 1.53 ± 0.28 0.96 ± 0.13 0.44 ± 0.04 3.00 ± 0.07
Ulva australis 0.25 ± 0.01 0.64 ± 0.01 0.26 ± 0.01 1.04 ± 0.02 3.27 ± 0.01
Ulva intestinalis 0.35 ± 0.05 0.57 ± 0.04 0.23 ± 0.01 1.39 ± 0.13 3.19 ± 0.03
Ulva reticulata 0.11 ± 0.02 1.31 ± 0.05 0.35 ± 0.27 0.33 ± 0.02 3.67 ± 0.01
Costaria costata 1.40 ± 0.18 1.37 ± 0.16 0.54 ± 0.08 1.28 ± 0.12 3.63 ± 0.06
Undaria pinnatifida 0.68 ± 0.13 0.69 ± 0.08 0.28 ± 0.06 1.66 ± 0.23 3.71 ± 0.04
Saccharina japonica 0.65 ± 0.09 0.67 ± 0.04 0.20 ± 0.02 2.23 ± 0.08 3.88 ± 0.04
Sargassum aquifolium a 2.66 ± 0.07 1.42 ± 0.25 1.23 ± 0.20 0.67 ± 0.07 3.40 ± 0.01
Sargassum fusiforme 0.57 ± 0.01 0.62 ± 0.02 0.24 ± 0.01 1.76 ± 0.06 3.93 ± 0.00
Sargassum horneri 0.82 ± 0.05 0.53 ± 0.05 0.26 ± 0.03 1.82 ± 0.16 3.86 ± 0.02
Gloiopeltis furcata 0.19 ± 0.00 0.50 ± 0.05 0.19 ± 0.02 2.46 ± 0.26 4.75 ± 0.01
Chondrus yendoi 0.81 ± 0.03 0.79 ± 0.03 0.41 ± 0.02 1.48 ± 0.05 4.46 ± 0.01
Mazzaella japonica 0.56 ± 0.01 1.14 ± 0.03 0.58 ± 0.03 0.97 ± 0.03 4.49 ± 0.00
Gracilariopsis longissima 7.69 ± 1.58 2.03 ± 0.24 2.80 ± 0.25 0.44 ± 0.03 3.87 ± 0.02
Chondria crassicaulis 0.42 ± 0.03 1.19 ± 0.09 0.47 ± 0.03 0.86 ± 0.05 4.13 ± 0.03
a Non-edible seaweeds. Abbreviations: AI: atherogenicity index; TI: thrombogenicity index; h/H: fatty acids
hypocholesterolemic/hypercholesterolemic ratio; UI: unsaturation index.
2.5. Alpha Tocopherol
α-Toc content varied with seaweed species (Table 6). Relatively lower α-Toc levels were found in
Chlorophyta (C. lentillifera, U. reticulata, U. australis, U. intestinalis). Seaweeds belonging to Ochrophyta
and Rhodophyta showed relatively higher levels of α-Toc, except for C. crassicaulis. Specifically,
C. yendoi showed the highest α-Toc content (9.34 mg·100 g−1), followed by two species of Sargassum
(S. fusiforme and S. horneri).
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Table 6. α-Tocopherols content (mg·100g−1 DW) *.
Seaweeds α-Toc
Caulerpa lentillifera 0.87 ± 0.21
Ulva australis 0.44 ± 0.01
Ulva intestinalis 0.83 ± 0.06
Ulva reticulata 1.13 ± 0.08
Costaria costata 1.37 ± 0.10
Undaria pinnatifida 1.09 ± 0.05
Saccharina japonica 1.82 ± 0.02
Sargassum aquifolium a 2.40 ± 0.02
Sargassum fusiforme 3.56 ± 0.08
Sargassum horneri 3.65 ± 0.031
Gloiopeltis furcata 2.71 ± 0.34
Chondrus yendoi 9.34 ± 0.19
Mazzaella japonica 1.72 ± 0.009
Gracilariopsis longissima 2.58 ± 0.015
Chondria crassicaulis 0.54 ± 0.009
* The data value is expressed as the mean ± SD of three replicate measurements, a non-edible seaweeds.
2.6. Multivariate Analysis
A statistical analysis was performed using the 15 fatty acids composition measured in this study in
order to establish the relationship between geographical location and phylum. The fifteen FA variables
explained the variability presented in the data, with principle component 1 (PC-1) accounting for
33.1% and principle component 2 (PC-2) for 22.5% of the variation (Figure 1a). Although the total
percentage was only 55.6%, the analysis revealed a correlation of each seaweed within the phyla.
Axis I separated the Rhodophyta species from the Chlorophyta, while Ochrophyta was positioned
intermediately between these two, based on the principle component analysis (PCA) shown in the
bi-plot data. However, these results could not determine whether the geographical location affected
the fatty acids composition. Therefore, the PCA on the FA groups was analyzed. The bi-plot of the FA
groups’ data matrix showed 81.5% of variance with PC-1 contributing 51.9% and PC-2 contributing
22.5% (Figure 1b). These data exhibited a broad diversity of fatty acids in the seaweed samples.
The analysis revealed that the tropical seaweeds were rich in SFAs, while temperate seaweeds were
dominated by PUFAs, including n-3 and n-6 PUFAs, excluding C. costata, M. japonica, and C. crassicaulis.
When PCA was used for clustering of the fatty acids group, the seaweeds could be grouped within the
sampling location.
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Figure 1. Bi-plot of the seaweeds’ sample received from PCA analysis of (a) fatty acids (FAs) data
composition (15 fatty acids), (b) FAs group (SFAs, MUFAs, PUFAs, n-3 PUFAs, and n-6 PUFAs).
Abbreviations: Cl: Caulerpa lentillifera; Ua: Ulva australis; Ui: Ulva intestinalis; Ur: Ulva reticulata; Cc:
Costaria costata; Up: Undaria pinnatifida; Sj: Saccharina japonica; Sa: Sargassum aquifolium; Sf: Sargassum
fusiforme; Sh: Sargassum horneri, Cr: Chondria crassicaulis; Cy: Chondrus yendoi; Gf: Gloiopeltis furcata;
Gl: Gracilariopsis longissima; Mj: Mazzaella japonica. The seaweeds species codes are colored based on
the seaweeds’ phyla (green: Chlorophyta; brown: Ochrophyta; red: Rhodophyta). The fatty acids
composition and FAs group variable are colored in black. The circles were drawn based on geographical
sampling location (orange circle: tropical seaweeds; blue circle: temperate seaweeds).
3. Discussion
Seaweeds have been an integral part of Japanese cuisine for the past one hundred years, similar
to the diet of coastal communities in several Indonesian regions [52,53]. Industries use seaweeds
as marine hydrocolloids and ingredients for foods and animal feed. Utilization of seaweeds as
a dietary staple is because of their characteristic nutrients, which are shown to have therapeutic
effects in humans [28,54–57]. Seaweeds are a source of novel bioactive compounds, such as certain
polysaccharides and antioxidants, which are not found in terrestrial plants. The consumption of
seaweeds has been linked to a lower incidence of chronic diseases, such as cancer, hyperlipidemia,
and coronary heart disease [58]. Recently, seaweed lipids have drawn increased interest because of
the presence of many kinds of bioactives, such as n-3 and n-6 PUFAs, carotenoids, and sterols [16].
Although seaweeds have a lower lipid content than marine fish, they are still a potential source of
functional lipids because of their large stock in coastal waters.
Among bioactive seaweed lipids, much attention has been paid to the lipid soluble pigments,
such as chlorophylls and carotenoids [28]. In addition, seaweed lipids are known to be rich in n-3 and
n-6 PUFAs. However, little information has been available on the relationship between the multiple
lipid bioactives from different species of seaweed. The present study analyzed the lipids from 15
different species of seaweed collected from two different regions, tropical (Indonesia) and temperate
(Japan) regions, with an emphasis on the content of potentially bioactive components, chlorophylls,
carotenoids, n-3 and n-6 PUFAs, and α-Toc. The results confirmed that the TL content and composition
varied widely among species. Moreover, TL was sometimes affected by the location. As shown in
Table 1, the TL level was higher in the temperate seaweeds than in the tropical seaweeds, although
there were exceptions. It is generally accepted that the TL content of seaweeds varies with temperature,
salinity, and light intensity. Specifically, the temperature strongly affects the TL level of seaweeds.
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Several studies have revealed that the TL content in temperate seaweeds is much higher than that
in tropical seaweeds. The TL variation observed in the present study is consistent with previous
studies [14,33,34,46].
Although the major components of the seaweed TL content are glycerolipids, such as
glycoglycerolipids [16], other kinds of lipid-related compounds, such as photosynthetic pigments,
are also abundant [28]. Chlorophylls and carotenoids are representative and major photosynthetic
pigments found in seaweeds [59]. Chlorophylls are the most abundant pigments on earth and allow
seaweeds to convert light into biological energy [22]. Carotenoids also have an important function as
light energy harvesters in photosynthesis by passing on light excitation to chlorophylls. In addition,
carotenoids act as antioxidants that inactivate reactive oxygen species formed by exposure to light
and air during photosynthesis. Both lipid soluble pigments have been known to show a variety of
nutritional effects in humans [20,25,26,28,60].
In seaweeds, the most important chlorophyll is Chl a, which absorbs the energy from the
wavelength of violet blue and orange-red light [61]. Chl b and Chl c are also important chlorophylls
found in seaweeds. They are accessory pigments in the antenna system of Chl a [62–65]. The present
study revealed that the variation of these three kinds of chlorophylls was mainly affected by phylum,
namely, Ochrophyta, Chlorophyta, and Rhodophyta, but not by sampling location (Table 2). In addition,
the study also showed less Chl a and Chl b in the tropical seaweeds compared with those in the
temperate seaweeds, while considerable amounts of the corresponding pheophytin derivatives, Phy
a and Phy b, were detected in the tropical seaweeds. Seaweeds from the tropical area were dried
before the analysis; therefore, most of the Chl a and Chl b in the tropical seaweed samples would
have decomposed to produce corresponding derivatives, Phy a and Phy b, respectively. The heating
treatments on seaweeds cause the central magnesium ion losses in the chlorophylls, which convert
into degradation products, i.e., pheophytins [21,66]. Therefore, considering the degradation of Chl a
and Chl b during the treatment of the tropical seaweeds, the major chlorophylls may be considered
to be Chl a and Chl c for Ochrophyta, Chl a and Chl b for Chlorophyta, and Chl a for Rhodophyta.
This study is in accordance with another study by Chen et al. [43].
In the present study, Chl c was found in two species of Rhodophyta, C. crassicaulis and M. japonica
(Table 2). This finding is noteworthy because Chl c has been regarded as a specific chlorophyll in
Ochrophyta [43,67]. Wilhelm [68] detected Chl c in Chlorophyta, namely, Mantoniella comigrates;
however, there has been no report on the presence of Chl c in Rhodophyta. Chl c is also found in
diatoms as their major chlorophyll. Diatoms use the blue-green spectral region for photosynthetic
energy. They have Chl a and Chl c as their major chlorophylls and Fx as their major carotenoid. In the
diatoms, the fucoxanthin–chlorophyll protein complex is mainly responsible for light-harvesting [69,70].
The present study suggests that the fucoxanthin–chlorophyll protein complex may be the key molecular
complex for light harvesting, not only in diatoms, but also in several kinds of seaweeds [69,71].
As described above, the content of chlorophylls and their derivatives mainly varied among the
seaweed phyla, but not with the different locations. The same trend was also found in the carotenoids
composition (Table 3). The carotenoid content in each phylum is related to the difference in the
carotenoid biosynthesis of each species [59]. Ochrophyta species were rich in Fx, with a considerable
amount of β-Car and Zx and with a small amount of Vx. The presence of Fx, Zx, and Vx in
Ochrophyta suggests the involvement of the xanthophyll-cycle pathway in carotenoid biosynthesis
in this phylum [14,59]. On the other hand, α-Car and Lut were detected as major carotenoids in
Chlorophyta and Rhodophyta. The presence of both carotenoids is closely related to the presence of
the α-Car pathway in Rhodophyta and Chlorophyta [72]. Two species (C. yendoi and M. japonica) of
Rhodophyta analyzed in this study lacked Zx. The lack of Zx may be related to photo-acclimation in
these species [73].
Chlorophylls and carotenoids have been considered as the most important biomolecules for
photosynthesis. In addition, both pigments have attracted major interest from biochemists and
nutritionists alike, because they are known to have significant biochemical and physiological
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effects, and primarily exhibit a positive influence on human nutrition and health [28]. Specifically,
much attention has been paid to the antioxidant activity of chlorophylls and carotenoids. Carotenoids
are one of the most famous natural antioxidants, together with tocopherols and polyphenols. They are
regarded as the most efficient natural quenchers of singlet oxygen (1O2), and this effect has been
attributed to a physical mechanism where the excess energy of singlet oxygen is transferred to
conjugated double bonds of carotenoids [19]. In addition to the singlet oxygen quenching ability,
carotenoids can scavenge free radicals. The reactions with free radicals are much more complex than
those with singlet oxygen. Chlorophylls are also known to scavenge free radicals, and the effect may be
strongly related to their chemical structure, especially the porphyrin ring, phytyl chain, and extended
system of conjugated double bonds [28].
The strong ability of these seaweed pigments to quench singlet oxygen and/or to scavenge
free radicals has been suggested as the main mechanism by which they afford their health
benefits [19,22,28,74]. The seaweed lipids examined in the present study contained carotenoids
and chlorophylls as major lipid soluble antioxidants. In addition, α-Toc, the most popular natural
antioxidant, was detected in these lipids. Therefore, the seaweed lipids may be a potential source
of natural antioxidants that can be used as cosmetic and food ingredients [70,75]. α-Toc is a major
tocopherol analogue found in seaweeds [45]. In this study, the α-Toc content in two species of seaweeds
from the Sargassaceae family (S. fusiforme and S. horneri) was higher than that of other seaweeds, except
for C. yendoi (Table 6). This result is in accordance with previous studies [76,77]. The present study
also suggests the relatively lower α-Toc level in Chlorophyta seaweeds (C. lentillifera, U. reticulata,
U. australis, U. intestinalis) as compared with the other phyla, Ochrophyta and Rhodophyta.
Table 4 together with Tables S1a, S1b and S1c show the FAs composition of seaweed lipids.
The composition was strongly affected by the sampling location, as seen in the TL analysis. As shown
in Table 4, total PUFAs were the most dominant FAs class in the temperate seaweeds, and the level
was higher than that in the tropical seaweeds. In the seaweeds collected from the tropical area,
SFAs were a major FAs class. This result is consistent with other studies [14,48,49,78]. Gerasimenko
and Logvinov [79] reported that FAs content and composition in seaweeds differed not only by
species, but also by seawater temperature. The lower temperature of seaweed habitats results in the
high accumulation of n-3 PUFAs for accelerating cell metabolism, especially during the winter [38].
The present study revealed that three phyla grown in the temperate area greatly accumulated EPA and
SDA in Ochrophyta, ALA and SDA in Chlorophyta, and EPA in Rhodophyta, while these n-3 PUFAs
levels were relatively lower in the corresponding phyla grown in the tropical area (Tables S1a, S1b and
S1c). On the other hand, there was not much difference in the n-6 PUFAs levels between the seaweeds
collected from the temperate and the tropical areas. The higher level of total PUFAs in temperate
seaweeds may be derived from the higher accumulation rate of n-3 PUFAs.
It is known that TL content and fatty acids composition varies seasonally. For example,
the seasonal changes of fatty acids composition have been determined in Egregia menziesii
(Turner) [80], S. japonica [81,82], C. costata (Turner) [83], Stephanocystis hakodatensis [38], S. horneri [38],
S. oligocystum [78], and U. pinnatifida (Harvey) [84]. In all cases, the higher level of total n-3PUFAs
has been found during winter or spring; this is the growing period for these seaweeds. Seasonal
variation was also found in photosynthetic pigments, such as chlorophylls and carotenoids [38,85–90].
In the present study, no concern has been given to the seasonal changes in the seaweed pigments.
These pigments are strongly related to the growing rate of each seaweed species. Therefore,
much attention has been paid to the relationship between the growth rate of seaweeds and the
level of lipid compounds, especially focusing on the photosynthetic pigments such as chlorophylls
and carotenoids.
The lower n-6/n-3 PUFAs ratio in dietary lipids has been considered to reduce the risk for many
kinds of chronic diseases [91]. Although, a balanced ratio between n-6 and n-3 PUFAs, usually 1:2
to 1:4 (w/w) [30], has been recommended. However, in modern society, intake of the n-6 PUFAs is
much lower than that of the n-3 PUFAs, resulting in the increase in the n-6/n-3 PUFAs ratio. Most of
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the seaweeds, except for G. longissima, showed a lower n-6/n-3 ratio, mostly less than 1.0 (Table 5).
In addition, TI and AI values in all seaweeds were less than 3, especially in the temperate seaweeds.
The lower TI and AI values of temperate seaweeds are because of the considerable accumulation of n-3
PUFAs in the temperate seaweeds. TI and AI values found in the present study were lower than those
in Indian macrolagae, namely, Gracillaria salicornia, Sarconema cinaioides, Hypnea spinella, and Laurencia
dendroidea [49]. Overall, all indices shown in Table 5 indicate that seaweed lipids analyzed in the
present study, especially those from the temperate seaweeds, have a cardio-protective FA composition.
Prabhasankar et al. [92] reported the change in the n-6/n-3 ratio of pasta lipids after incorporation of
the powder of brown seaweed collected from the temperate area. When 10% of the brown seaweed
powder was incorporated in the pasta, the n-6/n-3 ratio changed from 15.2 to 3.4. This result indicates
that a drastic change could be found in the low-fat food by mixing seaweed powder rich in n-3 PUFAs.
4. Materials and Methods
4.1. Materials
Standards for Chl a, Phy a, Phy b, and β-Car were obtained from Wako Pure Chemicals (Tokyo,
Japan). Chl b and Chl c1 were purchased from Sigma-Aldrich Japan Co. (Tokyo, Japan) and DHI
Laboratory Products (Hørsholm, Denmark), respectively. α-Carotene, Lut, Zx, Vx, and Nx were
purchased from Carote Nature GmbH (Münsingen, Switzerland). dl-α-Tocopherol (α-Toc) was obtained
from Kanto Chemical Co. Inc. (Tokyo, Japan). Fx standard for use in this study was purified from
the TL content of S. horneri, as described previously [20]. Tricosanoic acid (C23:0), used as an internal
standard in the gas chromatography (GC) analysis, was obtained from Sigma-Aldrich (Tokyo, Japan).
High-performance liquid chromatography (HPLC) grade solvents were used for the HPLC analysis
and purchased from Wako Pure Chemicals, Ltd. (Osaka, Japan). All other solvents and chemicals used
in the study were of analytical grade.
4.2. Sample Collection and Handling
Seaweeds were collected from two different regions, Indonesia (tropic) and Japan (temperate).
The 15 seaweeds including harvesting locations, phylum, family, scientific and local name, and date
of collection are listed in Table 1. After collection, tropical seaweeds were washed, air-dried at room
temperature (3–5 days; 27–30 ◦C) to reduce their water content, and transported to the laboratory.
Temperate seaweeds were kept in plastic bags, stored on ice, and transported to the laboratory.
These samples were then stored in a freezer (−30 ◦C).
4.3. Moisture Determination and TL Extraction
Before moisture determination, all temperate seaweed samples were thawed and washed several
times with running tap water until there were no debris, sand, or other contaminants. Before extraction,
the moisture content of 15 seaweeds species was estimated with an oven-drying method, as described
by Gómez-Ordóñez et al. [93], and used for expressing TL, chlorophylls, carotenoids, n-3 PUFAs,
and α-Toc content in seaweed samples on a DW basis. The TL content from the seaweeds was obtained
by overnight extraction with a ten-fold portion of ethanol (w/v). For the extraction, the samples were
crudely cut into small pieces. In the case of tropical seaweeds, a nine-fold portion of water was added
to the washed sample before the ethanol extraction. After immersion for one hour, the sample was
subjected to the ethanol extraction, while the temperate raw seaweed sample was directly subjected
to the ethanol extraction. The filtrate obtained by the extraction was filtered with Advantec No. 2
filter paper (Advantec Toyo Kaisha Ltd., Tokyo, Japan), and the residue was subjected to a further
overnight extraction with the same solvent proportion. Both filtrates were combined and were
vacuum-concentrated at 30 ◦C using a rotary evaporator to obtain the ethanol extract (dark green mass).
The ethanol extract was dissolved in a chloroform/methanol/water solution with a ratio of 10:5:3 (v/v/v),
and the solution was placed into a separatory funnel. After allowing the funnel to stand overnight,
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the solution was separated into two layers. The lower layer evaporated under reduced pressure in
a rotary evaporator. The last traces of the solvent and water were removed using nitrogen and using
a high-powered vacuum to obtain the seaweed TL content. The TL content was dissolved in ethanol
and stored at −30 ◦C for further analysis.
4.4. Pigment Analysis
The contents of chlorophylls, their derivatives, and carotenoids in the seaweed TL content were
analyzed using HPLC. HPLC was performed with a Hitachi HPLC La Chrome system (Hitachi
Seisakusho Co., Tokyo, Japan) equipped with an auto sampler (L-2200), pump (L-2130), column
oven (L-2300), and photodiode array detector (L-2455). An aliquot of the TL content was weighed
and dissolved in acetone. The sample solution was filtered with a 0.45 μm membrane filter of
polytetrafluoroethylene (PTFE) (Ekicrodisc 13CR; Nippon Genetics Co. Ltd., Tokyo, Japan) and
subjected to HPLC analysis. The analysis was performed on an octadecylsilyl (ODS) column (TSK-gel
ODS 80-Ts, 250 × 4.6 mm i.d., 5 μm particle size; Tosoh, Japan) protected with a guard column
(15 × 3.2 mm) with the same stationary phase. The mobile phase consisted of methanol/acetonitrile/1
M ammonium acetate (5:3:2, v/v/v) (A) and acetonitrile/ethyl acetate (1:1, v/v) (B) [94] with slight
modification. A gradient elution procedure was programmed as follows: 0–2 min, 100:0 (A/B, v/v);
2–28 min, a linearly elution gradient from A to B; and 28–37 min, 0:100 (A/B, v/v). The flow rate was kept
at 1.0 mL min−1. The UV/visible spectra absorption was recorded from 350 to 800 nm with a photodiode
array detector, and sequential detection was carried out at 410, 430, 450, and 666 nm [43]. Quantification
of chlorophylls, their derivatives, and carotenoids was performed with the corresponding calibration
curves. A calibration curve for each pigment was prepared using an authentic standard.
4.5. Fatty Acids Analysis
The fatty acids composition of the TL content was determined by GC after conversion of fatty
acyl groups in the lipid to their methyl esters. The fatty acid methyl esters (FAMEs) were prepared
as per the method by Prevot and Mordret [95], with a slight modification. Briefly, 1 mL n-hexane
containing an internal standard (tricosanoic acid, C23:0) and 0.2 mL 2 M NaOH in methanol were
added to an aliquot of the TL content (ca. 10 mg), vortexed for 10 seconds, and incubated at 50 ◦C
for 30 seconds. After the incubation, 0.2 mL 2 M HCl in methanol solution was added to the solution
and vortexed for 60 seconds. The mixture was separated by centrifugation at 1000× g for five minutes.
The upper hexane layer containing FAMEs was recovered and subjected to GC. The FAMEs analysis
was performed on a Shimadzu GC-2014 (Shimadzu Seisakusho, Kyoto, Japan) equipped with a flame
ionization detector and a capillary column (Omegawax-320; 30 m × 0.32 mm i.d.; Supelco, Bellefonte,
PA, USA). The detector, injector, and column temperatures were 260, 250, and 200 ◦C, respectively.
The carrier gas was helium at a flow rate of 1.0 mL s−1. FA content was expressed as the relative
weight percentage of the total FAs weight. Each n-3 PUFAs level (mg·g−1 TL content) was quantified
by comparing the peak ratio to that of the internal standard (23:0). Total n-3 PUFAs (mg·g−1 DW)
were calculated from the content of each n-3 PUFAs in the TL content and the TL content g−1 DW.
FAME peaks were identified by comparison of their retention time and log RRT with GLC-Reference
standards by GC FID (Shimadzu GC-2014) after analysis. The fatty acids standard was prepared with
GLC-Reference Standard, fatty acid methyl esters: GLC-462, and Echium oil, according to Susanto et
al [34].
Several factors predicting the nutritional quality of the seaweed TL were calculated based on the
formula as below [79,96,97]:




Atherogenicity index (AI) =
C12 : 0 + 4×C14 : 0 + C16 : 0∑
MUFAs+
∑
n− 6 PUFAs+∑n− 3 PUFAs (2)
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Unsaturation Index (UI) =
∑
(% PUFAs×DB); DB is the number of double bonds. (5)
4.6. α-Toc Analysis
The content of α-Toc in the TL content was analyzed by HPLC with a silica column (Mightysil
Si 60 silica, 250 × 4.6 mm i.d.; Kanto Chemical Co., Ltd., Tokyo, Japan). HPLC was carried out with
the same system as described in the pigment analysis, except that the fluorescence detector (Hitachi
L-7485) was used for the peak detection. The mobile phase was hexane/2-propanol (99.2:0.8, v/v) at
a flow rate of 1.0 mL min−1. The fluorescence detector was set at Ex. 298 nm and Em. 325 nm.
4.7. Data Analysis
All analytical data were conducted in triplicate and the mean values are presented. The PCA
was performed using JMP 14.0 statistical analysis. Two principal components based on the fatty
acids composition and group (SFAs, MUFAs, PUFAs, n-3 PUFAs, and n-6 PUFAs) were used to make
clear the relationship between different sampling areas and seaweed phyla. Fatty acids composition
(supplementary data) and FAs group composition (Table 4) were used for the multivariate analysis.
However, an insignificant amount of fatty acids was not included in this analysis, these fatty acids
were dodecanoic acid (C12:0), tridecanoic acid (C13:0), 7-tetradecenoic acid (C14:1n-7), pentadecanoic
acid (C15:0), 8-pentadecenoic acid (C15:1n-7), heptadecanoic acid (C17:0), 10-heptadecenoic acid
(C17:1n-7), 11,14,17-eicosatrienoic acid (C20:3n-3), docosanoic acid (C22:0), 13-docosaenoic acid
(C22:1n-9), 13,16-docosadieonic acid (C22:2n-6), tetradocosanoic acid (C24:0), and 17-tetracosaenoic
acid (C24:1n-7).
5. Conclusions
In conclusion, the present study clearly shows the major factors affecting the variation of seaweed
lipid compounds. Liphophilic pigments were explained by seaweeds’ phyla, while the geographical
location influenced fatty acids composition. Lipid soluble pigments were one of the major compounds
of interest in the present study. Among these pigments, relatively little attention has been paid to
chlorophylls, despite the fact that chlorophylls are abundant in our diet and their biological significance
has been recognized for a long time. The results for the compositions of chlorophylls and their
derivatives will provide valuable information for the application of each seaweed’s lipids as a good
source of these chlorophyll compounds and other lipid soluble compounds, such as carotenoids
and PUFAs.
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Abstract: Cystoseira barbata is an edible brown seaweed, traditionally used in the Black Sea area as
functional food. Both alginate and brown seaweed biomass are well known for their potential use as
adsorbents for heavy metals. Alginate was extracted from C. barbata recovered from the Romanian
coast on the Black Sea with a yield of 19 ± 1.5% (w/w). The structural data for the polysaccharide was
obtained by HPSEC-MALS, 1H-NMR. The M/G ratio was determined to be 0.64 with a molecular
weight of 126.6 kDa with an intrinsic viscosity of 406.2 mL/g. Alginate beads were used and
their adsorption capacity with respect to Pb2+ and Cu2+ ions was determined. The adsorption
kinetics of C. barbata dry biomass was evaluated and it was shown to have an adsorption capacity
of 279.2 ± 7.5 mg/g with respect to Pb2+, and 69.3 ± 2 with respect to Cu2+. Alginate in the form of
beads adsorbs a maximum of 454 ± 4.7 mg/g of Pb2+ ions and 107.3 ± 1.7 mg/g of Cu2+ ions.
Keywords: alginate; Cystoseira barbata; Black Sea; heavy metals adsorption; diffusion model
1. Introduction
Edible seaweeds have significant potential as functional food, especially as they are active
against various human non-communicable diseases such as cardiovascular diseases, cancers,
type 2 diabetes/metabolic syndrome, auto-immune diseases, due to their high level of bioactive
components—polysaccharides, peptides, polyunsaturated fatty acids, polyphenols, vitamins and
minerals [1,2]. One of the main active components of edible brown seaweed is alginate, a polysaccharide
composed of two different uronic acids, mannuronic and guluronic [3]. Due to the fact that alginates
are not digested by human enzymes, they act as prebiotics, supporting the production of short-chain
fatty acids, and as potential immunomodulators [4].
Traditionally, alginates have been used as tablet excipients and for the treatment of stomach ulcers,
gastric reflux and heartburn [5]. Alginates’ absorptive, swelling and haemostatic features are involved
in their mode of action against such health conditions. These features also substantiate the use of
alginate in wound treatment [6]. Their absorptive and swelling features have also been linked to many
other health-related effects. For example, binding of glucose and α-amylase inhibition, which reduce
post-prandial glucose levels [7,8]. Alginates (calcium) have the ability to absorb bile acids and lipids
and therefore to lower cholesterol [9] and lipid levels [10].
The adsorption of heavy metal ions (biosorption) from the intestinal system is related to organism
detoxification. Treatment with calcium alginate in a dose of 500 mg/kg removes the lead accumulated
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in rats after intoxication with lead acetate [11]. Simultaneous intoxication of lead acetate and treatment
with calcium alginate significantly reduced lead accumulation in rat organs [12]. Administration of
alginate in combination with modified citrus pectin reduces the total body burden of heavy metals [13].
Heavy metals are highly toxic to the environment and to humans. The recommended values for
human consumption are in the very low ppm ranges: Pb, 0.01 ppm; Cu, 2 ppm; Hg, 0.001 ppm; As,
0.01 ppm; Ni, 0.02 ppm; etc. [14]. High levels of heavy metals have been reported in sources of drinking
water [15], which have been contaminated from a variety of sources such as pipe corrosion [16,17] or
industrial activities [18–20]. Other activities that have been associated with high contamination risks
are petrochemistry [21] and electronics waste disposal (E-waste) [22]. In many cases, the recovery of
heavy metal contaminants using adsorbents [15,23] is mainly due to their reduced costs as compared to
other methods such as membrane filtration, chemical precipitation, ion exchange and others [15,24–26].
Biosorption is the process by which some type of biological material is used as an adsorbent
to bind certain compounds [27]. It is regarded as a promising alternative to classical methods due
to its cost-effectiveness and environment-friendly nature [21]. The biosorbents that are currently
under development are mostly trying to take advantage of the adsorption properties of natural
biomasses [28], or of composite materials based on natural sources [21,29]. Apart from bacteria [30–32]
and fungi [21,33,34], agricultural [35] and algae-based adsorbents [28,36] have also been used. Among
macroalgae, brown seaweeds are of particular interest because they contain alginate, which has a
chemical affinity for divalent metals [37,38]. In fact, alginate chains form a tridimensional matrix in the
presence of divalent metals by ionic crosslinking following the egg-box model [39]. Ca2+ ions are used
for this purpose. However, divalent metals of higher atomic mass replace the calcium ions as the active
sites in the alginate hydrogel have increased affinity for larger divalent metal ions [40]. For decades,
alginate has been extracted from brown seaweed with a good yield at an industrial level to be used
as a thickening and gelling agent in the food and cosmetics industry [41,42]. The main species that
are currently exploited industrially are Macrocystis pyrifera, Laminaria hyperborea, Laminaria digitata
and Asphyllum nodosum [43]. However, alternative uses are proposed for alginate in the biomedical
field as a drug delivery system, for wound healing and tissue engineering [6], or as a biosorbent
material. In fact, both brown seaweed biomass and alginate, in the form of gel beads have been
extensively studied as biosorbents [28,37,44–47]. Recently, composite materials based on alginate have
been derived with improved properties. For instance, including magnetite has enhanced the recovery
of biosorbents. In this case, adsorption of Cd2+ ions was improved by also including activated carbon
in the alginate matrix leading to an improved material in terms of adsorption capacity and costs [48].
Another approach is to obtain a compressive alginate sponge where the contaminant is recovered
after adsorption simply by compressing the biosorbent before reuse. The efficiency of this system was
proven in the case of treating methylene blue contaminated wastewaters [49]. The crosslinked alginate
matrix has also been used as a coating for composite materials that are to be used as controlled drug
release systems [50].
Cystoseira is a polyphyletic genus of brown seaweed, included in the Sargassaceae family, which
is found extensively on the coasts of the Mediterranean Sea and the eastern Atlantic Ocean and also in
the Black Sea [51,52] Most studies of Cystoseira sp. have shown a large variety of secondary metabolites
with biological activity including phlorotannins, terpenoids and carbohydrates [53]. Cystoseira barbata
recovered from the coasts of Tunisia has been proven to contain compounds that show biological
activity, including laminarin, which has antioxidant, antibacterial and wound healing properties [54];
fucoxanthin, used as a color enhancer and oxidative stability enhancer of meat products [55]; and
polyphenolic-protein-polysaccharide ternary conjugates, which are used as biopreservatives [56]. In the
Black Sea, C. barbata and Cystoseira crinita are the only representatives of Cystoseira sp., although a
Cystoseira bosphorica member has sometimes been reported [51,57]. C. barbata is traditionally used in the
Black Sea area as functional food [2,58]. Recent studies have been based on ecological interest in the
levels of heavy elements in certain parts of the Black Sea coast [59–61], as well as the structure of certain
metabolites found in C. barbata and C. crinita [62]. The use of Cystoseira spp. biomass as a biosorbent has
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been shown in one study involving C. amentacea var. stricta (formerly C. stricta) [47]. Dried C. barbata
biomass from the Turkish coast of the Black Sea has also been investigated as a biosorbent [46]. To the
best of our knowledge, the structure of alginate extracted from C. barbata and its use as a biosorbent in
the form of beads to adsorb heavy metals has never been studied.
The aim of this paper is to characterize alginate extracted from C. barbata recovered from the
Romanian Black Sea and to prove that this bioactive component presents heavy metal adsorption
properties compatible with its use as an adsorbent/biosorbent for heavy metal detoxification.
The adsorption properties of the initial seaweed powder were also evaluated.
2. Results and Discussion
2.1. Extraction and Structural Characterization
In recent years, many studies on the characterization of polysaccharides extracted from brown
algae, and more specifically on Cystoseira sp. have been conducted and described in the literature [63–65].
Nevertheless, alginate extracted from C. barbata recovered from the Romanian Black Sea coast has
never been investigated from a structural point of view.
The extraction method (Figure 1) that was employed for the extraction of alginate had a yield of
19 ± 1.5% (w/w) and relative to the algae dry matter estimated at 95 ± 2%. This method is presented in
detail in Section 3.2. The final alginate product is obtained as a fine powder (under 0.2 mm), which is
referred to as CBA UF.
Figure 1. Processing steps for the extraction of alginate from C. barbata dry seaweed biomass.
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2.2. HPSEC-MALS
The average molecular weight in mass (Mw), average molecular weight in number (Mn) and the
intrinsic viscosity of alginate (CBA UF) extracted from C. barbata were determined by high performance
size-exclusion chromatography equipped with a multi-angle light diffusion detector coupled to a
differential refractometer and an in-line viscometer. The recovery rate of the sample was estimated
at 90%.
The values of the determined average molecular weights and hydrodynamic radius are reported
in Table 1. The Mn and Mw of alginate (CBA UF) were estimated at 85.2 (±2.7%) kDa and 126.6 (±1.0%)
kDa, indicating a low polydispersity index (PDI =Mw/Mn =1.49). These results are similar to those
for other alginates obtained from brown algae, and especially from Cystoseira sp. such as Cystoseira
sedoides [66], Cystoseira compressa [63,66], C. crinita [66]. In fact, our present results for the Mw values
were very consistent with earlier investigations on alginates from Fucales algae families, for example,
Fucus vesiculosus, A. nodosum, C. compressa or C. sedoides, which have Mw values ranging from around
100 kDa to 200 kDa [66,67]. Nevertheless, compared to other brown algae from Sargassum species,
where Mw values ranged from 300 to 1000 kDa, the Mw of alginate fractions (CBA UF) extracted from
Romanian C. barbata were lower [67,68].
Table 1. Characterization of alginate (CBA UF) extracted from C. barbata collected from the Romanian
Black Sea.
Mn (kDa) Mw (kDa) PDI Rh(w) (nm) [η] (mL/g)
CBA UF 85.2 126.6 1.49 19.2 406.2
Mn—average molecular weight in number; Mw—Average molecular weight in mass (Mw); PDI—polydispersity
index; Rh(w)—hydrodynamic radius; [η]—intrinsic viscosity.
Compared with other alginates from brown algae, and especially from Cystoseiraceae species, the
PDI value of 1.49 is very close to the alginate from Tunisian C. compressa [63]. This PDI value of alginate
from Romanian C. barbata confirms a good Mw polysaccharides distribution, and indicates that there
is no depolymerization of polysaccharides during the extraction/purification process steps. Finally,
the intrinsic viscosity, which signifies the hydrodynamic volume occupied by the macromolecules in
a dilute solution, was estimated for CBA UF at 406 mL/g. This value is lower than the alginate [η]
values from Sargassum (800–1300 mL/g) brown algae but is close to other intrinsic viscosity values
of alginate extracted from Cystoseiraceae species [63,64,68]. Notably, a similar [η] was observed with
alginate extracted from Tunisian brown algae C. compressa [63]. As generally described, these observed
differences are related to the origin of the algae and the extraction / purification processes used, which
affect molecular weight and intrinsic viscosity.
2.3. NMR Analysis
Alginate extracted from C. barbata (CBA UF) was analyzed by 1H NMR. As observed in Figure 2,
the 1D 1H-NMR spectrum showed the specific signal characteristics of the sodium alginate fraction,
revealing high purity [69,70].
As well defined in the literature [69,70], 1H-NMR analysis identifies the alginate structure with
three signals in the anomeric region: Signal I corresponds to the anomeric proton of the guluronic acid
residue (G-1), Signal II corresponds to the overlap between the mannuronic acid anomeric proton (M-1)
and the H-5 of alternating blocks (GM-5), and Signal III corresponds to proton H-5 guluronic acid from
the GG-5G block (G-5). As a general rule, by using the NMR method we could estimate the proportions
of each individual block of guluronic and mannuronic acids (FG and FM), the homogeneous (FGG and
FMM) and heterogeneous (FGM and FMG) blocks of alginate [70] extracted from C. barbata (CBA UF)
using the areas (A) of signals I, II and III and the Equations (1), (2) and (3):
FG = AI/AII + A_III (1)
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FM = 1− FG (2)
FGG = AIII/AII + AIII (3)
Figure 2. 1H NMR analysis of CBA UF extracted from C. barbata with: signal I = guluronic acid
anomeric proton (G-1), signal II = overlap between the mannuronic acid anomeric proton (M-1) and
the H-5 of alternating blocks (GM-5), signal III = guluronic acid H-5 position (block GG-5G), G-6 the
C-6 from guluronic acid residue and M-6 the C-6 from mannuronic residue.
Regarding the estimation of the block FGM, FMM and M/G molar ratio of alginate extracted from
C. barbata (CBA UF), we used the following equations:
FGM = FG − FGG (4)
FMM = FM − FGM (5)
M/G = FM/FG (6)
Consequently, Equations (4), (5) and (6) allow the complete structural characterization [70] of CBA
UF, which is summarized in Table 2.





3 FGM or FMG
4 FMM
5 M/G 6
CBA UF 0.61 0.39 0.34 0.27 0.12 0.64
1 FG—fraction of individual blocks of guluronic acid units; 2 FM—fraction of individual blocks of mannuronic
acid units; 3 FGG—fraction of homogeneous block of guluronic acid; 4 FGM or FMG—fraction of heterogeneous
blocks of alternating mannuronic and guluronic acids; 5 FMM—fraction of homogeneous block of mannuronic acid;
6 M/G—ratio between FM and FG.
The frequencies of structural blocks shown in Table 2 provide information about the alginate
composition in C. barbata. For example, the ratio between mannuronic and guluronic acid gives
information about the quality of Ca2+ reticulated gels which, in this case, has a strong and rigid
quality [71]. This value is generally higher than those reported for other species from Cystoseira genus
such as Sirophysalis trinodis (formerly C. trinodis) (0.59), C. myrica [68], although it is lower in some cases,
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C. compressa (0.77) [63], C. humilis (1.46) [72]. Compared to other species from Laminaria or Sargassum,
this value is higher in some cases (L. hyperborea, 0.41 [70]; Sargassum filipendula, 0.19 [73]), and lower in
other cases (S. vulgare, 1.27 [69]; L. digitata, 1.12 [74]).
Structural information can be derived by evaluating the parameter η = 1.13 obtained using
Equation (7). The value suggests that alginate extracted from C. barbata is of an alternate block type
since it is greater than 1 [75]. Surprisingly, alginates extracted from other species from the Cystoseira




2.4. Kinetics of Adsorption
Sodium alginate beads were obtained as described in Section 3.5. Photos (at 10×magnification)
of the beads (not shown here) were taken and analyzed digitally in order to determine the diameter.
Twenty beads were analyzed, and the mean diameter was determined to be 4413 ± 134 μm.
Initially, the kinetics of adsorption was studied by contacting sodium alginate beads and dry
seaweed powder (<500 μm) with Cu2+ and Pb2+ solutions at 20 ppm and 74 ppm, respectively (Ci). [14]
Four pairs of substrate/heavy metal were obtained. The instantaneous sorption capacity (qt) was
determined as defined in Equation (8) where Ct is the concentration of heavy metals at time t. This
equation is deduced from mass balance. Sm represents the value of substrate mass divided by the





The kinetic curves for copper and lead adsorption of each of the two substrates are shown in
Figures 3 and 4.
Figure 3. Kinetics of copper adsorption by the two substrates: (a) C. barbata alginate (CBA UF) and
(b) C. barbata powder (CB 500).
The diffusion equation represented by Equation (9) [76] was used to simulate the experimental
results of adsorption of Pb2+ and Cu2+ and is based on the diffusion of ions from a solution at a given
ion concentration until the solution is solid free or has a constant negligible concentration of ions,
which is the case of the present study. α in Equations (9) and (10) represents the ratio between the
volume of the liquid and the volume of the solid. In the case of the alginate beads, the volume of
solid is represented by the total volume of the beads used. When algal powder is used, the volume
of the solute can be approximated by the equivalent volume of water and powder, which is taken
up by the powder when swelling. This value is 4.14 times greater than the mass of the used powder.
The ratio of a sphere equivalent in volume to the substrate needs to be found for both the alginate and
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the powder. This term is named a. The effective diffusivity of the solute in the solid is termed Deff
(m2/s). qn represents the six non-zero roots of Equation 10. qe represents the equilibrium value of the








−De f f qn2t/a2
)




3+ ∝ qn2 (10)
Figure 4. Kinetics of lead adsorption by the two substrates: (a) C. barbata alginate (CBA UF) and
(b) C. barbata powder (CB 500).
Figures 3 and 4 compare the experimental and theoretical results from using Equation (9) by
regression. The parameters that were optimized are qe and Deff. The optimization algorithm, GRG
Nonlinear was applied in Excel 2013 by the Solver tool. The Multistart feature was used with a
population size of 100, using central derivatives to converge towards the solution. Upper and lower
bounds with physical significance were applied for each optimized parameter. The combinations of
Deff and qe which best fitted the experimental data for all 4 combinations of substrate and divalent
metal ions are summarized in Table 3.
Table 3. Crank diffusion model for a sphere. Model coefficients for 4 pairs of substrate / heavy metal.
Substrate/Metal Ion Deff × 10−9(m2/s) qe (mg/g)
CBA UF/Pb2+ 0.85 359.8
CBA UF/Cu2+ 3.98 43.8
CB 500/Pb2+ 1.39 172
CB 500/Cu2+ 1.79 37.3
Deff—the effective diffusivity of the solute in the solid; qe—the equilibrium value of the adsorption.
The values of Deff in all cases are similar to the self-diffusivity of Cu2+ and Pb2+ in water:
0.71 × 10−9 m2/s and 0.95 × 10−9 m2/s [77]. This can be explained by the high content of water in the
beads and the swollen biomass. Alginate gels are generally nanoporous [6,78], leading to high diffusion
rates of small solutes [6]. However, in this case Deff is accelerated by the affinity of divalent metal ions
towards the egg-box structure of gels [39] formed by the G fractions in the alginate structure. The Ca2+
ions, which occupy this site initially, are replaced by the Pb2+ and Cu2+ ions, which have a higher
affinity [40]. The qe is the maximum adsorption capacity in the given setup, which was not meant to
saturate the substrate. The diffusivities obtained for the substrates used in this work are higher than
those obtained for materials used in a similar work for Pb2+ and Cu2+ [79].
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2.5. Adsorption Isotherms
The experimental values for the maximum sorption capacities deduced from the adsorption
isotherms are represented in Figures 5 and 6 and are presented in Table 4. Such levels of Pb2+
concentration are in the range of contaminated mine waters [80,81].
Figure 5. Copper adsorption isotherms for: (a) C. barbata alginate (CBA UF) and (b) C. barbata
powder (CB500).
Figure 6. Lead adsorption isotherms for: (a) C. barbata alginate (CBA) and (b) C. barbata powder (CB500).
Table 4. Adsorption isotherms - model parameters (Langmuir).
Substrate/Metal Ion qmax (mg/g) KL (mg/L) Ut (mmol/g)
CBA UF/Pb2+ 454 ± 4.7 0.32 ± 0.04 0.77
CB 500/Pb2+ 279.2 ± 7.5 0.069 ± 0.005 0.15
CBA UF/Cu2+ 107.3 ± 1.7 0.092 ± 0.005 0.77
CB 500/Cu2+ 69.3 ± 2 0.16 ± 0.03 0.15
qmax—maximum theoretical adsorption capacity according to Langmuir, KL—Langmuir constant, Ut—theoretical
egg-box sites per mass of substrate.
On the same figures, the Langmuir adsorption model is shown for optimized parameters: qmax
and KL. This model has been used in many studies that involve the adsorption of pollutants such as
heavy metals, dyes and phenol [24,82,83]. This model is represented by Equation (11). Ce represents
the concentration of metal ions still in the solution.
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The optimized parameters for each substrate/metal pair are shown in Table 4.
In all cases the capacity of the substrates to adsorb the heavy metals used in this work remains high
and reliable because the standard deviation is very low. Interestingly, the seaweed powder without
any treatment also had excellent capacity for the adsorption of heavy metals. This is an interesting
result because it shows that the brown seaweed recovered from the Romanian Black Sea can be used
in its native form for heavy metal adsorption. The values obtained for qmax show that the substrates
used for both metal ions have good theoretical adsorption capacity according to Langmuir (infinite
equilibrium time considered). These values are similar to results obtained in a previous work [79]
where for Pb2+, alginate beads were found to have a qmax of 390.3 mg/g, while brown seaweed biomass
(L. digitata) was shown to have a qmax value of 264.2 mg/g [79]. For Cu2,+ similar results can be found
in the literature with, for example, values of 107.5 mg/g and 74.5 mg/g for alginate and algal biomass
(L. digitata), respectively [79]. The algal biomass can also be compared to other agricultural wastes
that have been investigated as heavy metal adsorbents, such as treated green coconut (Cocos nucifera)
shells, Pb2+: 54.62 mg/g, Cu2+: 41.36 mg/g [84]; apricot stone activated carbon, Pb2+ 22.85 mg/g,
Cu2+ 24.21 mg/g [85]; tea waste, Cu2+: 48 mg/g [86]; and rose waste biomass, Pb2+: 151.51 mg/g [87].
As can be observed, the algal powder has a better adsorption capacity than other dried biomasses.
The heavy metals adsorption capacity of C. barbata from the Black Sea has been studied before on
samples recovered from the Turkish Black Sea Coast [46], where dried C. barbata biomass was found
to have a maximum sorption capacity of 253 mg/g for lead, which is only slightly lower than the
value obtained in this study. Other seaweed from Cystoseira sp. have also shown to have heavy metal
adsorption properties when used directly as dried biomass. Cystoseira amentacea var. stricta (formerly
C. stricta) recovered on the Algerian coast proved to adsorb 64.5 mg/g of lead ions after undergoing
several chemical treatments [47].
The good performance of alginate from C. barbata can be explained by the low value of the M/G
ratio (0.64), which indicates the higher availability of G blocks [40,88]. This could explain the better
performance compared to other studies where alginate from L. digitata was used [79]. L. digitata was
shown to have an M/G value of 1.12 [74] or 1.63 [44].
The natural capacity of C. barbata to adsorb heavy metals is proven in this study and confirms
the high adsorption capacity which was also proven in a previous study [46]. The affinity of brown
seaweed for heavy metals can be explained by the presence of alginate, especially the G homogeneous
block fractions, which chelate divalent metal ions. This is why alginate extracted from C. barbata has an
increased capacity.
The good heavy metal absorption characteristics of the edible brown seaweed C. barbata and of its
major bioactive component, alginic acid, offer a possible explanation regarding the traditional use of
this seaweed as functional food. Further studies on biological systems are needed.
Beside its use as nutraceutical/functional food, the biomass of C. barbata and/or of its bioactive
component, alginic acid, could be used for water treatment to recover heavy metals ions. In this case,
this seaweed and the alginate extracted from it have the potential to be used to develop systems such
as cartridges, which could facilitate their use in processes under continuous conditions [44]. Also, the
behavior during sorption/desorption cycles needs to be determined to prove reusability.
3. Materials and Methods
3.1. Raw Material and Chemicals
C. barbata seaweed was recovered from the Romanian seashore of the Black Sea in the city of
Mangalia (GPS coordinates at latitude: N 43◦ 49.2′, longitude: E 28◦ 35.4′). The biomass was thoroughly
washed with tap water to remove sand particles and epiphytes and dried at room temperature for one
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week in the dark to prevent any possible degradation associated with sunlight. Afterwards, the dry
biomass was milled and sieved at 500 μm to obtain the material referred to as CB 500. The powder
recovered under the sieve was used for further manipulation. The chemicals used for this work were
analytical grade and were purchased from Sigma-Aldrich (Sigma-Aldrich, Saint-Louis, MO, USA).
3.2. Extraction of Alginate
Alginate was extracted by adapting several methods used in the literature [64]. Initially, 25 g
of dried seaweed powder underwent a mild depigmentation and defatting in EtOH (70% v/v, 24 h,
250 mL). The solid was removed by vacuum filtration (Whatman filter paper, 25 μm, Whatman,
Maidstone, UK) and added to HCl (0.1 M, 2 h, 60 ◦C, 500 mL). After vacuum filtration, this operation
was repeated for the recovered wet pellets. The excess acid was washed away with distilled water
before extracting the alginate in a Na2CO3 solution (3% (w/v), 2 h, 60 ◦C). The sodium alginate extract
was left to cool before separating it from the solid waste by centrifugation (15,000 g, 30 min, 4 ◦C).
After neutralization with dilute HCl, the extract was treated by ultrafiltration on a Vivaflow 200
crossflow cassette module (100 kDa, polyethersulfone, Sartorius, Göttingen, Germany) fitted with a
peristaltic pump. Following the treatment in diafiltration mode with 5 diavolumes, alginate remained
in solution in the retentate while most of contaminants were removed in the permeate. This procedure
was followed by a concentration process, which reduced the volume of the retentate 3 times before
precipitating the alginate by adding 3 volumes of EtOH (96%, −18 ◦C). The alginate pellets were
dehydrated twice with 20 mL of acetone at −18 ◦C. The pellets were then dried at 50 ◦C, milled and
sieved (0.2 mm) to obtain a fine powder called CBA UF.
3.3. NMR Analysis
The sample was prepared and analyzed under conditions described in the literature [63]. CBA
UF was dissolved in D2O (99.9% D) at a concentration of 50 g/L. After dissolution the sample was
freeze-dried resulting in CBA UF alginate with exchangeable protons replaced by deuterium. In total,
this operation was done 3 times. Before analysis, the CBA UF lyophilized sample was dissolved again
in D2O (99.9% D) at a concentration of 40 g/L. NMR spectra were obtained at 80 ◦C using a 400 MHz
Bruker Avance spectrometer (Bruker, Billerica, MA, USA), equipped with a BBFO probe. A spectral
width of 3000 Hz was used for acquiring the data obtained under the following acquisition parameters:
acquisition mode = 2 s, pulse 90◦ = 8 μsec, scans = 64, recovery = 5 s (for a complete return after the
90◦ pulse).
3.4. HPSEC-MALS
High pressure size exclusion chromatography (HPSEC) was used to determine the number average
molar mass, (Mn), the mass average molar mass (Mw), intrinsic viscosity ([η]), hydrodynamic radius
(Rh) and gyration radius (Rg) for CBA UF. Three detectors were used in parallel, and were coupled to the
chromatograph: multi-angle light scattering (MALS, DAWN-EOS from Wyatt Technology Corp., Santa
Barbara, CA, USA) with a Ga-As laser (690 nm) and a K5 cell (50 μL) (HELEOS II Wyatt Technology
Corp., USA), a viscosimeter (Viscostar II, Wyatt Technology Corp., USA) and refractive index detector
(RID, RID10A Shimadzu, Kyoto, Japan). One OHPAK SB-G, two OHPAK SB 804 and 806 HQ columns
were used in series for the HPSEC line (Shodex Showa Denko K.K., Tokyo, Japan). The system was
eluted with LiNO3 0.1 M, filtered using a 0.1 μm unit (Millipore, Merck Group, Darmstadt, Germany)
and degassed (DGU-20A3 Shimadzu, Kyoto, Japan). The flow rate was set at a value of 0.5 mL/min
(LC10Ai Shimadzu, Kyoto, Japan). The sample was diluted to 1 mg/mL in LiNO3 0.1M under stirring
for 24h, filtered (0.45 μm, Millipore) before 500 μL was placed onto the analytical line of the instrument
with an automatic injector (SIL-20A Shimadzu, Kyoto, Japan).
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3.5. Preparation of Alginate Beads
CBA UF was dissolved in MilliQ water to obtain a solution with a concentration of 3% (w/v).
The solution was then pumped through a capillary (d = 1 mm) with its other end above a 0.5 M CaCl2
solution under stirring. Alginate beads are formed drop by drop as they contact the calcium solution.
They were stored for 12 h at 4 ◦C in a 0.5 M CaCl2 solution. A digital camera (Euromex CMEX-5000,
Arnhem, The Netherlands) was used to take photos of the alginate beads. The diameter of the beads
was measured using the ImageFocus software.
3.6. Adsorption Kinetics
The initial conditions for the kinetic experiments were adapted from the literature [79] and
are shown in Table 5. The substrate mass represents the quantity of alginate used to produce the
corresponding number of beads used or the mass of dried powder added. The initial concentration of
heavy metal ions is also given in Table 5 and was obtained from PbCl2 and CuSO4. The corresponding
quantity of substrate was added under stirring. The kinetics experiments were run for 100 h in order
to achieve equilibrium. The concentration of metal ions was determined using MP-AES (microwave
plasma-atomic emission spectrometry, Agilent 4200, Santa Clara, CA, USA).











CBA UF/Pb2+ 0.2 74 0.37
CBA UF/Cu2+ 0.4 20 0.05
CB500/Pb2+ 0.4 74 0.185
CB500/Cu2+ 0.4 20 0.05
3.7. Adsorption Isotherms
Following the adsorption experiments, it was observed that the equilibrium was well reached
after ~65 h. This value is used as the time necessary to achieve equilibrium in the adsorption isotherm
experiments. Ten solutions of 50 mL each were obtained for each substrate/heavy metal pair with a
concentration of heavy metal ions varying from 22.3 to 223 ppm for Pb2+ and from 8 to 79.6 ppm for
Cu2+(Ci). In this case, the mass of alginate contained in the beads with respect to the heavy metal
solution (Sm) was fixed at 0.4 g/L of solution. The corresponding mass of substrate was added to the
heavy metal solutions. The solutions are kept under agitation using a plate shaker until equilibrium
was reached. Afterwards, the final concentration of heavy metals was determined by MP-AES.
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Abstract: Seaweeds, which have been widely used for human consumption, are considered a potential
source of biological compounds, where enzyme-assisted extraction can be an efficient method to obtain
multifunctional extracts. Chemical characterization of Sargassum muticum and Osmundea pinnatifida
extracts obtained by Alcalase and Viscozyme assisted extraction, respectively, showed an increment
of macro/micro elements in comparison to the corresponding dry seaweeds, while the ratio of Na/K
decreased in both extracts. Galactose, mannose, xylose, fucose, and glucuronic acid were the main
monosaccharides (3.2–27.3 mg/glyophilized extract) present in variable molar ratios, whereas low free
amino acids content and diversity (1.4–2.7 g/100 gprotein) characterized both extracts. FTIR-ATR and
1H NMR spectra confirmed the presence of important polysaccharide structures in the extracts, namely
fucoidans from S. muticum or agarans as sulfated polysaccharides from O. pinnatifida. No cytotoxicity
against normal mammalian cells was observed from 0 to 4 mglyophilized extract/mL for both extracts.
The comprehensive characterization of the composition and safety of these two extracts fulfils an
important step towards their authorized application for nutritional and/or nutraceutical purposes.
Keywords: Osmundea pinnatifida; Sargassum muticum; enzymatic extracts; minerals; mono and
polysaccharides; FTIR-ATR; NMR; cytotoxicity
1. Introduction
Seaweeds are extremely versatile organisms that are widely used for direct human consumption,
being considered a food with high commercial value. Furthermore, they are also currently recognized as
a huge source of new untapped ingredients, many of which, with biological activity, playing a positive
role on health and with great potential to be exploited for food and/or nutraceutical applications.
According to Singh and Reddy [1], a wide variety of products derived from seaweeds (including food
products) are industrially produced, rendering an estimated total annual value of US $5.5 to 6 billion.
Extraction plays a major role in supporting this substantial increase in the importance of seaweeds
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as a source of new bioactive compounds. Enzyme-assisted extraction (EAE) has gained attention as
an effective tool to improve the extraction yield of bioactive compounds from different organisms
containing a cell wall, such as seaweeds, while being able to maintain the bioactive properties of the
derived extracts [2,3].
Among the edible seaweeds, Sargassum muticum (Phaeophyceae) is a brown seaweed of an
invasive nature in Europe, containing a high content of antioxidant compounds, such as carotenoids
and phenols [4], and therefore its exploitation as a potential food ingredient would be an added value
helping to overcome its invasive character. In turn, Osmundea pinnatifida (Rhodophyta), an edible red
macroalgae, is also found in several parts of European coasts, and recent studies have revealed its
huge potential as a food ingredient [5]. Enzymatic extracts from O. pinnatifida and from S. muticum
have demonstrated important biological properties, such as antioxidant, antidiabetic, and prebiotic
activities [3]. Therefore, further insights into their chemical and structural properties as well as a
potential cytotoxicity evaluation would consolidate the knowledge and safety criteria required for
these seaweeds’ enzymatic extracts, with demonstrated biological potential, to be used for food or
nutraceutical applications.
To the best of our knowledge, the chemical and structural characterization of S. muticum and of
O. pinnatifida seaweeds’ enzymatic extracts, and the consecutive correlation with previously observed
bioactivities [3], has not been performed. Hence, after identifying this important need, the main aim
of the research was to determine: i) The elemental, as well as the amino acid and monosaccharide
composition for each extract; ii) structural characterization based on FTIR-ATR and 1H NMR analysis;
and iii) safety validation by assessment of cytotoxicity by testing the metabolic activity of cells when
in contact with the extracts. Safety validation as well as structural and chemical elucidation of the
underlying multifunctional O. pinnatifida and S. muticum enzymatic extracts’ roles in nutritional and
supplement use were achieved.
2. Results and Discussion
2.1. Elemental Inorganic and Organic Composition of Seaweeds’ Enzymatic Extracts
The elemental inorganic composition of the S. muticum and O. pinnatifida enzymatic extracts are
shown in Table 1. For the majority of the macro and micro elements evaluated, increments were
observed in comparison to the concentrations found in the corresponding dry seaweeds as supported by
the respective ratios. Despite the higher contents in minerals, concentration factors thereof, represented
by the calculated ratio, differed between both the macro element and extract origin.
The main constituent in both extracts was indeed K and it was also the macro element with the
maximum associated ratio in the case of the S. muticum extract (ratio of 7.1, Table 1) and the second
highest in the case of the O. pinnatifida extract (ratio of 6.7, Table 1). In the latter case, the macro
element with the largest associated ratio was Mg (ratio of 7.7, Table 1), albeit it had almost a 5-fold
lower content (compared to the K content—174 mg/mglyophilized extract). Magnesium levels were in
the same range of values for both extracts (29.3–36.8 mg/mglyophilized extract) and represented the third
major macro element found in both extracts (after K and Na); magnesium is known as an important
mineral for cardiovascular function. The S. muticum extract also enabled a significant concentration
of the P macro element with a ratio of 5.1 (Table 1). Phosphorus is essential because it is part of the
skeletal structure and teeth, but it also has other important functions, such as its contribution to the
control of the acid-base balance in the blood and to carbohydrate metabolism where it, contributes to
the intestinal absorption of glucose by the process of phosphorylation [6].
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K 407 ± 13 7.1 174 ± 3 6.7
Na 66 ± 2 1.8 222 ± 3 2.4
Ca 2.31 ± 0.06 0.3 8.34 ± 0.04 1.5
Mg 29.3 ± 0.3 2.0 36.8 ± 0.8 7.7
P 11.6 ± 0.5 5.1 6.30 ± 0.09 3.6
Micro
elements
Zn 0.033 ± 0.002 1.3 0.34 ± 0.02 5.9
B 0.319 ± 0.004 3.0 0.28 ± 0.01 2.2
Mn 0.045 ± 0.004 4.1 0.34 ± 0.06 29.2
Fe 0.17 ± 0.02 0.9 1.8 ± 0.1 4.9
Al <LOD - 0.085 ± 0.07 0.6
Cu 0.065 ± 0.002 14.4 0.026 ± 0.001 5.3
Ni <LOD - 0.20 ± 0.01 -
Pb 0.040 ± 0.001 - 0.020 ± 0.001 -
Organic
%N 2.5 - 1.3 -
%C 17.1 - 16.8 -
%H 2.5 - 3.5 -
%S 0.7 - 1.7 -
1 Ratio = content in lyophilized extract/content in dry seaweed; values of organic elements are presented as average
of triplicate samples. LOD: Limit of Detection.
Despite the widespread increase in the content of the various macro elements, the ratio of Na/K
diminished in both extracts in comparison to the corresponding dry seaweeds. In the case of the
S. muticum extract, the ratio of Na/K diminished four-fold from 0.65 to 0.16 whereas the three-fold
decrease for O. pinnatifida extracts was of a larger amplitude, from 3.6 to 1.3. Extracts with a low ratio
of Na/K are good candidates to be used as added-value multifunctional salt replacers contributing to
the important current trend of salt reduction in food formulation and production.
In both enzymatic extracts, variations in terms of microelements content were observed. In general,
S. muticum extract was poorer in microelement composition than the O. pinnatifida counterpart, namely
in Zn, Fe, and Mn contents, which were 10-fold higher in the O. pinnatifida extract. Concerning the
other microelements, higher variability was observed in both extracts. Noteworthy, there was a high
increment of Cu and Mn in S. muticum and in O. pinnatifida extracts, respectively (Table 1), in comparison
to the corresponding dried seaweeds’ contents [5]. The Fe ratio increased 5 times in the O. pinnatifida
extract (ratio of 4.9, Table 1) in comparison to the dried seaweed, being the major microelement found
in this extract. In turn, in the S. muticum extract, the Fe ratio decreased slightly relative to the dried
seaweed. The importance of Fe for human beings is well-known; Fe is a natural component of several
enzymatic systems, being crucial for the transport of oxygen, and its deficiency has been reported as
one of the most common nutritional disorders worldwide that may cause anaemia [7].
Regarding the elemental inorganic composition of the enzymatic S. muticum and O. pinnatifida
extracts, some evidences are highlighted: i) Enzymatic extract of O. pinnatifida obtained with Viscozyme
could be a good contributor of K, Mg, Zn, and Mn (added value) to recommended daily intakes (RDIs)
as well as of Fe (similarly to the dried seaweed) whereas S. muticum obtained with Alcalase could be a
good contributor of K, Mg, and P to RDIs (added value of extract given the concentration factor for P);
ii) in general, enzymatic aqueous extraction enables concentrations of the majority of the macro and
micro element in both extracts.
Observing the organic elemental data of both seaweed extracts (Table 1), slightly higher contents
of %N and %C were observed for the S. muticum enzymatic extract, which was correlated with the
higher nitrogen content found in this extract in comparison with the O. pinnatifida enzymatic extract [3].
In turn, slightly higher values of %H and %S were observed in O. pinnatifida enzymatic extract,
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which was correlated with the higher contents of polysaccharides, including sulfated polysaccharides,
present in this extract in comparison to the S. muticum enzymatic extract [3].
2.2. Monosaccharides and Free Amino Acids
The composition of monosaccharides, uronic acids, and amino-monosaccharides in seaweed
extracts is displayed in Table 2.
Table 2. Composition of monosaccharides, uronic acids, and amino-monosaccharide in enzymatic







Galactose 19.1 ± 0.3 25.3 ± 0.2
Mannose 7.8 ± 0.2 11.4 ± 0.2
Arabinose 0.10 ± 0.01 0.16 ± 0.01
Xylose 3.23 ± 0.02 4.8 ± 0.1
Rhamnose 0.27 ± 0.01 0.52 ± 0.01
Fucose 4.3 ± 0.1 5.60 ± 0.09
Uronic acids
Glucuronic acid 17.4 ± 0.3 27.3 ± 0.2
Galacturonic acid 1.07 ± 0.01 1.50 ± 0.02
Amino-mon. Glucosamine 7.9 ± 0.1 12.7 ± 0.4
All these compounds play important physiological roles in the original source as well as in the
host ingesting these extracts. The most abundant monosaccharides in both seaweed extracts were
galactose, mannose, glucuronic acid, and glucosamine.
Brown marine seaweeds are recognized as a source of complex polysaccharides, such as fucoidans,
laminaram, and alginate. For example, fucoidans are made up of glucose, xylose, fucose, mannose,
galactose, uronic acids, and acetyl groups, which can also contain some protein components as well as
sulfate substituents [8].
According to Dore et al., (2013) [9], fucan sulfated polysaccharides extracted from the brown
seaweed, Sargassum vulgare, were composed of galactose, fucose, xylose, mannose, and glucuronic acid;
proportions varied according to the fractions of the fucans extracted. In the S. muticum extract obtained
with Alcalase, the relative proportions of these monosaccharides found were 1.0:0.22:0.17:0.41:0.91
(Table 2), which provides evidence of the presence of fucoidans in the extract.
Studies on the Sargassum genus concerning fucans shows that they are generally composed
of mannose, galactose, and glucuronic acid residues with partially sulfated-chains consisting of
fucose, xylose, and galactose [9]. For example, alginate-free aqueous extracts of S. muticum had
variable relative proportions of glucose, galactose, fucose, xylose, mannose, and uronic acids [8].
In addition, other factors, such as environmental conditions, geographic location, harvest season,
species, and life-cycle stage, as well as extraction can have impacts on fucoidans’ composition, structure,
and molecular mass [8].
Fucoidans from brown seaweeds do not always have the same backbone: In some cases, a backbone
of 3-linked α-l-fucopyranose is present, whereas in other cases, the backbone has alternating 3- and
4-linked α-l-fucopyranose residues and sulfated galactofucans [10]. The latter are mainly found in
various Sargassum species [11]. These are built of (1→2)-β-d-mannose and/or (1→6)-β-d-galactose
units with branching points formed by (1→4)-α-d-glucuronic acid, (1→4) and/or (1→3)-α-l-fucose,
terminal β-d-xylose, and sometimes (1→4)-α-d-glucose [11].
The presence of glucosamine (Table 2) in the enzymatic extract of S. muticum (7.9 mg/glyophlized extract)
indicates the presence of a proteoglycan-like material, such as that reported for Sargassum filipendula
(Phaeophyceae) by García-Ríos et al. [12]. Glucosamine has been studied as an important amino-sugar
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with beneficial physiological roles in joint health [13]. Although experts have mentioned the need for
more research to explore possible beneficial effects of glucosamine in healthy subjects or on risk factors
of osteoarthritis, prophylactic evidence has been shown in some animal models. According to a survey
of supplements available in the market [14], S. muticum extract may be used to develop glucosamine
rich powder formulations.
Osmundea pinnatifida extract showed higher contents of amino-monosaccharides, uronic acids,
and monosaccharides than the S. muticum counterpart (Table 2), which parallels the total sugars and
sulfated sugars quantified therein. These uphold the potential role of prebiotic activity confirmed
by high counts (>107 Log cfu/mL) of viable cells of Bifidobacterium animalis subsp. lactis BB-12 [3].
The richness of the O. pinnatifida extract in galactose and the lower quantities of xylose are in agreement
with agaran polysaccharides. Agarans are galactans biosynthesized by red seaweeds constituted by
3-linked β-d-galactose alternating with 4-linked α-l-galactose units presenting different degrees of
cyclization of the α-l-galactose residues to give 3,6-anhydro-α-l-galactose [15]. Agarans also present a
certain degree of substitution with methyl ethers, pyruvate ketals, sulfate ester groups, d-xylose, and/or
4-O-methyl-l-galactose side chains, and different percentages of 3,6-anhydrogalactose [16]. Higher
galactose contents with variable proportions of glucose, mannose, xylose, and fucose were reported by
Canelón et al. [15] for aqueous extracts of Laurencia spp. (red seaweed). No data was found in the
literature for red seaweed O. pinnatifida extracts.
Very low contents (1.4–2.7 g/100gprotein) and a low diversity of free amino acids (aspartic acid,
glutamic acid, and methionine) characterized both seaweed extracts. Apparently, the higher nitrogen
content in the S. muticum extract obtained with Alcalase [3] was not reflected in a higher content of free
amino acids, which are probably present in the form of peptides.
2.3. Structural Characterization of Seaweed Extracts
The FTIR-ATR spectra of S. muticum and its enzymatic extract are displayed in Figure 1a.
Both spectra reveal high similarity with most of the bands being common between S. muticum seaweed
and corresponding extract. Practically, differences were only observed in the absorption intensity.
N-H stretching vibrations at 3700–2900 cm−1 as well as from amide I and amide II at 1700–1420 cm−1
are present in both spectra and could be related to proteins; this is in agreement with the previous
results for the nitrogen content [3].
A broad band at 3280–3350 cm−1 and a weaker signal at 2870–2960 cm−1 could be assigned to
O-H and C-H stretching vibrations, but also to N-H stretching vibrations, respectively [17]. The two
characteristic absorptions, a band at around 1630 cm−1 (C-O asymmetric stretching vibration) and a
band of 1410 cm−1 (C-O symmetric stretching vibration) [18], indicates the presence of carboxyl groups
in both S. muticum seaweed and in its extract. In the S. muticum Alcalase extract spectrum, there is
a noteworthy intensity increment of the 1410 cm−1 band in comparison to other bands. This could
indicate the higher presence of protein or peptides in the extract due to the role of the endopeptidase,
Alcalase. This enzyme was, in fact, responsible for a significantly higher nitrogen content (p < 0.05) in
the S. muticum extract [3], but lower contents of free amino acids were detected in this extract.
A focus on the 700–1400 cm−1 region is important because it is related to the seaweeds’
polysaccharides, namely carrageenan and agar in red seaweeds and alginates and fucoidans in
brown seaweeds. Alginate is a polysaccharide, which has been found in brown seaweeds, such as
S. muticum, known to be a linear copolymer of β-D-mannuronic acid and α-l-guluronic acid (1-4)-linked
residues arranged in heteropolymeric and/or homopolymeric blocks. The presence of these acids
can be evidenced especially by the bands around 1030 and 1060 cm−1 assigned to guluronic acid
and at 1320 cm−1 assigned to mannuronic acid, all present both in S. muticum seaweed and in its
extract obtained by Alcalase. In terms of the broad band around 1220–1260 cm−1 in the FTIR-ATR
spectrum, assigned to the presence of sulfate ester groups (S=O), which is a characteristic component
in fucoidan and other sulfated polysaccharides that can be found in some brown seaweeds [17,19],
it is particularly observable in the S. muticum seaweed spectrum and less in its extract obtained by
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Alcalase (Figure 1a). These results are in agreement with the monosaccharide compositions observed
previously for S. muticum extract, which evidences the presence of fucoidans (Table 2). Fucoidans
have been reported as being responsible for some α-glucosidase inhibitory activity from fractions of
Sargassum duplicatum [20]. The α-glucosidase inhibitory activity was also observed for S. muticum
extracts obtained with Alcalase [3].
Figure 1. FTIR-ATR spectra of the red edible seaweed, O. pinnatifida, and of its enzymatic extract
obtained by Viscozyme (a) and of the brown edible seaweed, S. muticum, and of its enzymatic extract
obtained by Alcalase (b).
In terms of the O. pinnatifida seaweed and its enzymatic extract obtained by Viscozyme,
a multi-enzyme complex of carbohydrases (arabanase, cellulase, β-Glucanase, hemicellulase,
and xylanase), the two spectra presented some qualitative differences in the region of 1100 to
1600 cm−1 (Figure 1b). In the extract spectrum, the bands at 1535 and 1212 cm−1 almost disappeared
whereas the band at 1150 cm−1 increased in comparison to the O. pinnatifida seaweed spectrum.
The absorbance bands at 1222 and 1150 cm−1 are characteristic of less sulfated polysaccharides,
such as agar. Strong absorption at 1220 to 1260 cm−1 have been reported by Yu et al., (2012) [21]
for agaran-type polysaccharides isolated from Grateloupia filicina (Rhodophyta), and according to
Rodrigues et al. [5], O. pinnatifida was considered a red seaweed agar-like producer. The increment in
the band at 1150 cm−1 may be related to the possible role of the multi-enzyme complex of carbohydrases
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on matrix polysaccharides (agar) and on cellulose, xylan, and manan fibrils of the complex composite
cell walls of red seaweeds. The extract of O. pinnatifida was characterized by the highest content of
sulfated sugars [5]. The absorbance band at 930 cm−1 in both spectra was assigned to the presence
of 3,6-anhydro-d-galactose found in carrageenan and agar polysaccharides [22]. These results are
in agreement with the monosaccharide compositions observed previously for O. pinnatifida extract,
which evidences the presence of agaran polysaccharides (Table 2).
Since the region of 1700 to 1420 cm−1 was attributed to amide I and amide II, which in turn could
be related to protein, the high reduction of the absorbance band at 1535 cm−1 is probably due to some
loss of nitrogen content during the extraction process. This correlates well with the fact that enzymatic
extracts of O. pinnatifida were characterized by low nitrogen contents [5] and low contents of free
amino acids.
The 1H NMR spectra of both seaweeds’ enzymatic extracts were quite similar (Figure 2a,b).
Figure 2. 1H NMR spectra of enzymatic extracts of Osmundea pinnatifida obtained by Viscozyme (a)
and Sargassum muticum obtained by with Alcalase (b) (the peak at 4.7 ppm indicates the water signal),
as well as the relative abundance of each type of proton (c) estimated as the partial integrals of the
spectra reported in Figure 2a,b for the enzymatic extracts of seaweeds where H-C: purely alkylic
hydrogen atoms; H-C-C=: allylic (H-Cα-C=), carbonyl or imino (H-Cα-C=O or H-Cα-C=N) groups;
H-C-O: aliphatic C-H directly bound to an oxygen atom; H-Ar: aromatic hydrogen atoms.
These spectra reveal distinct peaks overlaying much broader bands, an expected observation
given the nature of the NMR spectra of complex mixtures of organic compounds [23]. Despite the
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large variety of overlapping resonances, each 1H NMR spectrum was investigated on the basis of the
chemical shift assignments described in the literature for organic compounds [23,24]. Accordingly,
four main regions of chemical shifts were considered in each spectrum:
1) δH = 0.6–1.8 ppm: Aliphatic protons, H–C; -CH > -CH2 > -CH3.
2) δH = 1.8–3.2 ppm: Protons bound to carbon atoms in the alpha position to unsaturated groups
in allylic (H-Cα-C=), carbonyl, or imino (H-Cα-C=O or H-Cα-C=N) groups, and protons in
secondary and tertiary amines (H-C-NR2 and NR3, respectively).
3) δH = 3.2–4.1 ppm: Aliphatic protons on carbon atoms singly bound to oxygen atoms (H-C-O-CO-R
> H-C-OH or H-C-O-C) in alcohols, polyols, ethers, and esters.
4) δH = 6.5–8.5 ppm (aromatic protons).
In order to further understand the 1H NMR data, each spectral region was quantitatively integrated
so that the abundance of each of the different types of protons in the different extracts could be assessed;
the results are depicted in Figure 2c. Anomeric protons of glycosidic structures [25] related with the
fifth region (δH = 4.1–6.0 ppm) were also considered, but not integrated since the wide and intense
peak at 4.7 ppm is due to the water signal.
In accordance with the spectra, the relative abundance of each type of protons is, in general,
relatively similar to the different extracts, but some points are worthy of being highlighted. The higher
percentages of protons belong to the group of aliphatic H-C directly bound to an oxygen atom (H-C-O)
probably due to the presence of nonaromatic ring structures, such as sugars [24]. Higher values
(67%) are observed for the enzymatic extract of O. pinnatifida obtained with Viscozyme than for the
enzymatic extract of S. muticum (43%) obtained with Alcalase. These values are in agreement with
previously discussed trends for the FTIR-ATR spectra and sugars: Total sugar and sulfated sugar
contents found in the O. pinnatifida enzymatic extract were 2.3 and 8-fold higher than in the S. muticum
enzymatic extracts, respectively [3]. According to Bubb [26], 1H spectra of carbohydrates do contain
some well-resolved signals, including those of anomeric protons (δH = 4.4–5.5 ppm), acetyl (~δH =
2.0–2.1 ppm) and methyl (~δH = 1.2 ppm) groups as well as other protons that are influenced by specific
functionality, including amino groups, phosphorylation, sulfatation, glycosylation, and acetylation,
or lack of functionality as in deoxy-sugars. Signals due to polyols were described by Tanniou et al. [27],
who studied the biochemical composition of S. muticum populations by 1H HRMAS (high resolution
magic angle spinning) NMR and assigned chemical shifts to polyols (mannitol) at δH = 3.5–4.0 ppm.
Not many differences were observed for protons in the alpha position to unsaturated groups in
allylic (H-C∞-C=), carbonyl, or imino (H-C∞-C=O or H-C∞-C=N) groups for both seaweed extracts,
but the slightly higher value for the enzymatic extract of S. muticum (27%) could be related to Alcalase
activity, which lead to a 2.4 times higher content of nitrogen compounds in comparison to the enzymatic
extract of O. pinnatifida obtained with Viscozyme [3]. According to Gonzaga et al. [25], a chemical shift
at 2.78 ppm could be assigned to protein groups, which was visible in the spectrum of the S. muticum
enzymatic extract, but not in the corresponding O. pinnatifida enzymatic extract (Figure 2a,b). Proteins
were described as being associated to cell wall polysaccharides, being part of the structure of the
seaweed cell walls [28].
In terms of purely alkylic hydrogen atoms (H-C; 26%) and of aromatic hydrogen atoms (H-Ar;
4%), the enzymatic extract of S. muticum was richer (26 and 4%, respectively) in these atoms than the
enzymatic extract of O. pinnatifida (8.9 and 0.2%, respectively) (Figure 2c). Signals at δH = 7.2–7.3 ppm
and δH = 7.6–7.8 ppm (Figure 2a,b) are consistent with the presence of aromatic units containing both
electron-donor (e.g., phenolic groups) and electron-acceptor (e.g., carbonyl and carboxyl) substituents.
The content of phenolic contents in aqueous extracts was shown to be low; albeit contents of 290 and 123
μgcathecol equiv/glyoph extract were determined in the enzymatic extracts of S. muticum and O. pinnatifida
with some potential antioxidant activity, respectively [3]. Signals due to the presence of unsaturated
fatty acids were described by Tanniou et al. [27] in S. muticum at δH = 1.0–1.5 ppm.
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In the anomeric spectral region (δH = 4.1–6.0 ppm), different patterns were observed for both
seaweed extracts (Figure 2a,b). In the case of the enzymatic extract of O. pinnatifida, signals in the region
of δH = 4.2–4.5 and ~δH = 5.1 ppm could be assigned toα andβ reducing end units whereas no particular
signals were well resolved in this region for the enzymatic extract of S. muticum. According to Barros
et al. [29], the signal from an anomeric proton at δH = 5.13 was assigned to 3,6-α-l-anhydrogalactose
while the signal at δH = 4.56 was attributed to β-d-galactose for polysaccharides of a red seaweed,
Crassiphycus caudatus (formerly Gracilaria caudata). No literature references were found for the 1H NMR
spectra O. pinnatifida extracts. According to Llanes et al. [30], the absence of signals in the regions of δH
= 5.0–5.3 ppm and δH = 4.7–4.9 ppm expected for anomeric protons of α and β reducing end units
that are released (d-anomeric protons of mannuronosyl and l-guluronosyl residues from hydrolysis of
sodium alginate from Sargassum sp.) are an indication of limited hydrolysis of the Sargassum alginate
or resulted from overlapping resonance with the water signal at 4.7 ppm.
2.4. Cytotoxicity Evaluation
In order to consolidate the safety of both seaweed extracts, the cytotoxicity of O. pinnatifida and
S. muticum extracts was assessed by measuring the cellular metabolic activity of mammalian mouse
fibroblasts cultured with increasing concentrations of both extracts. A range of concentrations from 0
to 4 mglyophilized extract/mL was tested. The results are summarized in Figure 3, where cell metabolic
activity was evaluated by the resazurin assay. Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is
a blue and non-fluorescent compound, which is reduced by viable cells in the presence of mitochondrial
NADPH dehydrogenases into pink and highly fluorescent resorufin [31]. After applying the resazurin
assay, L929 cells were able to produce high amounts of the resorufin compound upon incubation
with different concentrations of both seaweed extracts, which reveals normal cell metabolism and
mitochondrial integrity/activity that can be inferred as a direct measure of cell viability.
Upon exposure to increasing concentrations of seaweed extracts, cells did not present cytotoxic
behavior (Figure 3), indicating that both extracts do not provoke a detrimental effect on the metabolic
activity of cells.
In contrast, the supplementation of the culture medium with the extracts seemed to promote
an increase of cell viability, which was especially noticeable for the O. pinnatifida extracts (Figure 3a).
When compared to the viability of cells cultured in the absence of extracts (0 mglyophilized extract/mL),
cells cultured in the presence of the different concentrations of these extracts demonstrated equal or
higher metabolic activity in comparison to the negative control (culture medium only), which can
be attributed to the supplementation of the culture media with nutrients from the extracts. For the
O. pinnatifida extracts, the time of exposure increased the cell metabolic activity for all tested
concentrations (Figure 3a), while for S. muticum, a slight decrease was observed after 72 h of
exposure (Figure 3b).
Consumer oriented applications, such as biomedical, pharmaceutical, or food applications,
are highly demanding in terms of the cytotoxic evaluation for new compounds [32]. Cytotoxic
evaluation of seaweed-based compounds [33–35] is under-exploited in the literature, and given their
significance, this study is of key importance. The anti-tumorigenic effects of compounds extracted from
seaweeds were reported [36,37], but it is also highly important to study the effects of these ingredients
on normal mammalian cells, an added-value of this study.
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Figure 3. Metabolic activity by the resazurin assay on mouse lung fibroblast cells (L929) cells exposed
to different concentrations of enzymatic extracts of Osmundea pinnatifida (a) and Sargassum muticum
(b). Time of exposure was statistically significant (p < 0.05) for each concentration of extract of both
seaweeds. Concentration of extract was not statistically significant (p > 0.05) for S. muticum extracts;
for O. pinnatifida extracts, statistically significant differences were obtained between 0 mg/mL (*) and
0.5–2.0 mg/mL (* *) and between 1.5 mg/mL (#) and 4.0 mg/mL (# #), respectively.
3. Materials and Methods
3.1. Seaweed Extracts
Specimens of the red seaweed (Rhodophyta, Florideophyceae), Osmundea pinnatifida (Ceramiales)
Rhodomelaceae family, and of the brown seaweed (Heterokontophyta, Phaeophyceae), Sargassum
muticum (Fucales) Sargassaceae family, were harvested in Buarcos bay (Figueira da Foz, Portugal),
and cleaned and dried according to Rodrigues et al., (2015b) [5]. Enzymatic extraction of O. pinnatifida
by Viscozyme L (Sigma-Aldrich, St. Louis, MO, USA) and of S. muticum by Alcalase (Sigma-Aldrich)
was performed according to procedures described by Rodrigues et al., (2015a) [3]. In this study,
the authors used lyophilized aliquots of the same extracts obtained by Rodrigues et al., (2015a) [3] in
order to enable accurate comparison and correlation analyses.
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3.2. Chemical Characterization
3.2.1. Elemental Analysis
Determination of the inorganic elements, Mo, B, Zn, P, Cd, Co, Ni, Mn, Fe, Mg, Ca, Cu, Na, Al,
and K, in lyophilized extracts was performed in two steps: Microwave-assisted digestion followed
by determination of the 15 elements using an inductively coupled plasma (ICP) optical emission
spectrometer (OES) with radial plasma configuration according to Rodrigues et al., (2015b) [5].
Three replicates were performed for each sample as well as blanks.
The organic elements, C, H, S, and N, in lyophilized extracts were quantified using a Truspec
630-200-200 Elemental Analyser (Mönchengladbach, Germany). Triplicate samples up to 3 mg for
each extract were placed under combustion at 1075 ◦C. Carbon, H, and S were detected by infrared
absorption whereas N was detected by thermal conductivity.
3.2.2. Analysis of Monosaccharide Composition
Monosaccharide composition was analyzed by high performance liquid chromatography coupled
to a UV detector (HPLC-UV, Agilent 1100, Waldbronn, Germany,) after acid hydrolysis. For each
lyophilized extract, 2.5 mg of sample was hydrolyzed with 2 mL of 2 M trifluoroacetic acid at
110 ◦C for 4 h. The hydrolysate was then dried by vacuum evaporation at 50 ◦C and re-dissolved
in 2 mL of deionized water. The hydrolysate solution (450 μL) was mixed with 450 μL of
1-phenyl-3-methyl-5-pyrazolone solution (0.5 M in methanol) and 450 μL of NaOH solution (0.3 M) and
then reacted at 70 ◦C for 30 min. The reaction was stopped by neutralizing with 450 μL of 0.3 M HCl,
and the product was then partitioned with chloroform three times. The aqueous layer was collected
and filtered through a 0.45 μM membrane and was applied to HPLC.
The HPLC analysis was performed using a ZORBAX ECLIPSE XDB-C18 column (Agilent)
(4.6 × 150 mm, 5 micro) at 25 ◦C with potassium phosphate buffer saline (0.05 M, pH 6.9) with
15% (solvent A) and 40% acetonitrile (solvent B) as mobile phases and detected by a UV detector at
250 nm. All analyses were made in quintuplicate and quantified using a calibration curve built with
monosaccharide standards (Sigma Aldrich, St. Louis, MO, USA) and expressed as mg/glyophilized extract.
Glucose, galactose, arabinose, fucose, mannose, xylose, rhamnose, glucuronic acid, galacturonic acid,
and glucosamine-6-phosphate were used as the standards. Recovery ranged between 93% and 99%
with an LOD of 0.095 mg/g.
3.2.3. Analysis of Amino Acids
The free amino acid contents of each extract was performed by pre-column derivatization with
the orthophthalaldehyde (OPA) methodology. Isoindole-type fluorescent derivatives were formed
in an alkaline solution (borate buffer pH 10.4) from OPA, 2-sulfanylethanol, and the primary amine
group of the amino acid. The derivatives were separated by HPLC (Beckman Coulter, California USA)
coupled to a fluorescence detector (Waters, Milford. MA, USA) according to the procedure of Proestos
et al., (2008) [38]. Of each sample, 100 μL, at concentration of 10 mg mL−1, was derivatized according
to the OPA method and the injection volume of derivatives was 20 μL. All analyses were made in
triplicate and quantified using a calibration curve built with amino acid pure standards (Sigma Aldrich,
St. Louis MO, USA) and expressed as g/100 g of protein content. Recovery ranged between 92% and
99% with an LOD of 0.02 g/100 g of protein content.
3.2.4. FTIR-ATR Analysis
Samples of lyophilized extracts were analyzed by Fourier Transform Infrared Spectroscopy with
attenuated total reflectance (FTIR-ATR) (Spectrum 100, PerkinElmer, Shelton, CT, USA) according to
procedures described in Rodrigues et al., (2015b) [5].
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3.2.5. 1H NMR Analysis
Twenty milligrams of each lyophilized extract were suspended in 700 μL of D2O and homogenized
for 10 min in a vortex. Then, an amount of dissolved lyophilized extract (650 μL) was placed in 5 mm
NMR tubes (Sigma-Aldrich, 528-PP, 5 mm).
All spectra were acquired on a Bruker Advance 300 spectrometer (Karlsruhe, Germany) with an
operating frequency of 300.13 MHz. Spectra were acquired with a spinning rate of 20 Hz, a contact time
of 4.75 s, and with the pulse program, ZG30. The recycle delay was 1 s and the length of the proton
90 pulses was 9.00 μs. About 56 scans were collected for each spectrum. A 0.3 Hz line broadening
weighting function and a baseline correction were applied. The identification of functional groups in
the NMR spectra was based on their chemical shift (δH) relative to that of the water (4.7 ppm).
3.3. Cytotoxicity Assessment
Mouse lung fibroblast cell line (L929) was used to assess cytotoxicity. Cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, Verviers, Belgium) supplemented with 10%
fetal bovine serum (FBS) (Lonza, Verviers, Belgium) and 1% of antibiotic–antimycotic mixture (Biowest,
Nuaillé, France). The cells were grown at 37 ◦C and 5% CO2 in a humidified incubator. Exponentially
growing cells were used throughout the experiment. TrypLE™ Express Enzyme (Gibco, New York,
NY, USA) was used to detach the cells.
For each cell culture assay, the cells were seeded in 48-well plates (n = 3) at a concentration of 2 ×
104 cells/well and allowed to attach for 24 h at 37 ◦C and 5% CO2. After that time, cells were washed with
phosphate buffered saline (PBS) and exposed for 24, 48, and 72 h to enzymatic extracts of O. pinnatifida
and S. muticum containing different concentrations (0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 mg/mL). All extracts
were previously prepared using DMEM and filtered using Vacuum Filtration rapid-Filtermax (PES
0.22 μL membranes) (Trasadingen, Switzerland). Dimethyl sulfoxide (DMSO 20%) was used as a
positive control of cell death, due to its strong cytotoxic effect. Culture medium was used as a
negative control of cytotoxicity, considered to be the ideal situation for cell growth. At each time
point, exposed and control wells were washed with PBS and cell metabolic activity was assessed
using the resazurin assay [31]. Cells with 20% v/v of stock resazurin solution (1 mg/mL, Sigma) in
culture medium were incubated for 2 h at 37 ◦C. Afterwards, 100 μL of supernatants were transferred
to a 96-well black plate (Greiner) and the relative fluorescence units (RFU) were measured using a
microplate reader, SynergyTM Mx HM550 (BioTek® Instruments, Vermont, NH, USA), set at 530/590 nm
(excitation/emission wavelength, respectively). The obtained results were normalized by subtraction
of the negative control (without cells). Samples were measured in triplicate and experiments repeated
at least three times.
3.4. Statistical Analysis
Two-way analysis of variance (ANOVA) was carried out for cytotoxicity assessment of both
extracts, with SigmaStat™ (Systat Software, Chicago, IL, USA) to assess if the concentration of the
extract and time of exposure were significant sources of variation for metabolic activity (resazurin
assay) of L929 fibroblasts. For each ANOVA, it was verified that both the normality and equal variance
tests were non-significant (p > 0.05) as well as interactions between the concentration and time (p > 0.05).
The Holm-Sidak method was used for pair-wise comparisons both for concentration and time effects.
4. Conclusions
The extensive chemical, structural, and cytotoxicity characterization of S. muticum and O. pinnatifida
enzymatic extracts enabled a deeper understanding and justification for their previously identified
multifunctionality. Analysis of the elemental inorganic composition of the seaweeds showed that
enzymatic aqueous extraction enabled an important concentration effect of almost all macro and micro
elements in comparison to the dry seaweeds’ contents, and in some cases, the nutritional value (an
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extract containing at least 15% of the mineral RDI value) was enhanced, in particular for K and P in the
S. muticum enzymatic extract and for K, Mg, Zn, and Mn in the O. pinnatifida extract.
Overall, the higher contents of monosaccharides, uronic acids, and glucosamine, which were
observed in the O. pinnatifida extract obtained with Viscozyme in comparison to the S. muticum extract,
were in agreement with the total sugars and sulfated sugars previously quantified in these extracts,
and were further well correlated with the structural analysis obtained from the FTIR-ATR and 1H
NMR spectra. The results highlight the relevance of such characterization since both seaweed extracts
showed a diversity of sugars in variable molar ratios. On the other hand, amino acids were not
representative both qualitatively and quantitatively.
According to chemical and structural analysis by FTIR-ATR and 1H NMR, both extracts,
with prebiotic and antidiabetic potential, are composed of important polysaccharide structures,
confirming, for example, fucoidans in S. muticum extract or agarans as sulfated polysaccharides in
O. pinnatifida extract among the main representative polysaccharides. No cytotoxicity against normal
mammalian cells was observed, making these seaweed extracts very interesting functional ingredients,
which could be explored as a food ingredient (salt replacer, nutrient vector) or nutraceutical supplement.
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Abstract: The deterioration of bone formation is a leading cause of age-related bone disorders. Lack
of bone formation is induced by decreased osteoblastogenesis. In this study, osteoblastogenesis
promoting effects of algal phlorotannin, phlorofucofuroeckol A (PFF-A), were evaluated. PFF-A was
isolated from brown alga Ecklonia cava. The ability of PFF-A to enhance osteoblast differentiation was
observed in murine pre-osteoblast cell line MC3T3-E1 and human bone marrow-derived mesenchymal
stem cells (huBM-MSCs). Proliferation and alkaline phosphatase (ALP) activity of osteoblasts during
differentiation was assayed following PFF-A treatment along extracellular mineralization. In addition,
effect of PFF-A on osteoblast maturation pathways such as Runx2 and Smads was analyzed. Treatment
of PFF-A was able to enhance the proliferation of differentiating osteoblasts. Also, ALP activity
was observed to be increased. Osteoblasts showed increased extracellular mineralization, observed
by Alizarin Red staining, following PFF-A treatment. In addition, expression levels of critical
proteins in osteoblastogenesis such as ALP, bone morphogenetic protein-2 (BMP-2), osteocalcin and
β-catenin were stimulated after the introduction of PFF-A. In conclusion, PFF-A was suggested to be
a potential natural product with osteoblastogenesis enhancing effects which can be utilized against
bone-remodeling imbalances and osteoporosis-related complications.
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1. Introduction
Prevalence of bone related complications is steadily increasing while osteoporosis and linked
syndromes are causing low life quality and mortality for more of today’s elder population compared
to the previous decade [1,2]. Among these complications, osteoporosis is one of the most commonly
seen bone disorders and is characterized by bone formation imbalance. Bone fractures of elderly
patients are mostly diagnosed with osteoporosis. Osteoporosis is being treated via different approaches,
including but not limited to synthetic and natural-origin drugs which are targeting different mechanisms
involved in bone formation [3–5]. The bone formation imbalance in osteoporosis is caused by bone
volume loss while the formation of new bone tissue diminishes through inhibited osteogenesis. Hence,
the stimulation of osteoblast formation is one of the main approaches to treat bone mass imbalance [6].
Additionally, links between osteogenesis and pathways related to onset of diabetes and obesity raises
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complex problems for elderly patients who are diagnosed with other metabolic syndromes along with
osteoporosis [7,8]. Natural product research is gaining attention for the treatment or prevention of various
metabolic syndromes including osteoporosis due their biocompatibility and fewer side effects compared
to on the market drugs. In this context, several studies have reported the in vitro osteoblastogenesis
inducing effects of marine-based nutraceuticals for the relief of osteoporotic complications [9,10].
Ecklonia cava (order Laminariales, family Lessoniaceae) is an edible brown alga growing abundantly
on the shores of Japan and Korea where it is consumed as a part of daily diet. Numerous studies
were conducted reporting its potential uses as rich source of bioactive secondary metabolites [11–13].
Phlorotannins are phloroglucinol oligomers [14] found richly in E. cava and credited for diverse
health benefits including but not limited to antioxidant [15], antibacterial [16], anti-inflammation [17],
anti-allergy [18], and anti-metastasis [19] activities. In this context, current study focused on the
possible osteogenesis enhancing effect of phlorofucofuroeckol A (PFF-A) isolated from E. cava, as a part
of ongoing research to elucidate natural compounds from marine sources with important bioactivities.
2. Results
PFF-A was obtained from E. cava and its chemical structure (Figure 1) was confirmed by comparison
of 1H NMR and 13C NMR spectral data with previously published reports as described earlier [20].
PFF-A was tested for its potential activity on enhancing osteoblastic differentiation in two different cell
lines; MC3T3-E1 murine pre-osteoblasts and human bone marrow-derived mesenchymal stem cells
(huBM-MSCs). Cells were induced to differentiate into osteoblasts with or without PFF-A treatment to
observe the enhancing effects of the PFF-A on osteoblastogenesis.
Figure 1. Chemical structure of phlorofucofuroeckol A (PFF-A).
2.1. Effect of PFF-A on the Differentiation of Murine Pre-osteoblasts
MC3T3-E1 cells are murine calvarial osteoblast precursor cells widely used in studies for their ability
to differentiate into mature osteoblasts. Therefore, any effect of PFF-A on osteoblastic differentiation
was tested first in differentiating MC3T3-E1 cells. Measurement of viable cells, alkaline phosphatase
(ALP) activity and extracellular mineralization as calcium deposits were used as markers for maturation
into osteoblasts.
Presence of PFF-A slightly stimulated the viable cell count of MC3T3-E1 osteoblasts at 5 μM
(Figure 2a) compared to the untreated control. Differentiated osteoblasts showed elevated ALP activity
which was significantly enhanced after PFF-A treatment at the concentration of 5 μM (Figure 2b).
Enhanced ALP activity and osteoblastogenesis was also confirmed by extracellular mineralization
assessed by Alizarin Red staining. The extracellular matrix calcium deposition levels were increased
during differentiation of MC3T3-E1 cells into mature osteoblasts as a marker of bone tissue formation.
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Treatment of MC3T3-E1 osteoblasts with PFF-A during differentiation exhibited elevated extracellular
mineralization shown by quantification of the calcium staining (Figure 3a). PFF-A treatment at 5 and
20 μM resulted in enhanced calcium deposition compared to untreated control osteoblasts. Effect of
PFF-A on the osteoblast differentiation pathways was analyzed by the investigation of the transcription
pathways of osteoblastogenesis-related proteins. Cells treated with increasing doses of PFF-A expressed
enhanced levels of ALP and osteocalcin mRNA expression (Figure 3b). In addition, protein expression
levels of ALP, bone morphologic protein (BMP)-2 and osteocalcin were strongly elevated in PFF-A
treated osteoblasts compared to untreated control (Figure 3c). Osteocalcin protein levels were enhanced
in higher levels than its mRNA expression.
Figure 2. Effect of PFF-A on the cell viability (a) and alkaline phosphatase (ALP) activity (b) of
MC3T3-E1 osteoblasts. Viability of cells and ALP activity were analyzed at 5 and 7 days after MC3T3-E1
cells were induced to differentiate, respectively. Cell viability was expressed as a percentage of
osteoinduced untreated control group (0 μM). ALP activity was given as absorbance (410 nm) values
of the colorimetric quantification of enzymatic activity. Values are means ± SD of three different
experiments run in triplicate (n = 3). a–c Means with the different letters are significantly different
(p < 0.05) by Duncan’s multiple range test.
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Figure 3. Images of MC3T3-E1 osteoblasts treated with PFF-A and stained with Alizarin Red for
extracellular calcium deposits, and absorbance values (560 nm) of eluted dye retained in the cells (a).
MC3T3-E1 osteoblasts were stained with Alizarin Red 14 days after the cells were induced to differentiate.
(Bk: Non-differentiated blank group which was given growth medium instead of differentiation cocktail).
Effect of PFF-A on the expression of mRNA (b) and protein (c) levels of osteoblast differentiation markers.
Cells were harvested for reverse transcription-polymerase chain reaction (RT-PCR) and Western blot
analysis 12 days after the cells were induced to differentiate. Expression levels quantified by densiometric
analysis of bands were given as percentage of osteoinduced untreated control group after normalization
using internal control β-actin. Non-induced untreated blank group was fed growth medium instead of
differentiation cocktail. Values are means ± SD of three separate experiments (n = 3). a–d Means with the
different letters are significantly different (p < 0.05) by Duncan’s multiple range test. Scale bar: 25 μm.
2.2. Effect of PFF-A on the Osteogenic Differentiation of huBM-MSCs
Following the confirmation of its potential osteoblast differentiation enhancing effect in
pre-osteoblasts, the mechanism behind this effect of PFF-A was investigated in bone marrow derived
mesenchymal stem cells. The cytotoxicity assay showed that PFF-A treatment did not cause any
significant toxicity in the huBM-MSCs up to concentration of 10 μM (Figure 4a). However, 20 μM PFF-A
treatment caused a decrease in cell viability of the huBM-MSCs. Stem cells induced for osteogenic
differentiation exhibited stimulated cell proliferation and PFF-A treatment (20 μM) enhanced the viable
cell amount by increasing cell viability 24.53% compared to untreated control (Figure 4b). Enhancing
effect of PFF-A was also confirmed on the ALP activity and extracellular mineralization of the osseous
differentiated MSCs. At the highest concentration treated (20 μM), ALP activity in the osteoinduced
huBM-MSCs was calculated 40.45 U/mL compared to 31.60 U/mL of untreated osteoblasts (Figure 5a).
Enhancing of ALP activity was also observed as elevated extracellular mineralization. PFF-A treatment
(20 μM) enhanced the extracellular calcium deposits by 20.52% compared to osseous differentiated
MSCs without PFF-A treatment (Figure 5b).
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Figure 4. Effect of PFF-A on the viability of non-induced huBM-MSCs (a) and the viability of
osteoinduced huBM-MSCs (b). Viability of osteoinduced huBM-MSCs was analyzed 5 days after
inducement of differentiation. Cell viability was expressed as percentage of untreated (a) and
osteoinduced untreated (b) control group (0 μM). Values are means ± SD of three separate experiment
run in triplicates (n = 3). a–c Means with the different letters are significantly different (p < 0.05) by
Duncan’s multiple range test.
Figure 5. ALP activity of osteoinduced huBM-MSCs treated with PFF-A (a). Images of osteoinduced
huBM-MSCs stained with Alizarin Red for extracellular calcium deposits and absorbance (560 nm)
values of eluted dye retained in the cells (b). Cells were analyzed after 7 days of incubation with
differentiation medium for ALP activity and 14 days of incubation with differentiation medium for
Alizarin Red staining. Values are means ± SD of three separate experiments (run in triplicates for ALP
activity) (n = 3). a–e Means with the different letters are significantly different (p < 0.05) by Duncan’s
multiple range test (Bk: Non-differentiated untreated blank group which was given growth medium
instead of differentiation cocktail). Scale bar: 50 μm.
Osteoblastogenesis enhancing mechanism of PFF-A was investigated by analyzing the expression
of osseous differentiation inducing and regulatory pathways during the osteoinduced huBM-MSC
differentiation. Osteoinduced huBM-MSCs expressed high levels of ALP mRNA as a marker of
differentiation, and Runx2 and osteocalcin mRNA as a marker of osseous differentiated MSCs.
Treatment with PFF-A dose-dependently increased the mRNA expression levels of ALP, osteocalcin
and Runx2 compared to untreated control (Figure 6a). Consequently, protein levels of same markers
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(ALP, osteocalcin and Runx2) were observed to be enhanced following PFF-A treatment in a dose
dependent manner (Figure 6b). In addition, osterix protein levels were investigated as osterix is a
transcription factor activated by Wnt/β-catenin pathway and responsible for the osseous differentiation
of huBM-MSCs. PFF-A treatment was also enhanced the levels of osterix in a dose-dependent manner
(Figure 6b).
Figure 6. Effect of PFF-A on the expression of mRNA (a) and protein (b) levels of osteoblast
differentiation markers in osteoinduced huBM-MSCs analyzed by RT-PCR and Western blotting,
respectively. Cells were harvested for RT-PCR and Western blot analysis 12 days after the cells were
induced to differentiate. Expression levels quantified by densiometric analysis of bands were given
as percentage of osteoinduced untreated control group after normalization using internal control
β-actin. Non-induced untreated blank group was fed growth medium instead of differentiation cocktail.
Values are means ± SD of three separate experiments (n = 3). a–e Means with the different letters are
significantly different (p < 0.05) by Duncan’s multiple range test.
Effect of PFF-A on BMP and Wnt/β-Catenin Pathway
Mechanism of the enhancing ability of PFF-A was further analyzed by protein levels of the
osteoblast differentiation ignitor pathways. Osteoinduced huBM-MSCs showed elevated levels of
Smad1/5/8 complex, and β-catenin (Figure 7). Two main intracellular pathways that further activate the
expression of osteoblast-specific genes. Activation of β-catenin and Smad1/5/8 complex were increased
seen as the phosphorylated Smad1/5 and β-catenin were significantly higher than non-differentiated
cells. Introduction of PFF-A enhanced the levels of this phosphorylation along with the expression of
BMP2 and Wnt10a. However, axin, a negative regulator of the osteoblast differentiation was observed
to be highly expressed during the differentiation and was not affected by PFF-A treatment (Figure 7).
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Figure 7. Effect of PFF-A on the levels of BMP2, Wnt 10a, and the inactive and phosphorylated (p-)
Smad1 and β-catenin in osteoinduced huBM-MSCs analyzed by Western blotting. Cells were harvested
for Western blot analysis 12 days after the cells were induced to differentiate. Expression levels of
BMP2, Wnt 10a and Axin quantified by densiometric analysis of bands were given as percentage of
osteoinduced untreated control group after normalization using internal control β-actin. Changes in
p-Smad1 and p-β-catenin levels relative to their unphosphorylated forms were given as percentage of
osteoinduced untreated control group after normalization using internal control β-actin. Values are
means ± SD of three separate experiments (n = 3). a–c Means with the different letters are significantly
different (p < 0.05) by Duncan’s multiple range test.
3. Discussion
Regulation of bone remodeling is a highly critical process for a healthy bone metabolism, and any
disorders of bone mass is evidently linked with variety of diseases such as arthritis, tumor growth and
osteoporosis [21,22]. As the bone formation during the remodeling is dependent on the osteogenic
differentiation in bone tissue, controlling the osteoblastogenesis is hence an important target to prevent
or treat bone mass complications, especially osteoporosis. Bone marrow stroma derived osteoblasts
are differentiated cells from mesenchymal stem cells, and they produce ALP for mineralization of the
bone, and osteocalcin, which is an important hormone taking crucial roles in energy metabolism [23].
Osteoblastic differentiation of bone marrow mesenchymal stem cells is regulated by more than one
signaling pathway mainly involving BMP growth factors and activation of Wnt/β-catenin/TCF
cascade along with transforming growth factor (TGF)-β and mitogen-activated protein kinase
(MAPK) pathways [24]. Among them, BMP pathway accompanied by β-catenin activation controls
the osteoblastogenesis and subsequent formation of bone tissue by mineralization and required
protein secretion.
Bone formation is carried out by increased proliferation of osteoblasts which is followed by
elevated ALP activity. Results showed that PFF-A enhanced the viable cell count of osteoinduced
pre-osteoblasts and huBM-MSCs. However, at 20 μM treatment PFF-A decreased the cell viability of
non-induced huBM-MSCs while showing an opposite effect in osteoinduced huBM-MSCs. Although
PFF-A was considered slightly cytotoxic for huBM-MSCs at 20 μM, osteoinducement was speculated to
hinder or negate this effect. Increased ALP activity is a marker of osteoblast maturation and is needed
for the last step of bone formation, extracellular mineralization [25]. Current data showed that PFF-A
was able to increase the ALP activity in the osteoblasts differentiated from both pre-osteoblasts and
stem cells. This also was confirmed by the elevated levels of osterix in huBM-MSCs treated with PFF-A.
These results suggested that PFF-A had an enhancing effect on the osteogenic differentiation of cells.
Runx2 is the key transcription factor for osteoblastogenesis and has important roles in the
maturation of osteoblasts. It is translocated into nucleus as a downstream factor in the Wnt and BMP
pathways [26,27]. Both pathways stimulate the translocation of Runx2 and subsequent maturation of
osteoblasts. Results showed that PFF-A increased the mRNA and protein expression levels of Runx2 in
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osteoinduced huBM-MSCs indicating that mechanism of PFF-A mediated osteoblast differentiation
enhancement might occurred via enhancing the Wnt and/or BMP pathways. Therefore, it was suggested
that PFF-A regulated the Wnt/β-catenin and BMP pathways which in turn induced Runx2 translocation
all of which consequently elevated ALP activity and committed the stem cell differentiation to
osteogenic lineage.
Mechanism of PFF-A mediated enhanced osteoblastogenesis was further analyzed via activation
and expression levels of Wnt and BMP pathways. The pathway that starts with activation of BMP
receptors stimulates and induces the commitment of stem cells to osteogenic lineage instead of
adipogenic [28]. This signaling cascade includes phosphorylation of Smad1/5/8 complex in order
to facilitate its interaction with Smad4 and their translocation to nucleus for further expression of
osteoblast-specific genes via Runx2 [29,30]. Various plant-based metabolites such as flavonoids,
phlorotannins, polysaccharides and similar phenol-based compounds were shown to stimulate
osteoblast differentiation via BMP pathway by inducing the expression of BMP or any other activator
protein in the cascade [31–33]. Current results showed that PFF-A presence not only increased BMP-2
expression levels for both mRNA and protein, but also notably stimulated the phosphorylation
of Smad1/5/8 protein. Elevated levels of both BMP-2 and phosphorylated Smad1/5/8 compared to
untreated control cells further confirmed that PFF-A-induced increase in osteoblast differentiation is
related to BMP pathway.
Aside BMP pathway, Wnt/β-catenin pathway is also a key regulator for the stem cell commitment
to osteogenic lineage [34]. It is heavily involved in new bone tissue remodeling and new bone formation.
Activation of Wnt receptors in stem cells initiates a signaling cascade which involves activation and
translocation to nucleus of β-catenin and stimulates the transcription of osteoblast-specific genes such
as ALP and osterix [26]. The results showed that huBM-MSCs treated with PFF-A exhibited increased
levels of Wnt-10a and phosphorylation of β-catenin. Significant increase in the activation ratio of
β-catenin clearly suggested that Wnt/β-catenin pathway was also involved in the enhancing stem cell
osteoblastogenesis by PFF-A treatment.
Although there are not any reports on specific side-effects of PFF-A, it could be speculated that
it shares the common disadvantages of phlorotannins. Phlorotannins are known to be non-specific
inhibitors of several enzymes that act in digestive track such as α-glucosidase and α-amylase [35,36].
Also, it was reported that tannin derivatives could cause irritation in stomach and potential damage in
liver [37]. However, the doses that shown to exert serious side effects are significantly higher and not
comparable to the tested concentrations. Although, PFF-A was assumed to be possess minimal side
effects further studies to evaluate its dosage and relative side-effects would be urged.
In conclusion, present study showed that PFF-A could enhance the osteogenic differentiation of
pre-osteoblast and huBM-MSCs. Results demonstrated that PFF-A stimulated the osteoblastogenesis by
interacting with BMP and Wnt/β-catenin pathways and consequently by increasing ALP activity and
mineralization. As a result, PFF-A was suggested to be potential natural compound with therapeutic
properties against osteoporosis and related bone complications that urged further studies to elucidate
its detailed action mechanism and bioavailability.
4. Materials and Methods
4.1. Isolation of PFF-A from Plant Material
E. cava was collected between October 2014 and March 2015 from seashores of Jeju Island, Korea.
Specimens were identified by the corresponding author and a voucher sample was stored. Fronds of E.
cava were freeze-dried and stored at 25◦C prior to experiments. Freeze-dried samples were ground
to powder (4.0 kg) and extracted three times using EtOH (3 × 10 L). Solvent-partition of the crude
extracts (584.3 g) was carried out with n-hexane, n-BuOH and 85% aq. MeOH to yield solvent fractions
along with H2O residue. Forty grams of the n-BuOH fraction was further separated by a silica gel
column chromatography (60, 0/063–0.200 mm) (Merck, Kenilworth, NJ, USA) with the gradient mixture
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(30:1 to 1:1) of CH2Cl2:MeOH and CHCl3:MeOH, respectively. Phlorofucofuroeckol A (52.2 mg) was
isolated as a light brown powder from 3:1 CHCl3:MeOH sub-fraction by high performance liquid
chromatography (HPLC) (C18, 40% aq. MeOH). The chemical structure of phlorofucofuroeckol A
(Figure 1) was verified by spectral data as previously reported [20].
4.2. Cell Culture and Differentiation
Murine osteoblast-like MC3T3-E1 cells obtained from ATCC (CRL-2593™) and huBM-MSCs
obtained from PromoCell (C-12974) were cultured in 6-well plates unless otherwise noted. MC3T3-E1
cells were fed with α-Modified minimal essential medium (αMEM) containing 10% fetal bovine serum
(heat-inactivated, v/v), 1 mM sodium pyruvate, 100 units/L penicillin and 100 mg/L streptomycin in
an atmosphere of 5% CO2 at 37 ◦C. Following the confluence, osteoblast differentiation was induced
with a differentiation cocktail of 50 μg/mL ascorbic acid and 10 mM β-glycerophosphate in cell culture
medium. PFF-A was introduced to the cells with differentiation medium and included in every
medium change (every second day).
huBM-MSCs were fed with mesenchymal stem cell growth medium (C-28009, PromoCell) and
incubated in an atmosphere of 5% CO2 at 37 ◦C. Following 100% confluence cells were induced by
MSC osteogenic differentiation medium (C-28013, PromoCell) and incubated until the time of analysis.
PFF-A was introduced with differentiation medium and included in all medium changes (every third
day).
4.3. Cell Viability Assay
Effect of PFF-A on the viability of MC3T3-E1 osteoblasts, and non-induced and osteoinduced
huBM-MSCs was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay as previously described [20]. Viability of MC3T3-E1 cells were measured at the day 5 of
differentiation inducement. Viability of non-induced huBM-MSCs that fed growth medium only
was measured after 2 days of incubation with or without PFF-A treatment while the viability of
osteoinduced huBM-MSCs was analyzed at the day 5 of differentiation. PFF-A was introduced to
the cells at the beginning of incubation or differentiation inducement and included in all medium
changes until the day of analysis (every second day for MC3T3-E1 and every third day for huBM-MSC).
Following the treatment period of the cells with PFF-A, cell culture medium was aspired, and wells
were added 100 μL of MTT reagent (1 mg/mL) prior to 4 h incubation. Formazan salt was dissolved
with the addition of 100 μL DMSO to the wells. Viability and proliferation of the cells were calculated
by measuring the absorbance values of the formed formazan salts for each well at 540 nm using a
Multiskan GO microplate reader (Tecan Austria GmbH, Grodig, Austria) and plotting the values as a
percentage of untreated control cells.
4.4. Cellular Alkaline Phosphatase (ALP) Activity
ALP activity was evaluated in differentiated MC3T3-E1 and osteoinduced huBM-MSCs treated
with or without PFF-A. Differentiated MC3T3-E1 osteoblasts were used for ALP activity assay at day 7
of differentiation. Also, a blank group which was not induced and untreated was analyzed after 7 days
of incubation in growth medium. Cells were washed with phosphate buffer saline (PBS) and lysed
with 0.1% Triton X-100 and 25 mM carbonate buffer. The cellular ALP activity was assessed using the
supernatants of the cell lysates following centrifugation at 4 ◦C 12,000× g for 15 min. Total protein
contents of the supernatants were analyzed and normalized by the Bradford protein determination
method. The absorbance of the reactive solution containing the supernatants and the enzyme reaction
buffer (15 mM p-nitrophenyl phosphate, 1.5 mM MgCl2 and 200 mM carbonate buffer) was measured
at 405 nm after 15 min. of incubation, using a Multiskan GO microplate reader (Tecan Austria GmbH,
Grodig, Austria).
Osteoinduced huBM-MSCs were analyzed for ALP activity using a commercial kit following the
manufacturer’s instructions. Cells were prepared for ALP activity assay at day 7 of treatment and the
131
Mar. Drugs 2019, 17, 543
data was obtained as absorbance values at 560 nm using a Multiskan GO microplate reader (Tecan
Austria GmbH). Also, a non-induced huBM-MSC blank group was analyzed after 7 days of incubation
with growth medium instead of differentiation medium.
4.5. Alizarin Red Staining
Extracellular calcium deposits of differentiated MC3T3-E1 and osteoinduced huBM-MSCs were
investigated and quantified by Alizarin Red staining with or without PFF-A treatment at day 14 of
differentiation. Also, a non-induced untreated blank group which was fed growth medium instead
of differentiation medium was stained for calcium deposits after 14 days of incubation. Cells were
fixed on 6-well plates with 30 min incubation in 70% ice-cold ethanol which was followed by removal
of ethanol and washing with distilled H2O. Staining was carried out by introduction of Alizarin Red
solution followed by 10 min incubation at room temperature. After the incubation, the Alizarin Red
solution was aspired from wells and cells were washed with distilled H2O to remove to unbound
Alizarin red stain. Stained calcium deposit images showing extracellular mineralization were taken by
an Olympus microscope (Tokyo, Japan). Subsequently, the Alizarin red dye was eluted from wells
with 10% cetylpyridinium chloride (Sigma-Aldrich, St. Louis, MO, USA) solution and mineralization
was quantified by absorbance values at 560 nm using a Multiskan GO microplate reader (Tecan Austria
GmbH).
4.6. Reverse Transcription-Polymerase Chain Reaction Analysis
Total RNA was obtained from differentiated MC3T3-E1 and osteoinduced huBM-MSCs with or
without PFF-A treatment using Trizol reagent (Invitrogen, CA, USA) at day 12 of differentiation. Also,
a non-induced untreated blank group which was fed growth medium instead of differentiation medium
was analyzed after 12 days of incubation. Synthesis of cDNA was started with addition of total RNA
(2 μg) to RNase-free water containing oligo (dT) and followed by denaturation at 70 ◦C for 5 min.
Next, the mixture was reverse transcribed in a master mix (1 X RT buffer, 1 mM dNTPs, 500 ng oligo
(dT), 140 U M-MLV reserve transcriptase and 40 U RNase inhibitor) using an automatic T100 Thermal
Cycler (Bio-Rad, Hercules, CA, USA) with a cycle of 42 ◦C for 60 min and 72 ◦C for 5 min. Sense
and antisense primers previously detailed [38] were used for the amplification of the target cDNA.
The cDNA amplification was carried out using T100 Thermal Cycler (Bio-Rad) with cycle settings at
95 ◦C for 45 s, 60 ◦C for 1 min and 72 ◦C for 45 s for 30 cycles Final PCR products were separated by
gel electrophoresis on 1.5% agarose gel for 30 min at 100 V. Bands were then observed following the
staining with 1 mg/mL ethidium bromide under UV light using CAS-400SM Davinch-Chemi imagerTM
(Seoul, Korea).
4.7. Western Blotting
Protein immunoblotting was performed with standard Western blotting procedures. Differentiated
MC3T3-E1 and osteoinduced huBM-MSCs with or without PFF-A treatment were lysed by pipetting
with 1 mL of RIPA lysis buffer (Sigma–Aldrich) at 4 ◦C for 30 min at day 12 of differentiation. Also,
a non-induced untreated blank group which was fed growth medium instead of differentiation medium
was analyzed after 12 days of incubation. The acquired cell lysate (25 μg) was used for Western
blot analysis. Proteins in cell lysate were separated by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) on 4% stacking and 12% separating gels. Proteins subjected to separation
were then electrotransferred to a polyvinylidene fluoride membrane (Amersham Biosciences, Little
Chalfont, England, UK), which was blocked with 5% skim milk powder in TBST buffer after transfer.
The membrane was hybridized with primary antibodies diluted (1:1000) in primary antibody dilution
buffer containing 1X TBST with 5% bovine serum albumin at 4 ◦C overnight and incubated with
horseradish-peroxidase-conjugated secondary antibody at room temperature for 2 h. Immunoreactive
proteins bands were visualized by a luminol-based chemiluminescence assay kit (Amersham Biosciences)
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according to the manufacturer’s manual. Images of protein bands were captured using a Davinch-Chemi
imagerTM (CAS-400SM, Seoul, Korea).
4.8. Statistical Analysis
The data were presented as mean of three independent experiments ± SD. Statistically significant
differences among the means of the individual test groups were determined by one-way analysis of
variance (ANOVA) followed by Duncan’s multiple range tests using SAS v9.1 software (SAS Institute,
Cary, NC, USA), p < 0.05 being the defining level for the significance of differences.
Author Contributions: Conceptualization, B.-N.A. and F.K.; methodology, B.-N.A., J.-A.K. and J.H.O.; validation,
B.-N.A., J.-A.K. and J.H.O.; formal analysis, F.K. and Y.S.; investigation, B.-N.A., J.-A.K., J.I.L. and J.H.O.;
writing—original draft preparation, F.K.; visualization, F.K., J.I.L., Y.S. and C.-S.K.; supervision, Y.S. and C.-S.K.;
project administration, C.-S.K.; funding acquisition, C.-S.K.
Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the
Korea government (MSIP) (No. NRF-2017R1A2B4009588).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Rachner, T.D.; Khosla, S.; Hofbauer, L.C. Osteoporosis: Now and the future. Lancet 2011, 377, 1276–1287.
[CrossRef]
2. Harvey, N.; Dennison, E.; Cooper, C. Osteoporosis: Impact on health and economics. Nat. Rev. Rheumatol.
2010, 6, 99–105. [CrossRef] [PubMed]
3. Eriksen, E.F.; Díez-Pérez, A.; Boonen, S. Update on long-term treatment with bisphosphonates for
postmenopausal osteoporosis: A systematic review. Bone 2014, 58, 126–135. [CrossRef] [PubMed]
4. Reginster, J.Y.; Burlet, N. Osteoporosis: A still increasing prevalence. Bone 2006, 38, 4–9. [CrossRef]
5. Silverman, S.; Christiansen, C. Individualizing osteoporosis therapy. Osteoporos. Int. 2012, 23, 797–809.
[CrossRef] [PubMed]
6. Djouad, F.; Guérit, D.; Marie, M.; Toupet, K.; Jorgensen, C.; Noël, D. Mesenchymal stem cells: New insights
into bone regenerative applications. J. Biomater. Tissue Eng. 2012, 2, 14–28. [CrossRef]
7. Rawadi, G.; Vayssière, B.; Dunn, F.; Baron, R.; Roman-Roman, S. BMP-2 controls alkaline phosphatase
expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res. 2003, 18, 1842–1853.
[CrossRef]
8. Gimble, J.M.; Nuttall, M.E. The relationship between adipose tissue and bone metabolism. Clin. Biochem.
2012, 45, 874–879. [CrossRef] [PubMed]
9. Rho, J.R.; Hwang, B.S.; Joung, S.; Byun, M.R.; Hong, J.H.; Lee, H.Y. Phorbasones A and B, sesterterpenoids
isolated from the marine sponge Phorbas sp. and induction of osteoblast differentiation. Org. Lett. 2011, 13,
884–887. [CrossRef] [PubMed]
10. An, J.; Yang, H.; Zhang, Q.; Liu, C.; Zhao, J.; Zhang, L.; Chen, B. Natural products for treatment of osteoporosis:
The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016, 147, 46–58.
[CrossRef]
11. Li, Y.X.; Li, Y.; Qian, Z.J.; Ryu, B.; Kim, S.K. Suppression of vascular endothelial growth factor (VEGF)
induced angiogenic responses by fucodiphloroethol G. Process Biochem. 2011, 46, 1095–1103. [CrossRef]
12. Kim, M.-M.; Van Ta, Q.; Mendis, E.; Rajapakse, N.; Jung, W.-K.; Byun, H.-G.; Jeon, Y.-J.; Kim, S.-K.
Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Sci. 2006, 79, 1436–1443.
[CrossRef] [PubMed]
13. Li, Y.; Qian, Z.J.; Ryu, B.M.; Lee, S.H.; Kim, M.M.; Kim, S.K. Chemical components and its antioxidant
properties in vitro: An edible marine brown alga, Ecklonia cava. Bioorganic Med. Chem. 2009, 17, 1963–1973.
[CrossRef] [PubMed]
14. Shibata, T.; Kawaguchi, S.; Hama, Y.; Inagaki, M.; Yamaguchi, K.; Nakamura, T. Local and chemical
distribution of phlorotannins in brown algae. J. Appl. Phycol. 2004, 16, 291–296. [CrossRef]
133
Mar. Drugs 2019, 17, 543
15. Kang, H.S.; Chung, H.Y.; Kim, J.Y.; Son, B.W.; Jung, H.A.; Choi, J.S. Inhibitory phlorotannins from the edible
brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation. Arch. Pharm. Res. 2004, 27,
194–198. [CrossRef] [PubMed]
16. Eom, S.H.; Kim, Y.M.; Kim, S.K. Antimicrobial effect of phlorotannins from marine brown algae. Food Chem.
Toxicol. 2012, 50, 3251–3255. [CrossRef] [PubMed]
17. Kong, C.S.; Kim, J.A.; Ahn, B.N.; Kim, S.K. Potential effect of phloroglucinol derivatives from Ecklonia cava on
matrix metalloproteinase expression and the inflammatory profile in lipopolysaccharide-stimulated human
THP-1 macrophages. Fish. Sci. 2011, 77, 867–873. [CrossRef]
18. Kim, S.K.; Lee, D.Y.; Jung, W.K.; Kim, J.H.; Choi, I.; Park, S.G.; Seo, S.K.; Lee, S.W.; Lee, C.M.; Yea, S.S.; et al.
Effects of Ecklonia cava ethanolic extracts on airway hyperresponsiveness and inflammation in a murine
asthma model: Role of suppressor of cytokine signaling. Biomed. Pharmacother. 2008, 62, 289–296. [CrossRef]
19. Kong, C.S.; Kim, J.A.; Yoon, N.Y.; Kim, S.K. Induction of apoptosis by phloroglucinol derivative from Ecklonia
Cava in MCF-7 human breast cancer cells. Food Chem. Toxicol. 2009, 47, 1653–1658. [CrossRef]
20. Kim, H.; Kong, C.S.; Lee, J.I.; Kim, H.; Baek, S.; Seo, Y. Evaluation of inhibitory effect of phlorotannins from
Ecklonia cava on triglyceride accumulation in adipocyte. J. Agric. Food Chem. 2013, 61, 8541–8547. [CrossRef]
21. Yaturu, S.; Humphrey, S.; Landry, C.; Jain, S.K. Decreased bone mineral density in men with metabolic
syndrome alone and with type 2 diabetes. Med. Sci. Monit. 2009, 15, 5–9.
22. McFarlane, S.I.; Muniyappa, R.; Shin, J.J.; Bahtiyar, G.; Sowers, J.R. Osteoporosis and cardiovascular disease:
Brittle bones and boned arteries, is there a link? Endocrine 2004, 23, 1–10. [CrossRef]
23. Fakhry, M. Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts. World J.
Stem Cells 2013, 5, 136–148. [CrossRef] [PubMed]
24. Guo, X.; Wang, X.F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 2009, 19, 71–88.
[CrossRef] [PubMed]
25. Van Straalen, J.P.; Sanders, E.; Prummel, M.F.; Sanders, G.T.B. Bone-alkaline phosphatase as indicator of bone
formation. Clinica Chimica Acta 1991, 201, 27–33. [CrossRef]
26. Gaur, T.; Lengner, C.J.; Hovhannisyan, H.; Bhat, R.A.; Bodine, P.V.N.; Komm, B.S.; Javed, A.; Van Wijnen, A.J.;
Stein, J.L.; Stein, G.S.; et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2
gene expression. J. Biol. Chem. 2005, 280, 33132–33140. [CrossRef]
27. Komori, T. Regulation of osteoblast differentiation by Runx2. In Proceedings of the Advances in Experimental
Medicine and Biology; Springer: Boston, MA, USA, 2010; Volume 658, pp. 43–49.
28. Kang, Q.; Song, W.-X.; Luo, Q.; Tang, N.; Luo, J.; Luo, X.; Chen, J.; Bi, Y.; He, B.-C.; Park, J.K.; et al.
A Comprehensive Analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation
of mesenchymal progenitor cells. Stem Cells Dev. 2008, 18, 545–558. [CrossRef]
29. Wan, M.; Cao, X. BMP signaling in skeletal development. Biochem. Biophys. Res. Commun. 2005, 328, 651–657.
[CrossRef]
30. Liang, W.; Lin, M.; Li, X.; Li, C.; Gao, B.; Gan, H.; Yang, Z.; Lin, X.; Liao, L.; Yang, M. Icariin promotes bone
formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line.
Int. J. Mol. Med. 2012, 30, 889–895. [CrossRef]
31. Tang, D.Z.; Yang, F.; Yang, Z.; Huang, J.; Shi, Q.; Chen, D.; Wang, Y.J. Psoralen stimulates osteoblast
differentiation through activation of BMP signaling. Biochem. Biophys. Res. Commun. 2011, 405, 256–261.
[CrossRef]
32. Hyung, J.H.; Ahn, C.B.; Je, J.Y. Osteoblastogenic activity of ark shell protein hydrolysates with low molecular
weight in mouse mesenchymal stem cells. RSC Adv. 2016, 6, 29365–29370. [CrossRef]
33. Ming, L.G.; Chen, K.M.; Xian, C.J. Functions and action mechanisms of flavonoids genistein and icariin in
regulating bone remodeling. J. Cell. Physiol. 2013, 228, 513–521. [CrossRef] [PubMed]
34. Taipaleenmäki, H.; Abdallah, B.M.; AlDahmash, A.; Säämänen, A.M.; Kassem, M. Wnt signalling mediates
the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Exp. Cell
Res. 2011, 317, 745–756. [CrossRef] [PubMed]
35. Roy, M.C.; Anguenot, R.; Fillion, C.; Beaulieu, M.; Berube, J.; Richard, D. Effect of a commercially-available
algal phlorotannins extract on digestive enzymes and carbohydrate absorption in vivo. Food Res. Int. 2011,
44, 3026–3029. [CrossRef]
134
Mar. Drugs 2019, 17, 543
36. Lee, S.H.; Li, Y.; Karadeniz, F.; Kim, M.M.; Kim, S.K. α-Glucosidase and α-amylase inhibitory activities
of phloroglucinal derivatives from edible marine brown alga, Ecklonia cava. J. Sci. Food Agric. 2009, 89,
1552–1558. [CrossRef]
37. Sieniawska, E.; Baj, T. Chapter 10—Tannins. In Pharmacognosy: Fundamentals, Applications and Strategies;
Badal, S., Delgoda, R., Eds.; Academic Press: Cambridge, MA, USA, 2017; pp. 192–232.
38. Karadeniz, F.; Ahn, B.N.; Kim, J.A.; Seo, Y.; Jang, M.S.; Nam, K.H.; Kim, M.; Lee, S.H.; Kong, C.S. Phlorotannins
suppress adipogenesis in pre-adipocytes while enhancing osteoblastogenesis in pre-osteoblasts. Arch. Pharm.
Res. 2015, 38, 2172–2182. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Low-Molecular-Weight Fucoidan Enhances Innate
and Adaptive Immune Responses and Protects
against Mycoplasma pneumoniae Antigen Stimulation
Pai-An Hwang 1,*,†, Hong-Ting Victor Lin 2,†, Hsin-Yuan Lin 1 and Szu-Kuan Lo 3
1 Department of Bioscience and Biotechnology, National Taiwan Ocean University, No. 2, Beining Road,
Keelung 20246, Taiwan; 2063B003@mail.ntou.edu.tw
2 Department of Food Science, National Taiwan Ocean University, Keelung 20246, Taiwan;
HL358@ntou.edu.tw
3 Gi-Kang Clinic, No. 155, Yanping Rd., Zhongli Dist., Taoyuan 32043, Taiwan; a912164@yahoo.com.tw
* Correspondence: amperehwang@gmail.com or amperehwang@ntou.edu.tw;
Tel.: +886-2-24622192 (ext. 5570); Fax: +886-2-24634732
† These authors equally contributed to this work.
Received: 15 February 2019; Accepted: 14 March 2019; Published: 18 March 2019
Abstract: In this study, the low-molecular-weight (LMW) fucoidan, rich in fucose and sulfate,
was extracted and purified from the edible brown seaweed, Laminaria japonica. In this study,
we orally administered LMW fucoidan to mice for 6 weeks. We then examined fucoidan’s effects
on innate immunity, adaptive immunity, and Mycoplasma pneumoniae (MP)-antigen-stimulated
immune responses. Our data showed that LMW fucoidan stimulated the innate immune system
by increasing splenocyte proliferation, natural killer (NK) cell activity, and phagocytic activity.
LMW fucoidan also increased interleukin (IL)-2, IL-4, and interferon (IFN)-γ secretion by splenocytes
and immunoglobulin (Ig)-G and IgA content in serum, which help regulate adaptive immune cell
functions, and decreased allergen-specific IgE. In MP-antigen-stimulated immune responses, the IgM
and IgG content in the serum were significantly higher in the LMW fucoidan group after MP-antigen
stimulation. Our study provides further information about the immunomodulatory effects of LMW
fucoidan and highlights a potential role in preventing M. pneumoniae infection.
Keywords: low molecular weight fucoidan; Mycoplasma pneumoniae; NK cell; antigen-specific
antibody; adjuvant
1. Introduction
Before the 1950s, seaweeds were used as traditional folk medicines [1]. Over the past two
decades, polysaccharides of brown seaweeds, such as fucoidan, alginate, and laminarin, have been
investigated for their biological activities [2,3]. The health-promoting effects of these compounds,
especially fucoidan, give brown seaweed great value for developing natural dietary supplements.
Fucoidans are a class of fucose-containing sulfated polysaccharides found in brown seaweed [4].
Most fucoidans have complex chemical compositions, and their structures and biological
activities vary from species to species [5]. Its non-animal origin has been related to particular
pharmacological activities [6]. Fucoidan has been associated with antitumor [7–9], antiviral [10],
anti-inflammatory [11,12], anticoagulant [13], and osteogenic-enhancing differentiation activities [14].
These activities are closely related to its molecular weight [15] and sulfate content [16].
Fucoidan’s immunomodulatory effects have been reported in different experimental models.
It has been shown to activate and promote the maturation of human monocyte-derived dendritic
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Mar. Drugs 2019, 17, 175
cells [17], and stimulate lymphocyte [18,19] and macrophage activity [18,20] in vitro. According to
Do et al. [21], fucoidan is an immunomodulating nutrient which alters the sensitivity of glia and
macrophages. Jin et al. [22] found that intraperitoneal (i.p.) fucoidan injection in mice upregulated
CD40, CD80, and CD86 expression. It also increased production of interleukin (IL)-6, IL-12, and tumor
necrosis factor-α (TNF-α) in spleen dendritic cells (DC). Furthermore, fucoidan promoted interferon
(IFN)-γ generation by producing Th1 and Tc1 cells in an IL-12-dependent manner. Zhang et al. [23]
also showed that i.p. administration of fucoidan in the mice promoted natural killer (NK) cell, DC,
and T-cell activation. In addition, when mice are injected IP with ovalbumin (OVA) and fucoidan,
mice were found to produce remarkably higher amounts of anti-OVA Immunoglobulin G (IgG) than
OVA-control mice, and fucoidan was found to promote the generation of effector/memory T-cells
based on the surface expression of CD44. Intravenous administration of fucoidan upregulated CD40,
CD80, CD86, and the major histocompatibility complex in mouse spleen DCs [23]. Interestingly, oral
administration of 300 mg fucoidan per day to elderly men and women increased their immune
responses to influenza vaccination [24], but the underlying mechanisms of this are still unclear.
There are some reports on the relationship between the structure and immunomodulatory properties
of fucoidan [25]; however, less is known about the relationship between their molecular weight and
immunomodulatory properties. In our previous studies, we demonstrated that low-molecular-weight
(LMW) fucoidan has more favorable bioactivity in vitro and in vivo than high-molecular-weight
fucoidan [7–9,12], with no toxicological effects found in rats after 28 days of repeated oral
administration [26]. LMW fucoidan is expected to be a safe food supplement for immunomodulation.
Mycoplasma pneumoniae is one of the most common agents of community-acquired pneumonia
in previously healthy people, and infection can occur at any age [27]. M. pneumoniae is considered a
self-limiting disease, but some patients suffer from protracted and complicated courses [28]. In addition,
M. pneumoniae can change its cell membrane composition to mimic the host’s cell membrane, thus
avoiding immune system detection [27]. Currently, there is no vaccine to prevent M. pneumoniae infection.
Macrolide is one of the first-line drugs used to treat M. pneumoniae, but the prevalence of macrolide-resistant
M. pneumonia is increasing worldwide. In 2011, the macrolide-resistance rate was up to 23% in Taiwan [29].
A recent study has reported that early additional immune-modulators might can prevent M. pneumoniae
disease progression and reduce morbidity [30]. A natural and safe food supplement that enhances the
immune response to prevent M. pneumoniae infection could address this unmet need.
In this study, we evaluated the immunomodulatory effects of orally administered LMW fucoidan
on innate and adaptive immune responses in mice. We also evaluated the effect of LMW fucoidan
supplementation on immune responses to the M. pneumonia (MP) antigen.
2. Results and Discussion
2.1. Fractionation and Composition of Crude Fucoidan and LMW Fucoidan
A step gradient was used to selectively elute the sulfate and fucose-rich fucoidan from a crude
brown seaweed extract. The yields and compositions of the three fractions, purified from Laminaria
japonica, are shown in Figure 1 and Table 1.
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Figure 1. Fractionation of crude fucoidan isolated from the L. japonica on a DEAE
(Diethylaminoethyl)-Sephadex A-25 column.
The fucoidan fraction 1, which was eluted at the lowest NaCl concentration, was rich in galactose
(35.8 ± 0.5% mol) and glucose (20.6 ± 0.2% mol), but had low concentrations of fucose (12.9 ± 0.2%
mol) and sulfate (10.6 ± 0.6%). The fucoidan fraction 3, eluted at a higher concentration of NaCl,
was rich in fucose (48.2 ± 0.3% mol) and sulfate (39.5 ± 0.8%). Although the fucoidan fraction 2 had
the highest yield, the fucose (34.6 ± 0.4% mol) and sulfate (25.2 ± 0.5%) contents were lower than
in fraction 3. Fucoidan fractions presenting diversities in their sulfation degrees and patterns also
differed in their biological activities [31,32]. Thus, we selected fraction 3 as the purified fucoidan
and hydrolyzed it as our LMW fucoidan sample. The fraction 3 was hydrolyzed with glycolytic
enzyme preparation to obtain the LMW fucoidan sample with a molecular weight lower than 3000 Da.
The LMW fucoidan consisted of 40.5 ± 0.8% mol fucose, 5.7 ± 0.7% mol glucose, 28.3 ± 0.8% mol
galactose, 5.4 ± 0.5% mol myo-inositol, 15.6 ± 0.5% mol mannose, 3.3 ± 0.6% mol xylose, 1.2 ± 0.4%
mol rhamnose, and its degree of sulfation was 31.4 ± 1.6% (Table 1). Myo-inositol has been reported
to be the minor sugars in brown seaweed, such as Fucus vesiculosus [33], Himanthalia elongate [34],
and Bzjizrcaria bifurcate [35]. Tarakhovskaya et al. [33] indicated that the myo-inositols might have
several biological functions, which serve as an initial precursor of different cell-wall polysaccharides.
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2.2. Effects of LMW Fucoidan on Innate Immune Responses in Mice
Innate immunity is the first line of defense against almost any substance that threatens the body.
Poor environmental factors, such as malnutrition, stress, and wake-sleep disorders may cause innate
immune system deficiencies. Functional nutrient studies indicate a positive correlation between the
innate immune system and health [36]. Here, we first examined the effects of oral LMW fucoidan on
the innate immune response of non-immunized mice.
It was shown in our previous study that fucoidan was not toxic after intragastric administration
to Sprague Dawley (SD) rats at 2000 mg/kg/day [26]. Anti-diabetes activity of LMW fucoidan was
observed at the dose of 300–600 mg/kg/day in C57BLKS/J Iar-+Leprdb/+Leprdb (db/db) mice [37].
As a result, dosages of 200, 600, and 1000 mg/kg was chosen in this study for mice.
2.2.1. Spleen Weight and Proliferative Responses of Splenocytes
The spleen plays an important role in host defense, and is the site for innate and adaptive immune
processes. We first examined spleen weight and the proliferative response of splenocytes in LMW
fucoidan-treated mice. Mice were orally administered 200, 600, and 1000 mg/kg LMW fucoidan or
distilled water (control group) daily for 6 weeks, and then sacrificed. During the 6 weeks, a steady
rise in body weight (from 17.5 ± 0.2 g to 20.4 ± 0.3 g) was observed, and there were no statistically
significant differences between the treated and control mice. The spleen weights were obtained
post-mortem, and the spleen-to-body-weight ratio was calculated. No significant differences were
observed in the spleen-to-body-weight ratio among the four groups (Figure 2).
Figure 2. The spleen-to-body-weight ratios of mice treated with low-molecular-weight (LMW) fucoidan
for 6 weeks. Spleen-to-body-weight ratio = [spleen weight (g)/body weight (g)] × 100%. Data were
expressed as mean ± SD of ten mice.
This result is consistent with a previous study showing that feeding mice fucoidan from
Fucus vesiculosus had no effects on the spleen-to-body-weight ratio [38]. In addition, Jang et
al. [39] showed that LMW fucoidan was less toxic to spleen cells than high-molecular-weight
fucoidan. Therefore, LMW fucoidan is not a sensitive indicator to cause cell stress or immunotoxicity.
After harvesting spleen cells, splenocytes were prepared and stimulated with the T-cell mitogen
concanavalin A (Con A) or B-cell mitogen lipopolysaccharides (LPS) for 72 h. Splenocytes from
mice fed with 200, 600, and 1000 mg/kg LMW fucoidan showed significantly increased Con A and
LPS-stimulated proliferation compared to the control mice (Table 2), indicating that LMW fucoidan
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had increased both T- and B-cell proliferation. This is consistent with the results of previous studies by
Jang et al. [39], who reported that both low- and high-molecular-weight fucoidan increase spleen-cell
viability. Our results confirm that LMW fucoidan has immunostimulatory effects.
Table 2. Proliferative response of splenocytes from mice treated with LMW fucoidan.
Stimulation Index ‡
Con A LPS
Control 4.24 ± 0.66 a 1.78 ± 0.07 a
200 mg/kg 4.85 ± 0.74 b 1.95 ± 0.07 b
600 mg/kg 4.91 ± 0.45 b 1.93 ± 0.09 b
1000 mg/kg 4.92 ± 0.51 b 1.96 ± 0.10 b
‡ Stimulation index was expressed as OD490 of Con A, LPS, or OVA-stimulated cells/OD490 of unstimulated
cells. Data were expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s
multiple range test. Values with different letters in the same column were significantly different (p < 0.05).
2.2.2. Natural Killer (NK) Cell Activity
NK cells are a component of the innate immune system, which plays an important role in the
early stages of tumor cell elimination. Previous research has shown that NK cell activity is relatively
sensitive to diet and the intake of specific food components [40]. To investigate LMW fucoidan’s effect
on enhancing NK cell activity, we assessed whether LMW fucoidan could induce cytotoxic NK cell
activity against YAC-1 cells which are sensitive to lysis by activated NK cells. Our results showed that
NK cell activity was enhanced in mice receiving 200, 600, and 1000 mg/kg LMW fucoidan compared
to controls (Table 3). Namkoong et al. [41] and Maruyama et al. [42] also reported that fucoidan can
increase NK cell activity via oral administration. Together, these data indicate that LMW fucoidan
consumption can activate NK cells and, thus, might be a good way of enhancing the immune system.
Table 3. Natural killer (NK) cell activity of splenocytes from mice treated with LMW fucoidan.
NK Cell Activity ‡
E/T Ratio #: 10 E/T Ratio: 25
Control 14.4 ± 3.8 a 33.1 ± 1.8 a
200 mg/kg 20.8 ± 7.6 b 42.1 ± 1.6 b
600 mg/kg 21.0 ± 7.1 b 41.4 ± 1.7 b
1000 mg/kg 21.1 ± 4.4 b 42.0 ± 1.9 b
‡ NK cell activity was expressed as (test group fluorescence − spontaneous fluorescence)/(total target cell
fluorescence − spontaneous fluorescence) × 100%. # Effector cell (splenocytes) to target cell (YAC-1 cell) ratio.
Data were expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s
multiple range test. Values with different letters in the same column were significantly different (p < 0.05).
2.2.3. Phagocytic Activity of Peritoneal Cells
As part of the innate immune system, the body has developed defenses mediated by specialized
cells which destroy invading microorganisms by ingestion and phagocytosis. In the present study,
the phagocytic activity of peritoneal cells from mice which were fed LMW fucoidan was measured
by quantifying internalized Fluorescein isothiocyanate (FITC)-Escherichia coli (E. coli). Cells isolated
from mice treated with 1000 mg/kg LMW fucoidan exhibited a significant increase in phagocytosis
at multiplicities of infection of 12.5 and 25 (Table 4). These results are similar to those reported by
Anisimova et al. [43], who showed that fucoidan intensifies the engulfment of microorganisms by
human blood, increasing both the relative number and efficiency of phagocytes.
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Table 4. Phagocytic activity of peritoneal cells from mice treated with LMW fucoidan.
Phagocytic Activity ‡ (%)
MOI 12.5 MOI 25
Control 20.1 ± 3.6 a 28.7 ± 6.2 a
200 mg/kg 22.9 ± 3.0 ab 32.4 ± 4.4 ab
600 mg/kg 23.7 ± 4.4 ab 36.4 ± 5.0 b
1000 mg/kg 24.8 ± 3.8 bc 37.4 ± 5.6 b
‡ Phagocytic activity was expressed as FITC-positive peritoneal cells/total peritoneal cells × 100%. Data were
expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s multiple range
test. Values with different letters in the same column were significantly different (p < 0.05).
In summary, we found that LMW fucoidan effectively stimulates innate immunity, not only by
phagocytosis (Table 4) but also by activating extracellular killing by NK cells (Table 3) to destroy
invading pathogens.
2.3. Effects of LMW Fucoidan on Adaptive Immune Responses (OVA-Specific Immunity) in Mice
The above results prompted us to further investigate the adjuvant effects of LMW fucoidan
on adaptive immune responses. We orally administered LMW fucoidan daily for 6 weeks and
immunized mice with OVA to examine the effect on cytokine response and specific antibody production
against OVA.
2.3.1. Proliferative Response by Con A, LPS, and OVA Stimulation
Mice were orally administered distilled water (control group) or 200, 600, and 1000 mg/kg
LMW fucoidan daily for 6 weeks, and OVA immunization was conducted at the third and fifth
weeks. During the 6 weeks, a steady rise in body weight (from 18.6 ± 0.3 g to 21.4 ± 0.4 g) was
observed, and there were no statistically significant differences between the groups of mice. The spleen
weights were obtained, and the spleen-to-body-weight ratio was calculated. Interestingly, the ratios
of OVA-immunized and OVA-immunized + LMW fucoidan-treated mice were higher than those of
controls (Figure 3), although feeding LMW fucoidan alone for 6 weeks did not alter the ratio (Figure 2).
Figure 3. The spleen-to-body-weight ratios of ovalbumin (OVA)-immunized mice treated with LMW
fucoidan for 6 weeks. Spleen-to-body-weight ratio = [spleen weight (g)/body weight (g)] × 100%.
Data were expressed as mean ± SD of ten mice. Means with asterisks were significantly different from
the control (p < 0.05).
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A previous study reported that the spleen-to-body-weight ratio of LPS + fucoidan-treated mice
was higher than LPS-treated mice when fucoidan was administered intraperitoneally [38], suggesting
that different routes of fucoidan administration may lead to significantly different physiological
reactions. Our findings suggest that OVA plays a major role in increasing the spleen-to-body-weight
ratio, and that oral administration of LMW fucoidan does not support this effect. LMW fucoidan (200,
600, and 1000 mg/kg doses) significantly enhanced the mitogen (Con A and LPS)- and OVA-stimulated
splenocyte proliferation in OVA-immunized mice compared to the OVA-control group (Table 5).
These findings indicate that LMW fucoidan could significantly increase cell-mediated immune
responses in OVA-immunized mice.
Table 5. Proliferative response by ConA, LPS, or OVA stimulated splenocytes from OVA-immunized
mice treated with LMW fucoidan.
Stimulation Index ‡
Con A LPS OVA
Control 3.63 ± 0.56 a 1.52 ± 0.25 a 0.81 ± 0.03 a
OVA-immunized 3.86 ± 0.27 a 1.81 ± 0.09 a 1.10 ± 0.03 b
200 mg/kg-OVA 4.96 ± 0.28 b 2.25 ± 0.25 c 1.54 ± 0.04 c
600 mg/kg-OVA 5.02 ± 0.23 b 2.44 ± 0.18 c 1.54 ± 0.03 c
1000 mg/kg-OVA 5.05 ± 0.29 b 2.75 ± 0.24 c 1.60 ± 0.04 c
‡ Stimulation index was expressed as OD490 of Con A, LPS, or OVA-stimulated cells/OD490 of unstimulated
cells. Data were expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s
multiple range test. Values with different letters in the same column were significantly different (p < 0.05).
2.3.2. Cytokine Secretion by OVA-Stimulation
Cytokines serve as chemical messengers within the immune system and are primarily produced
by T-helper (Th) cells. In the activation phase of adaptive immune responses, cytokines stimulate
the growth and differentiation of lymphocytes. In the effector phases, they activate different effector
cells to eliminate microbes and other antigens [44]. We examined the effect of LMW fucoidan on
the production of cytokines that mediate and regulate adaptive immune responses. Th 1 cytokines,
including IL-2 and IFN-γ, and the Th 2 cytokine, IL-4, significantly increased following LMW fucoidan
administration. No significant differences in the production of the Th2 cytokine IL-5 were observed.
LMW fucoidan treatment during OVA-stimulation significantly decreased TNF-α, a multifunctional,
pro-inflammatory cytokine (Table 6). NK cell activity has been shown to be enhanced by IL-2 [45],
IL-4 [46], and IFN-γ [47], and our data also showed that IL-2, IL-4, and IFN-γ production (Table 6) and
NK cell activity (Table 3) were increased in splenocytes from mice treated with oral LMW fucoidan.
Both Jin et al. [22] and Zhang et al. [23] reported that IP injection of fucoidan led to increased IFN-γ
production compared to control mice immunized with OVA alone. These results indicate that fucoidan,
administered either orally or via IP injection, could function as an adjuvant by promoting Th1-type
immune responses.
The Th1/Th2 concept suggests that regulating the relative contribution of Th1- or Th2-type
cytokines will likely modulate the development and strength of immune responses [48]. A previous
study reported that ingesting brown seaweed enhanced OVA-specific Th1 and Th2 cytokine
responses by draining lymph nodes in mice [49]. Similarly, our results showed that both the
Th1 and Th2 responses in OVA-stimulated mice significantly increased after oral administration
of LMW fucoidan. Together, these results demonstrate that oral LMW fucoidan stimulates a healthy
Th1/Th2 balance.
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Table 6. Cytokines secretion by OVA-stimulated splenocytes from OVA-immunized mice treated with
LMW fucoidan.
Unstimulated Basal Level Mitogen Stimulation OVA
IL-2 (pg/mL)
Control 13.31 ± 2.40 a 193.8 ± 59.9 a
OVA-immunized 13.67 ± 1.44 a 219.8 ± 12.1 a
200 mg/kg-OVA 14.48 ± 3.66 a 299.9 ± 16.6 b
600 mg/kg-OVA 14.58 ± 2.70 a 368.0 ± 88.7 b
1000 mg/kg-OVA 14.51 ± 2.76 a 538.4 ± 122.3 c
IL-4 (pg/mL)
Control 3.36 ± 0.31 a 5.09 ± 0.64 a
OVA-immunized 3.61 ± 0.29 b 9.91 ± 0.42 b
200 mg/kg-OVA 3.43 ± 0.28 b 9.36 ± 0.61 b
600 mg/kg-OVA 3.45 ± 0.29 b 13.18 ± 0.59 c
1000 mg/kg-OVA 3.27 ± 0.25 b 14.23 ± 0.48 c
IL-5 (pg/mL)
Control 1.00 ± 0.50 a 5.07 ± 0.64 a
OVA-immunized 2.66 ± 0.15 b 9.91 ± 0.47 b
200 mg/kg-OVA 2.62 ± 0.13 b 9.36 ± 0.92 b
600 mg/kg-OVA 2.47 ± 0.13 b 9.30 ± 0.99 b
1000 mg/kg-OVA 2.56 ± 0.24 b 9.41 ± 1.07 b
IFN-γ (pg/mL)
Control 1.68 ± 0.23 a 1014.90 ± 38.52 a
OVA-immunized 51.13 ± 1.14 b 1628.13 ± 32.26 b
200 mg/kg-OVA 51.62 ± 2.86 b 1934.48 ± 39.83 c
600 mg/kg-OVA 50.91 ± 2.80 b 1944.67 ± 86.95 c
1000 mg/kg-OVA 51.66 ± 2.40 b 1975.95 ± 44.42 c
TNF-α (pg/mL)
Control 6.46 ± 0.96 a 9.08 ± 1.62 a
OVA-immunized 6.49 ± 0.35 a 21.12 ± 3.23 c
200 mg/kg-OVA 6.37 ± 0.64 a 16.46 ± 2.14 b
600 mg/kg-OVA 6.39 ± 0.46 a 15.25 ± 0.84 b
1000 mg/kg-OVA 6.31 ± 0.68 a 15.02 ± 1.45 b
Data were expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s
multiple range test. Values with different letters in the same column were significantly different (p < 0.05).
2.3.3. Serum Immunoglobulins Levels
Immunoglobulins, also known as antibodies, are glycoprotein molecules produced by plasma
cells that protect us from pathogen infections and antigen sensitization. Immunoglobulin M (IgM)
antibodies play an important role in the early stages of immune surveillance. Immunoglobulin A (IgA)
is a major humoral factor of mucosal immunity, and IgE is an allergen-specific immunoglobulin that is
stimulated by different allergens to produce the corresponding IgE [50]. We examined the effect of
LMW fucoidan on the serum levels of anti-OVA IgG, anti-OVA IgA, and anti-OVA IgE that mediate
adaptive immune responses. As expected, immunization with OVA significantly increased the serum
levels of anti-OVA IgG, anti-OVA IgA, and anti-OVA IgE compared to control mice. Anti-OVA IgG and
anti-OVA IgA were significantly increased in the serum from mice administered with LMW fucoidan
compared with OVA-immunized mice (Table 7). Similar results were found in the production of
IL-2 and IL-4, which stimulate B-cell activation and differentiation [51]. These data suggested that LMW
fucoidan functions as an adjuvant to enhance antigen-specific immune responses. Furthermore, in these
mice, anti-OVA IgE was significantly decreased (Table 7), so LMW fucoidan might be useful in
counteracting allergic responses. Collectively, LMW fucoidan had a significant effect on cytokine
expression by enhancing the production of IL-2, IL-4, and IFN-γ (Table 6). Thus, it is possible that
LMW fucoidan favors Th1 differentiation and decreases IgE [52].
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Table 7. Serum immunoglobulins levels of OVA-immunized mice treated with LMW fucoidan.
Serum Immunoglobulin (EU ‡)
Anti-OVA IgG Anti-OVA IgA Anti-OVA IgE
Control 0.04 ± 0.01 a 0.06 ± 0.01 a 0.02 ± 0.01 a
OVA-immunized 2.12 ± 0.78 b 0.96 ± 0.03 b 0.85 ± 0.29 c
200 mg/kg-OVA 2.39 ± 0.46 bc 1.05 ± 0.07 b 0.84 ± 0.11 c
600 mg/kg-OVA 2.61 ± 0.24 c 1.93 ± 0.04 c 0.57 ± 0.07 b
1000 mg/kg-OVA 2.77 ± 0.42 c 2.21 ± 0.08 c 0.37 ± 0.12 b
‡ EU was expressed as (OD450 of sample − OD450 of blank)/(OD450 of positive- OD450 of blank). Data were
expressed as mean ± SD of ten mice, and analyzed using one-way ANOVA followed by Duncan’s multiple range
test. Values with different letters in the same column were significantly different (p < 0.05).
2.4. Effects of LMW Fucoidan on MP-Antigen-Stimulated Immune Responses in Mice
According to the above data, LMW fucoidan showed strong immunomodulatory effects in innate
and adaptive immunity. As shown in Table 2; Table 3, the mice treated with LMW fucoidan showed
better proliferative responses and NK cell activity, and there were no significant differences between the
200, 600, and 1000 mg/kg groups. As shown in Table 4, the mice treated with LMW fucoidan showed
better phagocytic activity, and the 600 and 1000 mg/kg groups exhibited the best activities (Table 4).
As shown in Tables 5 and 6, the mice treated with LMW fucoidan showed better proliferative responses
and cytokines secretion, and there were no significant differences between the 200, 600, and 1000 mg/kg
groups (except IL-2 in Table 6). As a result, we chose the 600 mg/kg dose concentration to investigate
the effects of orally administered LMW fucoidan on MP antigen immunogenicity.
This evaluation was done to determine whether LMW fucoidan could function as an early
additional immunomodulator, preventing M. pneumoniae disease infection and reducing disease
morbidity. In this experiment, MP antigen inoculation was carried out twice. The first MP antigen
inoculation was considered the first infection by M. pneumoniae, and the second MP antigen inoculation
was considered the re-infection. As expected, after the MP antigen inoculation, IgM, IgG, and IgA
contents in the serum were higher in the LMW fucoidan group than in the control group. IgM and IgG
significantly increased (p < 0.05) in the serum from 600 mg/kg LMW fucoidan + MP-antigen-inoculated
group mice compared to the MP-antigen-inoculated group mice after both the first and second
inoculations. There was no significant difference in IgA with or without LMW fucoidan after
MP antigen inoculation (Figure 4). Our data show a possible adjunctive role of LMW fucoidan
by stimulating antibody production upon repeat infection of M. pneumoniae. Fucoidan has also
been reported to increase immune responses to seasonal influenza vaccinations [24] and improve M.
pneumoniae vaccine efficacy [40]. Based on our previous research and these results, we suggest that
LMW fucoidan might help prevent the spread of M. pneumoniae.
In this study, we investigated the immunomodulatory effects of orally administrated LMW
fucoidan on innate immunity, adaptive immunity, and MP-antigen-stimulated immune responses.
Our results indicate that LMW fucoidan can increase splenocyte proliferation, NK cell activity,
and phagocytic activity, as well as IL-2, IL-4, and IFN-γ production. In addition, LMW
fucoidan enhanced antigen-specific antibody production in OVA- and MP-antigen-stimulated mice.
LMW fucoidan, in the form of a natural food supplement, could enhance immune responses and
attenuate the effects of M. pneumoniae infection.
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Figure 4. The IgM (A), IgG (B), and IgA (C) productions of Mycoplasma pneumoniae (MP)
antigen-inoculated mice treated with 600 mg/kg LMW fucoidan for 6 weeks. Data were expressed as
mean ± SD of ten mice. Values are expressed as mean ± SD. Means with asterisk were significantly
different from the other groups (p < 0.05).
3. Materials and Methods
3.1. Animal
The female BALB/c mice (Albino mice maintained by Halsey Bagg) were obtained from
BioLASCO Taiwan CO., Ltd (Taipei, Taiwan). All mice were weighted and given provisional numbers
upon arrival. The animals were subjected to acclimation in a housing facility for at least eight days
before starting the experiment. Only healthy mice were selected for use in the study. The mice were
eight weeks of age at the start of the experiment, and were housed in a normal, environmentally
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controlled animal room with free access to pathogen-free feed and water ad libitum. These mice were
randomly divided, with ten mice in each group.
3.2. LMW Fucoidan Preparation
LMW fucoidan extracted from Laminaria japonica were collaboratively manufactured by Hi-Q
Marine Biotech International Ltd. (New Taipei City, Taiwan). Seaweed samples were ground to
flour with a miniblender, and then dried with a dryer at 50 ◦C. The 100 g dried seaweed was treated
with 5 L of distilled water and boiled at 100 ◦C for 30 min, and the extract was centrifuged at
10,000× g for 20 min. The supernatant was added with 4 M CaCl2 incubated for 1 h to separate
alginic acid, and re-centrifuged at 10,000× g for 20 min. All polysaccharides were dialyzed (cut off
10,000 Da) using deionized water for 48 h, and precipitated by the addition of ethanol at the ratio of
1:3 (V/V) and left overnight to give the crude fucoidan. The fucoidan so obtained was fractionated
by anion-exchange chromatography using DEAE-Sephadex A-25 (Cl− form, Pharmacia, Uppsala,
Sweden) using gradually increasing concentrations of sodium chloride (0–2.5 M) at a flow rate of
1 mL/min, and eluents (5 mL/tube) were separately collected. Each fraction was analyzed for sulfate
content (Section 3.3) and monosaccharide composition (Section 3.4). The fraction of rich sulfate and
fucose content (fraction 3) was extracted and hydrolyzed with a mixture of crude glycolytic enzymes,
isolated from Bacillus subtilis by our lab (Section 3.5). The reaction mixture was passed through a filter
(3000 Da cut off) by using Amicon Stirred Cells (Merck Germany) to collect the LMW fucoidan with a
molecular weight lower than 3000 Da. The hydrolysis reaction of the fucoidan by the crude glycolytic
enzymes was performed at pH 6.5, 37 ◦C for 24 h and heated at 95 ◦C for 20 min for inactivation of
the enzyme.
3.3. Analysis of Degree of Sulfation
Sulfate content was determined according to the gelatinbarium method [53] using sodium sulfate
(1 mg/mL) as a standard after acid hydrolysis of the polysaccharide extract sample in 6 N HCl at
100 ◦C for 6 h.
3.4. Monosaccharide Composition Analysis
The monosaccharides compositions of the eluted fractions from anion-exchange chromatography
were separated by a High-performance anion-exchange chromatography (HPAEC) (Dionex BioLC
system) using an anion-exchange column (DionexTM Carbopac PA-10, 4 × 250 mm, Dionex, Thermo
Fisher Scientific, Waltham, MA, USA). The analysis of monosaccharides was carried out at an isocratic
NaOH concentration of 18 mM at ambient temperature [54].
3.5. Preparation of the Crude Enzyme Mixtures from B. subtilis Cultures
One colony of B. subtilis, isolated from natto in Keelung local market, was cultivated in tryptic
soy broth (TSB, Becton, Dickinson and Company, Sparks, MD, USA) at 30 ◦C, 150 rpm for 24 h.
The cell cultures were centrifuged to remove bacterial cells to obtain the mixtures of extracellular
glycosidic enzymes.
3.6. Animal Experiments
The LMW fucoidan was a light brownish-white powder, and well-soluble below the highest
concentration. In this study, three independent experiments were undertaken to evaluate the innate
immune, adaptive immune, and MP antigen-inoculated immune response, respectively. The first
experiment was performed to assay innate immune, mice were assigned to four groups (n = 10);
concentrations of 200, 600, and 1000 mg/kg LMW fucoidan were dissolved in distilled water and then
administered by oral gavage in 10 mL/kg on a daily basis for 6 weeks. The control group (0 mg/kg
LMW fucoidan) mice were treated identically with equal volumes of distilled water also via oral
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gavage throughout the study. Mice were weighted and sacrificed, and blood samples were collected at
the end of the experiment for serum immunoglobulins assay. Spleens were collected and weighted,
and the splenocytes were analyzed for cell proliferation, the cytokines secretion assay, and natural
killer cell activity assay. Peritoneal cells were collected form mice abdominal cavity for the phagocytic
activity assay. Each mouse was weighted once a week during the study period.
The second experiment was performed byadaptive immune mice assay, and five groups of mice
(control, OVA-immunized, 200, 60,0 and 1000 mg/kg LMW fucoidan, then OVA-immunized) were
orally administered distilled water or LMW fucoidan for 6 weeks. The first OVA IP immunization
was conducted after 3 weeks of administration. 6.25 μg OVA was emulsified in the complete
Freund’s adjuvant (CFA) and intraperitoneally injected into the mice. Two weeks after the first
OVA immunization, mice were given a second injection of 12.5 μg OVA emulsified with incomplete
Freund’s adjuvant (IFA) in order to enhance the OVA-specific immune responses. Blood samples were
collected before the OVA inducement at the end of the experiment for the serum immunoglobulins
assay. Mice were then sacrificed by isoflurane inhalation. Spleens were collected and weighted, and the
splenocytes were analyzed for cell proliferation and the cytokines secretion assay.. Each mouse was
weighted once a week during the study period.
The third experiment was performed to assay MP antigen-inoculated immune responds, three
groups of mice (control, MP antigen-stimulation and 600 mg/kg LMW fucoidan then MP antigen
stimulation) were orally administered distilled water or LMW fucoidan for 6 weeks. First, MP
antigen (10 μg/mouse, MP901, Native Antigen, UK) IP stimulation was conducted after 3 weeks
of administration. Two weeks after the first stimulation, mice were given a second injection of MP
antigen (10 μg/mouse) [40]. Blood samples were collected before the first MP antigen stimulation,
after one week of stimulation, and at the end of the experiment for the serum immunoglobulins assay.
Each mouse was weighted once a week during the study period.
3.7. Splenocyte Proliferation Assay
Splenocytes were prepared from treated mice and resuspended in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), 50 U/mL penicillin, 50 mg/mL
streptomycin, and 0.5 mg/mL amphotericin B. 2 × 105 cells/well of splenocytes were treated with
Con A or LPS for 72 h in an innate immune experiment, and treated with Con A, LPS, or OVA
for 72 h in an adaptive immune experiment. Cell proliferation was measured by OD490 using the
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). Results were expressed as the
stimulation index, and the formula for calculating stimulation index is shown below:
Stimulation index = OD490 of Con A, LPS, or OVA-stimulated cells/OD490 of un-stimulated cells.
3.8. NK Cell Activity Aassay
NK cell activity was measured by the release of the fluorescent marker from YAC-1 target
cells (A lymphoma which was induced by inoculation of the Moloney leukemia virus (MLV) into a
newborn A/Sn mouse) [American Type Culture Collection (ATCC) TIB-160, Food Industry Research
and Development Institute, Hsinchu, Taiwan]. Splenocytes (effector cells, including NK cells) were
cultured in the supplemented RPMI 1640 medium. YAC-1 cells were incubated with 2′-7′-bis
(carboxyethyl)-5(6)-carboxyfluorescein (BCECF) (ThermoFisher) for 30 min at 37 ◦C. After being
washed with culture medium, cells were re-suspended in the medium and cultured for 2 h at
37 ◦C. 2′,7′ –bis-(Carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF)-labeled YAC-1 cells were mixed
with splenocytes as effector cells to make a 10 and 25 ratio of effector cells to target cells (E/T).
After incubation for 4 h, the cultured supernatant was harvested and measured fluorescence with
excitation and emission wavelengths of 485 nm and 538 nm. The total target cell fluorescence was
determined by lysis of cells with 0.25% (v/v) Triton X-100. Spontaneous fluorescence was measured
from target cells incubated without effector cells. Test group fluorescence was measured from the
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effector cell mixing with target cells. Results were expressed as NK cell activity, and the formula for
calculating NK cell activity is shown below:
NK cell activity = (test group fluorescence-spontaneous fluorescence)/(total target cell
fluorescence- spontaneous fluorescence) × 100%.
3.9. Phagocytic Activity Assay by Peritoneal Cells
Mice were scarified and peritoneal cells were harvested by injecting 5 mL of Hank’s balanced salt
solution (HBSS) into the peritoneal cavity and gently shaking it. Then, peritoneal fluid was collected
and centrifuged at 450× g, 4 ◦C for 10 min. The cell pellet was resuspended at 1 × 106 cells/mL in
supplemented RPMI 1640 medium. The phagocytosis was performed by monitoring the engulfment of
FITC-labeled E. coli by the peritoneal exudate cells. Cells were mixed with FITC-E. coli at Multiplicity
of infection (MOI) of 12.5 and 25 for 30 min. Fluorescence from non-internalized FITC-E. coli was
quenched by the addition of acidified trypan blue, and the cells were then washed and analyzed
by flow cytometry (BD FACSAria, Becton Dickinson Biosciences, San Jose, CA, US). Results were
expressed as phagocytic activity, and the formula for calculating phagocytic activity is shown below:
Phagocytic activity = FITC positive peritoneal cells/total peritoneal cells × 100%.
3.10. Cytokines Secretion Assay
Cytokines including IL-2, IL-4, IL-5, TNF-α, and IFN-γ were measured by using enzyme-linked
immunosorbent assay (ELISA) kits (R&D Systems Inc., Minneapolis, MN, USA) according to the
manufacturer’s instructions. Splenocytes were prepared from treated mice and resuspended in
supplemented RPMI 1640 medium. Cells were incubated at 1 × 106 cells/well with 25 μg/mL OVA
for 72 h in the second experiment for adaptive immune assay. After 72 h incubation, the cell-free
supernatants were collected, centrifuged 450× g, 4◦C for 10 min, and cytokines were measured by
using the ELISA kits.
3.11. Serum Immunoglobulins Assay
In the second experiment for the adaptive immune assay, blood was centrifuged at 450× g,
4 ◦C for 10 min, and serum samples were collected for OVA-specific anti-IgG, OVA-specific anti-IgA,
and OVA-specific anti-IgE. OVA-specific antibodies were detected by an indirect ELISA (Bethyl
Laboratories). Results were expressed as ELISA units (EU), and the formula for calculating EU is
shown below: EU = (OD450 of sample- OD450nm of blank)/(OD450 of positive- OD450 of blank).
A positive OD450 indicated a serum with a high titer of OVA-specific antibodies [52]. In the third
experiment, serum samples were collected for serum immunoglobulins assay by using a mouse
immunoglobin quantitation set (Bethyl Laboratories) to measure the concentrations of IgM, IgG,
and IgA, respectively.
3.12. Statistical Analysis
Numerical data are presented as means ± standard deviation. The data was analyzed by a
one-way analysis of variance (ANOVA) and Student’s t-test.
4. Conclusions
In this study, we investigated the immune modulatory effects of orally administrated LMW
fucoidan on the innate immune, adaptive immune, and MP antigen-stimulated immune response.
Our results provided evidence that LMW fucoidan could increase splenocyte proliferation, NK cell
activity, and phagocytic activity, as well as IL-2, IL-4, and IFN-γ secretion. In addition, LMW fucoidan
enhanced antigen-specific antibody production in OVA- and MP antigen-stimulated mice. Our hope
is that LMW fucoidan, a natural food supplement, could enhance immune responses, be needed for
immunopotentiation, and attenuate the M. pneumoniae infectious disease.
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Abstract: Toxicity of particulate matter (PM) towards the epidermis has been well established in many
epidemiological studies. It is manifested in cancer, aging, and skin damage. In this study, we aimed
to show the mechanism underlying the protective effects of eckol, a phlorotannin isolated from brown
seaweed, on human HaCaT keratinocytes against PM2.5-induced cell damage. First, to elucidate
the underlying mechanism of toxicity of PM2.5, we checked the reactive oxygen species (ROS) level,
which contributed significantly to cell damage. Experimental data indicate that excessive ROS caused
damage to lipids, proteins, and DNA and induced mitochondrial dysfunction. Furthermore, eckol
(30 μM) decreased ROS generation, ensuring the stability of molecules, and maintaining a steady
mitochondrial state. The western blot analysis showed that PM2.5 promoted apoptosis-related protein
levels and activated MAPK signaling pathway, whereas eckol protected cells from apoptosis by
inhibiting MAPK signaling pathway. This was further reinforced by detailed investigations using
MAPK inhibitors. Thus, our results demonstrated that inhibition of PM2.5-induced cell apoptosis by
eckol was through MAPK signaling pathway. In conclusion, eckol could protect skin HaCaT cells
from PM2.5-induced apoptosis via inhibiting ROS generation.
Keywords: phlorotannin; particulate matter; reactive oxygen species; keratinocytes
1. Introduction
Natural compounds can be effective candidates for various skin diseases. Particularly,
phlorotannins extracted from seaweeds have interesting properties that make them useful for
cosmeceutical applications. They can whiten the skin by inhibiting melanin synthesis [1], and
delay skin wrinkles by inhibiting matrix metalloproteinase [2]. Moreover, phlorotannins show
antioxidant [3], anti-inflammatory [4], and hair-growth promotion activities [5]. Studies have shown
that eckol, which is a kind of phlorotannin present in brown seaweeds (Phaeophyceae), decreases
ultraviolet B (UVB)-induced oxidative stress in human keratinocytes at a dose of 27 μM [6], and
inhibits cancer in SKH-1 mice via inhibiting UVB-induced inflammation [7], and declines matrix
metalloproteinase-1 level in human dermal fibroblasts implying anti-aging effects at a dose of 10 μM [8].
Our earlier studies have proved that eckol could clear excess reactive oxygen species (ROS) and protect
skin keratinocytes from apoptosis [6].
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Air pollution by continuous emission of various pollutants into the atmosphere has led to the rapid
decline of public health and accelerated climate change [9]. In addition, more than 90% population
in the world breathed unhealthy air in 2017, which suggests that particulate pollution is a global
challenge [10]. According to previous studies, particulate matter (PM) increases the public health
risks for various diseases, such as respiratory disease [11], cardiovascular disease [12], and lung
inflammation [13]. Fine particulate matter with a diameter less than 2.5 μm, denoted as PM2.5, is
present in the air for over several hours to weeks [14]. Significantly, PM2.5 could deeply penetrate
the skin and the respiratory tract [15]. Skin damage caused by PM2.5 is manifested as inflammatory
skin diseases, such as atopic dermatitis, acne, and psoriasis, aging, and cancer via multiple signaling
pathways [16].
A recent study presents a comprehensive summary of the characteristics of eckol relevant for
its therapeutic potential, including antioxidant activity following exposure to H2O2, radiation, and
PM [17]. PM2.5 is a fine particulate matter that causes skin apoptosis related to the ROS generation [16],
and it would be interesting to investigate whether eckol protected skin cells from ROS-induced damage.
Moreover, the mode of action of eckol on PM2.5 is not well-established. Here, we have investigated
the potential benefits of eckol on keratinocytes by studying its inhibitory effect on molecular damage,
mitochondrial dysfunction, apoptosis-related factors, and MAPK signaling related proteins. In this
study, our aim was also to gain insights into the mechanism underlying the protective action of eckol
on PM2.5-induced skin cell apoptosis.
2. Results
2.1. Eckol Showed Anti-oxidative Effects to Protect Cells from PM2.5-Induced Apoptotic Cell Death
Previous studies have shown that eckol exhibited no cytotoxicity to HaCaT cells at a concentration
of 30 μM [18] but showed antioxidant activity [6]. Therefore, in this study, we used 30 μM of eckol
(Figure 1a) as the optimal concentration. From Figure 1b,c, it is evident that while PM2.5 increased the
levels of ROS as indicated by 2’,7’-dichlorofluorescein diacetate (DCF-DA) staining, eckol inhibited
intracellular ROS generation. The results demonstrated that PM2.5-induced ROS could accelerate cell
apoptosis and death. To confirm that eckol could help cells escape from this damage, we checked
nuclei integrity, and cell viability. According to results, PM2.5 treatment led to sub-G1 cell population
after 24 h (Figure 1d), fragmented nuclei (Figure 1e), and cell death (Figure 1f). However, it was noted
that following treatment with eckol, the apoptotic cell death was decreased, and the cell viability was
also enhanced.
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Figure 1. Eckol (30 μM) decreased cell apoptotic bodies by inhibiting PM2.5-induced ROS level. (a)
Chemical structure of eckol. Intracellular ROS level (DCF-DA staining) induced by PM2.5 (50 μg/mL)
was inhibited via treatment with eckol as observed by (b) flow cytometry and (c) confocal. (d) Sub-G1
cell population induced by PM2.5 was blocked by treatment with eckol, as determined by propidium
iodide staining. (e) Apoptosis induced by PM2.5 was reduced by treatment with eckol, observed by
Hoechst 33342 staining. The arrow indicated the apoptotic bodies. (f) Cell deaths induced by PM2.5
were reduced via treatment with eckol, determined by trypan blue assay. The arrow indicated the dead
cell (stained cells by trypan blue). All experiments were performed after treatment with PM2.5 for 24
h, and n = 3 for every group. * p < 0.05 and # p < 0.05 compared to control cells and PM2.5-exposed
cells, respectively.
2.2. Eckol Protected Cells against PM2.5-Induced Intracellular Molecular Damage
Previous studies have shown that increment in ROS disrupted intracellular molecules involved
in apoptosis [19,20]. Thus, we detected lipid peroxidation, protein carbonylation, and DNA damage.
The confocal images show that PM2.5 caused generation of phosphine oxide, which is a marker of
lipid peroxidation. However, this was reversed by treatment with eckol (Figure 2a). Moreover,
PM2.5 aggravated protein carbonylation level, which was decreased by eckol treatment (Figure 2b).
DNA lesions and strand breaks were studied by staining the cells with avidin-tetramethylrhodamine
isothiocyanate (TRITC) conjugate (Figure 2c) and comet assay (Figure 2d). The data show that eckol
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Figure 2. Eckol (30 μM) protected intracellular molecules from PM2.5-induced damage. (a) Lipid
oxidation induced by PM2.5 was mitigated via treatment with eckol through diphenylpyrenylphosphine
(DPPP) staining. (b) Protein carbonylation induced by PM2.5 was declined via treatment with eckol as
observed by a protein carbonylation assay. DNA damage induced by PM2.5 was inhibited via treatment
with eckol, as confirmed through (c) avidin-TRITC staining and (d) comet assay. All experiments were
performed after treatment with PM2.5 for 24 h, and n = 3 for every group. * p < 0.05 and # p < 0.05
compared to control cells and PM2.5-exposed cells, respectively.
2.3. Eckol Prevented PM2.5-Induced Mitochondrial Dysfunction
Mitochondria play an important role in cellular energy production, and their biogenesis is related
to synthesis of molecules, such as lipids and proteins, DNA transcription, and even cell apoptosis [21].
Next, we examined mitochondrial functions. Dihydrorhodamine 123 (DHR123) staining images
show that mitochondrial ROS was accumulated in PM2.5-treated group. Whereas, ROS level was
decreased by pretreatment with eckol (Figure 3a). Both flow cytometry (Figure 3b) and confocal
microscopy (Figure 3c) data demonstrate that PM2.5 caused mitochondrial depolarization, which was
arrested by treatment with eckol. Furthermore, the flux of mitochondrial calcium was increased in the
PM2.5-treatment group, and it was decreased in eckol-treatment group, which was monitored using
the calcium indicator, Rhod-2 acetoxymethyl ester (Rhod-2 AM), by confocal microscopy (Figure 3d)
and flow cytometry (Figure 3e).
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Figure 3. Eckol (30 μM) prevented PM2.5-induced mitochondrial dysfunction by balancing
mitochondrial membrane potential and calcium level. (a) Mitochondrial ROS induced by PM2.5
was decreased via treatment with eckol through DHR123 staining. Depolarization of mitochondrial
membrane potential (JC-1 staining) induced by PM2.5 was repolarized via treatment with eckol through
(b) flow cytometry and (c) confocal microscopy. Extra-mitochondrial Ca2+ (Rhod-2 AM staining)
induced by PM2.5 was blocked by treatment with eckol was monitored using (d) confocal microscopy
and (e) flow cytometry. All experiments were performed after treatment with PM2.5 for 24 h, and n = 3
for every group. * p < 0.05 and # p < 0.05 compared to control cells and PM2.5-exposed cells, respectively.
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2.4. Eckol Modulated PM2.5-Induced Apoptotic Factors
It has been reported that urban particulate pollution penetrates the skin barrier and causes
apoptosis in keratinocytes by activating caspase-3 [22]. Therefore, we evaluated the levels of the
proapoptotic protein-Bax, antiapoptotic protein-Bcl-2, and cleaved caspase-3 (Figure 4a). The protein
levels of Bax and activated caspase-3 were increased by PM2.5, but expression of Bcl-2 was decreased
by treatment with PM2.5. However, these were reversed by eckol treatment. To investigate whether
PM2.5 could induce apoptosis, we counted apoptotic bodies via Hoechst 33342 dye staining (Figure 4b).
The number of apoptotic cells in PM2.5 group surged four times compared to that in the control group.





Figure 4. Eckol (30 μM) regulated apoptosis-related proteins induced by PM2.5. (a) Increase of Bax and
cleaved caspase-3 and decrease of Bcl-2 by PM2.5 were reversed by treatment with eckol, as observed
by western blotting (WB). (b) Apoptosis induced by PM2.5 was reduced by treatment with eckol or
caspase inhibitor (Z-VAD-FMK), as seen by Hoechst 33342 staining. All experiments were performed
after treatment with PM2.5 for 24 h, and n = 3 for every group. * p < 0.05 and # p < 0.05 compared to
control cells and PM2.5-exposed cells, respectively.
2.5. Eckol Reduced MAPK Signaling Pathway Activated by PM2.5
In a review, Sun et al. have pointed out that many anti-cancer therapeutics induced apoptosis
by modulating the MAPK/ERK signaling pathway [23]. Thus, we checked the expression levels
161
Mar. Drugs 2019, 17, 444
of MAPK-related proteins, ERK, p38, and JNK, and the results showed that PM2.5 could stimulate
ERK, p38, and JNK (Figure 5a). However, eckol inhibited the activation of ERK, p38, and JNK. Next,
we examined PM2.5-induced apoptotic bodies by treatment with MAPK pathway inhibitors, U0126,
SB203580, and SP600125 (inhibitors of ERK, p38, and JNK, respectively), and the results showed that
all these three inhibitors could reduce the number of apoptotic bodies (Figure 5b). In addition, eckol
enhanced the anti-apoptotic effect of MAPK-related inhibitors.
 
(a) (b) 
Figure 5. Eckol (30 μM) reduced PM2.5-induced MAPK signaling pathway. (a) Western blot showing
that activation of ERK, p38, and JNK induced by PM2.5 was reversed via treatment with eckol.
(b) Apoptosis induced by PM2.5 was reduced by treatment with eckol or ERK, p38, and JNK inhibitors
(U0126, SB203580 (SB), and SP600125 (SP), respectively), as observed through Hoechst 33342 staining.
All experiments were performed after treatment with PM2.5 for 24 h, and n = 3 for every group.
* p < 0.05, # p < 0.05 and ## p < 0.05 compared to control cells, PM2.5-exposed cells, and both inhibitor
and PM2.5-exposed cells respectively.
3. Discussion
There have been several investigations into the bioactivities of eckol, since it was first isolated
from Ecklonia cava [3]. Eckol has multi-protective effects towards several cell lines, including lung
fibroblast cells [24], human dermal fibroblasts [8], Chang liver cells [25], and human keratinocytes [6].
Furthermore, eckol is a compound with therapeutic potential in many areas, such as anti-oxidative
stress [24], radioprotective action [26], antithrombotic and profibrinolytic activities [27], and anticancer
activity [28]. Piao et al. studied PM2.5-induced ROS generation at different concentrations (25, 50, 75,
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and 100 μg/mL) for 24 h in HaCaT keratinocytes, and found that PM2.5 50 μg/mL caused excessive
ROS and skin dysfunction [29]. Usually, oxidative stress is caused by excessive accumulation of ROS
or lack of the ability to eliminate them. PM2.5 produces large amounts of ROS beyond the clearance
ability of cells [30]. In our study, eckol showed its ability to protect cells against PM2.5-induced ROS,
cell cycle arrest, and apoptosis, and improved cell viability.
To explore the mechanism in detail, we checked the state of intracellular molecules such as lipids,
protein, and DNA, which play various important roles in the cells [31]. Furthermore, intracellular
macromolecular damage can be recognized as oxidative stress [32]. Our results demonstrated that
PM2.5 indeed induced oxidation of molecules, whereas eckol relieved intracellular molecular damage.
The review also points out that mitochondria-dependent ROS generation subsequently caused cell cycle
arrest and apoptosis, which is ROS-mediated apoptosis via mitochondrial mechanism [33]. In addition,
our previous studies showed that calcium level and mitochondrial membrane potential affect the
function of mitochondria [30,34]. The data in Figure 3 show that PM2.5 increased the calcium level
and depolarized mitochondrial membrane potential as compared to the control cells, whereas eckol
regulated the mitochondria and maintained a stable state. The mechanism of mitochondrial damage is
related to Bcl-2 proteins, which maintains mitochondrial membrane integrity [35]. The interaction
between Bcl-2 and Bax also influences antiapoptosis [36]. Bcl-2 plays an anti-apoptotic role, whereas Bax
is proapoptotic [37]. There is a complex crosslink between Bcl-2 family proteins and caspase proteins
in cell apoptosis, in which Bcl-2 indirectly activates the caspase cascade [38]. The caspase-3 results
in apoptosis induced by both extrinsic and intrinsic stimulus [39]. The results elucidated that except
for the decrease of Bcl-2, Bax and cleaved caspase-3 (activated caspase-3) were increased by PM2.5.
However, eckol reversed these effects. Then, we treated cells with caspase inhibitor (Z-VAD-FMK) and
found that upon pretreatment with caspase inhibitor, the apoptotic bodies were decreased significantly.
These data prove that caspase proteins contributed to cell apoptosis induced by PM2.5. MAPK signaling
pathway plays a role in many systems of cell proliferation, migration, and apoptosis [23]. Many
drugs are used to modulate MAPK signaling pathway to induce cell apoptosis in cells, such as lung
cancer [40], human colorectal cancer [41], and cervical cancer HeLa cells [42]. Finally, we checked
MAPK signaling pathway-related proteins, ERK, p38, and JNK. The results show that PM2.5 activated
all three proteins, but eckol exhibited the ability to inactivate them. When we used inhibitors of ERK,
p38, and JNK to treat PM2.5-damaged cells, the numbers of apoptotic bodies were decreased, similar to
eckol. These data further prove that MAPK signaling pathway plays a vital role in the inhibition of
PM2.5-induced apoptosis by eckol.
Although the protective effects of eckol on human keratinocytes from PM2.5-induced skin damage
has been shown, there are limitations to this study. These results from in vitro experiments need to be
validated by animal studies and clinical trials. Moreover, the concentration of air pollutants in the
natural environment is different from the PM2.5 purchased from the company, which provide certain
ingredients for reference. In the future, there should be in vivo animal trials on skin protection to
elucidate the protective effects and side effects of eckol under the complicated living environments.
4. Materials and Methods
4.1. Eckol and PM2.5
Eckol was provided by Professor Nam Ho Lee of Jeju National University (Jeju, Korea), which
belonged to Phaeophyceae. Preparation of the extract and its purification was following the reported
protocol [43]. The dried brown alga Ecklonia cava was extracted with 80% methanol and the crude
extract was purified by HPLC. After purification, 20 mg of pure eckol was obtained from 1 kg dry
weight of the brown algae. A stock solution of eckol was prepared by dimethyl sulfoxide (DMSO).
The NIST particulate matter SRM 1650b (PM2.5) was bought from Sigma-Aldrich (St. Louis, MO, USA)
and a stock solution in DMSO was prepared to obtain a concentration of PM2.5 at 25 mg/mL. DMSO
was as the control.
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4.2. Cell Culture
The human HaCaT keratinocytes were purchased from Cell Lines Service (Heidelberg, Germany)
and were grown in Dulbecco’s modified Eagle’s medium (Life Technologies Co., Grand Island, NY, USA)
with 10% heat-inactivated fetal calf serum, streptomycin (100 μg/mL), and penicillin (100 units/mL).
The cells were cultured at 37 ◦C in an incubator in an atmosphere containing 5% CO2 [6].
4.3. ROS Detection
To examine the intracellular ROS scavenging ability of eckol, DCF-DA (Sigma-Aldrich) staining
assay was performed. Cells (1.5 × 105 cells/mL) were treated with eckol (30 μM) for 30 min, PM2.5
(50 μg/mL) for another 24 h, and DCF-DA (25 μM) sequentially. Then, the stained cells were detected
by using a flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and confocal microscope
(Carl Zeiss, Oberkochen, Germany). Similarly, mitochondrial ROS levels were detected by DHR123
(Molecular Probes) staining (10 μM) [30].
4.4. Sub-G1 Cell Detection
Cells were treated with eckol (30 μM) and PM2.5 (50 μg/mL) sequentially. After 24 h, cells were
harvested and dyed with PI and RNase A (1:1000) for 30 min. Finally, the fluorescence emission was
detected with a FACSCalibur flow cytometer (Becton Dickinson) [30].
4.5. Hoechst 33342 Staining
The apoptotic bodies were examined with Hoechst 33342 (Sigma-Aldrich), which is a
nucleus-specific dye. All cells were stained with Hoechst 33342, and the images were captured
under a Cool SNAP-Pro color digital camera (Media Cybernetics, Silver Spring, MD, USA) in a
fluorescence microscope [44].
4.6. Cell Viability
Cells were cultured with eckol and/or PM2.5 for 24 h, and the dead cells were stained with 0.1%
trypan blue solution. Then, unstained bodies (live cells) and stained bodies (dead cells) were counted
separately. Cell viability (%) was determined as: Live cells/ (live cells + dead cells) × 100% [45].
4.7. Lipid Peroxidation Assay
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 24 h in the chamber slides.
The lipid hydroperoxides in cells were reacted with diphenylpyrenylphosphine (DPPP, Molecular
Probes) and the lipid adducts of DPPP oxide were detected by a confocal microscope [30].
4.8. Protein Carbonylation Assay
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 24 h in the culture dish.
The OxiselectTM protein carbonyl ELISA kit (Cell Biolabs, San Diego, CA, USA) was used to detect
protein oxidation following the manufacturer’s instructions [34].
4.9. Detection of 8-Oxoguanine (8-oxoG)
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 24 h in the chamber slides.
The avidin-TRITC conjugate was used to detect 8-oxoG, an indicator of oxidative DNA damage.
The stained cells were visualized under a confocal microscope [27].
4.10. Single Cell Gel Electrophoresis (Comet Assay)
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 30 min in the microtubes,
and the harvested cells were fixed on a microscopic slide with low-melting agarose (1%). The slides
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with cells were permeated into lysis buffer (pH 10) for 1 h, which contained NaCl (2.5 M), Na-EDTA
(100 mM), Tris (10 mM), Triton X-100 (1%), and DMSO (10%). Finally, the slides were subjected to
electrophoresis, and the samples were dyed with ethidium bromide. The fluorescent images of the tails
were captured with a fluorescence microscope and the tail lengths (50 cells per slide) were analyzed by
the image analysis software (Kinetic Imaging, Komet 5.5, Liverpool, UK) [29].
4.11. Quantification of Ca2+ Level
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 24 h in the chamber slides.
Cells were stained with Rhod-2 AM to check mitochondrial calcium levels, and the images were
captured by confocal microscopy and flow cytometry [30].
4.12. Mitochondrial Membrane Potential (ΔΨm) Analysis
Cells (1.5 × 105 cells/mL) were cultured with eckol and/or PM2.5 for 24 h in the chamber slides.
Cells were stained with 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide
(JC-1, Invitrogen, Carlsbad, CA, USA) to observe changes in cell membrane potential. The fluorescence
emission was analyzed by confocal microscopy and flow cytometry [6].
4.13. Western Blotting
The protein lysates from harvested cells were subjected to SDS-PAGE and transferred into
membranes in sequence. The membranes were incubated with primary and secondary antibody
(Pierce, Rockford, IL, USA) for 1 h separately. Protein bands were visualized via X-ray film (AGFA,
Belgium). The following primary antibodies were used: caspase-3, phospho-p38, phospho-ERK, and
phospho-JNK (Cell Signaling Technology, Beverly, MA, USA), Bax and Bcl-2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and actin (Sigma-Aldrich) [44].
4.14. Statistical Analysis
All data were collected from three experiments and presented as mean ± standard error, which
were analyzed by variance (ANOVA) with Tukey’s test using Sigma Stat (v12) software (SPSS, Chicago,
IL, USA). P-values < 0.05 were considered statistically significant.
5. Conclusions
PM2.5 causes skin cell damage by generating ROS, excess of which oxidizes intracellular molecules
and causes mitochondrial dysfunction, and activates MAPK signaling pathways. The skin is the
first protection from various pollutants in the air, and it is important to identify effective biological
compounds to prevent skin damage. Eckol has been known to inhibit UVB-induced ROS generation in
keratinocytes [6]. In this study, we show that eckol could protect keratinocytes from PM2.5-induced
apoptosis by halting ROS generation, suggesting that eckol is a suitable candidate for skin protection
and can be useful in the cosmetics industry as well as in medicine.
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Abstract: (1) Background: Brown and red algal sulfated polysaccharides have been widely described
as anticoagulant agents. However, data on green algae, especially on the Ulva genus, are limited.
This study aimed at isolating ulvan from the green macroalga Ulva rigida using an acid- and
solvent-free procedure, and investigating the effect of sulfate content on the anticoagulant activity of
this polysaccharide. (2) Methods: The obtained ulvan fraction was chemically sulfated, leading to a
doubling of the polysaccharide sulfate content in a second ulvan fraction. The potential anticoagulant
activity of both ulvan fractions was then assessed using different assays, targeting the intrinsic
and/or common (activated partial thromboplastin time), extrinsic (prothrombin time), and common
(thrombin time) pathways, and the specific antithrombin-dependent pathway (anti-Xa and anti-IIa),
of the coagulation cascade. Furthermore, their anticoagulant properties were compared to those of
commercial anticoagulants: heparin and Lovenox®. (3) Results: The anticoagulant activity of the
chemically-sulfated ulvan fraction was stronger than that of Lovenox® against both the intrinsic and
extrinsic coagulation pathways. (4) Conclusion: The chemically-sulfated ulvan fraction could be a
very interesting alternative to heparins, with different targets and a high anticoagulant activity.
Keywords: Ulva rigida; ulvan; chemical sulfation; anticoagulant activity
1. Introduction
Marine macroalgae are used in several industrial applications and have represented a sharply
increasing annual market over the last decades, going from about USD 6 billion in 2003 to
currently USD 10.6 billion, and exhibiting an annual growth rate close to 10%, due to the high
expansion of the aquaculture sector, which represents today 97% of the global seaweed production
worldwide [1–3]. Seaweed and seaweed products are mainly used for human consumption
(85%) and in the hydrocolloid industry. The three main groups of marine algae (Phaeophycae,
Rhodophyta, and Chlorophyta) are rich sources of various compounds of interest such as proteins,
pigments, and polysaccharides, whose potential market is estimated at several USD billion [3–5],
and have been studied for their potential pharmaceutical, cosmetic, or nutraceutical applications.
Polysaccharides from brown and red marine macroalgae are widely used in the industry for
their gelling properties, alginates, agar, and carrageenans in particular [1,3]. It has also been
shown that sulfated polysaccharides from marine macroalgae have numerous biological activities,
including immunoinflammatory [6–8], antioxidant [9,10], antitumor [11–13], antiviral [7,14–16],
and anticoagulant [17–20] properties. Conversely, although they have been consumed for centuries,
green macroalgae are still relatively unexploited. Nevertheless, the discovery of ulvans, the sulfated
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polysaccharides from green algae of the Ulva genus (including species from the formerly genus
Enteromorpha), has increased the interest for these seaweeds. Ulvans are mainly composed of rhamnose
and uronic acids (glucuronic or iduronic acid) [21,22]. The main repeated disaccharide units of
ulvans are [→4)-β-d-Glcp-(1→4)-α-l-Rhap3S-(1→]n (type A) and [→4)-α-l-Idop-(1→4)-α-l-Rhap3S-(1→]n
(type B) [7].
Heparin, a polysaccharide belonging to the glycosaminoglycan family, is mainly composed of
l-iduronic-2-O-sulfate acid and d-glucosamine-N-sulfate, 6-O-sulfate. Unfractionated heparin (UFH)
has an average molecular weight (MW) of 15 kDa [23]. Its anticoagulant activity is primarily due
to its specific antithrombin-binding pentasaccharide sequence, where the central glucosamine is
not only 2- and 6-O-sulfated but also 3-O-sulfated [24]. Despite of its major anticoagulant activity,
UFH may cause serious adverse events (AE), such as heparin-induced thrombocytopenia [25] or
hemorrhage [26]. Moreover, its low bioavailability [27] makes such a treatment really expensive.
To reduce the risks of AE, heparin may be depolymerized to produce smaller molecules, known as
low-molecular-weight heparins (LMWH, MWavg ≥∼6 kDa) [28]. Although LMWH significantly reduce
the risks of AE associated with UFH, their recommended use as first-line treatment for cancer-associated
venous thromboembolism (VTE), for at least 3 to 6 months, still exposes patients to allergic reactions,
heparin-induced thrombocytopenia, recurrent VTE, and major bleeding events, leading to high rates
of treatment discontinuation [29,30]. Given the risks and high costs of these treatments, there is a
compelling need for further investigations to identify new sources of anticoagulants.
The first studies assessing the anticoagulant activity of sulfated polysaccharides from macroalgae
have shown that polysaccharides from brown algae could be alternative sources of new anticoagulant
compounds. Sulfated fucoidans from brown algae and sulfated galactans from red seaweeds (also
referred to as carrageenans) seem to have a strong anticoagulant activity. Data on the anticoagulant
activity of polysaccharides from green macroalgae are limited compared to brown and red algae,
but a few studies have demonstrated their potential. Regarding the anticoagulant activity, the most
studied genera are Codium [31–36], which contains sulfated arabinans and arabinogalactans, and then
Monostroma, which contains sulfated rhamnans [37–42]. Only two studies have shown the potential
anticoagulant properties of ulvans extracted from Ulva conglobata and Ulva reticulata [43,44].
The relationship between the polysaccharide chemical structure and the anticoagulant activity
is complex but previous studies have shown that several factors, such as MW, osidic composition,
and sulfate content and substitution pattern, may significantly affect the anticoagulant activity [17,45–47].
Polysaccharide sulfate content appears to have a major impact on its anticoagulant potential. Thus,
Cianca et al. have demonstrated that sulfated galactans extracted from Codium fragile and Codium
vermilara with a high MW and high sulfate content have a higher anticoagulant activity than LMW
and low sulfate content polysaccharides [36]. Furthermore, the only published studies that have
highlighted a strong activity of sulfated rhamnans from the Ulva genus were based on highly sulfated
ulvans (sulfate content of 26–35%) [43,44].
In this study, a solvent- and acid-free process to extract and purify ulvan from Ulva rigida was
developed. To study the effect of sulfate content, a chemical sulfation procedure based on the sulfur-trioxide
pyridine complex method was performed on the ulvan fraction obtained. The anticoagulant activity of
both the native and chemically-sulfated ulvan fractions was then assessed against the intrinsic and/or
common (activated partial thromboplastin time: APTT), extrinsic (prothrombin time: PT), and common
(thrombin time: TT) pathways, and the specific antithrombin-dependent pathway (anti-Xa and anti-IIa),
of the coagulation cascade.
2. Results and Discussion
2.1. Extraction, Purification, and Sulfation of Ulvan from U. rigida
The extraction of ulvan from the green macroalga U. rigida was carried out in hot water
and was followed by a multistep purification procedure previously developed [48]: ultrafiltration,
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ion exchange, and precipitation of remaining proteins. After neutralization with 1 M NaOH, the sulfated
polysaccharides were recovered in a sodium salt form in the ULVAN-01 fraction, with an extraction
yield of about 5% of the non-desalinated dry biomass (initially containing about 50% of salt).
The sulfation procedure was finally carried out starting from 500 mg of ULVAN-01 fraction, to give
200 mg of ULVAN-02 fraction.
2.2. Chemical Characterization of the ULVAN-01 and ULVAN-02 Fractions
The efficacy of the extraction and purification procedure of ulvan from U. rigida in terms of
sulfated polysaccharide production was high with less than 4% of remaining contaminant proteins in
the ULVAN-01 fraction. The purity of the polysaccharide was even higher after chemical sulfation
with a percentage of remaining proteins less than 1% in the ULVAN-02 fraction (Table 1). This better
purification was very likely due to the last step of the sulfation procedure, i.e., ethanol precipitation of
sulfated polysaccharides.





Uronic acids 34 31
Sulfates on the polysaccharide backbone




Ashes 23 nd (d)
Monosaccharide composition
(% molar ratio)
Glc/Gal 12.2 nd (d)
Xyl 8.0 nd (d)
Rha 42.6 nd (d)
GlcN 6.9 nd (d)
GlcA/IdoA 30.3 nd (d)
Mn (a) (kDa) 31.3 39.0
Mw (b) (kDa) 56.7 55.3
I (c) 1.8 1.4
(a) number-averaged molecular weight; (b) weight-averaged molecular weight; (c) polydispersity index; (d) not determined.
Both ulvan fractions contained about 30% of uronic acids, a value that was in the higher range
of what could be observed in ulvans from Ulva species [49]. Conversely, the sulfate content of about
11%, corresponding to a sulfate to uronic acid molar ratio of 0.65, was in the lower range of ulvan
sulfate content [22,49]: this could be explained by the harsh conditions of extraction, ultrafiltration and
protein precipitation used during the isolation process (80 ◦C, 5 bars), which may have led to partial
desulfation. ULVAN-01 was mainly composed of rhamnose and glucuronic and/or iduronic acid,
and to a lesser extent of glucose and/or galactose, xylose, and glucosamine. It is noteworthy, however,
that chemical sulfation allowed to almost double the initial sulfate content of ULVAN-01: indeed
ULVAN-02 exhibited 20% of sulfate groups on the polysaccharide backbone, for a sulfate to uronic
acid molar ratio of 1.30. Moreover, a very interesting feature of the extraction procedure developed by
SEPROSYS was the high purity of the resulting ulvan in the ULVAN-01 fraction, which was estimated
at 86% by adding the contents of neutral sugars, uronic acids, and sulfate esters, taking into account
that sulfates are not burned at 550 ◦C and are also part of the ash content, together with sodium cations.
2.3. Structural Characterization of the ULVAN-01 and ULVAN-02 Fractions
A MW of about 57 kDa was estimated by SEC (Figure 1 and Table 1) for ULVAN-01, based on a
calibration curve of dextran standards. After chemical sulfation of ULVAN-01 using sulfur trioxide
pyridine complex in pyridine and dimethylformamide (DMF), the resulting ulvan in ULVAN-02 had an
estimated MW of about 55 kDa, slightly lower than ULVAN-01 MW. SEC chromatograms of ULVAN-01
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and ULVAN-02 were very similar, except that the major peak eluted from 30 to 40 min seemed narrower
for ULVAN-02 and eluted slightly sooner than that of ULVAN-01. On the other hand, a peak eluted at
about 44 min, corresponding to oligosaccharides, was only found in ULVAN-01, while a peak eluted
at about 47 min, likely corresponding to low-molecular-weight oligosaccharides, was only found in
ULVAN-02. Besides, the polydispersity of ULVAN-02 (I = 1.4) was lower than that of ULVAN-01
(I = 1.8). The fact that the sulfate content in ULVAN-02 was double to the respective measured
in ULVAN-01 should highly affect MW, considering the hydrodynamic size of the polysaccharide
that is strongly affected by sulfate groups, due to anionic charges. Therefore, the weak difference
between ULVAN-01 and ULVAN-02 Mw may appear very surprising. However, these observations
could be explained by a slight cleavage of the glycosidic linkages in the polysaccharides that likely
occurred during chemical sulfation, as proposed by Nishino and Nagumo [50]. This would lead to
the transformation of bigger polysaccharides into polysaccharides of intermediary MW, and therefore
to the increase in Mn observed in ULVAN-02, concomitant with the decrease in polydispersity index,
resulting in the narrower shape of the major peak eluted from 30 to 40 min. This would also cause the
depolymerization of oligosaccharides to smaller oligosaccharides, which might explain the appearance
of the peak eluted at 47 min for ULVAN-02 as the peak eluted at 44 min found in ULVAN-01 disappeared.
Furthermore, this would be in accordance with the slightly lower value of ULVAN-02 Mw as small
oligosaccharides strongly affect the Mw value.
 
Figure 1. Size exclusion chromatograms of the ULVAN-01 and ULVAN-02 fractions.
ULVAN-01 was also characterized in a previous work by 13C NMR [48]. The chemical shifts were
attributed on the basis of references reporting assignments of ulvans and oligosaccharides [51].
As previously reported, the assignment signals corresponding to the carbons of both type A
(β-d-Glcp-(1→4)-α-l-Rhap3S) and type B (α-l-Idop-(1→4)-α-l-Rhap3S) ulvanobiouronic acid 3-sulfate
were detected, confirming the presence of this sequence. On the other hand, the ultra high pressure
liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) analyses of the 9kDa
ulvan fraction obtained after controlled depolymerization of ULVAN-01 revealed characteristic ions
that could be attributed after selective pseudo-MS3 fragmentation to oligosaccharide sequences with a
polymerization degree up to 12 (Table 2).
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Sequences 1 to 4 were determined by pseudo-MS3 analysis and shown to exhibit a repeated
disaccharide sequence, sulfated or not, composed of a rhamnose moiety and an uronic (glucuronic
or iduronic) acid, i.e., ulvanobiouronic acid 3-sulfate [48]. However, this typical structure of ulvans
was found associated to 3 variable moieties, despite being quite uncommon: glucose (or possibly
a galactose since these epimers cannot be distinguished by MS/MS analysis) (sequence 3), xylose
(sequence 4), or uronic acid (sequence 1). Together, 13C NMR and MS analyses were thus in line with
the biochemical and monosaccharide compositions of ULVAN-01, which put forward a high proportion
of neutral sugars (mainly rhamnose) and uronic acids. Glucosamine was not found in these products
of ulvan-01 depolymerization.
The MS2 analyses also revealed four disaccharide sequences in ULVAN-02 that were characterized as
Z2 ions (m/z) obtained after fragmentation of the polysaccharidic chain in the spectrometer source, in line
with the work by Saad and Leary [53], who observed the same dissociation mechanism when analyzing
heparin disaccharides by electrospray ionization MS2 analysis. The dissociation mechanism of ULVAN-02
giving access to the Z2 ion (m/z) 401.0385 (sequence 5 in Table 2) is shown as an example on Scheme 1.
The regio- and stereo-specificities of the osidic linkages could not be determined from these analyses so
that the reported structures were designed according to the established structure of ulvans [22].
Scheme 1. Dissociation mechanism resulting in Z2 ion formation (example of the ion (m/z) 401.0385:




Figure 2. Negative-ion mode electrospray ionization-mass spectrometry targeted fragmentation spectra
(ESI−-pseudo-MS3) of the ions (m/z) 401.0383 (A, sequence 5 in Table 2), 502.9776 (B, sequence 6 in
Table 2), 604.9166 (C, sequence 7 in Table 2), and 706.8558 (D, sequence 8 in Table 2).
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The fragmentation profiles of the four disaccharide sequences obtained after pseudo-MS3 analysis
proved that these sequences exhibited sulfate groups on both rhamnose and uronic acid moieties,
with one to two sulfate groups on each residue (sequences 5–8 in Table 2 and Figure 2). This result
demonstrated that the chemical sulfation method used was completely random and could sulfate up
to all four free alcohols of the ulvanobiouronic acid disaccharide: two of rhamnose and two of uronic
acid (GlcA or IdoA). Besides, given both the sulfate content of ULVAN-02 of about 20%, indicating
an average sulfation of two sulfate groups every three residues, and the observation of disaccharide
sequences with up to four sulfate groups, it was concluded that the chemical sulfation of the ULVAN-01
polysaccharide led to a high heterogeneous sulfation pattern, involving both hyper-sulfated and
scarcely sulfated zones within ULVAN-02 polysaccharidic structure.
2.4. Anticoagulant Activity
The potential anticoagulant activity of ULVAN-01 and ULVAN-02 was investigated using different
clotting and enzymatic assays, targeting the intrinsic and/or common (activated partial thromboplastin
time, APTT), extrinsic (prothrombin time, PT) or common (thrombin time, TT) pathways of the
coagulation cascade, as well as the specific antithrombin-dependent pathway (anti-Xa and anti-IIa).
Furthermore, the anticoagulant properties of ulvan fractions were compared to those of commercial
anticoagulants, one UFH and one LMWH, the so-called Lovenox®.
The APTT test mainly assesses the anticoagulant activity on the intrinsic pathway, and, to a lesser
extent, on the common pathway. ULVAN-01 activity on the intrinsic pathway was very low (Figure 3A).
Indeed, at a concentration of 1000 μg/mL, the clotting time of the plasma was less than 100 s, i.e.,
100- and 1000-fold higher than that of Lovenox® and UFH, respectively. Conversely, ULVAN-02
showed a very interesting anticoagulant activity that was higher than that of Lovenox® and just slightly
lower than that of UFH. While 500 μg/mL of ULVAN-01 were needed to double the clotting time,
only 2.4 μg/mL of ULVAN-02 gave the same result: this concentration was two-fold lower than that of
Lovenox® (4.7 μg/mL) and only three-fold higher than that of UFH (Table 3). ULVAN-02 appeared
thus to be more effective than Lovenox® on the intrinsic pathway.
(A) (B) (C) 
Figure 3. (A) Activated partial thromboplastin time (APTT), (B) prothrombin time (PT), and (C)
thrombin time (TT) assays of ULVAN-01 (Δ), ULVAN-02 (), unfractionated heparin (UFH) (),
and Lovenox® (). The clotting times of the plasma in the absence of fractions (negative control,
0.9% NaCl) were (A) 38.2 s, (B) 13.1 s, and (C) 12.9 s. The maximum clotting times measured by the
coagulometer were (A) 120 s, (B) 70 s, and (C) 60 s (no coagulation within this time range). Data shown
as the mean +/−SD, n = 6.
Therefore, the chemical sulfation procedure significantly increased the activity of ULVAN-01
on the intrinsic and/or common coagulation pathways. Several sulfated polysaccharides from
green macroalgae species have been studied for their anticoagulant activity, including high
arabinose-containing sulfated polysaccharides, arabinogalactans, or galactans found in Codium [32,34,36]
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or Ulva (formerly Enteromorpha) [54,55]; polysaccharides rich in sulfated galactose from Caulerpa [56];
and high-rhamnose-containing sulfated polysaccharides from Monostroma [38,40,41,57]. It has mainly
been shown that these polysaccharides could extend the APTT. Only one study has assessed, by APTT
assay, a significant anticoagulant activity of sulfated ulvans extracted from an Ulva species (Ulva
conglobata) [43]. These polysaccharides were naturally highly sulfated (between 23.0 and 35.2%), with a
rhamnose content between 63 and 72%. The most effective ulvan contained 35.2% of sulfates and
prolonged the clotting time to 120 s at a concentration of 2.5 μg/mL, versus 4 μg/mL and 5 μg/mL for
two other ulvans with 23 and 28% of sulfate content, respectively. Interestingly, the concentration of
4 μg/mL in ULVAN-02 (sulfated at 20%) resulted in the same clotting time, thus making its activity
very similar to that of Ulva conglobata ulvans.






Activated partial thromboplastin time (APTT) (a) 0.75 4.7 500 2.4
Prothrombin time (PT) (a) 14.25 480 inactive 45
Thrombin time (TT) (a) 0.45 1.82 117 2.62
Anti-Xa (b) 0.2 0.125 inactive 17.5
Anti-IIa (b) 0.25 1.75 inactive 18
(a) Sample concentration needed to double the clotting time compared to the negative control (0.9% NaCl); (b) sample
concentration for which the enzyme maintained 50% of residual activity.
The PT test, assessing the ulvan activity on the extrinsic coagulation pathway, also showed a
major effect of the sulfation procedure on the polysaccharide activity. Indeed, ULVAN-01 was inactive
on this coagulation pathway whereas the activity of the sulfated fraction ULVAN-02 was high and
only three-fold lower than that of UFH (Figure 3B). ULVAN-02 activity was more than ten-fold higher
than that of Lovenox®, with respective concentrations needed to double the clotting time of 45 and
480 μg/mL (Table 3).
Furthermore, a significantly increased anticoagulant activity was associated with ULVAN-01
sulfation, based on the TT assay, which evaluates the anticoagulant activity on the common pathway
of the coagulation process (Figure 3C). Indeed, the concentration of ULVAN-01 needed to double
the coagulation time of the negative control (117 μg/mL) was more than 40-fold higher than that of
ULVAN-02 (2.6 μg/mL) (Table 3). However, ULVAN-02 activity on this coagulation pathway was
slightly lower than that of Lovenox®, which was not the case on the other coagulation pathways.
Thus, for the common pathway, the chemical sulfation procedure led to a significantly increased
anticoagulant activity of U. rigida ulvan.
All these clotting time assays tended to show that the anticoagulant activity of ULVAN-02 was
mostly oriented towards the early steps of the coagulation cascade, both on the intrinsic and extrinsic
pathways, since its activity on the common pathway, which is the final coagulation with fibrin complex
formation (red thrombus), was low compared to both Lovenox® and UFH.
Finally, the anticoagulant activity of the ulvan fractions ULVAN-01 and ULVAN-02 was assessed
on two central enzymes of the coagulation process, factors Xa and IIa (also called thrombin).
The anticoagulant activity was measured in the presence of antithrombin, a coagulation inhibitor,
since UFH and Lovenox® are known for their antithrombin-mediated anticoagulant activity.
ULVAN-01 was devoid of any antithrombin-mediated anti-Xa activity (no activity at 1000 μg/mL,
data not shown) while ULVAN-02 showed a maximal activity at a concentration of 100μg/mL (Figure 4A).
However, despite a much higher antithrombin-mediated anti-Xa activity of ULVAN-02 compared to
that of ULVAN-01, this activity was 100-fold lower than that of UFH and Lovenox®. Indeed, factor
Xa residual activity was of 50% with UFH, Lovenox®, and ULVAN-02 concentrations of 0.2 μg/mL,
0.125 μg/mL, and 17.5 μg/mL, respectively (Table 3). The lack of antithrombin-mediated anti-Xa activity
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of the native ulvan fraction ULVAN-01 is in line with the study by Mao et al. [39], which has concluded
that rhamnan sulfates from Monostroma nitidum have a very low antithrombin-mediated anti-Xa
activity (concentration higher than 1000-fold than that of heparin for the same activity). Two sulfated
rhamnan extracts were compared by these authors, with MW of 70 kDa and 870 kDa, and sulfate
contents of 34.4 and 28.2%, respectively. Although their sulfate content was much higher than that
of ULVAN-01 or ULVAN-02 ulvans (11 and 20%, respectively), these sulfated polysaccharides were
not more active. Moreover, despite its sulfate content being about 65% lower than that of these
sulfated rhamnans described by Mao et al., the concentration of ULVAN-02 needed to achieve a similar
antithrombin-mediated activity was 10-fold lower. The work by Majdoub et al. on sulfated rhamnans
(20% of sulfates) from the cyanobacteria Arthrospira platensis (formerly Spirulina platensis) also showed
a lack of anti-Xa activity of this type of sulfated polysaccharide [58]. Conversely, Matsubara et al.
highlighted the anticoagulant anti-Xa activity of sulfated galactans extracted from the green seaweed
Codium cylindricum, containing 89% of galactose and only 13.1% of sulfates, and found an activity very
similar to that of ULVAN-02 [33]. In conclusion, the degree of sulfation seems to play a key role in the
antithrombin-mediated inhibition of factors Xa and IIa by ulvans, but it does not seem to be the only
structural feature that drives this reactivity when it comes to polysaccharides from other seaweeds.
  
(A) (B) 
Figure 4. Dose-response curves of antithrombin-mediated (A) anti-Xa and (B) anti-IIa activities of
ULVAN-02 (), unfractionated heparin (UFH) (), and Lovenox® (). Data shown as the mean, n = 6
(error bars are not indicated for better readability).
In addition, ULVAN-02 was also shown to exhibit an antithrombin-mediated anti-IIa activity
(Figure 4B), with a concentration of 18 μg/mL needed to reduce the enzymatic activity of factor IIa
by 50%, while ULVAN-01 had no activity (data not shown). Nevertheless, this activity was quite
low, 70-fold and 10-fold lower than those of UFH and Lovenox®, respectively (Table 3). Lovenox®
activity was thus much lower than that of UFH, which is consistent with the known anticoagulant
effect of Lovenox® since it mainly targets factor Xa. These results are also in accordance with those
obtained with other sulfated rhamnans from green macroalgae, which are able to inhibit thrombin in
the presence of antithrombin, but to a lesser extent than heparin. Rhamnose-rich polysaccharides from
Monostroma nitidum [39] or Arthrospira platensis (formerly Spirulina platensis) [55], and ulvans from Ulva
species [43], are, for instance, 100-fold and 10-fold less active than UFH, respectively.
All together, these results confirm previous findings showing that the anticoagulant activity of
macroalgal sulfated polysaccharides is affected by their degree of sulfation [46,47]. Indeed, almost
all the tests showed a highly significant increase in the anticoagulant activity of U. rigida ulvan after
chemical sulfation. The results obtained with ULVAN-02 on the PT test are of particular interest as
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they are not in line with previous studies on sulfated polysaccharides from green macroalgae that
have concluded that sulfated polysaccharides have a positive effect on the intrinsic and/or common
coagulation pathways, based on the APTT test, while they do not exhibit any activity on the extrinsic
coagulation pathway, based on the PT test. For instance, an ulvan from Capsosiphon fulvescens (15.4%
sulfate content) [59], sulfated rhamnans from Monostroma latissima (21–26% sulfate content) [38,40,41]
or from Monostroma nitidum (28.2–34.4% sulfate content) [39], did not show any activity on the extrinsic
pathway, whereas their sulfate content was very close to that of ULVAN-02. Thus, the degree of sulfation
does not seem to be the only parameter affecting the anticoagulant activity of ulvans. Other polyanionic
polysaccharides from various origins have been shown to have an anticoagulant activity strongly
related to their degree of sulfation ([43,44,46,47]: sulfated fucans, in particular, have been extensively
studied and their activity has been proved to be mainly mediated by thrombin inhibition by either
antithrombin or heparin cofactor II, at different extents. However, numerous studies on sulfated fucans
and galactans [60–62], and more recently on carrageenans [63], also established that anticoagulant
activity, particularly in terms of efficiency, is not merely a function of charge density and depends
critically on other structural features [46,47]: monosaccharide composition, glycosidic bounds, MW [50],
branching residues, and position of sulfate groups on the sugar backbone [18,60]. Among them,
the most important seem to be the sulfation pattern and monosaccharide composition [18,46,47,60].
According to Melo et al. [60], the anticoagulant activity of sulfated galactans is achieved mainly through
potentiation of plasma cofactors, including antithrombin, which are the natural inhibitors of coagulation
proteases but the structural basis of the interactions involved is very complex, due to the heterogeneity
of these polysaccharides. Their study on interactions with thrombin and its cofactors, in particular,
notably showed that sulfated galactans can link with antithrombin but require significantly longer
chains than heparin to interact with the antithrombin/thrombin complex, and bind to a different site.
In addition, Becker et al. highlighted, by molecular modeling techniques, that similarities obtained in
the glycosidic linkages and predominant 1C4 chair form of sulfated fucans and galactans could fully
explain their specific interaction with antithrombin and the differences between their anticoagulant
activity and that of heparin [62]. All these data indicate that the action mechanism of heparin mimetics
including sulfated polysaccharides from marine seaweeds differs from that of heparin, which is well in
accordance with the overall results obtained in the present study. It was indeed shown that ULVAN-01
was very slightly active on the intrinsic and common pathways, and inactive on the extrinsic pathway
of the coagulation cascade, based on the PT test. It was also inactive on the coagulation factor Xa,
which is the upstream common point for intrinsic and extrinsic coagulation pathways. On the contrary,
ULVAN-02 was active on all tested pathways, showing that chemical sulfation strongly enhanced
the anticoagulant activity of ULVAN-01 and could even enable it to inhibit the antithrombin/Xa or
antithrombin/IIa complexes. It was also demonstrated by UHPLC-HRMS analyses that the chemical
sulfation method used to obtain ULVAN-02 led to an ulvan with a very heterogenous sulfation
pattern, involving both hyper-sulfated and scarcely sulfated zones within the polysaccharidic structure,
which is very different from what is usually found in the native form of ulvans, i.e., a sulfation pattern
most exclusively involving the position 3 of rhamnose. The most likely hypothesis to explain the
anticoagulant activity of ULVAN-02 lies in the probability that a geometrical match between the
polysaccharide and its binding site on coagulation factors is increased by sulfation, the sugar backbone
providing the geometric constraints to accommodate the binding site, and the increased negative
charge due to sulfation pattern modifications in the hyper-sulfated zones providing higher physical
interaction properties, further enhancing the binding capacity of the polysaccharide.
2.5. Effect of ULVAN-01 and ULVAN-02 on Cell Viability
The in vitro cytotoxicity of ULVAN-01 and ULVAN-02 was assessed using the MTT assay on
human fibroblastic cells, and compared to those of UFH and Lovenox® (Figure 5).
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Figure 5. Viability of human fibroblasts treated for 72 h with ULVAN-01, ULVAN-02, unfractionated
heparin (UFH), and Lovenox®. Results are expressed as the relative percentage of viability compared
to the negative control. Data shown as the mean +/−SD, n = 5. Significant differences between samples
and negative control are indicated by * (p < 0.05), ** (p < 0.01), and *** (p < 0.001).
Results showed that ULVAN-01, ULVAN-02, and UFH had a very similar dose-response effect on
cell viability. Up to 250 μg/mL, they had a very limited impact on cell viability: about 80% viable cells
were indeed enumerated, compared to the negative control. Lovenox® even seemed to have slightly
less impact on cell viability. More importantly, ULVAN-02 was absolutely not cytotoxic to human
fibroblasts at concentrations within the range of 1–15 μg/mL, corresponding to the concentration range
where it was shown to be bioactive, regardless of the anticoagulant activity tested, which is an essential
prerequisite to consider any further development of this sulfated ulvan fraction extracted from U. rigida
as part of a therapeutic anticoagulation application.
3. Materials and Methods
3.1. Materials
Green macroalga U. rigida was cultivated in a pond in the “Ferme du Douhet,” a marine farm in
Ile d’Oléron (France). It was collected in 2012 and dried.
UFH was purchased from Interchim (Montluçon, France) (heparin sodium salt 12865E, batch 201274)
and Lovenox® was kindly provided by the the Saint-Louis Hospital (La Rochelle, France).
Unless otherwise stated in the text, all chemical reagents were purchased from Merck
(Darmstadt, Germany).
3.2. Methods
3.2.1. Extraction and Purification Process
First, 500 g of U. rigida thallus were washed in 15 L of distilled water (1/30 (w/w)) for 10 min
at room temperature (RT) and wrung with a fabric cone to remove as much water as possible [48].
The washed algae were then ground at 80 ◦C in a blender, in 5 L of deionized water, until obtaining
2-mm particles. The 5 L of minced algae in water were transferred into a thermostated tank at 80 ◦C
containing 2.5 L of distilled water. Extraction was processed under constant agitation with a bladed
stirrer at a rotation speed of 10 spins/min for 2 h. The pulps were then removed from the tank and
filtered with the fabric cone to collect the aqueous extract. The aqueous extract was then recovered and
filtered with an ultrafiltration unit equipped with a 15 kDa Kerasep KBW membrane (Novasep Process,
Pompey, France). Filtration was carried out at 80 ◦C at a pressure of 5 bars and a circulation flow of
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450 L/h (circulation speed of 5 m/s), until obtaining a retentate around 4◦Bx. Next, 1.5 L of retentate
was demineralized by passage on a column containing 100 mL of Amberlite FPA 98, a strong anionic
resin in the OH− form, in series with a column containing 200 mL of Amberlite IR 120 Na, a strong
cationic resin in the H+ form. Circulation was processed with a peristaltic pump at a flow rate of 2 BV/h.
The deionized product was finally decanted in a water bath at 80 ◦C for 2 h. After centrifugation at
5000× g for 15 min at RT, the fraction, referred to as ULVAN-01, was neutralized to pH 7 with 1 M
NaOH and lyophilized.
3.2.2. Sulfation Procedure
The sulfation procedure was carried out on the ULVAN-01 fraction using the sulfur-trioxide
pyridine complex (SO3–pyridine) method, in dimethylformamide (DMF) and pyridine [64].
Briefly, 500 mg of ULVAN-01 were dissolved in a mixture containing 10 mL of DMF and 1.4 mL of
pyridine. The mixture was heated to 60 ◦C and sulfation was then processed by progressive addition
of 3 g of SO3–pyridine complex for 2 h at 60 ◦C under constant stirring. The mixture was left for
two additional hours at 60 ◦C under stirring. After cooling of the mixture at RT, it was centrifuged
at 5000× g for 10 min at 4 ◦C. The supernatant was then removed and the pellet was dissolved in
5 mL of 2.5 M NaOH, and 45 mL of absolute ethanol were added (final concentration: 90% (v/v)).
After 12 h at 4 ◦C under stirring, the precipitate was isolated by centrifugation (10,000× g, 10 min,
4 ◦C) and dissolved in 60 mL of deionized water. The solution was finally dialyzed for seven days
against deionized water (cut-off: 1 kDa) and lyophilized. The resulting sulfated fraction was referred
to as ULVAN-02.
3.2.3. Chemical Composition
The neutral sugar content was determined according to the phenol-sulfuric method [65],
using glucose as a standard. The uronic acid content was measured as described by Bitter and Muir [66].
The protein content was determined using the Bradford protein assay [67]. The sulfate content was
obtained using 3-amino-7-(dimethylamino)phenothiazin-5-ium chloride (Azure A), which binds to
the sulfated groups in a polysaccharide chain [68,69]. The quantitation method of polyphenols was
adapted from the original one [70], using gallic acid as a standard: briefly, 50 μL of Folin–Ciocalteu
reagent and 200 μL of 20% sodium carbonate were successively added to 100 μL of sample and the
mixture was incubated in the dark for 45 min at RT, prior to absorbance reading at 730 nm. The ash
content of ULVAN-01 was quantified after 15 h at 550 ◦C. The ash content of ULVAN-02 could not be
determined due to a lack of material. All analyses were performed at least in triplicate, except the
determination of ULVAN-01 ash content (n = 2), and data are thus shown as the mean.
3.2.4. Analysis of the Fractions by High Performance Size Exclusion Chromatography
The structural and quantitative analyses of ulvan fractions were performed using a HPLC
1100 LC/RID system (Agilent technologies, Santa Clara, CA, USA), with two successive exclusion
chromatography columns of 30 cm in size: TSK gel 5000 PW and TSK gel 4000 PW (Tosoh Bioscience,
Tokyo, Japan). These analyses were carried out at 30 ◦C, after injection of 20 μL of 1 mg/mL fraction
or sample, at a flow rate of 0.5 mL/min of elution buffer (0.1 M ammonium acetate). Products
were detected and quantified by differential refractometry using the HP Chemstation software in
off-line mode for processing. The standard curve was made using dextran standards from 1000 to
50,000 Da. The number-averaged molecular weight (Mn), weight-averaged molecular weight (Mw)
and polydispersity index (I) were calculated as follows [71]:
Mn = (Σ Ni ×Mi)/Σ Ni
Mw = (Σ Ni ×Mi2)/(Σ Ni ×Mi)
I =Mw/Mn
where Ni is the number of moles of polymer species and Mi the molecular weight of polymer species.
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3.2.5. Nuclear Magnetic Resonance (NMR) and Ultra High Performance Liquid
Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS)
Carbon (13C) NMR analysis of the ULVAN-01 fraction was performed using a JEOL JNMLA400
spectrometer (400 MHz, JEOL, Peabody, MA, USA) in D2O solution at a concentration of 50 mg/mL [48].
The monosaccharide composition and oligosaccharide sequences were determined by
UHPLC-HRMS. Analyses were carried out using an UHPLC system, “Acquity UPLC H-class,”
coupled to a HRMS system, “XEVO G2-S Q-TOF,” equipped with an electrospray ionization source
(Waters, Milford, MA, USA). The UHPLC system was formed by a quaternary pump (Quaternary
Solvent Manager, Waters) and an automatic injector (Sample Manager-FTN, Waters) equipped with a
10 μL injection loop. Analyses were performed according to the UHPLC and MS parameters given in
Table 4.
Table 4. Ultra high pressure liquid chromatography (UHPLC) and mass spectrometry (MS) parameters
used to determine the monosaccharide composition and oligosaccharide sequences.
Monosaccharide Composition Oligosaccharide Sequences
UHPLC Parameters
Column “Acquity UPLC BEH Amide” (Waters) (2.1 × 500 mm, 1.7 μm), maintained at 30 ◦C
Flow rate (μL/min) 0–15 min, 130–200; 15–18 min, 200;18–30 min, 200–130; 30–37 min, 200 200
Gradient: water (A)/acetonitrile
(B) + 0.015% (v/v) ammoniac
0–15 min, 90–55% B; 15–17 min, 55%
B; 17–18 min, 55–90% B; 18–37 min,
90% B
0–3 min, 100% B; 3–3.1 min 100–70% B; 3.1–10 min,
70–50% B; 10–10.5 min, 50–45% B; 10.5–18 min,
45–100% B
Injection 5 μL (7 ◦C)
MS Parameters
Mode ESI+ (centroid) ESI− (centroid)
Source temperature 120 ◦C
Desolvation temperature 250 ◦C 500 ◦C
Gas flow rate of the cone 50 L/h
Desolvation gas flow rate 800 L/h
Capillary voltage 2.5 kV
Sampling cone voltage 35 V 130 V
Source compensation 80 V
Acquisition mass range 50–1200 m/z 50–2100 m/z (down-regulated according to thefragmented ion with a scan time of 0.15 s)
Lock-mass Leucine Enkephalin (MW = 555.62 Da, 1 ng/μL)
The analyses of monosaccharide composition were performed after total acid hydrolysis of
ULVAN-01. Briefly, 1 mL of 10 mg/mL ULVAN-01 solution in HCL 3 M was prepared and heated
at 100 ◦C for 5 h (total hydrolysis was monitored over-time using reducing sugar assessment by the
dinitrosalicylic acid method [72]). After cooling at room temperature, the sample was centrifuged at
10,000× g for 10 min and filtrated through 0.22 μm filter, prior to UHPLC-HRMS analysis.
The analyses of oligosaccharide sequences were carried out on a 9 kDa ulvan fraction filtrated
through 0.22 μm filter, obtained after solid supported depolymerization of ULVAN-01. Briefly, 100 mL
of ULVAN-01 solution at 25 mg/mL were prepared and depolymerized, using a circuit consisting of the
ULVAN-01 solution, a peristaltic pump set at a flow rate of 12 mL/min and a column containing 10 mL
of AMBERLITE™ FPC23 H resin in the H+ form. The polysaccharide solution and the column were
maintained at 80 ◦C for 19 h. After cooling at room temperature, the samples were filtrated through
0.22 μm filter, prior to UHPLC-HRMS/MS analysis.
3.2.6. Clotting Time Assays
The anticoagulant activity of the different fractions was determined by measuring the APTT,
PT, or TT. All the assays were carried out using a Start4 coagulometer and assay kits from Stago
(Asnières-sur-Seine, France), according to the manufacturer’s instructions. Briefly, 90 μL of normal
human plasma were mixed with 10 μL of 0.9% NaCl solution containing various sample concentrations
for each assay. For the APTT assay, 100 μL of APTT assay reagent were added to the mixture prior to
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incubation for 3 min at 37 ◦C and addition of 100 μL of 0.025 M CaCl2, and the clotting time (APTT)
was recorded. For the TT and PT assays, the mixture was first incubated for 2 min (PT) or 1 min (TT) at
37 ◦C, before adding 200 μL of PT assay reagent (PT) or 100 μL of TT assay reagent (TT), and recording
the clotting time. The negative control used in all assays was 0.9% NaCl solution.
3.2.7. Assays of Antithrombin-Mediated Inhibition of Factors Xa and IIa
Stachrom ATIII and Stachrom Heparin kits (Stago, Asnières-sur-Seine, France) were used to assess
the antithrombin-mediated inhibition of factors Xa and IIa (thrombin), respectively, according to the
manufacturer’s instructions. Antithrombin was diluted 1:2 in 0.1X kit buffer. Then, 25 μL of sample
(aqueous solution of ulvan fraction, UFH or Lovenox® at various concentrations) were incubated
with 25 μL of antithrombin (0.626 μg/μL) at 37 ◦C for 30 s. Thereafter, 25 μL of factor Xa or factor IIa
(thrombin) (11.25 nKat/mL) were added. After 30 s of incubation, 25 μL of a 3.25 nM solution of factor
Xa chromogenic substrate (CBS 31.39; CH2-SO2-d-Leu-Gly-Arg-pNA, AcOH) or 25 μL of a 1.4 nM
solution of factor IIa chromogenic substrate (CBS 61.50; EtM-SPro-ARG-pNA, AcOH) were added.
Factor Xa or IIa activities were immediately measured at 405 nm every 6 s for 5 min. The initial velocity
was calculated as the slope of the linear segment of the kinetic curve. All assays were performed in
96-well NUNC microplates (Thermo Fisher Scientific, Waltham, MA, USA), using a Fluostar Omega
microplate reader (BMG LABTECH, Ortenberg, Germany).
3.2.8. Evaluation of Cell Viability
Normal human dermal fibroblasts (NHDF) were obtained from ATCC (Manassas, VA, USA):
product code CCD-1059Sk; ATCC® CRL-2072™, lot number 62062292, from the skin of a 20-year-old
woman according to the supplier’s information. Cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM, PAN Biotech, Aidenbach, Germany) supplemented with 10% (v/v) fetal bovine serum
(PAN Biotech, Dutscher, France) and 1% (v/v) antibiotic solution (10,000 U/mL penicillin, 10 mg/mL
streptomycin) (PAN Biotech, Aidenbach, Germany), referred to as complete culture medium thereafter.
The cells were cultured at 37 ◦C with 5% CO2, in a temperature-controlled, humidified incubator.
The cells were grown in 75 cm2 surface ventilated Falcon culture flasks (BD Biosciences, Franklin Lakes,
NJ, USA) and subcultured by trypsinization (0.05% (w/v) trypsin, PAN Biotech, Aidenbach, Germany).
The culture medium was changed every 2 or 3 days. Cells were used between the 3rd and 8th passages
for the experiments.
The MTT test was used to evaluate cell viability, according to the method described by
Mosmann [73]. This colorimetric assay allows assessing cell proliferation, based on the reduction
of a tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT), by living
cells. MTT is a yellow salt. In the presence of mitochondrial succinate dehydrogenase produced by
active living cells, the tetrazolium ring they contain is reduced and forms a violet product: formazan.
The yellow solution becomes purple and the intensity of the purple coloration is proportional to the
number of living cells.
Briefly, 100 μL of complete culture medium containing 5 × 104 cells/mL were seeded in 96-well
Falcon microplates (BD Biosciences, Franklin Lakes, NJ, USA) and incubated for 24 h. The medium
was then removed and 100 μL of samples prepared in DMEM supplemented with 1% (v/v) antibiotic
solution, or negative control (DMEM supplemented with 1% (v/v) antibiotic solution alone) were added
into the wells. After 48 h, 25 μL of MTT (5% (w/v) in PBS) were added in each well and the plates were
incubated for 4 h at 37 ◦C. The medium was then removed and 200 μL of dimethyl sulfoxide were
added into each well. The plates were then incubated for 10 min and absorbance was read at 550 nm
using a Fluostar Omega microplate reader (BMG LABTECH, Ortenberg, Germany).
3.2.9. Statistical Analysis
The one-way Anova was applied to determine significant differences between samples and
negative control, using Sigma Plot 12.5 (Systat Software Inc., San Jose, CA, USA).
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4. Conclusions
A solvent- and acid-free procedure was developed to extract and purify ulvan from U. rigida,
providing an ulvan fraction of high purity (ULVAN-01), with less than 4% of contaminant proteins
remaining at the end of the procedure. The sulfate content of this ulvan was 11%, which is in the lower
sulfation range of ulvans extracted from algae of the Ulva genus. Data on the anticoagulant activity
of ulvans are limited but previous studies focusing on other types of sulfated polysaccharides have
shown that sulfation is essential for their anticoagulant activity, although the osidic composition, MW,
and sulfate groups position are also important features. To investigate the importance of the degree of
sulfation of U. rigida ulvan, a chemical sulfation procedure was applied to ULVAN-01, which allowed
almost doubling the sulfate content of the native polysaccharide, reaching 20%. The resulting
chemically-sulfated ulvan fraction, ULVAN-02, thus exhibited a strongly enhanced anticoagulant
activity, regardless of the coagulation pathway tested. Its most significant activity was shown to target
the intrinsic and extrinsic pathways, with an activity higher than that of Lovenox® and close to that of
UFH. It was indeed less active on the common pathway, although its activity was only slightly lower
than that of Lovenox®. This last result was confirmed by the low antithrombin-mediated inhibition
activity exhibited by ULVAN-02 on two important coagulation factors of the common pathway, Xa and
IIa (thrombin), which was also significantly increased compared to ULVAN-01 but remained quite low
compared to UFH and Lovenox®. Hence, the ULVAN-02 fraction could be a very interesting alternative
to heparins, with different targets and a high anticoagulant activity. Moreover, ULVAN-02 did not
appear to be cytotoxic on human model cells but further studies are needed to confirm these findings.
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Abstract: Gigartina pistillata is a red seaweed common in Figueira da Foz, Portugal. Here, the
antitumour potential of G. pistillata carrageenan, with a known variable of the life cycle, the female
gametophyte (FG) and tetrasporophyte (T) was evaluated against colorectal cancer stem cell (CSC)
-enriched tumourspheres. FTIR-ATR analysis of G. pistillata carrageenan extracts indicated differences
between life cycle phases, being FG a κ/ι hybrid carrageenan and T a λ/ξ hybrid. Both carrageenan
extracts presented IC50 values inferior to 1 μg/mL in HT29-derived CSC-enriched tumourspheres, as
well as reduced tumoursphere area. The two extracts were also effective at reducing cellular viability
in SW620- and SW480-derived tumourspheres. These results indicate that carrageenans extracted
from two G. pistillata life cycle phases have antitumour potential against colorectal cancer stem-like
cells, specially the T carrageenan.
Keywords: antitumour activity; carrageenan; colorectal cancer; cancer stem cells
1. Introduction
Seaweeds are turning into one of the most attractive natural resources of compounds that can
replace chemically synthetized compounds, such as plastic and other petroleum-based products,
or those from animal origin, such as collagen (gelatin). Seaweeds main structural component is a
polysaccharide-based type; its main function is to maintain the structure of the cell wall, with alginic
acid being the main polysaccharide produced in brown algae (Ochrophyta, Phaeophyceae), and agar
(agarophytes) and carrageenan (carrageenophytes) in red algae (Rhodophyta).
The use of seaweed biopolymers is increasing in the food industry as natural gelling and
emulsifier agents [1]. Carrageenans are one of the main natural texturizing agents in food applications
(dairy products, jellies, pet foods, sauces) being considered safe food additives [2]. They are
also used in pharmacological formulations, in cosmetics, as biomedical polymer compounds or
as lubricant [2–4]. Overall, carrageenans principal functions in industry are as a gelling, stabilizing,
and viscosity-building agent.
Diverse types of carrageenan are acquired from different species of the Gigartinales (Rhodophyta).
Kappa (κ)-carrageenan is mostly acquired by extraction from the tropical seaweed Kappaphycus
alvarezii (identified as “cottonii”, in the seaweed commercial area related to the food industry),
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while iota (ι)-carrageenan is mainly extracted from Eucheuma denticulatum (commercial denomination
“spinosum”). In turn, lambda (λ)-carrageenan is acquired from various species from the genera
Gigartina and Chondrus (commercial denomination “Irish moss”).
This unique hydrocolloid consists of alternating galactose and 3,6-anhydrogalactose sugars linked
by alternating α-1,3 and β-1,4 glycosidic linkages [5,6]. Carrageenans can be classified as λ, κ, and ι
according to the number of sulphated groups by galactose unit (Figure 1), where number, chemical
location, and arrangement of these groups defines carrageenan function and bioactivity power [2,7].
 
Figure 1. Idealized structure of the chemical units of different types of carrageenan [8].
The Xi (ξ)-carrageenan, a non-commercial carrageenan, has two sulphated ester groups, minus one
that is the λ-carrageenan but identical to ι-carrageenan. ξ-carrageenan is a viscous type carrageenan
due to the number of sulphated esters present in the structure [8]. The k-carrageenan only has a
sulphated ester group by the galactose unit.
Commonly, seaweeds do not produce these flawless and clean carrageenans, but instead a full
variety of hybrid configurations of carrageenan within the species life cycle [8]. Intrinsic carrageenans
always show a complex hybrid chemical conformation and are frequently a combination of galactans
composed of different carrabiose types, where proportions and structures change within the species,
ecological, physiological, and developmental conditions [9,10]. Hence, carrageenans are a group of
polysaccharides with molecular weight varying between 30 and 5000 kDa but the average molecular
weight of extracted carrageenans is between 200 and 800 kDa. [5,11]. These huge polysaccharides are
nonnutritive and after ingestion have an analogous effect to dietary fibers, being extremely resistant in
the digestive tract [5].
Both the Food and Drugs Administration (FDA) and the European Food Safety Agency (EFSA)
have approved the commercial forms of λ-, κ-, and ι-carrageenans for the food industry [5,11].
In the European Union, the carrageenan application is regulated by the Commission Regulation
(EU) No 231/2012, which defines that the commercial carrageenan (E 407) comprises essentially
potassium, sodium, magnesium, and calcium sulphate esters of galactose and 3,6-anhydrogalactose
polysaccharides [11]. Sub-chronic toxicity studies performed in rats showed that a dose of E 407
between 3400–3900 mg/kg body weight per day had no-observed-adverse-effect, fulfilling the EU
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specification for food level carrageenan food level [11]. On the other hand, the poligeenan, a degraded
ι-carrageenan with average molecular weight of 10–20 kDa, is not authorized in food applications
within the European Union area. In fact, degraded carrageenans, also known as artificial products
derived from carrageenan, are associated with adverse effects [5,12].
Carrageenans are water soluble polymers, their solubility being determined by the type of
carrageenan derivation, temperature, pH, and the counter ion in the dissolving solution, where
κ-carrageenan is the most soluble. The sodium salt of κ-carrageenan is soluble in cold water, but the
potassium salt is soluble only by heating. ι-carrageenan has an intermediate solubility [2]. All types of
carrageenan are insoluble in organic solvents including alcohols and ketones [13].
The carrageenan extraction method plays a major role in purity control. As shown by EFSA,
when carrageenans are produced by alcohol procedure, they contain approximately 90% anhydrous
carrageenan, 8% moisture, and 2% inorganic salts (mainly chlorides), while those manufactured by gel
press procedure contain about 77% anhydrous carrageenan, 8% moisture, and up to 15% inorganic
salts [11].
Gigartina pistillata (Figure 2) is an edible red seaweed found in both Northeast and Southeast
Atlantic and Southeast Asia, and a carrageenan resource for extraction industry. Its morphology is
described as the type species of the genus Gigartina and their thalli are erect, up to 20 cm tall, dark-red or
red-brown, cartilaginous, elastic, dichotomously branched, attached to the substratum through a small
disk [14]. G. pistillata can show a rare presence of the heterosporic thalli (i.e., producing tetraspores and
carpospores in the thalli of one specimen), despite although having an isomorphic triphasic life cycle [6].
In Gigartinaceae, the life cycle phase strongly disturbs carrageenans configuration. Gametophytic life
cycle yields a κ/ι-type carrageenans, while tetrasporophytic life cycle yields a λ-type carrageenans, as
shown by Pereira et al. [6,9,15,16].
 
Figure 2. G. pistillata in nature, fixed in a rocky platform in Praia do Cabo Mondego, Figueira da
Foz, Portugal.
The maximum carrageenan content extracted in G. pistillata in the work of Pereira [6,17] was
obtained from female gametophyte (FG) samples, with 59.7% of dry weight in late spring; a sample of
heterosporic thalli had the minimum value in late autumn, with 22.7% of dry weight.
In the last decades, the biological potential of carrageenans has been explored. Since the 1960s,
carrageenan anticoagulant and antithrombotic activity has been studied with λ-carrageenan showing
higher anticoagulant potential than κ-carrageenan [18]. Carrageenans have also been shown to
selectively inhibit many enveloped viruses [19] and to have antioxidant properties [20]. Carrageenan
antitumour potential has only been studied more recently, with several in vivo and in vitro models
proposing an antiproliferative action against tumour cells [21], being compounds from marine
bio-sources increasingly relevant in the quest to find new biomolecules with antitumour potential.
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Cancer is undoubtedly a major cause of worldwide morbidity and mortality, with 18.1 million
new cases and 9.6 million deaths estimated in 2018, and with an increasing social and economic
impact. Cancer in the gastrointestinal tract plays an important role in these estimates with colorectal
cancer being the third most incident (10.2%) and second most mortal (9.2%) [22]. Several studies
have highlighted the role of cancer stem cells (CSCs) in colorectal cancer development, progression,
and resistance to therapy [23–27].
The increasing evidence of the existence of CSCs has challenged the classical stochastic model
of cancer dynamics and has laid the foundation for the hierarchical model of tumourigenesis,
where the tumour mass is viewed as a hierarchical and unidirectional system, with CSCs in a
foundational position giving rise to heterogeneous cell populations. CSCs display high self-renewal
capacities, plasticity potential, high resistance to tumour microenvironment stress factors and
quiescence. These properties are believed to be responsible for CSC resistance to chemotherapy,
cancer relapse, and metastization [27–30]. The key role of CSCs in cancer development and recurrence
opens new venues for novel therapeutic strategies based on the specific and effective targeting of
this cell subpopulation. For instance, drugs that selectively inhibit CSC growth, induce cell death,
force differentiation, or modulate microenvironment are promising therapeutic strategies [27,30].
By combining CSC-targeting drugs and conventional anti-cancer therapies, one can target both bulk
cancer cells and CSCs, being more effective and faster in eradicating the tumour. However, it is
important that noncancerous somatic stem cells are spared, particularly in tissues with high cellular
turnover rates such as colon [30]. Great efforts have been made in this direction, trying to find
novel drugs that specifically target CSC, particularly bioactive compounds from plant sources, where
compounds such as resveratrol or curcumin show promising results [29]. In this matter, compounds
from marine biosources have been less explored. Nevertheless, compounds isolated from red algae
have shown some potential against CSC in an in vitro model of breast cancer [31].
Here, G. pistillata carrageenans from two life cycle phases, FG and tetrasporophyte (T) were
analyzed by Fourier transform infrared attenuated total reflectance (FTIR-ATR) and their potential
against colorectal CSC-enriched tumourspheres was explored.
2. Results
2.1. Carrageenan Extraction Yields
Through the alkali extraction method, from 1 g of dried seaweed, it was possible to obtain 17% ±
0.1 of FG carrageenan and 31% ± 3.2 of T carrageenan.
2.2. FTIR-ATR
Carrageneenan extracts from G. pistillata FG and T life cycles were obtained and analyzed by
FTIR-ATR. This technique allowed carrageenan characterization in a fast, nondestructive manner,
requiring small amounts of the sample [16]. The obtained spectra were reviewed with bibliographic
support [6,8] (Figure 3 and Table 1).
In the G. pistillata’s FG FTIR-ATR spectrum (Figure 3a), the first band to emerge is the low intensity
802 band, corresponding to DA2S bond, indicating the presence of ι-carrageenan, while the bands at
845 and 927 cm−1, G4S and DA bonds, respectively, with very close intensities, indicate the presence of
κ-carrageenan. A strong percentage of κ-carrageenan is also supported by the 1066 cm−1 band (DA).
The 970 cm−1 band is related to the presence of galactose units.
In the G. pistillata T spectrum (Figure 3b) the first band appears at 830 cm−1, corresponding to the
G/D2S, this indicates the presence of λ-carrageenan. The following band at 930 cm−1, appears as a low
intensity shoulder, in opposition to the strong band observed in the FG carrageenan, the same band
(the 927 cm−1, belonging to the same type of bond) in the spectrum presents a more noted band.
Bands at 1007 and 1214 cm−1 correspond to sulphated esters groups which dominate the spectrum
with their very intense and broad profile, indicating a noted presence of sulphated esters groups in
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the T carrageenan, because T forms a nongelling carrageenan. It is noted that the 1214 cm−1 can be
derived from Xi (ξ) carrageenan.
Figure 3. FTIR-ATR spectra of the carrageenan extracted from FG (Female gametophyte) (a) and T
(tetrasporophyte) (b) G. pistillata life cycle.
Table 1. FTIR-ATR bands identification and characterization of the G. pistillata FG and T life cycle.
Wavelength Numbers (cm−1) Chemical Structure Bonds/Assignments Life Cycle Presence
802 C–O–SO3 on C2 of3,6-anhydrogalactose DA2S FG
830 C–O–SO3 on C2 of galactose G/D2S T
845 C–O–SO3 on C4 of galactose G4S FG
927 C–O of 3,6-anydrogalactose DA FG
930 C–O of 3,6-anydrogalactose DA T
970 Galactose G/D FG
1007 S=O sulphated esters T
1027 S=O sulphated esters FG
1066 C–O of 3,6-anydrogalactose DA FG
1214 S=O sulphated esters FG/T
2.3. Anti-CSC Potential of Carrageenan Extracts
The tumoursphere forming assay [32] allows the establishment of 3D spheroids enriched in CSCs
from originally 2D adherent colorectal cancer cell cultures (Figure 4a). This cellular model was applied
to evaluate the potential of T and FG carrageenan extracts against CSC-enriched tumourspheres
derived from colorectal cancer cell lines. In CSC-enriched tumourspheres derived from HT29 cell
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line, both extracts presented IC50 values inferior to 1 μg/mL (0.6572 and 0.7050 μg/mL for FG and T
extract, respectively), which are similar to salinomycin (0.1450 μg/mL), a known CSC-targeting agent
(Figure 4b) [33].
 
Figure 4. Carrageenan extracts reduce cellular viability in cancer stem cell (CSC)-enriched
tumourspheres derived from HT29 colorectal cancer cell line. (a) Strategy for CSC-enriched
tumoursphere formation; (b) IC50 determination for salinomycin, T and FG carrageenans in HT29
CSC-enriched tumourspheres. Cell viability was determined by ATP (adenosine triphosphate)
metabolism assays. Results are depicted as mean ± SD, n = 3.
To assess if this effect was cell line dependent, FG and T carrageenans were incubated at two
different concentrations (33 and 100 μg/mL) with CSC-enriched tumourspheres derived from three
different human colorectal cell lines: SW620, SW480, and HCT116 cells. T carrageenan extract markedly
reduced cellular viability in SW620- and SW480-derived tumourspheres in a dose-independent manner
(< 20% for both cell lines), while FG carrageenan was more effective in SW480-derived tumourspheres
(< 30% for SW480 and ~50% for SW620) (Figure 5). Reduction in cellular viability was less evident in
HTC116-derived tumourspheres (~75% for both T and FG carrageenans) (Figure 5).
Figure 5. Carrageenan extracts have broad anti-CSC action. Both T and FG carrageenans impact at
different extents in CSC-enriched tumourspheres derived from SW620, SW480, and HCT116 cell lines,
in a dose-independent manner. Cell viability was determined by ATP metabolism assays. Results are
depicted as mean ± SEM, n = 3.
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Moreover, in HT29-derived tumourspheres, both T and FG extracts impacted on tumoursphere
formation, by significantly reducing the tumoursphere area when incubated at their IC50 dose (p= 0.0017
and p = 0.0056 for T and FG, respectively) (Figure 6), similarly to salinomycin control (p = 0.0007). On
the other hand, tumoursphere numbers slightly increased, particularly for FG carrageenan, although
without statistical significance (Figure 6).
Figure 6. Carrageenan extracts impact on HT29-derived CSC-enriched tumoursphere formation when
incubated at their respective IC50 dose (FG carrageenan: 0.6572 μg/mL; T carrageenan: 0.7050 μg/mL;
salinomycin: 0.1450 μg/mL). (a) A significant reduction on tumoursphere size is observed, however
tumoursphere number is not significantly altered. Results are depicted as mean ± SEM, n = 3.
** p < 0.005; *** p < 0.001. Sal—salinomycin. (b) Representative images of seven-day tumourspheres at
10×magnification. Scale bar, 275 μm.
3. Discussion
Seaweed collection sites and season confer variability of the dominant generation (between
gametophytes and tetrasporophytes), and reproductive cycle stage specially affects the carrageenans
structure [10,17]. Here, the FG carrageenan yield (17%) was lower when compared with previous
reports (59.7%) [17]. This could be explained by differences on the collection season, since in this study
sampling was performed in late August and not in the Spring, which is considered the best season [17].
Concerning T carrageenan, the yield (31%) was comparable to that reported before by Amimi et al.
(37%) [10].
The extracellular matrix of carrageenans resides mainly in the hydrophilic sulphated polygalactans.
The existence of d-galactose and anhydrous d-galactose differentiates the highly sulphated carrageenans
from the fewer sulphated agar (anhydrous-l-galactose) [34]. Analyzing the FTIR-ATR spectra of
FG G. pistillata, strong absorption bands can be observed at ~927 cm−1 which is characteristic of
carrageenan κ, ι, beta (β), and theta (θ), indicating the presence of C–O of 3,6-anydrogalactose (DA).
Bands in the 845 cm−1 region (characteristic of the ι and κ carrageenan spectra, and mu (μ) and nu (ν)
biological precursors of κ-carrageenan), indicate the presence of C–O–SO3 on C4 of galactose (G4S),
and bands in the 970 cm−1 area indicate the presence of galactose (G/D), which is characteristic of κ, ι,
β, and θ carrageenans spectra. However, the FG spectrum presented absorbance in the 802 cm−1 region
indicating the presence of C–O–SO3 on C2 of 3,6-anhydrogalactose (DA2S), which is only observed
in the ι and θ carrageenan spectra, meaning the presence of small amounts of ι carrageenan [8,16].
These results indicate that the FG carrageenan spectrum belongs to a κ/ι hybrid carrageenan, which is
corroborated by previous results [16]. In turn, FTIR-ATR spectra of G. pistillata T carrageenan showed
a broad band in the 830 cm−1 spectral region, indicating the presence of C–O–SO3 on C2 of galactose
(G/D2S), which is observed in the λ-carrageenan spectra and λ-carrageenan precursors. In these spectra,
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bands in the 930 cm−1 region indicate the presence of 3,6-anhydrogalactose (DA), characteristic of the
κ, ι, β and θ carrageenan spectra [8,16]. Therefore, this spectrum belongs to a hybrid carrageenan λ/ξ
spectrum, mostly λ type. Both T and FG carrageenan spectra share strong absorption bands in the
1000–1100 and 1210–1260 cm−1 regions, corresponding to sulphated esters groups (S=O), which are
always present in sulphated polysaccharide samples, in contrast to other vibrational bands that are
characteristic of carrageenans [8]. These results are corroborated by the studies realized by Amimi [9]
and Pereira [16] that proved the production of a hybrid λ/ξ carrageenan by G. pistillata T and a hybrid
κ/ι carrageenan by the G. pistillata FG.
Sphere forming assays have been extensively used to evaluate the potential of conventional
and novel molecules to target CSCs, since it has been shown that culturing 3D spheres in specific
experimental conditions promotes CSC growth and propagation [29,35–37]. The anti-CSC potential of
T and FG carrageenan extracts from G. pistillata was evaluated using a recently described CSC-enriched
tumoursphere forming assay [32], evidencing their bioactivity particularly for T extract. Both T and
FG extracts presented IC50 values inferior to 1 μg/mL in HT29-derived CSC-enriched tumourspheres.
However, when tested in tumourspheres derived from other colorectal cancer cell lines, T extract, with
λ/ξ hybrid carrageenans, was more effective in reducing cellular viability, particularly in SW480 and
SW620 cell lines, but not in HCT116. This may be since HT29, SW620, and SW480 cell lines share
genetic features such as TP53 and APC mutations or chromosomal instability, which are not present
in the HCT116 cell line, suggesting potential mechanisms of action. In addition, by impacting on
tumoursphere formation through reducing the tumoursphere area, the potential anti-CSC action of T
and FG extracts may be due to antiproliferative activity. Conversely, the increase of tumoursphere
number could suggest an increase of stemness properties; however, these changes are not significant
when compared to the control. Carrageenan extract from Kappaphycus alvarezii inhibits cell growth in
several cancer cell lines, including HT29 colon cancer cell line with an IC50 value of 73.87 μg/mL [38].
Further, it has been demonstrated that carrageenans can delay cell cycle progression in HeLa cells,
where λ carrageenans prolonged cell cycle by stalling in G1 and G2/M phases, therefore presenting a
strong antiproliferative activity by preventing cellular division [39].
Interestingly, FITR-ATR analysis showed a presence of higher sulphate ester groups in T
carrageenan compared to FG carrageenan. The quantity of sulphated esters in the carrageenan
extracts may possibly be correlated with the observed antitumour effects. However, previous
reports are conflicting. While Murad et al. showed that sulphated carrageenans from the red algae
Palisada perforata (formerly Laurencia papillosa) induced apoptosis in a breast cancer in vitro model [40],
Calvo et al. [41] reported that the presence of sulphate groups in native carrageenans diminished their
cytotoxic activity in a murine mammary adenocarcinoma cell line.
Yet, several factors must be taken into consideration concerning the use of carrageenans. Although
without major toxic effects [21], it has been described that λ carrageenans activate the Wnt/β-Catenin
pathway in normal human colonocytes which may induce the development of intestinal polyps [42].
Moreover, one must be aware of a putative carrageenans proinflammatory potential, where reports are
again conflicting. While in the past, carrageenans have been shown to induce the formation of ulcerative
lesions in a guinea pig model [21] and have been used to induce paw edema in animal models [43],
more recent data suggest that carrageenans do not induce the expression on proinflammatory proteins
in vitro models [5]. Nevertheless, the immunomodulating effect of λ-carrageenan was explored before,
suggesting that this carrageenan could be an efficient adjuvant in cancer immunotherapy by not only
inhibiting cell growth but also by enhancing tumour immune response [44].
Overall, carrageenans seem to be a potential new therapeutic strategy against cancer, including
therapy against CSC. Further studies are required to evaluate T and FG carrageenans toxicity,
CSC-specificity, and potential mechanisms of action.
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4. Materials and Methods
4.1. Reagents
Methanol was purchased from José Manuel Gomes dos Santos, Lda., Odivelas, Portugal and
acetone from the Ceamed, Lda., Funchal, Portugal. Ethanol was obtained from Valente e Ribeiro. Lda.,
Belas, Portugal and sodium hydroxide from Sigma-Aldrich GmbH, Steinheim, Germany.
4.2. Seaweed Collection
The specimens of G. pistillata (S.G. Gmelin) Stackhouse were collected in Praia do Cabo Mondego,
Buarcos, Figueira da Foz (40◦ 10′ 18.6” N, 8◦ 53′ 44.4” W), Portugal. Sampling was conducted in August
2018 from the sites with well-established G. pistillata patches and without epiphytes or degradation
visible at eyesight. Once harvested, samples were stored in plastic bags for transport to the laboratory,
in a cool box. All samples were washed thoroughly with filtered seawater to remove sand, and
epiphytes. Specimens of G. pistillata were separated according to the different life cycle phases—T and
FG, using a magnifying glass, washed briefly with distilled water to remove salts and dried in an air
force oven (Raypa DAF-135, R. Espinar S.L., Barcelona, Spain) at 40 ◦C, 48 h. The dried algae were
finely ground with a commercial mill (Taurus aromatic, Oliana, Spain) (≤ 1 mm) in order to render
the samples uniform, and then, stored in a dark room, in a box with silica gel to reduce the humidity,
at ambient temperature (± 24 ◦C).
4.3. Carrageenan Refined Alkali Extraction
Alkali extraction was preformed according to the method described by Pereira et al. [15]. The milled
seaweed was weighed in a scale (Radwag WLC 1/A2, Radwag, Radom, Poland) and 1 g samples
of the FG and T phases was used (n = 3). Before extraction, the milled seaweed material (1 g) was
resuspended and pretreated with an acetone:methanol (1:1) solution in a final concentration of 1%
(m/v) for 16 h, at 4 ◦C, to eliminate the organic-soluble fraction. The liquid solution was decanted,
and the seaweed residues obtained were dried in an air force oven (Raypa DAF-135, R. Espinar S.L.,
Barcelona, Spain) at 40 ◦C before the extraction method. The samples were placed in 150 mL of NaOH
(1 M) (1 g of initial seaweed: 150 mL of NaOH solution) in a hot water bath system (GFL 1003, GFL,
Burgwedel, Germany), at 85–90 ◦C, for 3 h. The solutions were hot filtered, twice, under vacuum,
through a cloth filter supported in a Buchner funnel and a Kitasato flask. The extract was evaporated
(rotary evaporator model: 2600000, Witeg, Germany) under vacuum to one-third of the initial volume.
The carrageenan was precipitated by adding the warm solution to twice its volume of 96% ethanol.
The precipitated carrageenan was washed with ethanol, 48 h at 4 ◦C, before drying in an air force
oven. After drying, the carrageenan was maintained in a close air sample flask stored in a dark and
no humidity local, at room temperature before the antitumour and FTIR-ATR assay. For biological
assays, the dried carrageenans extracts were grinded and dissolved in ultra-pure, sterile water at a
final concentration of 5 mg/mL.
4.4. FTIR-ATR Assay
For FTIR-ATR analysis, the T and FG dried carrageenan extracts were milled using a commercial
mill (Taurus aromatic, Spain) to obtain a fine powder, which was subjected to direct analysis. FTIR-ATR
spectra were recorded on an IFS 55 spectrometer, using a Golden Gate single reflection diamond ATR
system, with no need for sample preparation, since these assays only required dried samples, according
to Pereira et al. [6]. All spectra are the average of two independent measurements with 128 scans, each
at a resolution of 2 cm−1.
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4.5. Cell Culture
Human colorectal carcinoma cell lines HT29, HCT116, SW620, and SW480 were obtained
from ECACC (Porton Down, UK). Cell lines were cultured under adherent conditions in RPMI
(HT29), McCoy’s 5A (HCT116) and Dulbecco’s modified Eagle’s medium (DMEM; SW620 and
SW480), all supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) and 1% (v/v)
antibiotic/antimycotic solution (all from Gibco, Thermo Fisher Scientific, Paisley, UK). All cell cultures
were maintained at 37 ◦C under a humidified atmosphere of 5% CO2 (HeraCell 150i CO2 incubator,
Thermo Fisher Scientific, Paisley, UK).
4.6. Tumoursphere Forming Assay
For the generation of tumourspheres, cell lines were grown as previously described [32]. Briefly,
cells were plated at low density (100 and 500 cells/well in 96- and 24-well plates, respectively),
in ultra-low attachment plates in a serum-free DMEM/F12 medium supplemented with 1%
penicillin-streptavidin, 1% nonessential amino acids, 1% sodium pyruvate, 2% B27 supplement,
1% N2 supplement, 40 ng/mL recombinant human epidermal growth factor (all from Gibco), 4 μg/mL
heparin (Biochrom GmbH, Berlin, Germany), and 20 ng/mL recombinant human basic fibroblast
growth factor (Peprotech, London, UK).
4.7. IC50 Determination
To quantitatively assess the carrageenan-extract inhibitory potency in CSC-enriched
tumourspheres, their half maximal inhibitory concentration (IC50) was determined through a 10-point
dose-response curve. Briefly, HT29 cells were plated in 96-well plates as described above and
treated with carrageenan extracts (concentrations ranging from 300 to 0.015 μg/mL), positive control
(salinomycin (Sigma-Aldrich, St. Louis, MI, USA); concentrations ranging from 13 to 0.023 μg/mL),
or vehicle control (DMSO). Following seven days of incubation, cell viability was assessed based on
measurement of ATP metabolism using CellTiter-Glo™ luminescent cell viability assay (Promega,
Madison, WI, USA). Luminescence signal was recorded using a GloMax®-MultiDetection System
(Promega). IC50 determination was preformed using GraphPad Prism 8.0.2. software.
4.8. Validation of CSC-Targeting Action
To assess whether the carrageenan extracts have a generic effect on colorectal CSCs or whether this
is a cell line dependent effect, they were tested on CSC-enriched tumourspheres from other colorectal
cell lines. Hence, HCT116, SW480, and SW620 cell lines were cultured in 96-well plates as described
above to promote CSC-enriched tumoursphere formation and treated with carrageenan extracts (100
and 33.3 μg/mL), positive control (salinomycin, at 0.751 μg/mL), or vehicle control (DMSO). Following
seven days of incubation, cell viability was assessed based on measurement of ATP as described before.
4.9. Impact on Tumoursphere Formation
The anti-CSC effect of the carrageenan extracts was further validated by assessing their impact
on tumoursphere formation. Hence, HT29 cells were plated in 24-well plates as described before
and treated with hit carrageenan extracts, positive control (salinomycin) all at their IC50 dose, and
vehicle control (DMSO). After seven days of incubation, tumoursphere images were acquired through
brightfield microscopy with Invitrogen EVOSTM FL Auto2 imaging system (Invitrogen, Thermo Fisher
Scientific). Tumourspheres number and area were determined using ImageJ analysis software (version
1.52a, NIH, USA). Data analysis was preformed using GraphPad Prism 8.0.2. software. A p-value
inferior to 0.05 was considered significant.
198
Mar. Drugs 2020, 18, 50
5. Conclusions
This work shows that the carrageenans extracted from the two G. pistillata life cycle phases,
particularly the T carrageenan, have potential against colorectal cancer CSC-like cells. This could be
explained by the higher sulphated ethers content in T carrageenan (λ/ξ) comparatively with the FG
carrageenan (κ/ι) with support by the identification via FTIR-ATR. Little is known about the interaction
between CSCs and carrageenan, and how this can affect human colorectal cell function. Hence, further
studies are needed to understand the carrageenan anti-CSC mechanism of action, particularly for the
T carrageenan.
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Abstract: Changes in lipid profile constitute the main risk factor for cardiovascular diseases. Algae
extracted carrageenans are long-chain polysaccharides and their ability to form gels provides for the
formation of vegetable jelly. The objective was to evaluate the bioactive potential of carrageenan
(E407) in the lipid profile, after ingestion of jelly. A total of 30 volunteers of both sexes, aged
20–64 years and with total cholesterol (TC) values ≥200 mg/dL, who ingested 100 mL/day of jelly
for 60 days, were studied. All had two venous blood collections: before starting the jelly intake
and after 60 days. At both times, TC, high density lipoprotein cholesterol (HDL-C), low density
lipoprotein cholesterol (LDL-C) and triglycerides (TG), were evaluated using commercial kits and
spectrophotometer. The statistics were performed using the SPSS 25.0 software and p < 0.05 were
considered statistically significant. Serum values after 60 days of jelly intake revealed a statistically
significant decrease in TC levels (5.3%; p = 0.001) and LDL-C concentration (5.4%; p = 0.048) in
females. The daily intake of vegetable jelly for 60 days showed a reduction in serum TC and LDL-C
levels in women, allowing us to conclude that carrageenan has bioactive potential in reducing
TC concentration.
Keywords: carrageenan; TC; HDL-C; LDL-C; TC reduction; TG
1. Introduction
Today, profound socioeconomic changes have led to changes in lifestyles. A sedentary lifestyle
and a poor diet, low in vegetables, sometimes associated with smoking habits, are a strong inducer of
alterations in lipid profile. This is evaluated in the laboratory by several parameters: total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and
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triglycerides (TG) levels. Modifications in lipid profile constitute the main risk factor in the development
of cardiovascular diseases (CVDs), particularly the increase in TC and LDL-C levels [1].
Despite the description of the main risk factors and availability of pharmacological treatment, 17.9
million people die each year due to CVDs, proving to be the leading cause of death worldwide and
presenting itself as one of the biggest epidemiological problems today [2]. A similar trend is observed
in Portugal, with a record of 31% of deaths from CVDs [3].
According to Shimazu and collaborators, 2007, epidemiological studies have revealed a low
incidence of CVDs and higher longevity in Japan, a region known for the wide introduction of algae
in the diet [4]. Based on this principle, experimental and observational descriptive studies were
performed on the benefits and applications of macroalgae. These studies demonstrate its richness
in minerals, vitamins, dietary fiber and lipid poverty, which probably explains the epidemiological
evidence [5,6].
In the diet, carrageenans are linear sulphated polysaccharides, constituents of the cell walls and
intercellular spaces of Chondrus crispus (Rhodophyta, Gigartinales). They are extracted by aqueous
or alkaline processes [7,8]. Industrially they are divided into three groups, Kappa (K), Lambda (λ)
and Iota (ι) [7–9], represented on food product labels with the acronym E407 [10]. They are classified
as hydrocolloids as they easily incorporate an aqueous solution leading to the formation of gels
without changing the taste or color of the mixture. This feature enhances its use in the food, cosmetic
and pharmaceutical industries (chocolate milk, gelatin, shampoo, and anti-inflammatories, among
others) [10,11].
Carrageenans represent one of the major texturizing agents in the food industry. They are natural
ingredients, which have been used for decades in food applications and regarded as safe [12]. The dairy
sector accounts for a large part of the carrageenan applications in food products, such as frozen desserts,
chocolate milk, cottage cheese, and whipped cream. In addition to this, carrageenans are used in
various non-dairy food products, such as instant products, jellies, pet foods, and sauces, and non-food
products, such as pharmaceutical formulations, cosmetics, and oil well drilling fluid [13,14]. In general,
carrageenan serves as a gelling, stabilizing, and viscosity-building agent.
The literature reports multiple benefits regarding carrageenan consumption, such as, antioxidants,
anticancer, antilipidemic, anticoagulants, immunomodifiers, antifungals, antivirals, and digestive
health support [8,15]. In agreement with the description of the consumption of macroalgae
and/or its components, such as carrageenan, its intake comes up as an alternative to the use of
pharmaceutical products.
Some studies have shown an efficient reduction of serum TC, TG and LDL-C levels and an increase
of HDL-C in the peripheral blood by the action of carrageenans, as a bioactive principle, mainly of Kappa
subtype, justified by the interaction of its constitution (alternating groups ofβ (1-3)-d-galactose-4-sulfate
and α (1-4)-3,6 anhydro-d-galactose) on the digestion [16–18]. The investigation was carried out
in vitro [17] and in vivo, the latter performed mainly on Wistar rats [18,19] and population samples,
where carrageenans were present as supplement [20] or in enriched foods [21].
The new concept of functional food aims to reconcile food and health benefits with the ease and
speed of cooking [22,23]. In the health sciences, the possible substitution of pharmacological therapy
for foods rich in bioactive and natural compounds represents a healthier and more appealing way to
promote the normal functioning of the organism [24].
Carrageenans are widely used in the food industry as a thickener, gelling agent, stabilizer, and
protein suspending agent [25]. Successive research and experiments on colloids led to the formation of
gels with an optimal texture resulting from the interaction of carrageenan subtypes (K and ι) leading
to the emergence of 100% vegetable origin jelly’s with a faster solidification [12,26,27]. The bioactive
effect of the carrageenan mixture present in the vegetable jelly makes its ingestion a health benefit
by reducing TC. Thus, the consumption of jellies of vegetable origin can be a healthy alternative
contributing to the prevention and reduction of CVDs.
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In Europe, the adherence to the Mediterranean Food Standard has been much studied to understand
if the practices of individuals come close to the recommended ones. In this context, we highlight the
PREDIMED instrument [28], used in a multicenter, randomized, nutritional intervention study for
the primary prevention of CVDs, developed in Spain as part of the study “PREvención with DIeta
MEDiterránea”, with the objective to study the effectiveness of this diet in the primary prevention of
CVD. It is user-friendly in clinical setting [29], allowing rapid evaluation and immediate feedback in
intervention studies.
The present investigation aimed to evaluate the impact of vegetable jelly consumption on lipid
profile parameters (TC, HDL-C, LDL-C and TG) in individuals with TC levels equal to or higher than
200 mg/dL and to relate them with the degree of adherence to the Mediterranean diet.
2. Results
2.1. Sample Characterization
The experimental group of 60 days (EG-60 days), with jelly ingestion, consisted of 30 participants,
80% females and 20% males, with an average age of 48.68 ± 10.63 years. The degree of Mediterranean
diet adherence was high in 50% of the individuals of this experimental group. The experimental group
of 30 days (EG-30 days), with jelly ingestion, involved 12 participants with a predominance of females,
66.6% women and 33.3% men, and an average age of 44.55 ± 11.61 years. Regarding the degree of
adherence to the Mediterranean diet, 8 of the 12 participants had a good adherence (Table 1).
Table 1. Sample characterization.
Ingestion Period
30 Days 60 Days
n = 12 n = 30








F: Female; M: Male; MeDiet: Mediterranean diet.
2.2. FTIR-ATR Spectroscopy
The different types of jelly samples were analyzed by vibrational spectroscopy in order to confirm
the existence and characterize the carrageenan type. Figure 1 shows that the four FTIR-ATR spectra
of all types of jelly present the same type of spectra, with an evident particular peak of 1065 cm−1.
This indicates a gelling type of carrageenan (DA) [9], verified in the kappa and iota carrageenans,
which have inherent gelling properties [30].
All the spectra showed a band at 849 cm−1, which is characteristic of D-galactose-4-sulfate (G4S)
present in the kappa and iota carrageenan types.
The peak at 908 cm−1 indicates the presence of 3,6-anydrogalactose-2-sulfate (DA2S), a type
of linkage that belongs to the iota carrageenan type. The peak at 943 cm−1 indicates the C–O–C of
3,6-anhydrogalactose (DA) linkage, which is related with the presence kappa or iota carrageenan in the
sample. The band at 987 cm−1 shows the presence of Galactose (G/D) typically present in the kappa
and/or iota types of carrageenan. Nonetheless, the peaks at 1005 cm−1, 1049 cm−1, 1115 cm−1, 1126 cm−1,
and 1134 cm−1 indicate the presence of sulfate groups, such as sulfate esters and sulfated galactans.
Concluding, vegetal jellies present the same spectra for four different flavors indicating that all
flavors have the same colloid, a hybrid kappa/iota carrageenan which is typically present in jellies
from vegetal origin (Figure 1) [31].
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Figure 1. The four FTIR-ATR spectra of different jelly flavors present the same type of spectra with an
evident peak of 1065 cm−1 that indicates kappa (κ) and iota (ι) hybrid carrageenan [9]. Vegetal jellies
present the same spectra indicating they have the same colloid, a hybrid kappa/iota carrageenan.
2.3. Total Cholesterol
The total cholesterol parameter, in the group that ingested carrageenan for 30 days (EG-30 days)
at T0 had a concentration of 244.86 ± 31.94 mg/dL and at T1 of 226.18 ± 40.99 mg/dL, representing
a statistically significant decrease of 7.63% (18.67 mg/dL), p = 0.021 (Figure 2). The group of
individuals evaluated after 60 days of ingestion (EG-60 days) presented TC concentration at T0
of 236.92 ± 30.48 mg/dL and at T2 of 224.40 ± 23.47 mg/dL, revealing a statistically significant decrease
of 5.3% (12.52 mg/dL), p = 0.001 (Figure 3). Analysis by gender showed a significant decrease (p = 0.004)
in women at T2, comparatively to T0 (Table 2).
Figure 2. Lipid profile evaluation in experimental group with vegetable jelly ingestion for 30 days. T0:
before consumption of jelly; T1: after 30 days of consumption of jelly; TC: Total cholesterol; HDL-C:
High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides;
* p < 0.05.
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Figure 3. Lipid profile evaluation in experimental group with vegetable jelly ingestion for 60 days. T0:
before consumption of jelly; T2: after 60 days of consumption of jelly; TC: Total cholesterol; HDL-C:
High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides;
* p < 0.05; ** p < 0.01.
Table 2. Characterization of lipid profile analytical parameters by sex on EG-60 days.
Sex
Female Male
TC (T0) 234.51 ± 31.06 244.95 ± 29.62
TC (T2) 220.43 ± 21.16 ** 237.76 ± 27.82
HDL-C (T0) 60.85 ± 13.15 46.78 ± 6.65
HDL-C (T2) 58.41 ± 12.10 43.46 ± 7.28
LDL-C (T0) 190.58 ± 33.85 220.12 ± 38.77
LDL-C (T2) 180.35 ± 29.07 * 221.48 ± 40.11
TG (T0) 87.88 ± 38.06 109.75 ± 40.18
TG (T2) 101.65 ± 31.16 135.87 ± 50.83 *
The results are presented in mg/dL. TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C:
Low-density lipoprotein cholesterol; TG: Triglycerides. T0: before consumption of jelly; T2: after 60 days of
consumption of jelly; * p < 0.05; ** p < 0.01 versus T0.
2.4. HDL-Cholesterol
The EG-30 days group, before ingestion of the jelly (T0), had an average concentration of
62.20 ± 19.30 mg/dL. After 30 days (T1), it presented 56.88 ± 17.39 mg/dL, which represents a
statistically significant decrease of 8.6% (5.32 mg/dL), p = 0.008 (Figure 2). The concentration of HDL-C
in EG-60 days presented at T0 a concentration of 57.60 ± 13.30 mg/dL and at T2 of 54.97 ± 12.78 mg/dL,
with a decrease of 4.6% (2.63 mg/dL) in the parameter, with statistical significance, p = 0.037 (see
Figure 3). The distribution by gender revealed no statistically significant differences and is shown in
Table 2.
2.5. LDL-Cholesterol
The LDL-C parameter concentration at EG-30 days presented mean values of 209.54 ± 57.13 mg/dL
at T0 and at T1 of 208.87 ± 64.36 mg/dL, showing no differences (Figure 2). The individuals belonging
to the EG-60 days presented a mean T0 concentration of 197.39 ± 36.5 mg/dL and T2 of 189.83 ± 33.73
mg/dL, showing a 3.8% decrease (7.56 mg/dL; p = 0.062) (Figure 3). Considering an evaluation by
gender of the individuals in the statistical analysis of the parameter, a statistically significant reduction
of 5.4% (10.28 mg/dL) was obtained for females, p = 0.048 (Table 2).
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2.6. Triglycerides
The EG-30 days exhibited at T0 a concentration of 116.09 ± 30.02 mg/dL and at T1 a concentration
of 151.28 ± 31.8 mg/dL, representing a 30.3% increase (35.19 mg/dL), statistically significant, p = 0.038
(Figure 2). The EG-60 days group presented at T0 the serum concentration of 92.93 ± 38.88 mg/dL
and at 60 days (T2) the average concentration was 109.55 ± 38.35 mg/dL, representing a statistically
significant increase of 17.8% (16 mg/dL), p = 0.014 (Figure 3). Analysis by gender revealed a significant
increase associated with males at time T2, versus T0 (Table 2).
2.7. MeDiet-Adherence to Mediterranean Diet
The analysis of the results considering the MeDiet questionnaire evaluation led to the conclusion
that the adhesion or not of a Mediterranean diet does not influence the action of carrageenan, present
in jelly, in the lipid profile.
3. Discussion
Changes in lipid profile constitute the main risk factor in the development of CVDs, considered the
leading cause of death worldwide [1,2]. The need to reduce the mortality rate has led to epidemiological
studies showing that seaweed ingestion induces an antilipidemic effect [4,5]. Intake of fiber-rich foods
has been described as a protective factor for numerous pathologies, such as hypertension, obesity,
diabetes, and many others [32]. Algae, rich in water-soluble fibers such as carrageenan, play an
important role as a source of fiber in the diet [13,22]. Introduction of seaweed constituents in food
products is nowadays frequently and widely used. As example, the inclusion of Kappa–Iota hybrid
carrageenan, identified by food additive code E407, does not alter the taste or color of mixtures and
optimizes their consistency, texture, and water retention [7,8]. Due to this characteristic, carrageenan
is widely used as a gelling agent in the food industry in the production of chocolate milk, ice cream,
beer, and jelly [10]. In addition to the antilipidemic effect, numerous benefits to human health are
attributed to carrageenan as antioxidant, immunomodulatory, antiviral, and digestive health support,
thus revealing its high bioactive potential [9,14]. However, for cultural reasons it is difficult to estimate
the impact of a carrageenan-rich diet associated with individuals not inserted in populations of Asian
culture and to evaluate their lipid profile, giving the present study a pioneer status. Thus, two time
periods of 30 and 60 days of daily ingestion of vegetable origin jelly were tested. In the absence of
studies with similar methodology developed in Caucasian populations, the time periods were based
on studies by Sokolova et al. [20] and by Panlasigui et al. [21].
According to Panlasigui and coauthors, participants ingested the mixed carrageenans in their
own food for eight weeks [21]. Also, Sokolova’s research applied carrageenan as a dietary supplement
to individuals previously diagnosed with CVDs [20]. Participants ingested 250 mL per day of a
supplement consisting of a hybrid K–λ carrageenan (3:1) for 20 days [20]. Our results showed a
statistically significant decrease in TC and HDL-C concentration in both periods (60 and/or 30 days)
after daily ingestion of 100 mL of vegetable jelly. Also, a reduction in TC and LDL-C levels in females
when assessed by gender distribution and EG-60 days was noted. In contrast, males recorded an
increase in TG concentration.
The TC levels decreased by 7.6% after 30 days and 5.3% after 60 days. The decrease was
corroborated by Sokolova et al. [20], but with a smaller percentage, which may be due to the different
study design involving cardiovascular patients with supplemental carrageenan consumption resulting
in a 16.5% decrease in TC [20]. Also, Panlasigui and coauthors [21], in their research on eating
carrageenan-rich foods at the three most important meals (breakfast, lunch and dinner) showed a
reduction in TC levels by 33%. Concerning HDL-C concentration, our results decreased by 8.6% and
4.6% after 30 and 60 days respectively, as opposed to the work of other authors [20,21] which showed
an increase. For the concentration of the LDL-C fraction after 60 days, it showed a tendency to decrease,
evidenced in relation to females showing a significant decrease, which is in accordance with the results
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of Panlasigui et al. and Matthan et al. [21,33]. The increase in TG concentration was 30.3% for 30 days
and 17.8% after 60 days of jelly ingestion. It should be noted that it has not reached the maximum
reference values [34]. For TG, the literature presents ambiguous results, since Panlasigui and coauthors
showed a 32% reduction [21], while Sokolova and collaborators showed an increase [20]. However,
low cholesterol absorption is known to be associated with increased TG and decreased HDL in both
sexes [33]. Despite the multiple benefits to human health, the mechanism of action of carrageenans is
not yet completely understood and only their interaction with the digestive process is documented,
being classified as long-chain carbohydrates [35,36]. When carrageenans reach the intestinal tract, the
volume and viscosity of the intestinal content increases and leads to increased digestion time and
reduced efficiency, since the availability of products for enzymatic action is compromised [37].
On the other hand, it is capable of capturing cholesterol and bile salts, inhibiting lipase, causing a
decrease in cholesterol absorption directly and indirectly, since the emulsifying action performed by
bile salts and lipase becomes deficient, disabling micelle formation [38–40]. However, the action of
carrageenans is not restricted to the partial effect of gastrointestinal barrier, but also has endogenous
repercussions. Excretion of bile salts precludes their reuse and, therefore, synthesis is required once
more [20,21,40,41]. The mobilization of TG occurs from energy reserves into the bloodstream because
cholesterol is required for synthesis and it is in low circulating concentrations [42].
The bioactive potential of carrageenan comes from its ability to decrease cholesterol absorption,
leading to a decreased cholesterol absorption rate and consequent increase in endogenous cholesterol
synthesis rate, maintaining the balance of values, a fundamental process to maintaining the proper
functioning of the body [33]. According to some researchers, the relationship between cholesterol
absorption markers and serum parameters has shown that when cholesterol absorption markers
decrease, serum triglyceride concentration increases and HDL-C levels decrease [33,43]. As a
complement, Matthan et al. [33] verified that when high endogenous cholesterol level marker
values were detected, the serum LDL-C fraction values decreased. An inverse relationship between
expression markers and LDL-C concentration is justified by the increased expression of the LDL-C
receptor in the cell, which causes an increase in cholesterol internalization rate, thereby decreasing
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity and, therefore, decreasing of
endogenous cholesterol synthesis [33,43]. Thus, carrageenan ingestion leads to decreased cholesterol
absorption rate, leading to increased serum TG concentration and reduced HDL-C. On the other hand,
the need for cholesterol for bile salt synthesis, as a result of carrageenan-induced excretion, leads to the
promotion of endogenous cholesterol synthesis, leading to a decrease in serum LDL-C levels [20,40,41].
Also, the gender difference leads to metabolic changes where the hypolipidemic properties of estrogens
induce a protective role in women [44]. The low activity of the enzyme HMG-CoA reductase in women
indicates that the neo-synthesis of cholesterol is physiologically lower in females, until menopause,
compared with males [33,44]. Also, adding the principle that the presence of estrogens increases
intestinal cholesterol absorption in humans, it seems to justify the significant reduction observed in
LDL-C and TC levels in women as a result of decreased absorption efficiency of induced cholesterol
molecules by vegetable jelly [41,44].
In conclusion, carrageenans constitute a bioactive potential in reducing total cholesterol levels in the
body. Regular consumption of vegetable origin jelly is beneficial, contributing to lower total cholesterol
levels and also to decreased LDL-C levels in females. Ingestion of vegetable jelly can therefore be
considered a good practice as a protection against the development of cardiovascular diseases.
Although these results are considered relevant, the need to increase the number of participants in
this type of study in order to consolidate the presented results in future complementary works must
be emphasized.
209
Mar. Drugs 2020, 18, 19
4. Materials and Methods
4.1. Sample Characterization
The study comprised 30 volunteers of both sexes, aged between 20 and 64 years. In the selection
of the sample, the following inclusion criteria were applied: over 18 years old, with previous indication
of elevated TC levels (equal to or higher than 200 mg/dL), and apparently healthy. No restriction
on participants’ eating habits was indicated. As exclusion criteria, pharmacological therapy for
hypercholesterolemia was considered.
The study participation involved the ingestion of 100 mL of vegetable jelly per day, preferably after
dinner, for 60 days. This feature allowed the formation of two experimental groups. The experimental
group with jelly ingestion for 60 days (EG-60 days) was composed of 30 participants. Of these, 12 were
harvested after 30 days, constituting the experimental group with jelly ingestion for 30 days (EG-30
days). In the jelly composition, the presence of a hybrid Kappa–Iota carrageenan polysaccharide,
integrated in the gelling agent, was equal in the various flavours (pineapple, green tea, mango,
strawberry). The analysis of the carrageenan composition present in the jellies was performed by
attenuated total reflectance Fourier transform infrared spectroscopy (FTIR-ATR) spectroscopy on
the IFS 55 equipment using the Golden Gate ATR single reflection diamond system. The jelly with
vegetable origin is available on any commercial food surface. In its composition we find the following
ingredients: sugar, gelling agent (carrageenan, potassium citrates and sucrose), acidity regulators
(citric acid and sodium citrates), aromas (sulfites), antioxidant (ascorbic acid, vitamin C) and dyes
(anthocyanins and beta carotene). For the composition and energy distribution of a portion of 92 g,
equivalent to 100 mL of jelly ingested, the following mean values are given: energy 266 kJ/63 kcal
(3% DR) where DR is the reference dose for an average adult (8400 kJ/2000 kcal) per serving; lipids,
including saturated 0 g; carbohydrates 16 g (6% DR), of which 15 g (17% DR) are sugars; fiber 0 g;
proteins 0 g; salt 0.08 g (1% DR); Vitamin C: 29 mg (36% NRV) where NRV is the nutrient reference
value. The preparation of jelly involves the addition of a 90 g sachet of powdered preparation to
500 mL of boiling water, followed by distribution into five portions.
According to the inclusion criteria, venous blood was collected at three different times: (T0) before
starting the consumption of vegetable jelly, (T1) after 30 days and (T2) 60 days after the first jelly.
Posteriorly, the analytical parameters TC, HDL-C, LDL-C and TG were performed at various times
and the adherence to the Mediterranean diet was evaluated.
4.2. Sample Collection and Preparation
Venous blood samples were collected (about 5 mL) into a vacuum-dried gel tube and centrifuged
at 1800× g, 4 ◦C for 10 min. Serum was aliquoted and stored at −20 ◦C until adjustments were made.
The TC was quantified by the Liquick cor-CHOL KIT, from Cormay, Poland, according to the enzymatic
colorimetric glycerophosphate oxidase method. The determination of TG was performed by the Liquick
cor-TG KIT, from Cormay, Poland, using the enzymatic colorimetric method with cholesterol esterase
and cholesterol oxidase. The HDL-C quantification was performed with the Prestige 24i HDL-DIRECT
KIT, Cormay, Poland with help of the enzymatic direct colorimetric method using cholesterol esterase
and cholesterol oxidase. The concentrations were evaluated by spectrophotometry according to the
protocol and the Prestige 24i equipment, Tokyo Boeki Medical System Ltd., Tokyo, Japan.
The determination of LDL-C was calculated by Friedewald’s formula (LDL-C =
[TC]–[HDL-C]–([TG]/5)) using the TC, HDL-C and TG concentrations previously quantified. The
formula is applied only at TG concentrations <400 mg/dL [34,45].
The adherence to the Mediterranean diet was evaluated by applying the MeDiet questionnaire,
integrated in PREDIMED [28]. Demographic characterization was also obtained by the questionnaire.
The PREDIMED questionnaire presents 14 questions from which the respondent is categorized as
having good or poor adherence to Mediterranean diet. The response to each of the 14 items is scored
1 if it meets the criteria defined as characteristic of this type of feed (possible range 0–14 points).
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A final score of 10 points or higher represents good adherence to the standard. This questionnaire uses
predefined targets for food consumption [46].
4.3. Statistical Analysis
The statistical treatment was performed using SPSS 25.0 Software, IBM®, United States and the
graphs using GraphPad Prism version 8.1.2. Descriptive analysis of the variables was performed with
mean, maximum, minimum, and standard deviation calculations. The Wilcoxon’s t-test was used for
comparison of paired quantitative variables. The results are presented as mean ± standard deviation
and considered statistically significant for p-value < 0.05.
4.4. Confidentiality and Data Protection
The study was conducted in accordance with the principles of the Declaration of Helsinki, ensuring
maximum protection and confidentiality of data, having been previously approved by the Ethics
Committee of the Polytechnic Institute of Coimbra. All subjects gave their informed consent for
inclusion before they participated in the study. The study was conducted in accordance with the
Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Polytechnic
Institute of Coimbra (nº 44/2018).
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